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ABSTRACT
The aetiology of depression and mechanisms of action of antidepressant drugs continue 
to be evasive. Evidence suggests that alterations in brain corticosteroid receptors may 
be a crucial factor in these events. Previous measurements of corticosteroid receptors 
(CR) and CR mRNA in animal tissues following stress and/or antidepressant 
administration have not attempted to measure CR in intact animals using different 
antidepressants, in various tissues or in putative animal models of stress.
The following investigations were aimed at quantifying CR and plasma corticosterone 
concentrations using radioligand binding and high performance liquid chromatography 
or radio-immunoassays, respectively. Behavioural investigations conducted in animal 
models of stress were extended to study the effects of antidepressants.
Antidepressant administration to intact animals had various effects. Cortical CR were 
increased after 14 days of DMI; paroxetine induced a reduction in cortical CR after 14 
days; no changes were observed following venlafaxine for up to 28 days. There were 
no significant changes in CR binding parameters in the hippocampus, striatum or 
hypothalamus following antidepressant administration. CR in the thymus were reduced 
following paroxetine.
No significant effects of olfactory bulbectomy or antidepressant administration were 
observed on CR binding parameters. However, significant increases in^locbmotor 
activity were observed in bulbectomised rats, which were attenuated by chronic, 
antidepressant treatment.
In a putative stress model involving chronic exposure of mice to predator odour, no 
significant effects were observed on locomotor activity following predator exposure 
and/or antidepressant administration. Sucrose intake was decreased, representing a 
possible anhedonic response to chronic predator stress. Predator stress and/or 
antidepressant administration had no significant effects on cortical or hippocampal CR 
binding or plasma corticosterone concentrations.
The results of these investigations demonstrate that CR alterations observed in 
stress/depression are not reflected in the chosen animal models. CR changes following 
chronic antidepressant administration, though forming part of a biochemical cascade, 
are not likely to constitute a common mechanism of action for antidepressant drugs.
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CHAPTER 1
INTRODUCTION
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1.1. Characteristics and origins of depression
Affective disorders are an important psychiatric problem. Primary features of these 
disorders are characterised by mood disturbances of either a depressed or elated nature, 
these being connected with an extensive range of cognitive, physiological and 
interpersonal impediments. Characteristic clinical symptoms of major depression 
include a pervasive dysphoric mood, generalised loss of drive, anhedonia, psychomotor 
retardation/agitation, diminished appetite, fatigue/lethargy, insomnia/hypersomnia and 
recurrent pessimistic or suicidal thoughts (Caldecott-Hazard et al, 1991a; 1992). The 
manifestations of depressive symptoms can range from brief, mild, downward mood 
swings to more extreme conditions requiring medical treatment and subsequent 
hospitalisation or even fatality due to suicide.
The taxonomy of mood disorder symptoms is complicated and diagnostic criteria 
associated with these states are classified in both the “Diagnostic and Statistical Manual 
of Mental Diseases” of the American Psychiatric Association (DSM-IH, DSM-DI-R, 
DSM-IV) and the World Health Organisation’s “International Classification of 
Diseases” (ICD-10). The DSM divides depressive disorders broadly into the categories 
of unipolar (consisting of depressive episodes only) and bipolar (characterised by 
depressive episodes with periods of mania). Mood disorders may also be classified as 
primary or secondary depending on the absence or presence of other pre-existing 
psychiatric disorders. Reactive, or neurotic depression is found to arise in response to 
an identifiable external cause and is more easily treated than endogenous (psychotic) 
depression. The endogenous form of depression generally has an acute onset, arises 
from no apparent cause, can be accompanied by delusions and hallucinations and does 
not respond to attention and reassurance.
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Major depression has the highest incidence of all mental health disorders with up to 
20% of the population suffering depressive symptoms at any given time in the United 
States and England (Gold et al, 1988). Epidemiological reports have noted an increased 
prevalence of hospitalised patients with depression since 1950 and a growing risk of 
depression among young adults, adolescents and children. The life-time risk for a 
single first unipolar episode is 3-4% for men and 5-10% for women (5-12% for men 
and 10-20% for women in the United States), with increased chances (60-75%) of 
repeated episodes following recovery from the first major depressive episode 
(Caldecott-Hazard et al, 1991a; Nemeroff, 1998). Studies in industrialised nations 
indicate that approximately 2-3% of the population is hospitalised or seriously impaired 
by affective disorders at any given time. Patients diagnosed with major depression are 
also at increased risk from co-morbidity with substance abuse and anxiety disorders 
(Hale, 1997). A strong link also exists between depression and suicide, with 15% of 
depressed patients committing suicide (Grothe et al, 1992).
Although cognitive and electro-convulsive therapies are effective in treating some 
types of depression, the contemporary treatment of major depression is dominated by 
dmg therapy. The pharmacological treatment of depression utilises a number of 
different classes of drugs that act via various mechanisms e.g. the monoamine oxidase 
inhibitors (MAOls), tricyclic antidepressants (TCAs), selective serotonin reuptake 
inhibitors (SSRls) and noradrenaline reuptake inhibitors (NARls). Approximately 80% 
of patients respond to pharmacological and psychological therapy, either alone or 
combined. In the absence of continuous antidepressant treatment, more than 80% of 
patients will have repeated episodes within 2 years - this figure drops to 20% with 
antidepressant treatment (Frank et al, 1990). The extensive and recurrent nature of 
depressive disorders requires therapies that would benefit many people, offering a
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discernible improvement in quality of life. However, approximately 15% of patients are 
poor or non-responders to pharmacotherapy and adverse effects with many 
antidepressant medications can be severe. The reduction of adverse effects from 
existing antidepressant medications and development of novel treatments is therefore 
imperative in the attempt to alleviate depressive symptoms.
It appears that, with its potentially severe, incapacitating nature and characteristic 
physical and biochemical changes, depression must be regarded as residing outside the 
normal, healthy human condition and therefore as a pathological state. Research into 
the aetiology and treatment of affective disorders is therefore warranted by virtue of 
their intensity, pervasiveness, persistence and interference with physiological and social 
functioning.
The origins of depressive symptoms are as yet unknown. There are a number of 
psychodynamic and cognitive theories of depression, focusing on childhood exposure 
to hypercritical, exploitative, emotionally unresponsive environments that can lead to 
the emergence of poorly integrated emotions and negative and distorted thinking in 
later life. In the last 30 years however, multidisciplinary approaches to the study of 
major mental disorders have provided evidence that major depression does in fact, 
possess biological components and is not, as previously thought, a functional disorder 
arising solely from a poor childhood environment or psychosocial stressors.
Many lines of evidence confirm the heritability of symptoms and therefore the 
involvement of genetically predisposing factors in depressive illness (reviewed in Gold 
et al, 1988). Several other possible biological précipitants of depression have been 
identified including hypothyroidism, adrenocortical hyperactivity, and effects due to
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oestrogen, which may account for increased depression in women (Leibenluft, 1998). 
There is also evidence to suggest that seasonal changes may precipitate depressive 
symptoms (as in seasonal affective disorder, SAD) and the implication of viral 
infections has not been eliminated as causes of symptoms of depression (Mestel, 1997).
Many alterations in monoamine neurotransmitter functioning have been observed 
following the onset of depressive symptoms leading to theories that altered monoamine 
systems may be the primary cause of depression. An extensive body of evidence 
implicating the immune system with depression has also recently lead to an 
immunological hypothesis for depression. A factor which is of great importance in the 
development of the depressive syndrome is the prolonged exposure to various 
psychological and social stressors, which ultimately results in an impaired general 
coping strategy. This is reflected in the altered status of the endocrine system in 
depressed patients thus also creating an endocrinological theory of depression.
Though the origins of depression remain to be established, various proposed theories 
concerning the pathology of depression are briefly reviewed in the following sections.
1.2. Neurochemistry of depression
The first major hypotheses to address the biological basis of affective disorders were 
the catecholamine and indoleamine deficiency hypotheses proposed by Schildkraut 
(1965), Bunney & Davies (1965) and Coppen (1967). The combination of these 
hypotheses comprises the monoamine hypothesis of depression, which postulates that 
depression is causally related to decreased activity of the neurotransmitters 
noradrenaline (NA), 5-hydroxytryptamine (5-HT) and dopamine (DA) at certain central 
neuronal synapses.
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Support for the monoamine hypothesis came from the observations that reserpine and 
tetrabenazine precipitated depressive symptoms in some hypertensive patients by 
depleting monoamines. Symptoms were alleviated by treatment with the antitubercular 
compound, iproniazid, a monoamine oxidase inhibitor (MAOI) from which a series of 
clinically useful MAOIs were developed. The tricyclics (TCAs), which restored 
monoamines to normal concentrations by inhibiting NA and 5-HT uptake, also 
alleviated symptoms of depression.
Reduced concentrations of the major NA, 5-HT and DA metabolites, MHPG (3- 
methoxy-4-hydroxyphenylethylene glycol), 5-HIAA (5-hydroxyindole acetic acid) and 
HVA (homovanillic acid) in CSF, urine and plasma from depressed patients were found 
to return to normal concentrations following antidepressant treatment (reviewed by 
Willner, 1987b). Other studies however reported an increased activation of the locus- 
coeruleus-NA system and increased NA and MHPG concentrations in depressed 
patients (Kelly & Cooper, 1998), these being consistently reduced following 
antidepressant therapy. Post mortem investigations of adrenoceptors have yielded 
conflicting results but generally do not demonstrate any alterations. Higher numbers of 
cortical 0 C2 adrenoceptors have been reported in post mortem tissue from depressed 
suicides. Blunted growth hormone responses to clonidine also indicate decreased 
responsiveness of the a 2.adrenoceptor system in depression. Post mortem human brain 
studies of P-adrenoceptor binding have yielded conflicting results (reviewed in Willner, 
1987b). Peripheral p-adrenoceptor studies have demonstrated reduced p-adrenoceptors 
on leucocytes and/or lower cAMP production in response to P agonists.
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A low central 5-HT turnover is generally characteristic though the complexity of 5-HT 
systems makes it difficult to simplify the specific role of 5-HT in depressive disorders. 
5-HT uptake into platelets is consistently lower in depressed patients than in controls. 
An underactivity of the 5-HT system in depression is also indicated by blunted 
prolactin/growth hormone release in response to L-tryptophan. A blunted prolactin 
response to the 5-HT releaser fenfluramine and 5-HT uptake inhibitor clorimipramine 
also supports this. Post mortem studies in depressed patients have also consistently 
shown no differences in 5-HT and 5-HTia binding sites between depressed and control 
values. However, several studies have reported an increased density of 5-HT2a binding 
sites in the frontal cortex of suicide victims (Caldecott-Hazard et al, 1991b; Hrdina et 
al, 1993).
The involvement of DA in depression is unclear and DA concentrations appear to 
follow NA alterations indicating that the former may result from the latter. Platelet 
studies suggest that there may be a defect of dopamine uptake in depression. 
Neuroendocrine challenge tests, investigating prolactin and growth hormone release, 
have yielded inconsistent results (see reviews by Van Praag, 1982; Willner, 1987b; 
Ackenheil, 1990; Brown & Gershon, 1993).
It soon became apparent that a wide range of neurotransmitters may be implicated in 
the pathophysiology of depression. The “classical” monoamine hypotheses of 
depression were extended to include possible roles for various other neurotransmitter 
systems. It has also been postulated (based on data which indicate that cholinergic 
agonists can induce depressive symptoms) that patients with major depression possess a 
hyperresponsive cholinergic system, which contributes to the disturbance of REM sleep 
patterns (Janowsky et al, 1972; Hasey & Hanin, 1991). Plasma and CSF concentrations
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of the major inhibitory neurotransmitter GAB A are reported to be lower in depressed 
patients (Gold et al, 1988). Many tricyclic and atypical antidepressants are found to 
inhibit the histamine stimulated increase of cAMP concentrations in the brain; however 
the role of histamine in depression remains unclear (Sugrue, 1983).
The most apparent discrepancy in the neurotransmitter hypothesis however was the 
contrast between the delay in the onset of therapeutic action of antidepressants 
compared with their acute neurochemical effects. This and several other ambiguities in 
this hypothesis led to its subsequent reformulation to the “neurotransmitter receptor 
sensitivity hypothesis” of depression. This associated secondary adaptive responses in 
neurotransmitter receptor systems, induced by chronic (not acute) antidepressant 
treatment, with the delayed onset of action of antidepressant medication and is logically 
consistent with the monoamine/neurotransmitter hypothesis. Alterations in 
neurotransmitter receptors following antidepressant administration have been reviewed 
in depth by Sugrue (1983), Maj (1984) and Caldecott-Hazard et al (1991b) and are 
briefly summarised below.
Receptor binding studies in animals display contradictory data regarding (%i- 
adrenoceptor numbers following the administration of various antidepressant 
compounds (Menkes et al, 1983; Maj, 1984). Clonidine induced locomotor 
activity/aggression is found to be enhanced by repeated administration of some 
antidepressants suggesting increased adrenoceptor responses following
antidepressant administration (U’Prichard et al, 1978). Electrophysiological studies 
also indicate increased sensitivity of ai adrenoceptors, as do peripheral studies in 
human subjects (see Sugrue, 1983).
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Results of a 2 -receptor binding studies have also been contradictoiy demonstrating 
increased, decreased and unaltered QL2 sites in various brain regions following 
antidepressant administration in animals (Schoffelmeer et al, 1984; Garcia-Sevilla et al, 
1986). The ai-adrenoceptor desensitisation hypothesis (reviewed by McNeal et al, 
1986; Ackenheil et al, 1990) states that presynaptic (%2-adrenergic autoreceptors are 
supersensitive in depression and antidepressants act to desensitise them. This 
hypothesis is supported by the attenuation of clonidine-induced hypothermia by 
repeated imipramine and ECS in animal studies. Electrophysiological experiments also 
confirm the presence of subsensitive a 2-adrenoceptors in rat brain following chronic 
desipramine. The principal tool for investigating a 2-adrenergic receptor function in 
humans is growth hormone (GH) secretion induced by the a 2-agonist clonidine. 
Blunting of the GH response has been demonstrated in several studies involving 
depressed patients; this being normalised following antidepressant administration 
(Matussek et al, 1980; Siever et al, 1984). It has been suggested that the reduced 
responsiveness of QL2 receptors may be associated with the mechanism responsible for 
dexamethasone non-suppression (see section 1.4.3.i).
The P-adrenoceptor downregulation proposal (Vetulani & Sulser, 1975; Peroutka & 
Snyder, 1980, Gillespie et al, 1988) suggested that TCAs may act by down-regulating 
postsynaptic p-adrenergic receptors in the brain following observations that central p- 
adrenergic receptor density was reduced following prolonged antidepressant 
administration. This reduction in p-adrenoceptors is the most consistent finding 
following long term TCA, MAOI, atypical antidepressant and ECT administration 
(Racagni et al, 1983; Byerley et al, 1987; 1988). The administration of a variety of 
antidepressants to animals is also found to result in decreased p-adrenoceptor 
stimulated cAMP formation in the limbic forebrain and cortex or in peripheral tissues
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in humans. Electrophysiological investigations indicate a reduction of rat brain f- 
adrenoceptor sensitivity following chronic antidepressant administration (Sugrue, 
1983). This indicates p-adrenoceptor down regulation or, possibly an uncoupling of the 
receptor and its effector which, interestingly, does not occur in the absence of a 
serotonergic input (Brunello et al, 1982; Sulser et al, 1983)
The overall picture at 5-HT synapses following antidepressant administration is one of 
enhanced transmission. Investigations into 5-HT receptors are made difficult due to the 
large numbers of subtypes that exist and the results of many studies into antidepressant 
effects on 5-HT receptors are inconsistent (reviewed by Sugme, 1983; Fuxe et al, 1983; 
Willner, 1985; Stahl, 1986). Generally, 5-HTi receptors are unaltered by chronic 
antidepressants (except MAOIs). The rat ‘serotonin syndrome’ and hypothermia in the 
mouse, both induced by 5-HTia receptor agonists and thought to be mediated by 5-HTi 
receptors, are attenuated by chronic TCA, MAOI and ECT administration. Cortical 5- 
HT% receptors are found to be down-regulated by the administration of various 
antidepressants (except SSRIs) suggesting that this action may relate to antidepressant 
effects (Peroutka & Snyder, 1980). Many behavioural and electrophysiological studies 
point to an increased sensitivity of postsynaptic 5-HT receptors in the rat brain 
following long term antidepressant administration; however a lack of correlation 
appears to exist between these and results of binding studies (Sugrue, 1983; Ackenheil,
1990).
No consistent DA receptor alterations have been suggested however, a decreased 
sensitivity of D2 autoreceptors has been reported in some animal studies (reviewed by 
Kapur et al, 1992). Studies of the postsynaptic D2  receptor have generally found no 
effects of chronic administration of various antidepressants (Peroutka & Snyder, 1980;
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Willner et al, 1983a; 1983b). It has been suggested that, given the enhancement of 
dopaminergic responses, but unaltered DA turnover and pre- and postsynaptic receptors 
following antidepressant administration, that changes in D2 responsivity may be 
induced via facilitatory alterations in Di receptors, or at sites distal to the receptors via 
the second messenger system (Kapur et al, 1992).
Acetylcholine and histamine do not appear to be consistently affected by antidepressant 
administration. There is a reported increase in density of muscarinic ACh receptors 
following chronic amitriptyline administration. However this observation may be due 
to the drug’s high anticholinergic effects (McNeal et al, 1986).
Though GABAa receptors are blocked by many antidepressants, it is the GAB As 
receptor upon which recent attention has been focused. There are many discrepancies in 
the results of investigations of GABAb receptor binding following antidepressant 
administration with some studies demonstrating up-regulation and others showing 
down-regulation of GABAb receptors on multiple dosage of antidepressants (reviewed 
in Broekkamp et al, 1995).
These reformulated hypotheses of neurotransmitter involvement in depression are more 
viable as possible explanations of the pathophysiology of depression. The popularity of 
monoamine hypotheses for depression can be assessed by the fact that they have 
dominated the field for more than 30 years. However, these concepts have been further 
complicated by observations that various neurotransmitter systems are interactive and 
quite frequently, alterations in one neurotransmitter system are found to affect another. 
The NA/5-HT link hypothesis proposes that NA and 5-HT systems are 
neuroanatomically linked and affect each other at various sites on the neural axis -  this
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link possibly being at the level of the |3-adrenoceptor (Gillespie et al, 1988). This 
interaction was proposed following observations that the down-regulation of 
cortical/limbic forebrain pi-adrenoceptors after up to 3 weeks of DMI administration 
only occurs in the presence of an intact 5-HT system. The simultaneous alterations seen 
in various neurotransmitter systems in depression and following antidepressant 
administration indicate extensive interactions between systems. Connections exist 
between ai, a 2 , pi-adrenoceptors, 5-HT% and 5 -HT2  receptors with influences on the 
dopaminergic system, and acetylcholine (reviewed by Ackenheil, 1990). Chronic 
administration of NMDA receptor antagonists also results in p-adrenoceptor down- 
regulation and adaptations of the NMDA receptor complex (Paul et al, 1994; Skolnick 
et al, 1996) suggesting a more fundamental role for these receptors in the 
pathophysiology of depression.
The interaction of a wide range of neuromodulators (such as neuropeptides and 
prostaglandins) with components of various neurotransmitter systems also means that 
“classical” hypotheses of depression are being extended to include possible roles for 
the benzodiazepine receptor (File, 1996) and more recently, immunological factors 
such as cytokines and positive acute phase proteins (Connor & Leonard, 1998), 
neuroactive peptides such as substance P, cholecystokinin (CCK), corticotrophin- 
releasing factor (CRF) and steroids (Murphy, 1991; Kramer et al, 1998; Rupprecht & 
Holsboer, 1999; Griebel, 1999). Observations that peptides and ‘classical’ 
neurotransmitters can co-exist in the same neurone also suggest it is possible that 
antidepressants may owe their activity to an ability to modulate such inter­
relationships. The presence of peptides and especially immunological factors in the 
same cell, combined with the pronounced effects of stress/depression on immunity has
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also led to the formulation of an immunological hypothesis for depression. This is 
summarised briefly in the next section.
1.3. Immunology of depression
Widely reported immunological alterations in depressed patients have also led to the 
recent proposal for a macrophage hypothesis of depression. This suggests that 
depressive symptoms arise as a consequence of abnormally secreted cytokines and 
positive acute phase proteins from macrophages which subsequently lead to 
hypersecretion of CRF (corticotropin releasing factor), adrenocorticotrophic hormone 
(ACTH), prolactin and cortisol in depression (reviewed in Ur, 1992). Further support 
for this hypothesis comes from observations that administration of various 
immunological challenges in animals produces alterations in behaviour, monoamine 
neurotransmitter and endocrinological systems that are similar to those seen in 
depression (reviewed in Connor, 1998).
Some studies have demonstrated impaired mitogen stimulated lymphocyte 
proliferation, zymosan-induced neutrophil phagocytosis and natural killer (NK) -cell 
toxicity in depressed patients. Decreased lymphocyte, neutrophil and monocyte counts 
have also been reported (O’Neill & Leonard, 1986; reviewed in Connor, 1998).
Depression is also associated with increased serum levels of interleukin-ip and -6  (IL- 
Ip, IL-6), tumour necrosis factor-alpha (TNF-a), interferon-alpha (INF-a) and ai-acid 
glycoprotein (Maes et al, 1993). IL-ip, IL-6 and ai-acid glycoprotein levels have been 
reported to return to normal in patients who responded to chronic antidepressant 
therapy (Connor, 1998), Increased numbers of T-helper (CD4+), T-memory (CD4+, 
CD44RO+) and activated T-cells (CD25+, HLA-DR+) in serum from depressed
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patients also indicates immunological activation (Maes et al, 1995). Song et al (1994) 
have also demonstrated raised plasma concentrations of the positive acute phase 
proteins (haptoglobin, ai.antitrypsin, ai and macroglobulin) in depressed patients, in 
addition to increased cortisol and semm complement levels and decreased negative 
acute phase proteins.
There appears to be a large degree of interplay between components of the nervous, 
immune and endocrine systems. The hypothalamic-pituitary-adrenocortical (HPA) axis 
is the key player in endocrinological responses to stress. A variety of consistently 
observed endocrinological and HPA axis changes have been observed in depression 
culminating in an HPA-axis based hypothesis for the origin of depressive syndromes 
which forms the basis for the majority of work in this thesis. This hypothesis is 
discussed in more detail in the following sections which deal with the physiology and 
regulation of the HPA axis before moving on to the HPA dysfunction observed in 
depression and effects of various pharmacological treatments.
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1.4. Endocrinology and depression
1.4.1. The HPA axis
The HPA axis plays a fundamental adaptive role in the face of stress on mammalian 
systems primarily via the secretion of corticosteroids. Hypothalamic neuropeptides, 
CRF, a 41 amino acid peptide and arginine-vasopressin (AVP) are synthesised by 
neurones of the paraventricular nucleus (PVN) which are innervated by nerve fibres 
containing various neurotransmitters or neuropeptides (Swanson et al, 1983). CRF and 
AVP, along with oxytocin and NA act as ACTH secretagogues. The production and 
secretion of oxytocin occurs in the supraoptic nucleus (SON) of the hypothalamus and 
NA is derived mainly from brainstem catecholaminergic nuclei, however it is mainly 
CRF that subsequently stimulates the release of adrenal corticosteroids. CRF and AVP 
are released from the median eminence into the hypophyseal circulation from where 
they travel to the anterior pituitary and are thought to act in a synergistic fashion on 
pituitary corticotropes to stimulate the release of ACTH (along with other pro­
opiomelanocortin derived peptides, including endorphins). The secretion of cortisol 
from the adrenal gland is driven by ACTH, which stimulates cholesterol uptake and 
synthesis in the adrenal cortex (Figure 1.4.l.i; reviewed by Stokes, 1987; de Kloet,
1991). The adrenal steroids are synthesised from step-wise enzymatic modifications of 
cholesterol from the blood or from acetate within the adrenocortical cells.
Cortisol is the major corticosteroid in humans with small amounts of corticosterone 
synthesised as a by-product. Corticosterone is produced as the major corticosteroid in 
the rat. Small amounts of mineralocorticoids, androgens and oestrogen are also 
produced as by-products of corticosteroid synthesis (reviewed in Dallman et al, 1987).
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Figure I.4.I.I. Schematic diagram showing structure and regulation of the hypothalamic- 
pituitary-adrenocortical axis (HPA) axis. The hypothalamic factors, CRF (corticotropin 
releasing factor) and AVP (arginine vasopressin) act synergistically to induce POMC-derived 
ACTH (adrenocorticotropin) secretion from the anterior pituitary. ACTH stimulates the 
secretion of corticosteroids from the adrenal cortex, which in turn, can elicit a negative 
feedback effect on the anterior pituitary and hypothalamus. Inhibitory feedback effects of the 
peripheral effector hormones are mediated through a binary corticosteroid receptor system 
within the brain; GR (glucocorticoid receptors) and MR (mineralocorticoid receptors).
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1.4.2. Corticosteroid receptors
Biologically active free corticosteroids exert their effects through their genomic actions 
on two types of corticosteroid receptors (CR), the mineralocorticoid receptor (MR) or 
type I CR and the glucocorticoid receptor (GR) or type II CR. Both types of CR are 
members of the steroid hormone receptor family (also including androgen and 
progesterone receptors) which are all similar with regards to their structure and 
organisation into discrete functional domains. In addition to highly conserved domain 
structures within this receptor group, MR and GR display a particularly high degree of 
sequence homology (Figure 1.4.2.i.).
The carboxy-terminal domain contains the ligand/heat shock protein (Hsp) binding site 
and receptor dimérisation, transactivation and nuclear localisation functions. The 
sequences between the steroid and DNA binding regions are known as the hinge region 
and are thought to contribute to the nuclear translocation, transcription and steroid 
binding activities of the receptor molecule. The DNA binding domain is located 
roughly in the centre of the molecule and directs dimérisation, sequence-specific DNA 
binding of the receptor and also contains a nuclear localisation signal. This cysteine- 
rich region consists of highly conserved peptide projections containing two Zn^ "^  motifs 
that promote the interaction of CR with target enhancers (see Figure 1.4.2.i, Schwabe & 
Rhodes, 1991). Each zinc finger is important for high affinity binding to target DNA 
sequences and are involved with the initial contact and correct orientation of residues 
that enable DNA-protein interaction and/or receptor dimérisation. Structural studies 
indicate that the first (N-terminal) finger plays a more important role in sequence 
specific DNA recognition. The interfinger region/C-terminal finger are required for 
prevention of non-specific binding to other steroid hormone responsive DNA elements 
and perhaps for activated steroid-receptor complex dimérisation (Bodine & Litwack,
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1990; O ’Malley & Tsai, 1992). The highly variable amino-term inal domain largely has 
a modulatory function and regulates interactions with other transcription factors 
(Gehring, 1993; Funder, 1993; reviewed by Simons, 1994).
■ Figure 1.4.2.1 Domain structure and homologies of human corticosteroid receptors
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Domain structure and sequence homology of GR and steroid hormone receptors. Key; N, 
amino terminus; C, carboxy terminus; HSP, 90,000 dalton heat shock protein; P, 
phosphoserine residues; GR, glucocorticoid receptor; MR, mineralocorticoid receptor; PR, 
progesterone receptor; AR, androgen receptor; ER, eostrogen receptor; VDR vitamin D 
receptor; THR, thyroid hormone receptor; RAR, retinoic acid receptor; AHR, aromatic 
hydrocarbon receptor, Taken from Bodine & Litwack (1990).
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a) Amino acid sequence of DNA binding domain of the human glucocorticoid receptor (GR 
and mineralocorticoid receptor (MR). Solid squares indicate P-box amino acids which 
determine sequence specificity and bold type indicates D-box amino acids which mediate 
dimérisation, b) Functional domains of human GR (777 amino acids) and MR (984 amino 
acids). A= modulatory region, B=DNA-binding region, C= ligand-binding region. Percentage 
sequence homology of the human MR relative to the human GR is shown. Diagram taken from 
Trapp & Holsboer (1996).
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The two receptor systems represented by MR and GR, located in the brain as well as 
peripherally, have been identified based on their affinities for endogenous and synthetic 
corticosteroids. MR and GR display considerable sequence homology therefore share 
numerous ligands however, many of these produce very specific responses at these 
receptors. This suggests a dual action of the corticosteroid hormones in the control of 
brain function.
The type I MR has a dissociation constant (Kd) for corticosterone of 0.5-InM and with 
relative steroid binding affinities of corticosterone > aldosterone »  dexamethasone (a 
synthetic glucocorticoid). MR in the brain are found mostly in the CA3 area of the 
hippocampus and the septum. The mediation of tonic actions of corticosteroids is 
proposed as the primary function of MR as these are under most circumstances, 
extensively occupied by corticosteroids. Type II GR have a lower affinity for 
endogenous corticosteroids ~2-5nM) and the following rank order of steroid 
binding affinities, dexamethasone> corticosterone »  aldosterone (Moses et al, 1991). 
Type n  GR exhibit a more ubiquitous distribution in the brain. They are present in the 
PVN and other hypothalamic nuclei, the limbic system (including the hippocampus -  
CAl and CA2 pyramidal neurones, septum and amygdala), the cerebral cortex and 
many brainstem monoaminergic nuclei (Reul et al, 1985; Eekelen et al, 1987). 
Observations that these receptors become occupied concurrently with rising plasma 
corticosteroid concentrations following stress (Reul et al; 1987a; 1987b) suggest that 
GR primarily mediate feedback actions of corticosteroids aimed at switching off stress- 
activated brain mechanisms. The responsiveness of GR to varying plasma 
corticosteroid levels infers on them greater plasticity and capacity for autoregulation.
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Corticosteroids exert and regulate neuronal excitability via several different, diverse 
mechanisms beginning with the determination of access of hormone to the receptors by 
corticosteroid binding globulin (CBG), and steroid metabolising enzymes such as 11 p- 
hydroxysteroid dehydrogenase type I (abundant in the kidney) which results in 
location- and receptor-specific activation. Corticosteroids enter brain cells by diffusion 
through cell membranes and bind to intracellular receptors which form part of a 
cytoplasmic multiprotein complex consisting of one corticosteroid receptor molecule 
and several heat shock proteins (Hsp-90, Hsp-70, Hsp-56 and immunophilins). These 
proteins are necessary to enable the receptor to bind ligands with high affinity as 
ligand-independent dissociation of these proteins would prevent efficient receptor- 
ligand binding. The steroid binding activities of CR are also stabilised by complexes 
formed between thiol groups and sodium molybdate, which is thought to interact with 
cysteine residues of the receptor molecule (Bodine & Litwack, 1990).
The binding of corticosteroids results in dissociation of the receptor-Hsp complex, 
several phosphorylation stages, alteration in the conformation of the receptor protein 
and an activated receptor with increased affinity for nuclear DNA binding domains 
(Figure 1.4.2.Ü). Seven major phosphorylation sites, many containing Ser-Pro 
sequences, have been identified in the mouse GR, all of which are located in the region 
N-terminal to the DNA binding domain. The steroid free CR is a phosphoprotein and 
steroid binding causes a 2-4 fold increase in phosphorylation which plays important 
roles in nuclear translocation, DNA binding, interactions with other proteins and 
transactivation - and can alter the activity/stability of the receptor protein in response to 
different signalling pathways (Weigel, 1996). Reduced cysteines are thought to be 
required for steroid binding and the conversion of the receptor to a DNA binding form.
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Hormone-activated receptors undergo ‘transactivation’ which involves topological 
alterations that expose the DNA binding domain of the receptor. After nuclear 
translocation, activated receptors associate with specific DNA sequences (hormone 
response elements, HRE’s) in regulatory regions of target genes to mediate 
transcriptional activity. Recent evidence suggests that MR/GR can bind to DNA 
sequences as homo- or heterodimers (Trapp et al, 1994). Heterodimerisation may form 
an important mechanism in regions in which MR and GR are co-localised (in major 
regulatory areas of the HPA axis) whereas it may only play a minor role in other target 
areas such as the liver where the MR concentrations are low. For example, in the 
hippocampus, the relative concentrations of the receptors and their ligands enables a 
definition of the proportion of each type of CR dimer - with its own DNA and 
transactivation properties, allowing a more finely tuned regulation of corticosteroid 
responses and more diverse hormone signalling processes (Trapp & Holsboer, 1996). 
The relative activation of MR/GR is an important factor which may synergistically 
determine changes in the excitability of such cells containing co-localised receptors 
(Simons, 1994; Zakon, 1998).
The mechanisms by which CR regulate transcription are as yet unclear and constitute 
an intensively pursued area of research. Activated CR dimers are thought to bind to the 
consensus sequence of a simple HRE comprised of 15 base pair palindrome 5’- 
GGTACA-nnn-TGTTCT-3’. Aside from activated-CR binding to DNA, little is known 
about the actual interaction of the receptor complex with chromatin. It is possible that 
the activated receptor-complex binds to nucleosomes which appear to contain HREs 
and the binding of the activated receptor complex dismpts this structure resulting in the 
opening of the DNA helix. This would enable protein transcription factors such as the 
CAAT-box and the TATA-box to bind to promoter regions of a corticosteroid-
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responsive gene which may create a DNA-protein complex to which RNA polymerase 
n  can bind and initiate mRNA synthesis (Bodine & Litwack, 1990).
A proposed mechanism by which activated CR complexes may alter nucleosome 
structure and activate other factors involves the demonstration that the receptor 
complex is associated with a protein kinase forming a complex capable of 
phosphorylating histones. In the presence of calcium, the receptor is phosphorylated on 
threonine residues by the protein kinase representing an ‘autophosphorylation’ reaction. 
This process may at least partly form the mechanism by which transcription is 
enhanced by corticosteroids (Bodine & Litwack, 1990).
CR dimers may mediate different effects at composite HREs an example of which is 
‘pflG’, a 25-nucleotide consisting of a low-affinity HRE and AP-1 (activating protein- 
1) binding site. The AP-1 site in this response element is capable of binding c-Fos and 
c-Jun (modulatory proto-oncogene products) homo- or heterodimers. These dimers are 
thought to form leucine ‘zipper ‘ complexes which non-covalently bring together the 
domains of the CR in a functionally active form that binds to the HRE of DNA. The 
ratio of c-Fos and c-Jun homo- or hetero-dimers formed is also a mechanism through 
which receptor activity can be selected (Miner & Yamamoto, 1991). Activated GRs can 
block c-Jun-c-Fos-enhanced transcription from the composite GRE but activated MRs 
cannot, thus conferring specificity also at this stage of the interaction (Funder, 1993). It 
is thought that transcription may be induced via the steroid activated TAF-2 (tau2) 
sequences that are brought into proximity of the transcriptional machinery by a Jun- 
Fos-mediated associated with the HRE-bound binding domain. This regulatoiy 'cross­
talk' may also occur between activated CR and other nuclear factors such as the 
CCAAT-box and CACCC-box binding proteins, nuclear factor-1, promoter selective
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transcription factor, cAMP response element binding protein (CREB) and nuclear 
factor-icB (NF-kB), interleukin-6 which may be activated by various other agents 
(neurotransmitters and other hormones).
Transactivational interactions with other transcription factors, along with modulation of 
activity through second messenger-coupled membrane receptors, are also important for 
the net result of steroids on neuronal firing. However, it is clear that the complexities of 
steroid receptor regulation in neurones serve to produce numerous very specific effects. 
Direct transcriptional regulation by CR appears to be at the level of mRNA initiation 
and does not affect the rate of transcription - which appears to be more dependent on 
the cellular concentration of the steroid-receptor complex. In addition to their direct 
effects on transcription, corticosteroids can also exert indirect and post-transcriptional 
effects (Bodine & Litwack, 1990).
Activated CR complexes can also act as repressors of transcriptional activity. This is 
thought to be conducted via a ‘steric hindrance’ mechanism. In the case of the POMC 
gene in the anterior pituitary, the activated CR-complex inhibits transcription by 
binding to a negative HRE located within the promoter region of the POMC gene. This 
DNA binding site overlaps the binding site for a putative member of the COUP- 
transcription factor group thus the receptor may inhibit transcription by preventing the 
binding of a COUP-like transcription factor to its DNA recognition sequence. Similar 
mechanisms may exist for other corticosteroid-responsive genes (Bodine & Litwack, 
1990). Following translocation and transcription (if it occurs) the steroid-receptor 
complex dissociates with the steroid being metabolised and the receptor being degraded 
down to amino acids or recycled back to a steroid-binding form.
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Figure 1.4.2.11. Model of corticosteroid receptor-activated gene expression.
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Steroids enter the cell by passive diffusion where they bind to the cognate receptor, the glucocorticoid 
receptor (GR) or the mineralocorticoid receptor (MR). This binding leads to a conformational change in 
the receptor and its dissociation from the inhibitory hetero-oligomeric structure. After intranuclear 
translocation, the MR or GR homodimers or the corticosteroid receptor (CR) heterodimer is constituted 
depending on the relative concentrations of both receptors. The different CR dimers bind to 
glucocorticoid response elements (GREs) in the flanking regions of target genes with particular DNA 
binding kinetics. Binding of the GRE leads to mRNA production and protein synthesis. The unique 
transcriptional activities and DNA-binding kinetics of the CR dimers are represented by different 
coloured arrows. The use of different genes in this illustration indicates the idea that different 
corticosteroid dimers may regulate an overlapping set of genes and activate the expression of dimer- 
specific candidate genes. The regulation of certain genes by a specific CR dimer may predominantly 
depend on dimer specific, protein-protein interactions with other transcription factors that are represented 
in this model by a DNA-binding factor X. Diagram taken from Trapp & Holsboer (1996).
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1.4.3. Regulation o f the HPA axis
i) Feedback - Like all neuroendocrine axes, the HPA axis possesses a number of sites 
of inhibitory feedback in order to maintain an intrinsic homeostatic system (Figure
1.4.Li). Feedback mechanisms of plasma corticosteroid regulate HPA activity under 
basal and stress conditions. When corticosteroid concentrations are high, CRF and 
ACTH production is suppressed thereby reducing corticosteroid secretion. Conversely, 
CRF and ACTH levels increase when corticosteroid levels are inappropriately low. 
CRF and ACTH are important control factors in HPA regulation producing activation 
of CNS function when centrally administered (Holsboer et al, 1985; Dunn et al, 1990).
Corticosteroid feedback can be conducted in a proactive (maintenance of basal HPA 
activity) or reactive (termination of stress-induced HPA adaptation) manner. 
Regulation is mediated by MR/GR and the HPA axis responds rapidly and transiently, 
via “fast feedback” mechanisms to acutely changing rates of plasma corticosteroids and 
in a “delayed” manner following chronic alterations of corticosteroid secretion (de 
Kloet, 1998).
Fast feedback sites are thought to be mainly located in the pituitary (Smelik et al, 
1977) and hippocampus (McEwen et al, 1969; Sapolsky et al, 1984a; 1994b). This 
response operates over a time scale of minutes and is proportional to the rate of change 
in plasma corticosteroids. It can be tested in humans by the suppression of plasma 
ACTH and p-endorphin/(3-lipotropin following an infusion of hydrocortisone (Young et 
al, 1991). It is thought that mechanisms for fast feedback may involve a direct 
antagonistic action of glucocorticoids on CRF binding to its pituitary receptors or 
antagonism of CRF-dependent cAMP generation in pituitary corticotrophs. In vivo 
studies however suggest that rapid feedback is probably mediated at
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hippocampal/hypothalamic sites (Sapolsky et al, 1984b). NA input also appears to be 
necessary in this type of feedback process as experiments in rats involving pre­
treatment of noradrenergic neurones with 6-hydroxydopamine (6-OHDA) demonstrate 
an inhibition of fast feedback effects of corticosterone on histamine-induced CRF 
synthesis (Stokes & Sikes, 1987). The neural pathways that mediate steroid feedback 
inhibition are not yet clear.
The delayed response is progressive, persists for as long as corticosteroid levels are 
elevated and may require adaptations at receptor level to enable the system to tolerate 
higher corticosteroid concentrations. Delayed feedback occurs over several hours and is 
proportional to the mean plasma corticosteroid concentration over that time. It can be 
tested in clinical practice by the suppression of HPA function by dexamethasone/CRF, 
a test that involves GR in the pituitary. The dexamethasone suppression test (DST) uses 
a l-2mg dose of dexamethasone orally administered around 23.00 hours, which 
suppresses cortisol secretion. A large proportion (-60%) of depressed patients exhibit 
early escape from dexamethasone suppression when tested in the morning (Carroll et 
al, 1981; Coryell, 1990). Recent modifications to this test involve the administration of 
lOOpg human CRF to subjects on the day of the test. In controls, release of ACTH and 
cortisol are prevented; however, in depressed patients, an increased secretion of ACTH 
and cortisol is observed (Heuser et al, 1994). Delayed feedback also involves 
corticosteroid action, mainly at hippocampal, hypothalamic and pituitary levels 
(Jacobson & Sapolsky, 1991; Dallman et al, 1992, Young et al, 1990).
The hippocampus exerts predominantly inhibitory influence on HPA responses to stress 
and several studies have demonstrated the inhibition of corticosteroid secretion 
following hippocampal stimulation. Experiments have also demonstrated that
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adrenalectomised (ADX), hippocampectomised rats show circadian peak plasma 
ACTH levels similar to those in adrenalectomised rats not subjected to 
hippocampectomy. Reduced efficacy of dexamethasone suppression of the 
corticosteroid response in rats is also observed following damage to the hippocampus 
or fornix (Jacobsen et al, 1991). However, lesions to the hippocampus or fornix result 
in impaired dexamethasone suppression or reduced feedback sensitivity and not 
complete resistance to corticosteroid feedback. These data suggest that the primary 
function of the hippocampus is mediation of corticosteroid feedback regardless of 
whether or not it also contributes a tonic inhibitory influence in the face of fluctuating 
corticosteroid concentrations. It also appears that the hippocampus is not the only 
regulatory site of corticosteroid feedback activity or its elimination would result in total 
corticosteroid insensitivity.
Further studies have also implicated the pituitary and parvocellular PVN as sites of 
corticosteroid feedback. It is thought that different regions may be involved with 
regulation of various levels of corticosteroids via MR and GR thus mediating context- 
dependant feedback to circuits that are activated in a stressor-specific manner. It has 
been suggested that hippocampal MR are involved in the proactive maintenance of 
basal HP A activity throughout the circadian cycle whereas corticosteroid activation of 
hippocampal GR inhibits MR-mediated inhibition of the HPA axis. Parvocellular GR 
mediate reactive feedback inhibition aimed at terminating the HPA stress response (de 
Kloet, 1998).
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ii) Circadian rhythms - Under basal conditions, regulation of the HPA axis occurs via 
circadian rhythms. The central mechanisms responsible for this are unknown but 
appear to be controlled by oscillators in the suprachiasmatic nucleus (SCN) and 
serotonergic innervations (Stokes & Sikes, 1987). There is also a circadian pattern in 
hippocampal 5-HT receptor mRNA (Holmes et al, 1997). The circadian rhythm of 
corticosteroid output roughly parallels the activity cycle, with plasma corticosteroid 
concentrations generally at their highest before waking and lowest before sleeping 
(Figurel.4.3.i.A). This cycle of corticosterone secretion is reversed in rats and mice 
(Figure 1.4.3.i.B and 1.4.3.i.C).
Basal HPA activity at the trough of the circadian cycle is thought to result from 
pituitary and adrenal secretions without hypothalamic inputs. This suggestion is based 
on observations that lesions of the basal hypothalamus, PVN or SCN do not decrease 
a.m. ACTH concentrations below their already low levels, but do prevent peak ACTH 
concentrations. Also basal corticosterone in ADX rats is indistinguishable from that of 
normal rats but peak plasma corticosterone is markedly reduced (Dallman et al, 1992). 
Regulation of HPA activity at the nadir of the cycle is achieved mostly by 
corticosteroid occupation of MR (de Kloet & Reul, 1987; Reul et al, 1987a). These 
receptors are thought to provide sufficient tonic control of HPA responses and under 
basal levels of corticosteroid output, are found to be -25% occupied (Jacobsen, 1991).
HPA activity during the peak of the rhythm is thought to require hypothalamic inputs 
that may be driven by signals from the SCN. The increased levels of corticosteroids at 
this time involve the occupation of both MR and GR in feedback control of HPA 
function (Reul et al, 1987b). Under basal conditions, GR are -10% occupied, with
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occupation increasing with rising corticosteroid concentrations which, in turn, increase 
with varying degrees of stress (Jacobsen, 1991; Reul et al, 1985).
Underlying mechanisms of circadian corticosteroid output are thought to involve steady 
MR-controlled hippocampal excitatory output during low corticosteroid levels, which 
regulates GABA-ergic tone on PVN neurones. Activation of hippocampal GR as 
plasma corticosterone concentrations increase, inhibits MR-mediated inhibition of the 
HPA axis. GR appear to be more involved with regulating peak level and also stress 
induced corticosteroid concentrations. The hippocampus is proposed as the main site 
for mediating this procedure as i) it contains both types of CR ii) lesions of this region 
have demonstrated reductions in the diumal changes in plasma corticosteroids, 
primarily by elevation of the nadir corticosteroid concentration toward that of the peak 
(De Kloet, 1987; Jacobsen et al, 1991; de Kloet, 1998).
Figure 1.43.1. Circadian rhythm of plasma cortisol/corticosterone secretion in humans (A) 
taken from Dallman et al, 1992, rats (B) and mice (C)-taken from Shimuzu et al, 1983.
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Figure 1.4.3.1 (continued). Circadian rhythm of plasma corticosterone secretion in rats (B) and 
mice (C) -  taken from Shimuzu et al\ 1983.
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iii) Neurotransmitters - Most of the putative neurotransmitters have been identified in 
the median eminence of the hypothalamus however, the specific effects of any given 
neurotransmitter on CRF/ACTH release remain controversial. Current consensus 
supports the idea of a facilitatory role for NA in the regulation of corticosteroid 
secretion (Trestman et al, 1993). Activation of the HPA response to rising 
corticosteroid concentrations may be driven by catecholamine-producing pathways that 
project directly onto CRF neurones in the PVN. These effects appear to be mediated by 
PVN a-adrenoceptors as clonidine and phenylephrine (a-adrenoceptor agonists) are 
reported to increase rat plasma corticosterone when injected directly into the PVN
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(Kovacs et al, 1993). The role of p-adrenoceptors is not clear however, the P- 
adrenergic agonist, isoproterenol, has been reported to increase corticosterone 
concentrations and propanolol has been found to block stress-induced ACTH release in 
one investigation (Saphier & Feldman, 1989). Maccari et al (1992) also found NA 
systems to influence corticosteroid receptors in a region specific manner; MR in 
hypothalamus and amygdala were reduced, whereas hypothalamic GR were increased 
following NA lesions using 6-OHDA in ADX rats.
The role of 5-HT in HPA regulation has been extensively debated, with most studies 
agreeing on an excitatory action of 5-HT on ACTH and corticosteroid secretion (Fuller, 
1981; Bruni et al, 1982; Fuller, 1992). 5-HT involvement in HPA feedback control is 
supported by observations that many HPA feedback sites express numerous 5-HT 
receptors and serotonergic projections to limbic and HPA control sites. 5-HT is also 
thought to be important in the control of the diumal cycle of ACTH secretion (Stokes & 
Sikes, 1987). ACTH and corticosterone release is found to be stimulated by 
administration of 5-HT precursors (5-HTP, L-tryptophan) and releasing agents (d,l- 
fenfluramine; Dinan, 1996a; 1996b). There is an abundance of data suggesting a role 
for 5-HTiA receptors in the regulation of corticosteroid secretion; the 5-HTia receptor 
agonist ipsapirone, induces an increase in ACTH and cortisol - this response being 
blocked by metergoline, a 5-HT%/2 antagonist (Welch et al, 1993; Dinan, 1996a; Meijer 
et al, 1998). 5-HT2 receptors are also thought to be involved in the control of HPA 
activity (Mitchell et al, 1990). Lesions of 5-HT neurones, chronic 5-HT depletion and 
inhibition of 5-HT synthesis are reported to decrease hippocampal GR binding sites and 
mRNA (Seckl et al, 1990, 1992) and increase MR binding sites and mRNA expression 
(Semont et al, 1999). 5-HT also elevates GR, but not MR in cultured hippocampal 
cells, possibly via an interaction with a 5 -HT2 receptor (Mitchell et al, 1990).
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Dopaminergic effects on HPA activity are also unclear, with investigations suggesting 
both stimulatory and inhibitory roles in the control of corticosteroid secretion (Casolini 
et al, 1993; Puri et al, 1994). The administration of corticosteroids and CRF is reported 
to increase vulnerability to the acquisition of an amphetamine self-administration task 
(Piazza et al, 1996) implicating the HPA axis with the modulation of reward systems 
which could be important in relation to anhedonic symptoms seen in depression.
Other neurotransmitters have also been implicated in HPA regulation. Cholinergic 
agonists such as carbachol and oxytremorine, have been demonstrated to stimulate 
HPA axis activity in rats, with this effect being blocked by atropine. Physostigmine, the 
cholinesterase inhibitor, has been found to increase corticosteroid secretion in rats and 
humans (Janowsky et al, 1972). These data suggest a stimulatory role of acetylcholine 
on HPA activity. Several studies support a stimulatory role for histamine on HPA 
activity. It has been suggested however, that the excitatory effects of histamine on 
secretion of corticosterone and ACTH may be due to peripheral rather than central 
mechanisms (Calagero et al, 1986; 1988b). GABAergic mechanisms are found to exert 
inhibitory effects on corticosteroid and ACTH release since the G ABA antagonists, 
picrotoxin and bicuculline both stimulate ACTH release (Calagero et al, 1988a). 
Regions associated with inhibitory pathways are reported to contain substantial 
populations of GABAergic neurones (containing G ABA), which are known to inhibit 
ACTH and corticosterone secretion. The presence of GABA-immunoreactive terminals 
on PVN neurones has also been demonstrated, implying a direct interaction between 
G ABA and the PVN.
It appears that HPA activity is controlled by a variety of neurotransmitter pathways, a 
number of which are involved in CRF secretion and terminate on hypophysiotrophic
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CRF-synthesising neurones in the PVN. One recent study has suggested that NMDA, 
GAB A -a  and |3-adrenoceptors are involved in the down-regulation of hippocampal GR 
mRNA following stress demonstrating the complexity of interactions involved (Tritos 
et al, 1999). Neurotransmitter control of the HPA axis is complex and the data 
pertaining to roles of specific neurotransmitters in HPA regulation still requires some 
clarifying. The bed nucleus of the stria terminalis (BNST) is also thought to 
communicate additional HPA excitatory information through its links with the 
amygdala and hippocampus and the hypothalamus and brainstem regions. Aminergic 
and serotonergic input to the HPA axis from the locus coeruleus and raphe nucleus 
respectively may occur via other indirect pathways as these regions are reported to have 
limited innervations of hypothalamic areas. Another recent theory postulates that the 
changes in monoaminergic pathways observed in depression may occur as a direct 
result of a hyperactivity of the HPA axis (Dinan, 1994).
iv) Stress - Stress is the primary stimulus of HPA activity. Under stressful conditions, 
CRF, ACTH and corticosteroid production is increased with the concentrations of 
corticosteroids produced generally reflecting levels of stress. Very high concentrations 
of corticosteroids may be secreted and if the response is not adequately regulated at 
primary (adrenal), secondary (pituitary) or tertiary (hypothalamic) levels, then 
physiological and psychological problems may ensue (e.g. Addison’s disease, 
Cushing’s disease, hypoadrenalism).
The HPA axis responds to stress with increased activity at any time during the 
circadian cycle of corticosteroid secretion. However, magnitudes of stress responses 
(ACTH and corticosteroid measurements) are reported to be higher during the nadir of 
the diumal cycle than those to the same stress at the peak of the rhythm (Dallman et al.
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1992). Studies by Bradbury et al {\99\) have demonstrated that this effect is not due to 
concentrations of circulating corticosterone, as there is similar stress responsiveness in 
adrenalectomised (ADX) animals thereby suggesting that this rhythm may have a 
neural basis.
Initiation of the HPA stress response could be attributed to the excitatory effects of the 
numerous neurotransmitters (especially NA) and neuropeptides on HPA activity. The 
process of maintaining corticosteroid secretion within tolerable limits appears to be 
accomplished by multiple pathways. Corticosteroid negative feedback mainly acts at 
the PVN neurone itself as demonstrated by the downregulation of CRF mRNA, 
decreased ACTH secretion and inhibition of PVN neurones following direct injections 
of corticosteroids into the PVN and also the presence of GR in hypophysiotrophioc 
PVN neurones (Herman, 1997). Inhibitory influences of corticosteroids are exerted 
primarily at the hippocampus and multiple levels of the HPA axis (i.e. the pituitary and 
adrenals). Sapolsky et al (1984b) have also reported enhanced restraint-induced 
increases in plasma corticosteroids following kainate lesions of the hippocampus in 
which at least 50% of hippocampal neurones were destroyed. This again suggests that 
the hippocampus is an important site of HPA axis feedback and plays a large role in 
termination of the stress response. However, the observation that inhibition of ACTH 
release occurs in the absence of a feedback signal suggests that there may be neuronal 
pathways involved in the regulation of HPA stress responses in addition to 
corticosteroid feedback. Lesion studies have also shown that several extrahypothalamic 
structures such as the locus coemleus, medial or cortical amygdaloid nuclei, 
(stimulation of which is found to elicit corticosterone release), lateral septum, 
prefrontal cortex and hippocampus extend neurotransmitter pathways that project 
directly onto CRF neurones in the PVN.
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The control of stress responses by the HPA system is complex and it appears that 
stress-induced regulatory feedback circuits may be stressor-specific (Jacobsen et al, 
1991; Herman, 1997). Lesions of the limbic system are demonstrated to affect HPA 
responses to restraint, novel environments and fear conditioning (all processive 
stressors), none of which pose an immediate threat to the animal’s physiology. HPA 
activation by hypoxia, respiratory, cardiovascular and immune stimuli (systemic 
stressors) are all unaffected by limbic system lesions. This has led to the proposal that 
there may be two generalised stress pathways within which there are distinct 
interactions activated by various stressors thus allowing a wide range of information 
processing mechanisms (Herman, 1997).
During chronic stress, a number of alterations take place within the HPA axis and also 
in extrahypothalamic structures which are involved in HPA regulation, with definite 
disruption of corticosteroid inhibitory feedback observed in chronically stressed 
humans and rats. This will be further discussed in the following section.
1.4.4. The HPA axis and chronic stress
In the 1930’s, Selye’s “General Adaptation Syndrome” proposed a generalised stress 
response, biologically effected principally by the corticotrophin-releasing factor (CRF) 
and locus coeruleus-noradrenaline (LC-NA) systems which became a valuable model 
linking stress with disease. Following activation of the sympathetic LC-NA system, NA 
is released resulting in enhanced arousal, cognition, vigilance, concentration and 
increased anxiety. Activation of the CRF system subsequently leads to increased heart 
rate, blood glucose and blood pressure and intraventricular injections of CRF are also 
reported to potently exaggerate behavioural responses, enhancing arousal and 
promoting cautious restraint whilst concurrently inhibiting vegetative functions such as
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feeding and reproduction (Chrousos et al, 1992). Administration of the CRF antagonist, 
a-helical CRF, reverses behaviour reflecting stress/anxiety in rats (Adamec et al, 
1993b). The LC-NA and CRF systems are closely linked with many potential sites of 
interaction. It appears that activation of one of these systems will also activate the other 
in a positive feedback loop. The application of CRF onto LC neurons markedly 
increases their firing rate, the central administration of a CRF antagonist diminishes the 
response of the LC to various stimuli while |3-adrenergic blockade attenuates the 
arousal producing effects of centrally administered CRF (Dunn et al, 1990; Chrousos et 
al, 1992).
This stress response is initiated when homeostasis is threatened. An important function 
of corticosteroid release is the counter-regulation of the effectors of the stress response 
in order to prevent its prolonged and excessive activation. This could occur possibly via 
the antagonism of CRF and the LC-NA systems directly through CR mediated increase 
in tyrosine hydroxylase in the LC or indirectly, via effects of CRF on the LC
Recent experiments in humans and animals have demonstrated that the sympathetic 
adreno-medullary / LC-NA system is preferentially activated in response to acute stress 
providing the survival aspect of the stress response. The hypothalamic-pituitary- 
adrenocortical (HPA) axis / CRF system becomes activated following prolonged 
exposure to the stressor when the subject feels a loss of control. This provides the 
conservation-withdrawal mode of stress response that is associated with helplessness 
and depression (Henry, 1993). In larger doses the central administration of CRF 
produces anxiogenic-like effects including hyper-responsiveness and freezing on 
exposure to sensory stimuli, decreased exploration in novel environments and enhanced 
fear-conditioned responses to aversive stimuli (de Boer et al, 1990; Dunn et al, 1990).
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The neuroendocrinological response to chronic stress is achieved at several levels of 
the HPA axis. Hypersecretion of corticosteroid hormones (corticosterone in the rat and 
cortisol in humans) constitutes the central drive of the HPA stress response. Consistent 
increases in corticosteroid secretion have been observed in both animals and humans 
following exposure to stress (Sapolsky et al, 1985; Linkowski et al, 1985). The 
expression of CRF/AVP and mRNA (especially in parvocellular cells of the PVN), is 
also found to be higher in stress and depression (Nemeroff et al, 1984; Raadsheer et al, 
1994; Ur et al, 1995; Schulkin et al, 1998). Chronic stress also appears to result in 
defective negative feedback in many of the stress paradigms investigated - thought to 
be due to a down-regulation of CR predominantly in the hippocampus (Young et al, 
1990; Stec et al, 1994). Hypertrophy of the adrenal glands is also commonly reported 
following most forms of chronic stress (Herman et al, 1995).
The acute stress response is normally controlled by negative feedback at various levels 
of the HPA axis (see section 1.4.1.i). In the presence of chronic stress, the increased 
secretion of corticosteroid hormones is maintained despite negative feedback control 
mechanisms, resulting in many damaging symptoms. While response to stress is a 
necessary survival mechanism, prolonged stress can have severe repercussions leading 
to enhanced neuronal cell death and resulting in a variety of cognitive defects 
(Chrousos et al, 1992 - see Table 1.4.4.1; Sapolsky, 1996). Therefore it appears that a 
balanced and well-regulated HPA system may be very important for both physiological 
and psychological stability. This is important as the syndrome of melancholic 
depression also seems to represent a dysregulated generalised stress response (Table
1.4.4.1.) -  this is discussed further in the next section.
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Table 1.4.4J. Parallels between Selye’s “General Adaptation Syndrome” and symptoms 
of depression. Modified from Gold et al (1988).
OBSERVED
ALTERATIONS
ACUTE STRESS DEPRESSION
Redirection of 
behaviour by 
the central 
nervous system
Acute facilitation of adaptive •
neural pathways
Arousal, alertness •
Increased vigilance, focused •
attention
Aggressiveness when •
appropriate
Acute inhibition of non- •
adaptive pathways 
Decreased eating •
Decreased libido and sexual •
behaviour
Appropriate caution or •
restraint
Chronic maladaptive facilitation 
of neural pathways 
Dysphoric hyper-arousal and 
anxiety
Hyper-vigilance, constricted 
focus, obsessionalism 
Assertiveness inappropriately 
restrained by anxiety 
Maladaptive inhibition of neural 
pathways 
Decreased eating 
Decreased libido and sexual 
behaviour
Excessive caution, regardless of 
context
Redirection of 
energy in the 
periphery
Oxygen and nutrients to the 
stressed body site 
Increased blood pressure, 
heart, and respiratory rates 
Increased gluconeogenesis 
Increased lipolysis 
Inhibition of programs for 
growth and reproduction 
Acute glucocorticoid- 
mediated counter-regulatory 
responses (containment) 
Restraint of corticotropin- 
releasing-hormone system 
and the pituitary-adrenal axis
Restraint of the 
norepinephrine-locus 
coemleus system 
Restraint of the expected 
immuno-logic or 
inflanunatory response_____
Oxygen and nutrients to the 
central nervous system 
Increased blood pressure, heart, 
and respiratory rates 
Increased gluconeogenesis 
Increased lipolysis 
Inhibitions of programs for 
growth and reproductions 
Chronic inadequate or 
maladaptive counter-regulatory 
responses (containment) 
Inadequate restraint of the 
corticotropin-releasing- hormone 
system and the pituitary-adrenal 
axis
Inadequate restraint of the 
norepinephrine-locus coemleus 
system
Chronic immunosuppression
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1.4.5. The HPA axis and chronic stress/depression
The acute behavioural and physiological alterations that occur during the general 
adaptive syndrome are very similar to the chronic changes observed in major 
depression with many common features appearing to be consequences of the CRF and 
locus coeruleus-NA systems (Gold et al, 1988 -  see Table 1.4.4.1). Features such as 
elevated cortisol secretion and adrenal hypertrophy (Rubin et al, 1995; Nemeroff et al, 
1992) are commonly observed in depressed subjects as well as in chronically stressed 
animals (Marti et al, 1994; Herman et al, 1995). This implies that the symptoms of 
major depression may originate from acute stress responses that are maladapted and 
have eluded the normal regulatory controls.
Maintained hypersecretion of cortisol has consistently been demonstrated in the 
majority (>50%) of patients with depression, with increased basal concentrations of 
cortisol being found in urine, plasma and CSF (Carroll et al, 1976). This is thought to 
result from defective negative feedback which is frequently measured using the DST 
(see section 1.4.3.i), a test of neuroendocrine function in which depressed patients are 
found to have an abnormal early escape of plasma cortisol during a 24 hour overnight 
dexamethasone suppression test (Carroll et al, 1981; Heuser et al, 1994). The circadian 
rhythm of cortisol secretion is disrupted in depressed patients showing increased 
magnitudes, frequency and duration of secretory episodes (Linkowski et al, 1987). 
There appears to be some conflict regarding ACTH concentrations in depressed 
patients with some studies showing elevated ACTH in depression and others reporting 
no differences between depressed and control subjects (Yerevanian et al, 1983; 
Linkowski etal, 1985).
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There is also some evidence of increased CRF neurone activation leading to increased 
CSF concentrations of CRF in depressed patients (Nemeroff et al, 1984) and an 
increased pool of CRF in the median eminence following repeated stress in rats (Inoue 
et al, 1993). Elevated CRF concentrations are thought to be, at least partly responsible 
for the hyperactivity of the HPA axis seen in depression and mediation of some 
behavioural symptoms involving sleep and appetite disturbances and changes in libido 
and psychomotor activity (Ur et al, 1995; Mitchell, 1998; Arborelius et al, 1999). One 
study has reported a reduction in the number of CRF receptors in the frontal cortex of 
suicide victims (Nemeroff et al, 1986). Increased CRF receptors have also been 
demonstrated in amygdaloid and hypothalamic regions of the rat brain following 
repeated stress (Haugher et al, 1993; Garcia-Garcia et al, 1998; Mansi et al, 1998). 
Increased numbers of CRF expressing and CRF/AVP co-expressing neurones have also 
been observed in the PVN of depressed patients (Raadsheer et al, 1994).
Disturbances in corticosterone and ACTH secretion have also been reported in some 
animal models of depression (Caimcross et al, 1977; Marcilhac et al, 1997) and in 
numerous studies involving chronically stressed animals (Sapolsky et al, 1984; 
Dallman et al, 1987; Hashimoto et al, 1988; Lachuer et al, 1994). However, several 
investigations have not detected any increases in corticosterone and ACTH in stressed 
animals thus suggesting that these responses may be stressor specific (Hashimoto et al, 
1988; Azpiroz et al, 1999). Increased CRF concentrations and expression have been 
demonstrated in the median eminence and hypothalamus following stress with reduced 
CRF receptor binding and expression after stress (Inoue et al, 1993; Plotsky et al, 1993; 
Smith era/, 1998).
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As mentioned earlier, defective negative feedback control of the HPA axis (displayed 
by DST non-suppression) is commonly observed in depression. The ACTH/p- 
endorphin test is also impaired in depression providing evidence for defective negative 
fast feedback control of the HPA axis (Young et al, 1991). Dexamethasone resistance 
has also been reported in chronically stressed animals (Brooke et al, 1994a; Barden et 
al, 1997).
Impaired negative feedback of the HPA axis, as seen in depression, has often been 
attributed to a down-regulation of brain CR. This is particularly important with regards 
to this thesis and several investigations have generated data consistent with the 
hypothesis that an altered CR function or capacity underlies the exaggerated HPA 
response in depression. Using the combined dexamethasone/CRF test, Modell et al 
(1997) demonstrated that decreased feedback control of the HPA axis in depressed 
patients was likely to be due to a failure of GR-mediated feedback action and that CR 
function is reduced in depressed patients. Investigations of CR numbers in humans 
have been inconsistent with some studies showing reductions in CR in depressed 
patients and others showing no differences between control and depressed subjects 
(using whole cell and cytosolic assays in mononuclear cells, lymphocytes and cultured 
skin fibroblasts; reviewed in Pariante et al, 1995). Post-mortem studies in suicide 
victims have also shown an altered ratio of MR/GR in the CA3 subfield of the 
hippocampus (Lopez et al, 1998). Investigations involving the measurement of CR in 
peripheral tissues (lymphoid tissue, mono- and polynuclear leukocytes) have yielded 
inconsistent data with some studies showing reductions in MR following high cortisol 
(Armanini et al, 1994) and others showing no alterations in CR binding (Wassef et al, 
1992). Investigations in rats by Spencer et al (1991), which have demonstrated that the
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regulation of GR in neuronal and lymphoid tissues is similar, do not appear to clarify 
these data.
Several animal studies have demonstrated selective decreases in GR following chronic 
stress (Sapolsky et al, 1984a; Meaney et al, 1989) and some investigations have 
demonstrated increased corticosterone secretion following the depletion of GR or the 
destmction of glucocorticoid-sensitive hippocampal neurones (Sapolsky et al, 1984b, 
1985). Brooke et al (1994) has also demonstrated that dexamethasone resistant 
primates with a history of social instability had significantly fewer available 
hippocampal GR binding sites than dexamethasone responsive animals. Sustained 
elevations of circulating corticosterone by exogenous corticosterone administration 
have also resulted in reduced CR numbers in several studies (Sapolsky et al, 1985; 
Spencer et al, 1991). Chronic, stressful stimuli have been shown to result in decreased 
GR mRNA levels in the hippocampus (Herman et al, 1995; Gomez et al, 1996; Kitraki 
etal, 1999).
It is quite possible that the primary site of action of stressful influences may be the GR 
as it is known that, in transgenic animals with disrupted GR function, a secondary HPA 
activation develops along with various feeding, cognitive and behavioural deficits. 
Transgenic mice with impaired GR function display elevated corticosterone and ACTH 
concentrations, significant dexamethasone non-suppression, reduced GR binding and 
hypertrophic adrenal glands (Pepin et al, 1992c; Stec et al, 1994; Barden etal, 1997) as 
compared to normal animals.
Chronically elevated corticosteroid concentrations result in numerous defects leading to 
neurodegeneration or suppressed neurogenesis in the hippocampus via altered
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hippocampal transmission. Pyramidal neurones in the CA3 region of the hippocampus 
appear to be particularly susceptible with some defects also reported in the CAl and 
dentate gyrus (Beck et al ,1994; Magarinos et al, 1997). An imbalanced CA3/CA1 
network may favour excitatory over inhibitory signals and lead to increased Ca^ "^  
influx, which along with elevated GR occupation, is a prominent feature of 
corticosteroid hypersecretion (de Kloet, 1998). Alterations in glutamatergic 
transmission are also observed following high corticosteroid concentrations (GR 
activation has been demonstrated with numerous other factors involved in synaptic 
transmission). Hippocampal brain-derived neurotrophic factor (BDNF) and tyrosine 
kinase B expression is reduced following exposure to corticosteroids. The activation of 
GR also alters synthesis of nerve growth factor, transforming growth factor and 
glycoprotein cell adhesion molecules (de Kloet, 1998). High corticosteroid 
concentrations may therefore exert their damaging effects via these GR-related 
mechanisms.
A key role has also recently been suggested for CRF receptors in mediation of stress 
responses following consistent demonstrations of alterations involving CRH/receptors 
(as summarised earlier -  reviewed by Mitchell, 1998). Gene targeting experiments have 
also shown that mice with dismpted CRFi receptor genes exhibit impaired stress 
responses, reduced anxiety and defective HPA axis development and activity (Smith et 
al, 1998; Timpl et al, 1998). The relationship between CRF receptors and CR is likely 
to be complicated as both are involved in feedback regulation of the HPA axis and may 
impact at several sites. Lechner et al (1999) have shown GR immunoreactivity in the 
bed nucleus of the stria terminalis (BNST) and Barrington’s nucleus, both CRF 
releasing afferents to the LC and have suggested that alterations in corticosteroid 
concentrations or GR functions may affect the activity of these CRF systems and
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ultimately LC function. These consistently observed abnormalities in HPA axis 
function have led to the proposal that these may be the primary mediators of 
monoamine and immunological disturbances in stress and depression. Some evidence 
has accumulated to support the hypothesis that activation of the HPA by chronic stress 
may, via high levels of GR on central neurones, produce changes in central 
monoamines (de Kloet etal, 1986; 1987; Dinan, 1994).
NA stimulated cAMP formation in the cortex and hippocampus is found to be 
suppressed following high corticosteroid concentrations (de Kloet et al, 1986). 
ai-Adrenoceptors in the PVN are significantly down-regulated following ADX, an 
effect which is prevented by corticosterone administration (Dinan, 1995). 
pi-Adrenergic receptors are also down-regulated by corticosteroids with a significant 
up-regulation of p2 adrenoceptors in rat C-6 glioma cell cultures (Kiely et al, 1994). 
Patients displaying dexamethasone non-suppression were also found to show a blunting 
of the NA mediated growth hormone response (Dinan, 1996a; 1996b).
5-HT turnover is significantly decreased in the hypothalamus, hippocampus and raphe 
nucleus (all target sites for corticosteroid feedback) of ADX rats; these being 
normalised by corticosterone substitution (de Kloet et al, 1991). 5- HTia receptors are 
also found to be regulated by corticosteroids (Chalmers et al, 1993) and it is possible 
that 5-HT receptor subsensitivity may be partly induced by high corticosteroid 
concentrations as demonstrated by a blunted fenfluramine stimulated prolactin 
response. Other neurotransmitter abnormalities have not been intensely investigated 
however, ACh and G ABA may also be involved and regulated to some degree by HPA 
disturbances.
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It is clear that primary reductions of CR result in elevated corticosteroids, which may 
subsequently alter corticosteroid-sensitive neurotransmitter gene expression which in 
turn, results in neurotransmitter imbalance. Corticosteroid receptors appear therefore to 
play an important role in the pathogenesis of depression and stress-related disorders. 
This idea is further supported by observations that MR/GR can be manipulated by the 
administration of various antidepressant compounds.
1.4.6. The HPA axis and antidepressants
Initial acute actions of most antidepressant dmgs involve the blocking of 
neurotransmitter reuptake or inhibition of neurotransmitter degradation. In addition to 
these activities, many antidepressant drugs are found to exert effects on HPA function. 
The primarily NA blocking drugs, desipramine (DMI) and oxaprotiline (S+ enatiomer) 
are found to activate the HPA axis, possibly via effects at ai adrenoceptors. Fluoxetine, 
a 5-HT reuptake inhibitor, is found to elevate plasma CRF concentrations in rats 
(Holsboer & Barden, 1996).
Chronic administration of various antidepressants has been demonstrated to normalise 
defective HPA activity as assessed by corticosteroid hypersecretion in depressed 
patients (Barden, 1995; Holsboer & Barden, 1996). Several animal studies also support 
this finding. Shimoda et al (1988) found that chronic administration of imipramine, 
clomipramine and desipramine suppressed plasma corticosterone release in rats. Reul et 
al (1993; 1994) demonstrated that control rats exposed to novel environment stress 
secreted more ACTH and corticosterone than rats receiving amitriptyline or 
moclobemide prior to exposure. Chronic administration of tianeptine, a novel 
antidepressant, attenuated HPA activation in stressed animals by inducing a decrease in 
plasma ACTH and corticosterone levels, along with significant reductions in CRF
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concentrations in the hypothalamus (Delbende et al, 1994). Long term administration 
of imipramine is also reported to reduce CRF mRNA levels in the PVN (Brady et al, 
1991). In parallel with these findings, CRF binding capacity in the anterior pituitary is 
reduced following long term antidepressant administration (Reul et al, 1994).
Administration of antidepressants may attenuate HPA hyperactivity by normalising the 
defective negative feedback observed in depression. Many patients who are non­
suppressors in the DST or dexamethasone-CRF test display dexamethasone suppression 
after being given long-term antidepressant treatment (Holsboer & Barden 1996). 
Concentrations of CRF in CSF are also reduced following antidepressant 
administration (Holsboer & Barden, 1996). These results suggest that the long term 
administration of antidepressants may suppress the HPA system thereby raising the 
possibility that lowered HPA activity and a clinical response are causally related. 
Antidepressant effects on some neuroendocrine parameters can be seen within minutes 
of their administration. Torres et al (1998) showed that fluoxetine induced CRF and 
CRFi receptor mRNA expression 30 minutes after administration. However the clinical 
effects of antidepressants are not usually observed for 2 weeks or more therefore 
suggesting that the acute effects of antidepressant administration such as inhibition of 
neurotransmitter reuptake may constitute the start of a cascade resulting in the lowered 
HPA activity. The time course of CR changes following antidepressant treatment in 
many previous animal studies is found to be similar to that of onset of therapeutic 
changes (Reul et al, 1993; 1994) indicating that regulation of CR may form at least 
partly, the mechanism by which antidepressant compounds exert their clinical effects.
A number of studies have investigated the effect of repeated administration of various 
antidepressant drugs on CR binding and expression. Kitayama et al (1988) found
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increased brain GR immunoreactivity after chronic administration of imipramine. 
Chronic (over two weeks) exposure to various antidepressants (amitriptyline, 
moclobemide, imipramine, maprotiline) has been reported to increase MR and GR 
binding activity, mostly in rat hippocampal and hypothalamic regions (Reul etal, 1993; 
Reul et al, 1994; Budziszewska et al, 1994a; 1994b; Okugawa et al, 1999). The 
expression of GR and MR mRNA in rat brain and cell cultures is also found to be 
enhanced following long-term administration of the antidepressants imipramine, 
amitriptyline, desipramine, citalopram and maprotiline (Pepin et al, 1989; Peiffer et al, 
1991; Seckl & Fink, 1992; Pepin et al, 1992a; Barden, 1996 and Pariante et al, 1997). 
GR gene promoter activity in cell cultures is also stimulated by antidepressants (Pepin 
et al, 1992a, Okugawa et al, 1999) and a number of different antidepressants are found 
to modulate this receptor in vivo (Peiffer et al, 1991).
Barden et al (1995) suggested that antidepressants may aid in the maintenance of GR 
function in NA and 5-HT containing cell groups, an interesting hypothesis as the 
hippocampus, intricately involved in stress and depression related symptoms, receives 
ample NA and 5-HT innervations. A possible mechanism for this may involve the 
antidepressant-induced modulation of GR gene expression, which as a primary effect of 
antidepressant action would result in decreased HPA activity including a reduction in 
CRF gene expression. Secondary effects would therefore occur as a result of reduced 
corticosteroid concentrations and be exerted on corticosteroid-sensitive processes, such 
as neurotransmitter biosynthesis, leading to more balanced neurotransmitter processes. 
(Figure 1.4.6.i).
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Figure I.4.6.I. Antidepressant induced increases in glucocorticoid receptor (GR) and m ineralocorticoid 
receptor (M R) gene expression suggest a novel m echanism o f action of these drugs on the hypothalam ic- 
pituitary-adrenocortical (HPA) system. This figure shows stimulatory (-t-) and inhibitory (-) actions of 
neural inputs to brain regions involved in H PA  regulation and to sites o f corticosteroid retroinhibition. 
Arrows indicate the sites at which antidepressants can have stimulatory actions on GR and M R. Taken 
from Barden et al (1995).
The recent development of transgenic mice with primary G R defects has been 
extremely useful in elucidating HPA and related antidepressant mechanism s in stress 
and depression (Pepin et al, 1992b; Barden, 1996). Transgenic mice display higher 
ACTH and corticosterone levels, decreased GR mRNA and num erous behavioural 
deficits (Pepin et al, 1992b; 1992c; Stec et al, 1994) which are norm alised following 
antidepressant administration and appear to be a valid model for the 
neuroendocrinological disturbances seen in depression. However, the evidence is not 
entirely consistent, due to difficulties in attem pting to establish clinically relevant 
effects in laboratory animals.
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Many aspects of neuroendocrine dysfunction following stress and anxiety can be 
investigated via animal behaviour and biochemical procedures. One of the most 
problematic aspects of researching depressive syndromes however, is the lack of 
appropriate models on which to test various hypotheses -  many of which are extended 
theories of drug action and as such, do not provide any solid evidence. Also, much of 
the clinical evidence gathered is from tissues taken from suicide victims and may be 
subject to artefacts resulting from death. As a result, investigations involving the 
simulation of depressive symptoms in animals have become increasingly important in 
studying the psychobiology of depression in humans.
1.5. Animal models of depression
Recently, there has been a major expansion in the number of behavioural paradigms 
being proposed as animal models of depression. This situation has evolved through two 
main observations. Firstly, that there may be environmental précipitants to depression -  
which has subsequently led to the use of animal models to determine the relationship 
between anxiety, stress and depression. Many of the animal models being used to study 
depression today include a strong stress component, e.g. learned helplessness (King et 
al, 1993), behavioural despair (Porsolt et al, 1977; 1978; Hansen et al, 1997), chronic 
mild stress (Willner et al, 1992). Secondly, the potentially significant effects of chronic 
antidepressant administration on various biochemical parameters have also resulted in 
an increased number of studies correlating these with changes in behaviour that may 
follow a similar course. The greatest contribution of animal models at present lies in the 
investigation of the mechanism of action of antidepressant drugs. The chronic 
administration of antidepressants causes a variety of changes in the functioning of 
neuronal systems (as discussed earlier) and animal models can be used to establish the 
significance of these changes.
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Several symptoms of depression, excluding subjective feelings such as dysphoric 
mood, feelings of guilt and thoughts of suicide, can be translated into measurable 
behaviours. Psychomotor changes, agitation or retardation are well documented 
symptoms of stress and depression and can be measured with relative ease in animals. 
Loss of motivation, or insensitivity to rewards (anhedonia) is a major feature of 
endogenous depression that has been successfully simulated in a number of behavioural 
paradigms. These are central features of depression which have been simulated and 
measured in a number of animal models of depression and which form the basis of the 
animal model investigations in this thesis. Other features that have been studied include 
learning deficits, decreased persistence, decreased sexual activity and disturbed sleep or 
food intake.
The validity of the model is an important consideration when attempting to simulate 
human syndromes in a different species (Willner, 1991a; 1991b), this generally being 
assessed on the following groups of relatively independent criteria. Face validity refers 
to the degree of symptomatic resemblance between the model and the clinical 
condition. Predictive validity is primarily concerned with correspondence between drug 
actions in the model and in the disorder and finally, construct validity addresses the 
theoretical rationale of the model. Very few animal models display strong validity in all 
three of theses areas and the presence of a number of other features in the model are 
also desirable such as the modelling of an appropriate core symptom or the 
demonstration of a number of core features of the disorder. A realistic method of 
inducing symptoms and responsiveness to antidepressant treatment, preferably over a 
prolonged time course is also desirable.
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Animal models have been used during the course of this thesis to investigate the effects 
of various antidepressants on a number of behavioural parameters. In the context of 
studying the mechanisms of action of antidepressant drugs, the use of animal models in 
this thesis is required in order to investigate the changes, if any, in HPA function in 
these animal simulations of depressive symptoms. The large number of proposed 
animal models of depression have been the subject of a number of reviews (Jesberger 
& Richardson, 1985; Willner, 1991a; 1991b, Kelly et al, 1995) however for the 
purposes of this thesis, we will consider the relevance of two of these models in detail.
The olfactory bulbectomised rat model of depression makes use of surgical lesioning to 
induce a depression-like syndrome in rats. This model exhibits a number of the 
characteristics required of an appropriate model of depression and has received much 
attention as a model with which to screen compounds for potential antidepressant 
activity (Jesberger & Richardson, 1985; Van Riezen & Leonard, 1990). The 
bulbectomised rat, which possesses reasonable face and predictive validity displays 
many of the behavioural, neurochemical and immunological changes associated with 
depressed patients (see Table 1.6. Li). There is an abundance of experimental evidence 
to suggest that the olfactory bulbectomised rat may fulfil many of the criteria required 
of an animal model of depression (Chapter 4).
The induction of stress responses in animals by various means has provided a basis for 
many models of anxiety and depression and many behavioural paradigms being 
proposed as animal models of depression involve the long term exposure to one or 
more stress inducing stimuli. Recent investigations have involved the exposure of 
animals to a predator or its odour and have shown that this exposure can result in 
numerous behavioural and neurochemical stress responses in various species (File,
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1996). The proposed predator stress “model” is a relatively recent behavioural 
paradigm and possesses strong construct validity. There is some evidence that this 
paradigm may also display some face and predictive validity as a model of 
stress/depression however, given that this paradigm has not yet been established, much 
work is required to clarify its status as a model for depression (Chapters 5 and 6).
Table 1.6.1.:. Similarities between depressed patients and rats subjected to 
olfactory bulbectomy and predator stress
(partly adapted from Jesberger & Richardson, 1988).
Depressed patient Olfactory bulbectomised rat Predator stress
Changes in appetite and 
weight loss
Loss of interest in sexual 
activity
Disturbed sleep patterns 
Cognitive deficits
Agitated and irritable
Inability to experience 
pleasure
Altered functioning of NA, 5- 
HT, GABAergic, cholinergic 
and other neurotransmitter 
systems
Hyperactivity of the HPA- 
axis. Increased plasma cortisol 
levels.
Immune system alterations 
including reduced lymphocyte 
and neutrophil phagocytosis. 
Increased neutrophils and 
acute phase proteins
Respond to chronic 
antidepressant therapy
Abnormal daily eating pattern and 
reduced weight gain. Impaired 
food-motivated behaviour
Abnormal lordosis and other 
sexual behaviour
Abnormal sleep patterns
Impairments in avoidance and 
spatial tasks and food motivated 
behaviours
Hyperactive, reactive, increased 
aggression and nuricide
Anhedonic responses - Deficits in 
behavioural tasks involving 
positive reinforcement
Neurochemical disturbances 
including abnormal NA, 5-HT, 
GABAergic and cholinergic 
systems.
HPA-axis disturbances evident. 
Increased plasma corticosterone 
levels reported.
Immunological abnormalities 
include decreased lymphocyte and 
neutrophil phagocytosis. Increased 
neutrophils and acute phase 
proteins
Respond to chronic, not acute, 
antidepressant administration
Reduced growth. 
Reduced appetite.
Not yet determined.
Not yet determined.
Impaired risk assessment 
behaviour.
Increased proxemic avoidance 
behaviour.
Altered activity patterns.
Not yet determined.
Altered functioning of GAB A, 
benzodiazepine and 5-HT 
systems.
HPA axis activity increased. 
Increased corticosterone,
ACTH and CRH concentrations 
reported.
Not yet determined.
Reduction of stress-induced 
behaviours by chronic 
antidepressant administration.
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1.6. Objectives of this thesis
Several different types of antidepressants have been demonstrated to increase CR 
binding and mRNA in various regions of the rat brain over a period similar to the time 
course in which therapeutic effects are observed in depressed. For this reason, it has 
been suggested that the up-regulation of CR, thus normalising defective HPA activity, 
may be a mechanism common to the different classes of compounds used in the therapy 
of depression.
Many studies have investigated CR alterations following acute or repeated stress 
procedures and/or antidepressant administration in adrenalectomised, ‘naïve’ animals 
yet little attention has been given to any possible changes in CR in intact animals 
and/or in established and proposed animal models of depression. Given the features of 
the OB rat model of depression (chapter 4), it could be expected that a dysfunctional 
HPA axis as reflected by defective negative feedback resulting from stress-induced CR 
down-regulation would be observed. As yet, no CR measurements have been 
performed in the OB rat. The predator stress paradigm has not been studied or 
developed to the extent that the OB rat has, therefore requires substantial behavioural 
and endocrinological investigations (chapter 5 and 6).
The work presented in this thesis is primarily concerned with the monitoring of plasma 
corticosterone and corticosteroid receptor alterations under various stress situations and 
following administration of a variety of antidepressant drugs. CR were quantified using 
radioligand-binding assays and plasma corticosterone measured using high 
performance liquid chromatography or radioimmunoassay.
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Attempts were also made to compare endocrinological measures of plasma 
corticosterone and CR with behavioural parameters (locomotor activity and/or 
anhedonia) as measured in the olfactory bulbectomised rat, and a stress-related 
paradigm comprised of predator stress exposure. Therefore the objectives of this work 
were;
i) to investigate the effects of administration of various antidepressants (in rats)
on plasma corticosterone secretion and CR binding in various brain regions and 
peripheral tissues of intact rats.
ii) to examine the effects of olfactory bulbectomy on locomotor activity and brain
corticosteroid receptor binding in rats. The effects of administration of various 
antidepressant dmgs on locomotor activity and CR binding were also 
investigated.
iii) to establish a behavioural paradigm based on predator stress which could be
expanded to a potential model for chronic stress/depression.
iv) to determine the effects of predator stress and administration of various
antidepressants on locomotor activity and anhedonic measures in mice. Effects 
of predator stress and antidepressant administration were also investigated on 
plasma corticosterone and corticosteroid receptor binding in various brain 
regions.
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CHAPTER 2
GENERAL METHODS
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2.1. Introduction
This initial experimental chapter describes the basic procedures for performing the 
corticosteroid receptor (CR) radioligand binding assay used extensively throughout this 
thesis. The definition of optimal assay conditions and investigation of some established 
receptor binding criteria are also described. The aim of this chapter is to demonstrate 
that the specific binding of ^H-dexamethasone to sites in rat brain tissue preparations 
fulfils the necessary binding criteria and generates reliable data.
2.2. Introduction to radioligand binding studies
Prior to the widespread use of in vitro binding assays, the properties of receptors were 
inferred from the measurement of biological responses. The utilisation of radioligand 
binding assays to characterise receptors provides an enormous amount of information 
and also a direct approach to the study of drug-receptor interactions.
2.2.1. Basic criteria for receptor binding studies
Radioligands provide precise probes that allow the specific investigation of the 
interactions between a drug and its binding site. Usually, ligands that exhibit a high 
selectivity and affinity for the receptor system being studied are chosen for binding 
assays.
An essential initial undertaking when performing binding assays is to establish the 
nature of the site in the tissue preparation to which the radioligand is binding. The 
hypothesis that a given binding site represents the receptor for the particular radioactive 
ligand employed for the assay can be substantiated by fulfilling a number of important 
criteria. Some of these criteria (which are discussed in greater detail in the appropriate 
sections) include;
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1) saturability of the binding of radioligand to the site of interest (see section 2.4).
2) investigations of the pharmacology of binding between the radioligand and binding 
site via competition by non-radioactive drugs (see section 2.5).
3) the establishment of a linear relationship between tissue concentration and the 
number of binding sites (see section 2.6).
4) temperature dependence of radioligand binding (see section 2.7).
5) kinetics (association and dissociation) of binding of the radioligand (see section
These criteria were experimentally tested and attempts were made to establish i) the site 
to which the radioligand was binding as a pharmacological or physiological receptor 
and ii) the optimal conditions for binding of the ligand to the receptor. This was 
achieved through the combined use of published information and methodology 
developed in our own laboratory.
2.2.2. Receptor binding assay procedure
Tissue preparations containing the receptor of interest are incubated to equilibrium with 
one or more concentrations of the appropriate radioligand. Separation of the bound 
from free ligand is dependent on the equilibrium dissociation constant (Æg) of the 
radioligand for the binding site. For ligands with Æo values of lO’^ M or less, the rapid 
vacuum filtration method is generally most appropriate whereas for ligands with higher 
Æo values, separation by centrifugation, column chromatography and precipitation of 
ligand-receptor complex and adsorption of free ligand techniques are applied 
(Yamamura, 1990; Bylund, 1992). Measurement of the bound radioactivity trapped on 
the filter following the separation is by liquid scintillation counting.
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The radioactivity bound to the filter is termed the total binding. This consists of:
i) specific receptor binding - radioligand bound to its binding site on the receptor 
of interest and;
ii) non-specific binding - radioligand bound to other non-receptor components in 
the tissue preparation (e.g. membrane proteins and lipids, glass fibre filters).
The non-specific component of this binding can be measured by the inclusion of 
parallel samples of a non-radioactive compound that is known to interact with the 
receptor system under investigation at a concentration sufficient to totally displace the 
radioligand from specific binding sites.
The two main types of radioligand experiments 1) saturation experiments and 2) 
competition experiments are described in detail following a general description of the 
CR assay (sections 2.4 and 2.5 respectively).
2.2.3. Additional CR binding experiments
Various other preliminary CR binding experiments were carried out to investigate 
practical considerations relating to future studies. These studies are presented 
individually in this chapter along with results and analysis of data.
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2.3. Corticosteroid receptor binding assay using rat brain tissues
2.3.1, Animal husbandry
Experiments were carried out using male Sprague-Dawley rats (body weight 200 - 
250g). Animals were housed 4 per cage (45cm x 25cm x 20cm) and maintained in a 
temperature (19-22°C) and light (light period 07.00-21.00 hours) controlled room. A 
standard laboratory diet and drinking water were available ad libitum.
2.3.2 Dissection o f rat brain regions
All sacrifice and dissection procedures were conducted between 09.00 -  ll.OOhrs, a 
time when plasma corticosterone concentrations were low (see Figure 1.4.3.B). Rats 
were killed by cervical dislocation and decapitation. Trunk blood was collected in 
plastic Falcon tubes and prepared for serum extraction (as described in section 3.2.4). 
The brain was rapidly removed from the skull and placed on an iced glass plate prior to 
blunt dissection procedures. Cortical tissue was used for all experiments in this chapter 
except those investigating the effect of freezing on the binding parameters of 
corticosteroid receptors in the hippocampus (section 2.9). Blunt curved iris forceps 
were used to separate the cortices and layer them to either side of the mid-line. The 
clearly visible striata were pinched out with the forceps. The hippocampal and 
amygdala regions were then excised from the brain followed by the cortices and 
hypothalamus. Brain regions were immediately placed in cryovials, frozen on dry ice 
and stored at -70°C, or prepared directly for the assay (as required for the experiments). 
The distribution of corticosteroid receptors in a peripheral tissue, the thymus, was also 
investigated in some experiments, therefore this organ was also dissected from the body 
cavity of the animal.
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2.3.3 Radioactive ligand
^H-Dexamethasone (specific activity 8 1 - 8 9  Ci/mmol) was obtained from Amersham 
International Pic. The ligand was kept at -20°C and diluted to the required 
concentrations with incubation buffer on the day of the experiment.
2.3.4 Buffers
For list of drugs and chemicals (and suppliers), see Appendix 2.3.1. All buffers for the 
receptor binding assays were made up in distilled water. The required pH at 20°C was 
achieved by using 6M HCl (hydrochloric acid) for all the buffers. The buffers were 
kept at 4°C or on ice throughout the experiments.
i) Incubation buffer (pH 7.4):
Component (final assay concentration)
lOmM Tris
ImM EDTA (disodium salt)
35mM Sodium molybdate
ImM Dithiothreitol
10% Glycerol
Wash buffer (pH 7.4):
lOmM Tris-HCl buffer
2.3.5 Tissue Preparation
Cortical tissue was homogenised in 20 volumes (v/w) of ice-cold incubation buffer (pH 
7.4) using a motor driven Teflon pestle (Heidolph R2R2050, LabPlant, U.K.) and glass 
homogeniser (10 slow up/down strokes at 1400rpm). The resulting homogenate was
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centrifuged at 105,000g for 60 minutes at 4°C in a Beckman L-70 Ultracentrifuge 
(Beckman Instmments, Beckman Instruments Inc, U.S.A.) fitted with a 70.1Ti rotor. 
Tissue supernatant was immediately decanted and stored on ice until required for assay.
2.3.6 CR binding assay incubation procedure (general)
All assays were performed in lOmL borosilicate test tubes (16mm x 16mm x 100mm) 
which were maintained on ice throughout the assay procedure. The total incubation 
volume for the assay was 250jiL consisting of:
i. lOOjxL of tissue cytosolic preparation (equivalent to 5mg wet weight of the original 
tissue)
ii. lOOjiL of ^ H-dexamethasone solution (0.625-20nM final assay concentration)
iii. 50|xL displacing compound (at a range of concentrations) or 10% EtOH (the diluent 
for the displacing compound)
Total binding containing the tissue preparation, ^H-dexamethasone and 10% EtOH 
was determined in duplicate.
Non-specific binding containing the tissue preparation, ^H-dexamethasone and the 
displacing agent was determined singly or in duplicate.
^H-dexamethasone standards were prepared, in duplicate, on each experimental day 
and counted to determine the total assay concentration of radioligand.
The assay was initiated by the addition of tissue supernatant following which the tubes 
were thoroughly mixed and placed in a refrigerator, at 4°C, for approximately 24 hours 
(20-26 hours). Tissue supernatant was also stored at -70°C for subsequent protein 
determination using the method of Lowry (Lowry et al, 1951).
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2.3.7 Separation o f bound and free radioligand
The assay was terminated by rapid filtration under vacuum (600mm Hg) through 
Whatman glass fibre GF/F filter strips (Whatman International Ltd, U.K.), which had 
been pre-treated for approximately 24 hours with 0.3% polyethylenimine (PEI), using a 
Brandel Cell Harvester (Semat Technical Ltd, U.K.). The filters were quickly washed 
with 16mL of ice-cold lOmM Tris-HCl wash buffer (pH 7.4). This minimised the 
amount of non-specific binding bound to the glass fibre filters. The procedure of 
filtration and washing was conducted over approximately 15 seconds.
2.3.8 Determination o f radioactivity and scintillation counting
The glass fibre filters were cut out of the strips and placed into individual lOmL plastic 
scintillation vials. 6mL of scintillation fluid (Optiphase Safe, Wallac, U.K) was added 
and the vials capped and shaken for 1-2 hours before being transferred to the liquid 
scintillation counter (2200CA Tri-Carb LSC, Packard Instruments, U.K.) for the 
determination of radioactivity.
2.3.9 ^H~dexamethasone standards
The amount of radioligand added to the assay on each experimental day was 
determined by the inclusion of standards. These consisted of lOOjiL aliquots of each 
concentration of ^H-dexamethasone used in the assay and were used for subsequent 
calculations.
2.3.10. Calculations and analysis o f results
Analysis of the data generated using different types of radioligand binding experiments 
is detailed in the appropriate sections.
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2.4. Determination of the saturability of ^H-dexamethasone binding to rat cortical 
cytosolic preparations
2.4.1. Introduction
Saturation experiments investigate the specific binding of ligand to the receptor at 
various concentrations of radioligand to obtain estimates for Bmax (a measure of the 
receptor concentration in the sample) and Kd (the equilibrium dissociation constant). 
One of the most important and relevant uses of Bmax and Kd determinations by 
saturation binding studies is the estimation of changes in receptor concentration and 
affinity in disease or following pharmacological or other experimental interventions.
This section aims to demonstrate that the CR assay method used in the present 
experiments generates reliable saturation binding data relating to the specific binding of 
^H-dexamethasone to rat cytosolic tissue preparations.
2.4.2. Methods
Assay procedures were carried out as described in section 2.3. Binding was determined 
at a range of ^H-dexamethasone concentrations (0.625-20nM). Specific binding was 
defined in the presence of 5|xM hydrocortisone.
2.4.3. Calculations and analysis o f results
Radioactivity from saturation experiments (in dpm) was converted to the appropriate 
units (^H-dexamethasone standards to nM, and TB and NSB incubations to 
fmoles/assay). Mean values were obtained from the replicate determinations of TB and 
NSB following which specific ^H-dexamethasone binding was calculated by 
subtracting NSB values from TB values.
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The converted data were subjected to non-linear regression analysis (GraphPad Prism 
v2.1) to give estimates of Bmax and Kd following which, Bmax values were converted to 
fmoles/mg protein using protein values determined for each of the samples. For the 
preliminary saturation experiments, the data were also displayed as Scatchard plots 
with subsequent linear regression analysis, visual inspection of which provided some 
indication as to whether the ligand-receptor interaction being studied was described 
adequately by a simple bimolecular reaction. Hill plots of the saturation data enabled 
the quantitation of deviation of the ligand-receptor interaction from the law of mass 
action. Differences in binding constants between groups were determined using 
Students t-test or ANOVA with a significance level set at p<0.05.
2.4.4. Results
Figure 2.4.1(A) shows a typical saturation plot of ^H-dexamethasone binding. The non­
specific binding of ^H-dexamethasone in rat tissue preparations increased linearly over 
the ligand concentrations 0.625-20nM. The total and specific binding (defined using 
5pM hydrocortisone) of ^H-dexamethasone appeared to saturate at the higher ligand 
concentrations.
Non-linear regression analysis yielded a Bmax value of 23.6 fmol/assay, equivalent to a 
Bmax of 171 fmol/mg protein. A Kd value of 2.41 nM was obtained from this plot.
Figure 2.4.1(B) shows a Scatchard plot of the data in Figure 2.4.1(A) with subsequent 
linear regression analysis resulting in a Bmax of 23.5 fmol/assay equivalent to a Bmax of 
170 fmol/mg protein and a Kd of 2.17 nM.
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Figure 2.4.1(C) shows a Hill plot of the saturation data from Figures 2.4.1(A) and 
2.4.1(B). A Hill coefficient (ny) of 1.23 ± 0.21 was obtained from this plot.
The results of several saturation assays are shown in Table 2.4.1. Non-linear regression 
analysis using a one-site binding model resulted in similar values for binding 
parameters as Scatchard analysis. Statistical analysis of the data, using t-tests showed 
no significant differences between Bmax values estimated by non-linear regression and 
those estimated by Scatchard analysis (whether expressed in fmol/mg tissue or fmol/mg 
protein). One-way analysis of variance of the Kd data showed no significant 
differences in Kd values when calculated using non-linear regression, Scatchard or Hill 
analysis.
The mean Bmax value calculated from these experiments (using non-linear regression 
analysis) was 139 ± 12 fmol/mg protein and the mean Kd value calculated was 2.15 ± 
0.38 nM.
Figure 2.4.1.
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CR binding assays were carried out as 
described in section 2.4. Data represent the 
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duplicate. At a ligand concentration of 3nM, 
mean (± SD) values for bound in dpm were;
Total binding = 2348 ± 52
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Binding parameters (B^ax and Kd) were 
calculated using linear regression analysis. 
Values obtained were;
Bmax= 23.5 fmol/assay
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K d = 2.17 nM
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Table 2.4.1.
Binding parameters obtained from several preliminary saturation experiments 
conducted in rat cortical tissue preparations (Bmax is expressed as femtomoles per mg 
protein and per mg tissue wet weight) using;
1) non-linear regression analysis
2) linear regression analysis subsequent to Scatchard transformation
3) Hill analysis
NON-LINEAR REGRESSION ANALYSIS SCATCHARD ANALYSIS fflL L
ANALYSIS
Bmax Bmax Kjy fimax Bmax Kjy
(fm ol/m e (fmol/me (nM ) (fm ol/m e (fm ol/me (nM) (nM )
tissue) protein) tissue) protein)
Mean 3.6 ±  0.42 139 ±12 2.15 ±0.38 3.98 ±0.53 154 ± 18 2.08 ±0.33 2.05 ±  0.29
+ sem
(n=12) (n=12) (n=12) (n=12) (n=12) (n=12) (n=12)
Data is expressed as mean ± sem for each of the parameters obtained. No statistically 
significant differences were found between binding parameters obtained using non­
linear regression, Scatchard or Hill analysis using t-tests or one-way ANOVA at a 
significance level of p<0.05 (GraphPad Prism v3.0). ANOVA: CR {log Kd) F (2, 35) = 
0.083, p>0.05.
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2.5. Selective displacement of ^H-dexamethasone binding to rat cytosolic 
preparations using competition binding assays
2.5.1. Introduction
Competition experiments are important in defining the pharmacology of the binding 
between the ligand and the receptor. Given a single radioligand whose affinity for a 
particular receptor subtype has been established, radioligand competition assays 
provide a means for determining the binding affinity of any other unlabelled compound 
for the same receptor. Applications of the radioligand competition experiment include 
the validation of assays, screening for identification of ligands for a particular receptor, 
investigation of the interactions of various compounds with receptors and the 
determination of receptor density and affinity by use of the same compound as the 
labelled and unlabelled ligand. Competition experiments measure the binding of a 
single concentration of radiolabelled ligand in the presence of various concentrations of 
unlabelled ligands. The generation of an inhibitory constant, IC50 (concentration of 
unlabelled drug that results in 50% displacement of specific binding) or K, (affinity of 
the competing compound for the receptor) value is generally the purpose of performing 
displacement binding assays.
2.5.2. Methods
All assay procedures were carried out as described in section 2.3. Competition studies 
were carried out at a single concentration of 3nM ^H-dexamethasone. Compounds 
being tested for competition were added in concentrations ranging from 5x10'^^ to 
5xlO'^M. Specific binding was defined using 5|LlM hydrocortisone. The compounds 
tested for displacement of ^H-dexamethasone binding to CR were RU28362, 
dexamethasone, corticosterone, hydrocortisone, aldosterone and ethanol.
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2.5.5. Calculations and analysis o f results
Mean values were calculated from the replicates and converted to % specific binding. 
100% and 0% specific binding was equivalent to the amount of ^H-dexamethasone 
binding displaced in the absence and presence of 5(iM hydrocortisone, respectively. 
Competing drugs were tested over a range of concentrations for their capacity to 
compete for this specific binding. The data was plotted on a semilogarithmic plot 
resulting in a displacement curve and an IC5 0 value was determined by non-linear 
regression analysis (GraphPad Prism v3.0). This was subsequently used to calculate the 
inhibition constant (Ki) for each unlabelled compound using the equation of Cheng and 
Prusoff (1973). Ki values are expressed in Table 2.5.1 as geometric means of several 
determinations as, due to the log-normal distribution of drug affinities, these appear to 
be best described in this manner rather than by using arithmetic means (Hancock et al,
1988).
2.5.4. Results
Table 2.5.1 summarises the competition experiments for each compound tested while 
Figure 2.5.1 displays representative competition experiments for each compound. All 
of the steroids tested competed for specific ^H-dexamethasone binding to rat cytosolic 
fractions in a concentration-dependent manner. The affinity of competitors for ^H- 
dexamethasone binding to CR ranged from 0.018 -  6.03nM with the following rank 
order of potency; RU28362 > dexamethasone > corticosterone > hydrocortisone > 
aldosterone. There was no displacement of specific binding by EtOH.
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Table 2.5.1.
Displacement of specific ^ H-dexamethasone binding to CR in rat cytosolic preparations by 
RU 28362, dexamethasone, corticosterone, hydrocortisone, aldosterone and ethanol.
Summary of values obtained from experiments testing the displacement of specific ^H- 
dexamethasone binding to CR in rat cytosolic preparations by various compounds. Data from 
four independent experiments conducted on separate occasions were fitted to one-site 
competition curves resulting in estimations of IC5 0  (concentration of unlabelled compound 
which causes 50% displacement of maximal binding) from which Kj (affinity of the competing 
compound for the receptor) was calculated using the Cheng-Prusoff equation for each 
compound. The K d value of ^H-dexamethasone binding obtained in parallel saturation 
experiments used in these calculations was 2.5nM. Ki is expressed as a geometric mean with 
numbers in parentheses indicating the range for each value.
COMPOUND TESTED FOR 
DISPLACEMENT
K,
(nM)
RU 28362 0.018 (0.0068 -  0.049)
Dexamethasone 0.87 (0 .48-1 .58)
Corticosterone 3.16 (1.15-8.69)
Hydrocortisone 4.83 (2 .06-11.32)
Aldosterone 6.03 (3 .23-11 .2)
EtOH -
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Figure 2.5.1.
Displacement of specific ^H-dexamethasone binding from CR in rat cytosolic preparations 
by RU28362 (A), dexamethasone (B), corticosterone (C), hydrocortisone (D), aldosterone 
(E) and EtOH (F). Rat cytosolic fractions were prepared as described in section 2.5,2. Data 
shown is from a single experiment.
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2.6. Determination of the relationship between specific ^H-dexamethasone binding 
and concentration of rat cortical cytosol tissue
2.6.1. Introduction
The establishment of a linear relationship between specific binding and tissue 
concentration in binding experiments is important to demonstrate the absence of 
artefacts in the assay (such as receptor or ligand degradation, the presence of 
unrecognised endogenous ligands) thus ensuring the accurate estimation of binding 
parameters. The tissue dilution used in the assay must also yield measurable specific 
binding values which give a good ‘experimental gate’ to work with. In order to prevent 
the above problems, the tissue concentration used in the assay should bind no more 
than 10% of the added radioligand.
2.6.2. Methods
Rat cortical cytosol fractions were prepared as described in section 2.3.5 except that 
cortical tissue was homogenised in 1:5 w/v of incubation buffer and following 
centrifugation, the tissue supernatant was diluted to the required concentration. All 
other assay procedures were carried out as described in section 2.3.
2.6.3. Calculations and analysis
The specific binding of ^H-dexamethasone to CR in the cytosol preparation was 
calculated by subtracting NSB from TB and plotted against tissue concentration. Linear 
regression analysis was performed (using GraphPad Prism v3.0) to determine the 
effects of tissue concentration on the specific binding of ^ H-dexamethasone.
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2.6.4. Results
Specific binding of ^H-dexamethasone increased linearly with increasing tissue 
concentration (Figure 2.6.1). The values of specific binding observed at tissue 
concentrations of 5 and 3.3 mg wet weight original tissue were 1523 and 962 dpm 
(corresponding to 9.3 and 8.8 fmol/mg protein) respectively, thus giving measurable 
values for the specific binding of ^H-dexamethasone at these concentrations of tissue. 
The mean values for added ^H-dexamethasone in these experiments was 175990 ± 6101 
dpm at 3nM of ^H-dexamethasone and the amount of radioactivity bound expressed as 
a percentage of added radioactivity was approximately 1%.
FIGURE 2.6.1.
The effect of tissue concentration on specific binding of ^H-dexamethasone binding 
to CR in rat cortical cytosolic preparations.
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Rat cytosolic fractions prepared using a 1:5 w/v homogenisation volume were prepared 
as described in section 2.3. The resulting supernatant was diluted to give cytosolic 
fractions at tissue concentrations of 2.5 - 20mg wet weight of tissue/incubation. Assay 
procedures were carried out as described in section 2.4. Data shown represents the mean 
(± s.e.m) for five experiments.
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2.7. Effect of incubation temperature on the specific binding of ^ H-dexamethasone 
to rat cortical cytosol
2.7.1. Introduction
The incubation temperature of binding assays can strongly affect the rates of 
association and dissociation (see section 2 .8 ) and may affect equilibrium dissociation 
constants. The following experiments were designed to optimise the incubation 
temperature for the CR binding assays.
2.7.2. Methods
All assay procedures were carried out as described in section 2.3 except that assay 
tubes were incubated at temperatures of 4°C, 21°C and 32°C for 24 hours.
2.7.3. Calculations and analysis
Specific ^H-dexamethasone binding was determined and plotted against temperature. 
One-way ANOVA (using GraphPad Prism v3.0) was used to test the significance of 
any differences in specific ^H-dexamethasone binding to CR in rat cytosol.
2.7.4. Results
At temperatures of 32°C and 21°C, there was very little specific binding of 
dexamethasone to tissue fractions (23.1 and 39 fmol/mg protein respectively -  see 
Figure 2.7.1). Specific ^H-dexamethasone binding to CR was highest at 4°C (162.3 
fmol/mg protein). ANOVA and subsequent post-hoc analysis using the Newman-Keuls 
test showed a significant difference (p<0.001) between specific ^H-dexamethasone 
binding at 4°C as compared to binding at 21°C and 32°C.
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FIGURE 2.7.1
The effect of incubation temperature on specific binding of ^ H-dexametbasone 
binding to CR in rat cortical cytosolic preparations.
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Rat cortical cytosolic fractions (prepared as described in section 2.3.5) were incubated with 
3nM ^H-dexamethasone for 24 hours at various temperatures (32°C, 21 °C and 4°C). The assay 
was carried out as described in section 2.3. Data shown represents the mean (± s.e.m) for four 
experiments. Statistically significant differences between groups were determined using one­
way ANOVA followed by subsequent Newman-Keuls post-hoc analysis and are denoted by 
*p<0.01. ANOVA -  F (2, 11) = 31.34, p<0.0001.
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2.8. Kinetics experiments: association and dissociation
2.8.1. Introduction
Main objectives for performing kinetics experiments are to;
i) establish when steady state is reached so that saturation and inhibition 
experiments can be accurately performed
ii) determine the association rate constant (k+i) and dissociation rate (k.i) constant 
of the reaction so that the Kr, can be subsequently calculated.
Kinetics experiments produce a useful independent estimate of the Kd and therefore aid 
in the design of the assay with regards to methods of separation. Ki, values obtained 
using these calculations also provide a check on the internal consistency of the 
receptor-ligand system under investigation.
2.8.2. Methods
Assay procedures were carried out as described in section 2.3. In association 
experiments, tissue supernatant was incubated with 3nM ^H-dexamethasone over 
varying periods of time up to 48 hours.
In dissociation experiments, cytosolic fractions were incubated with 3nM 
dexamethasone at 4°C for 24 hours to achieve binding equilibrium (this time being 
determined by the association experiments). At 24 hours of incubation, sets of test 
tubes were filtered to determine TB (in triplicate) and NSB (in triplicate) at 
equilibrium. 50pL of hydrocortisone (25pM) was added to the remaining incubations to 
occupy all the free receptors thereby blocking the associative reaction so that only the 
dissociation reaction was measured. Individual sets of test tubes were filtered at various 
time intervals following the addition of hydrocortisone (1-25 hours).
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2.8.3. Calculations and analysis
The specific binding of ^H-dexamethasone was plotted against time. Non-linear 
regression analysis (GraphPad Prism v3.0) was used to fit the data to a one-phase 
exponential association equation. A pseudo 1®* order association plot of the data was 
constmcted and followed by linear regression analysis in order to calculate the 
parameter ^bs observed).
The rate constant for the dissociation reaction rate was calculated by non-linear 
regression analysis using the one-phase exponential decay equation (GraphPad Prism 
v3.0).
The association rate constant (/:+i) was calculated by substituting these values into the 
following equation;
^ + 1 = (Lh,-/:.i) where F = free ligand concentration 
F
Substitution of the k.\ and k+\ values obtained into the following equation resulted in a 
value for the dissociation constant (^d)-
K.Y) ”  -^1 / +^1
100
2.8.4. Results
Figure 2.8.1 (A) shows the mean (± sem) association data from five experiments. The 
association of ^H-dexamethasone to cortical preparations was slow (ti/2=6 . 4  hours) and 
achieved equilibrium after 24 hours of incubation. Binding equilibrium was maintained 
up to 48 hours of incubation. The parameter /robs {k observed) was calculated by a 
pseudo 1®‘ order association plot of the data (see Figure 2.8.1 (B)). Analysis of this data 
yielded a value of 0 . 1 1  min'^ for /robs-
Figure 2.8.1 (C) shows the mean (± sem) dissociation data from three experiments. The 
dissociation of ^H-dexamethasone from its binding sites was also very slow with a 1 1/2= 
17.55 hours. The rate constant (calculated by non-linear regression analysis) for the 
dissociation reaction rate {k.\) was 0.0395 m in'\
A value of 0.0169 min'  ^ nM'^ was calculated for the association rate constant (A:+i). 
Substituting these values into the following equation;
Ky) — k.\ / ^ +1
resulted in a calculated value of 2.34nM.
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Figure 2.8.1.
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Assay procedures were carried out as described 
in section 2.8.2. Data shown represents the mean 
(± s.e.m) for five experiments. Equilibrium was 
achieved at 24 hours of incubation at 4°C. 
Specific binding after 24 hours of incubation at 
4°C was 8.07 ± 0.86 fmol/mg protein.
Non-linear regression analysis was used to fit the 
data to a one-phase exponential association 
equation (see section 2.8.3).
Pseudo first order association plot
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where; Be = binding at equilbrium
B = binding at a particular time
This plot was constructed (see section 2.8.3) in 
order to calculate the rate constant (kobs)- The 
value for kobs was obtained from the slope of the 
plot shown here and was 0.112 ± O.Olmin-1.
Time course of dissociation of specific binding of 
^H-dexamethasone binding to CR in rat cortical 
cytosolic preparations.
Assay procedures were carried out as described in 
section 2.8.2. Data shown represents the mean (± 
s.e.m) for three experiments. Equilibrium was 
achieved at 24 hours of incubation at 4°C following 
which the association reaction was blocked by the 
addition of 5pM hydrocortisone. Specific binding 
after 24 hours of incubation at 4°C was 14.26 ± 
2.12 fmol/mg protein. Specific binding at 25 hours 
after the termination of the association reaction was 
1.96 ± 0.85 fmol/mg protein. Non-linear regression 
analysis was used to fit the data to a one-phase 
exponential decay equation.
Time (hours)
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2.9. The determination of specific ^H-dexamethasone binding to rat cytosolic 
preparations from fresh and frozen tissue
2.9.1. Introduction
This investigation examined the effects of freezing tissue samples at -70°C on the 
binding parameters of ^H-dexamethasone. This study was important in relation to 
future large studies that were being planned, as many of the samples would require 
freezing for some period of time prior to being assayed.
2.9.2. Methods
This study was carried out in both cortical and hippocampal tissues dissected from rat 
brain (as described in section 2.3.2) and frozen for periods of 1, 3, 6  and 12 months at 
-70°C. Fresh tissue was also dissected on each experimental day and assayed in 
parallel, to act as the control sample. Assay procedures were carried out as described in 
section 2.3. except that the separation of free and bound ^H-dexamethasone was carried 
out using a 12-hole Millipore manifold system.
2.9.3. Calculations and analysis
Saturation data obtained from these experiments was analysed as described in section
2.4.3. One-way analysis of variance (GraphPad Prism v2.1) was applied to the data to 
determine any differences in the binding parameters of fresh, 1, 3, 6  and 12 month 
frozen samples.
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2.9.4. Results
ANOVA revealed no significant differences in the binding parameters of specific 
dexamethasone to CR in fresh cortex over 12 months (p>0.05) therefore these were 
pooled to give overall values of 177 ±11 fmol/mg protein (n=24) for Bmax and 2.36 ± 
0.26 nM (n=24) for These pooled fresh values were used in subsequent statistical 
analysis. Bmax values of specific ^H-dexamethasone binding to CR were not 
significantly different from fresh values in 1, 3 and 12 month frozen cortex however a 
significant difference was observed between fresh and 6 month frozen values (Table 
2.9.1). There was no difference in Kd values in fresh or frozen cortex.
Tables 2.9.2. (A) and (B) show the Bmax and Ky) of specific ^H-dexamethasone binding 
to fresh hippocampal tissue preparations, which were consistent in assays performed 
over a 12 month period. These values were pooled giving overall values of 130 ± 8 
fmol/mg protein for Bmax and 2.21 ± 0.41 nM for K\y which were used in subsequent 
statistical analysis. No significant differences were observed following ANOVA and 
post-hoc tests in Bmax and values for 1, 6 and 12 month frozen hippocampal tissue as 
compared with pooled fresh values.
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Table 2.9.1. B m a x  (A) and K\^  (B) values of total CR obtained in cytosolic
preparations from fresh and frozen rat cortex.
(A) Bmax
FROZEN CORTEX
FRESH CORTEX 1 MONTH 3 MONTH 6 MONTH 12 MONTH
179 ±14  
(n=6)
133 ±15  
(n=6)
— — —
173 ±16  
(n=10)
— 152 ± 8  
(n=10)
— —
171 ±15  
(n=5)
— — 9 6 ± 1 0 *
(n=5)
—
193 ± 44  
(n=5)
— — — 154 ±37  
(n=5)
(B)^D
FROZEN CORTEX
FRESH CORTEX 1 MONTH 3 MONTH 6 MONTH 12 MONTH
2.91 ±0.71  
(n=6)
2.62 ± 0.59 
(n=6)
-- -- --
2.13 ±0.44  
(n=10)
— 1.65 ±0.24  
(n=10)
-- --
1.87 ±0.4  
(n=5)
— — 1.44 ±0.22  
(n=5)
--
3.25 ± 0.32 
(n=5)
— -- — 4.47 ±1.88  
(n=5)
CR binding assays were conducted in frozen cortical tissue (with fresh samples assayed in parallel) as 
described in section 2.3. Total binding determinations were made in duplicate. Non-specific binding was 
defined in single tubes in the presence of 5pM hydrocortisone. Data represent the mean ± sem values 
from the number (n) of samples indicated. One-way ANOVA revealed no significant differences 
between fresh samples at 1, 3, 6 and 12 months (ANOVA-fresh CR (Bmax) F (3, 25) =0.17, p>0.05; CR 
(log Kd) F (3, 25) = 1.66, p>0.05) therefore these were pooled (giving a value of 177 ± 1 1  fmol/mg 
protein (n=24) for B^ ax and 2.36 ± 0.26 nM (n=24) for ATd) which were used in subsequent analysis. Data 
were further analysed using ANOVA followed by Newman Keuls tests (GraphPad Prism v3.0). ANOVA: 
CR (Bmax) F (4, 49) = 3.17, p<0.05. CR (log Kd) F (4, 49) = 1.82, p>0.05. Significant differences 
between the pooled fresh values and frozen values are denoted by* p<0.05
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Table 2.9.2. B m a x  (A) and Kd (B) values of total CR obtained in cytosolic
preparations from fresh and frozen rat hippocampus.
(A) Bmax
FROZEN HIPPOCAMPUS
FRESH 1 MONTH 6 MONTH 12 MONTH
HIPPOCAMPUS
141 ± 8 147 ±13
(n=5) (n=5)
143 ±14 108 ± 6
(n=4) (n=4)
111±17 110±21
(n=5) (n=5)
(B)Æo
FROZEN HIPPOCAMPUS
FRESH 1 MONTH 6 MONTH 12 MONTH
HIPPOCAMPUS
1.57 ±0.17 1.5 ±0.21
(n=5) (n=5)
2.22 ± 0.6 1.3 ±0.06
(n=4) (n=4)
2.83 ± 1.05 3.7 ±  0.52
(n=5) (n=5)
CR binding assays were conducted in frozen hippocampal tissue (with fresh samples assayed in parallel) 
as described in section 2.3. Total binding determinations were made in duplicate. Non-specific binding 
was defined in single tubes in the presence of 5pM hydrocortisone. The data represent the mean ± sem 
values from the number (n) of samples indicated. One-way ANOVA revealed no significant differences 
between fresh samples at 1, 6 and 12 months (ANOVA-fresh CR (Bmax) F (2, 13) = 1.77, p>0.05; CR 
(log Kd) F (2, 13) = 0.27, p>0.05) therefore these were pooled (giving a value of 130 ± 8 fmol/mg 
protein (n=14) for B^ ax and 2.21 ± 0.41 nM (n=14) for Kd) which were used in subsequent analysis. Data 
were further analysed using ANOVA followed by Newman Keuls tests (using GraphPad Prism v3.0). 
ANOVA: CR (Bmax) F (3, 27) = 1.63, p>0.05. CR (log Kd) F (3, 27) = 5.25, p<0.05. No significant 
differences in B^ ax were found between the pooled fresh values and frozen values. ANOVA showed 
significant effects of freezing on Kd values however, subsequent post-hoc analysis between pooled fresh 
and frozen values did not display any significant differences.
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2.10. Determination of total CR (type I + II receptors) population and GR (type 
II receptors) using RU28362
2.10.1. Introduction
This study aims to investigate the specific binding of ^H-dexamethasone to type I (MR) 
and type II (GR) populations in rat cortical preparations. The wide distribution of type 
n  GR in the brain should make their detection in the cortex relatively simple and the 
different types of receptor can be distinguished from one another using synthetic, 
selective glucocorticoid agonists such as RU28362 (Up, 17P-dihydroxy-6-methyl- 
17a(l-propynyl)-androsta-l, 4, 6-trione-3-one) or RU26988 ( l ip,  17p-dihydroxy- 
17a-(l-propynyl)-androsta-l, 4, 6-trione-3-one).
2.10.2. Methods
Assay procedures were carried out as described in section 2.3. In addition to the total 
binding and non-specific binding tubes, another set of test tubes was added to the assay 
for determinations of specific ^H-dexamethasone binding in the presence of the 
selective GR agonist, RU 28362 (0.5pM or 100 times in excess of ^H-dexamethasone 
concentration), which were made singly.
2.10.3. Calculations and analysis
Specific ^H-dexamethasone binding to total CR was calculated. Specific ^H- 
dexamethasone binding to type II GR was calculated by subtracting the binding in the 
presence of RU28362 from the total binding.
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Saturation data obtained from these experiments was analysed as described in section
2.4.3. One-way analysis of variance (using GraphPad Prism v3.0) at a significance 
level of <0.05 was applied to the data to determine any differences in the specific 
binding of ^ H-dexamethasone when being displaced by RU28362;
1) at a fixed concentration of 0.5|xM or
2) at a concentration 100 times in excess of ^ H-dexamethasone in the assay.
2.10.4. Results
Table 2.10.1 shows the binding parameters obtained for total CR population, type II 
GR measurement using RU 28362 at a fixed concentration and at concentrations 100 
times in excess of ^H-dexamethasone in the assay. One-way analysis of variance 
showed no difference between the Bmax and Kd of total CR, type II GR defined using a 
fixed concentration of RU28362 and type II GR using RU28362 lOOx in excess of ^H- 
dexamethasone.
Table 2.10.1
Binding parameters of total CR (type I MR + type II GR) population and type II (GR) receptors 
in rat cortex using fixed and variable concentrations of RU28362.
PARAMETER Type I + II CR Type II GR 
(fixed - O.SiiM RU28362)
Type II GR 
(lOOx excess RU28362)
F  max 237 ± 32 219 ±28 233 ± 34
(fmol/mg protein) (n = 4) (n = 4) (n=4)
Kd 1.43 ± 0.6 1.17 ± 0.43 1.32 ± 0.47
(nM) (n = 4) (n = 4) (n = 4)
Assay procedures were carried out as described in section 2.3. Type II GR were defined using RU 28362 
at a fixed concentration of 0.5pM and at concentrations that were 100 times in excess of [^H- 
dexamethasone] in the assay. Statistically significant differences between groups were determined using 
one-way ANOVA followed by subsequent Newman-Keuls post hoc analysis. ANOVA revealed no 
significant differences between B^ ax (F (2, 11) = 0.094, p>0.05) or Kq (F (2, 11) = 0.039, p>0.05) values 
obtained for total CR population and type II GR population in rat cortex.
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2.11. Protein determination using the Lowry method
2.11.1. Introduction
Protein content in tissue samples was estimated using the colorimetric method of 
Lowry et al {\95\). This method utilises hydrolytic reactions to break the protein down 
into its constitutive amino acids. A coloured complex results from interactions between 
an alkaline copper-phenol reagent and tyrosine and tryptophan residues in the protein. 
The protein content of the sample is estimated via a spectrophotometric reading of 
absorbance.
2.11.2. Methods
The Lowry protein assay was adapted from the standard protocol (Lowry et al, 1951). 
The presence of Tris and glycerol as components of the incubation buffer used in the 
CR assay, posed a problem. These two compounds are found to interfere with the 
measurement of protein by the Lowry method by contributing blank colour and/or 
decreasing chromophore development with protein (Rej et al, 1974). This distortion 
was overcome by diluting the tissue samples with distilled water (1:4) therefore 
effectively diluting out the interfering components. Incorporation of the same amounts 
of these compounds in the standards also overcame the problems we encountered. The 
standard curve was therefore constructed in incubation buffer that had been diluted 
with distilled water by the same factor as the samples for the protein assay.
2.11.3. Results
Standard curves obtained in the Lowry protein assay were linear over the range of 10- 
SOjxg BSA (see Figure 2.11.1).
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Figure 2.11.1.
Protein determination using the Lowry method
0 .8-,
0.6-  i -
0 0.4-1
0.2 -
0.0
BSA concentration
mean protein concentration 
attained in Low ry assays
pg/lO O pL
Standard curve and mean protein concentration obtained using the Lowry assay. Standard 
curves were linear over the range of 10-80p,g BSA. Average values in our studies were 
41|Llg/100|xL volume (160 jUg/assay when multiplied by 4, the dilution factor for the tissue 
samples).
2,11.4. Protein determination using Lowry method
Protein values obtained using this method were very consistent. Dilution of the samples 
and construction of the standard curve in diluted incubation buffer overcame the 
problem of interfering compounds such as Tris and glycerol.
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2.12. Discussion
2.12.1. Determination o f the saturability of^H-dexamethasone binding to CR in rat 
cortical cytosolic preparations
Binding parameters in these experiments were determined using linear and non-linear 
regression analysis. Bmax and values obtained using both of these methods were in 
close agreement suggesting that the CR assay satisfies the required criteria for receptor 
binding experiments. The determination of binding parameters using linear regression 
analysis however is questionable due to the distortion of experimental error and 
alteration of values that occurs when performing linear transformations on saturation 
data (Motulsky, 1996). Displaying saturation data as Scatchard and Hill plots was 
useful however in determining whether or not the ligand-receptor interaction was 
described adequately by a simple bimolecular reaction and enabling the quantitation of 
deviation of the ligand-receptor interaction from the law of mass action. Non-linear 
regression was chosen as the standard method of analysis for saturation data as this is 
the statistically correct method. This type of analysis also minimises the contribution of 
outliers by introducing appropriate weighting whereas linear regression gives equal 
weighting to all the points.
Analysis of saturation binding data using non-linear regression is based on the 
following assumptions;
1) binding follows the law of mass action
2) there is only one population of receptors
3) there is no co-operativity between binding sites (i.e. constant)
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Results of the CR saturation binding experiments showed that;
1) Specific ^H-dexamethasone binding to rat cortical cytosol is saturable and follows 
the law of mass action (as indicated by a Hill coefficient close to unity).
2) ^H-dexamethasone is binding to a single binding site as shown by a Hill coefficient 
close to 1.
3) there is no cooperativity between sites as shown by linearity of the Scatchard plot 
and a Hill coefficient close to unity. The reaction between the receptor and its 
ligand is a simple, bimolecular reaction.
The interaction between ^H-dexamethasone and its binding site therefore appeared to 
follow the assumptions made when performing saturation analysis using non-linear 
regression analysis.
Non-linear regression analysis of cortical CR binding data gave Bmax and Æn values that 
ranged from 60-198 fmol/mg protein and 0.79-6.33 nM, respectively. The mean values 
for Bmax and Kj){\39 fmol/mg protein and 2.15 nM, respectively) calculated from these 
saturation experiments provided a guideline for binding parameters which were useful 
in future studies. These values also appear to be in agreement with those obtained for 
type n  GR in various brain regions in previous studies (Reul et al, 1985; Allen et al, 
1988; Spencer et al, 1990; Reul et al, 1993; 1994 and Budziszweska et al, 1994a). 
Mean values in these investigations were in the range of 50-200 fmol mg protein for 
Bmax (higher Bmax values were obtained in studies utilising adrenalectomised animals) 
and 0.4-2.0 nM for Kd.
The agreement of our data with that of other groups indicates that the binding of ^H- 
dexamethasone to CR in rat brain as assessed by this assay system is a viable method of
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measuring CR. It appears that the components of the assay buffer which include 
chelating agents and sulfhydryl moeties, are in proportion and allow stabilisation of the 
CR which, when unoccupied are generally very unstable in vitro. The physical 
conditions of the assay such as temperature and time of incubation have been chosen to 
allow optimal binding of ^H-dexamethasone to CR. The use of the rapid vacuum 
filtration technique as a method of separation of bound and free ligand is also thereby 
supported as previous investigations have used column and dextran-charcoal separation 
methods.
2.12.2. Selective displacement o f  ^ H-dexamethasone binding to rat cortical cytosolic 
preparations.
EtOH did not compete for specific ^H-dexamethasone binding to CR in rat cytosol 
preparations. Competing compounds used in the CR binding assay were dissolved in 
absolute ethanol and subsequently diluted in 10% EtOH (2% final assay concentration) 
and it was important to be certain that there was no interaction of the CR with this 
component of the assay. Results of the competition experiments showed relative 
binding affinities (RBA) for CR as follows; RU28362 > dexamethasone > 
corticosterone > hydrocortisone > aldosterone.
Hydrocortisone competition experiments gave a Ki value of 4.8nM. This value aided in 
determining the concentration of hydrocortisone to be used as the displacing compound 
for non-specific binding determinations in the CR assay. A concentration of 5fiM (final 
assay) was chosen for non-specific binding as this concentration is over 1000 times the 
Ki of hydrocortisone for CR and will displace up to 99% of the specifically bound 
radioligand.
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In experiments using RU 28362 to define ^H-dexamethasone binding to type II CR (see 
section 2.10), the concentration of RU 28362 was determined by the competition 
experiments for this compound. A Ki value of 0.018 nM was obtained from the 
competition curve for RU 28362. As a result of these experiments, a concentration of 
0.5|liM  was chosen for type II CR definition in the assay. The potency of RU28362 for 
^H-dexamethasone displacement from CR binding sites suggests that this compound 
may not be as selective for type II CR binding as was previously thought. Previous 
studies have shown that RU28362 competes for ^H-dexamethasone binding to type I as 
well as type II CR, but not for ^H-corticosterone binding to type I CR (Jacobson et al, 
1993). However, not all other investigators have observed similar results with ^H- 
dexamethasone (Spencer et al, 1991) therefore this issue remains unclear.
Competition profiles in these experiments were similar to those obtained previously by 
other laboratories with RU28362 as the most potent competitor for ^H-dexamethasone 
binding (Vedder et al, 1993). This was followed by dexamethasone and aldosterone 
thus revealing a competition profile characteristic of type II CR. Competition analysis 
of ^H-dexamethasone binding sites showed that the majority of labelled receptors were 
type n  CR.
2.12.3, Determination o f the linear relationship between specific ^H-dexamethasone 
binding and rat cytosolic tissue concentration
These experiments demonstrated that the use of this assay to measure the binding 
parameters of CR in rat cytosolic preparations yields consistent results, which are free 
from the artefacts mentioned in section 2.6.1. A tissue concentration of 5mg wet weight 
original tissue was chosen from the linear portion of the tissue linearity graph (Figure 
2.2) and was employed routinely for subsequent experiments except where mentioned.
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These experiments also ensured that measurable specific ^H-dexamethasone binding to 
CR was obtained at the concentration of tissue chosen in the assay and that no more 
than 10% of added radioligand was bound by the concentration of tissue chosen for 
subsequent experiments.
2.12.4. Effect o f incubation temperature on the specific binding o f ^H- 
dexamethasone to rat cortical cytosolic preparations
From the results obtained in these experiments, it was decided to proceed with the 
optimum incubation temperature of 4°C for all subsequent CR binding assays. This 
result was expected as CR are generally very unstable and deactivate at high 
temperatures due to the disruption of the complex structure of receptor protein.
2.12.5. Kinetics experiments (association and dissociation)
The association experiments showed that the incubation time chosen for the CR 
binding assay (approximately 24 hours) is sufficient for the receptor-ligand interaction 
to reach equilibrium in saturation and competition experiments. The linearity of the 
pseudo-first order association plot demonstrates that the interaction of the receptor and 
radioligand can be described by a simple bimolecular reaction (McGonigle & Molinoff,
1989).
The dissociation of the receptor-ligand complex appears to be a relatively slow process 
therefore the filtration method of separation used in the CR assay is rapid enough to 
prevent excessive loss of specific ^H-dexamethasone binding.
The Kd value of ^H-dexamethasone binding to CR obtained by performing these 
kinetics experiments was in close agreement to Kd values obtained in saturation
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experiments (section 2.4) thereby providing further support for the reliability of 
estimates produced using the saturation experiments.
2,12.6. The determination o f specific ^H-dexamethasone binding to rat cytosolic 
preparation from fresh and frozen tissue
Assays carried out in these experiments were initially filtered using a 12-hole manifold 
system therefore in order to keep the method of filtration consistent, the Millipore 
apparatus was used for all of the samples. However, preliminary experiments 
comparing the binding parameters obtained using the Millipore system and Brandel 
Cell Harvester showed no differences in Bmax and Kd values in tissues that have been 
filtered through the Millipore or Brandel systems.
The results of these experiments showed there were few differences in Bmax or Kd 
values obtained in fresh and frozen samples taken from different brain regions. Bmax 
values were reduced in 6 month frozen cortex, as compared to fresh values thus 
suggesting that specific ^H-dexamethasone binding to hippocampal CR may be altered 
following long periods of freezing (up to 6 months). However, the inconsistency of the 
observed reductions in Bmax values (seen after 6, but not 12 months of freezing) 
suggested that the differences are more likely to be due to experimental error than 
induced by freezing. All subsequent binding experiments were conducted in as short a 
time as possible after collection and freezing of samples and also with control samples 
being assayed in parallel. A closer investigation of CR binding parameters obtained 
over three years showed Bmax and Kd values to be quite stable over long periods of 
time. This is discussed further in Chapter 7.
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2.12.7. Determination o f total CR (type I  and II) and type 11 (GR) using RU28362 
There were no differences between specific ^H-dexamethasone binding in the presence 
of fixed or variable concentrations of RU28362. For subsequent experiments in which 
type n  CR were distinguished, a fixed concentration of RU28362 (0.5|xM) was used in 
the assay.
The very similar values obtained for specific ^H-dexamethasone binding parameters in 
type I + n  CR and in type II CR alone (as measured using RU28362), suggested that 
the receptors being measured in the total CR population were predominantly of the type 
n  variety. Type II receptor affinities for ^H-dexamethasone (Kd = 2-5nM) obtained in 
previous studies (Reul & de Kloet, 1985; Vedder et at, 1993) were consistent with our 
data supporting the hypothesis that the receptors we measured using this assay were 
mainly type II corticosteroid receptors.
The competition binding studies with ^H-dexamethasone have also demonstrated a 
glucocorticoid-like pattern of receptor binding, ie; RU28362 > DEX > ALDO (Vedder 
et al, \993).
Investigations into the relative occupancy of type I and II CR at the time of sacrifice 
and dissection have shown that approximately 70-90% of type I CR are occupied under 
basal levels of corticosterone output. At this concentration of plasma corticosterone 
(1-3 fig/lOOmL), only approximately 10-30% of type II CR would be occupied (Reul & 
de Kloet, 1985; Spencer et al, 1990). These levels of corticosterone would be produced 
during the morning trough of the circadian cycle corresponding with the time at which 
our animals were sacrificed.
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Previous studies have investigated changes in both type I and type II CR in the rat brain 
(Reul et al, 1993; 1994; Budziszweska et al, 1994a; 1994b). These have been made 
possible by adrenalectomising the animals prior to sacrifice and dissection thereby 
removing sources of endogenous ligand that could possibly impede specific ^H- 
dexamethasone binding in the CR assay. In our studies, CR concentrations were 
assessed in animals with intact adrenals therefore circulating endogenous corticosterone 
was present and, due to this, it is likely that many type I CR were occupied at the time 
of receptor measurement.
It is very likely therefore, considering the use of animals with intact adrenals in our 
experiments, that even without the use of RU 28362, the measurement of total CR 
populations using our methodology contains mostly available type II GR.
This section has demonstrated that the binding of ^H-dexamethasone to brain cytosolic 
fractions under the conditions in our assay is a valid method of investigating CR that 
fulfils the necessary criteria for receptor binding and generates reliable data pertaining 
to the measurement of CR binding parameters.
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CHAPTER 3
THE EFFECT OF ANTIDEPRESSANT ADMINISTRATION ON RAT 
PLASMA CORTICOSTERONE AND CORTICOSTEROID RECEPTORS
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3.1. Introduction
Normalisation of various features of the dysfunctional HPA axis seen in depression 
following chronic administration of antidepressants is well documented. The long-term 
administration of several antidepressants is found to reduce HPA axis hyperactivity 
(Barden eî al, 1995; Holsboer & Barden, 1996) and plasma cortisol release (Shimoda 
et al, 1988; Reul et al, 1993; 1994; Delbende etal, 1994). Chronic exposure to various 
antidepressants (amitriptyline, moclobemide, imipramine, maprotiline) has been 
reported to increase MR and GR binding, mostly in hippocampal and hypothalamic 
regions of the rat brain (Reul et al, 1993; Reul et al, 1994; Budziszweska et al, 1994a; 
1994b). The expression of GR and MR mRNA in rat brain and cell cultures is also 
found to be enhanced following long term administration with the antidepressants 
imipramine, amitriptyline, desipramine, citalopram and maprotiline (Pepin et al, 1989; 
Peiffer et al, 1991; Seckl & Fink, 1992; Barden, 1996; Pariante etal, 1997).
The elevation of CR binding and CR mRNA expression in brain regions following 
chronic administration of various antidepressant drugs has been proposed as an 
explanation of the therapeutic efficacy of these drugs in the treatment of depression. 
Two possibilities currently exist as mechanisms of antidepressant-induced regulation of 
CR;
1) many antidepressant drugs are found to inhibit the re-uptake of NA and 5HT and 
both of these neurotransmitter systems have been found to exert a modulatory 
effect on the regulation of hippocampal CR concentrations (Lowy et al, 1990; 
Mitchell et al, 1990; Dinan, 1996a; 1996b).
2) it has been suggested that a primary action of antidepressants could be exerted at a 
genomic level resulting in enhanced CR gene expression and a subsequent 
decrease in HPA activity (Pepin et al, 1992; Pariante et al, 1997).
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All previous investigations into the effects of chronic antidepressant administration on 
brain CR concentrations have been carried out in animals that were adrenalectomised 
prior to the measurement of CR binding activity. This procedure has the effect of 
removing residual endogenous ligand from binding sites thus enabling the 
measurement of changes in (available) CR concentrations under conditions of minimal 
nuclear occupancy. However;
i) the procedure of adrenalectomy itself is found to interfere with the regulation of 
CR (Reul et al, 1989; Chao et al, 1989; Spencer et al, 1991; Karst et al, 1997).
ii) in depression, CR regulation by stress and/or antidepressant treatment occurs in 
the presence of the endogenous ligand.
It is essential therefore to investigate CR binding activity in the presence of endogenous 
ligand in laboratory animals to determine whether the up-regulation of CR observed 
following long-term antidepressant administration is an effect observed in the 
adrenally-intact animal.
The neuroanatomical specificity of these effects also supports the hypothesis of altered 
CR plasticity following stress and antidepressant administration. Many changes in CR 
concentrations are observed in the hippocampus (the location of most brain MR and 
some GR) and the hypothalamus, both regions that are heavily involved with CR 
regulation. Since many of the changes in receptor plasticity are observed in GR (which 
are more widely distributed), the investigation of these receptors in various other brain 
regions (and peripheral tissues) would also be of interest.
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The aims of the present study were to investigate the effects of repeated administration, 
and withdrawal, of three antidepressants with differing initial mechanisms of action on 
various elements of the HPA system in adrenally intact animals (i.e. in the presence of 
endogenous ligand). The effects of the following antidepressants;
i) DMI (desmethylimipramine), a tricyclic
ii) paroxetine, an SSRI (selective 5-HT re-uptake inhibitor)
iii) venlafaxine, a SNRI (5-HT/NA reuptake inhibitor)
were studied on the following parameters in rats;
1. body and adrenal weights
2. the specific binding of ^H-dexamethasone to CR in various brain regions and in the 
thymus gland
3. basal plasma corticosterone concentrations
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3.2. Methods
3.2.1. Animals
Male Sprague-Dawley rats (200-250g; NES COT breeding colony, U.K.) were housed 4 
per cage under conditions of standard lighting (12:12 hour light-dark cycle), 
temperature (18-22°C) and humidity (-55%). Food and water were available ad 
libitum.
3.2.2. Antidepressant drug administration
The antidepressant drugs used in these studies were;
i) the tricyclic desmethylimipramine, DMI (Sigma, U.K.)
ii) paroxetine, a selective 5-HT reuptake inhibitor (SmithKline Beecham, U.K.)
iii) venlafaxine, a combined 5-HT/NA reuptake inhibitor (Wyeth Laboratories, U.K.).
Investigations into the effects of these drugs were carried out separately with control 
groups being assigned to each of the drug treatment groups. Animals were randomly 
assigned to a number of different groups (corresponding to the period after beginning 
drug administration at which the animals were sacrificed) each consisting of 8 control 
and 8 drug treated rats. Body weights were recorded regularly throughout the period of 
drug administration and withdrawal. Rats were dosed once daily p.o. (between 08.00- 
09.00hrs) for up to 28 days with either distilled water vehicle or desmethylimipramine 
(lOmg/kg), paroxetine (5 mg/kg) or venlafaxine (15 mg/kg). The oral route of drug 
administration was chosen to ensure that each of the animals received the stated dose of 
antidepressant and that metabolism of the dmg would occur via the gastro-intestinal 
route as in oral administration of antidepressants in humans.
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3.2.3. Tissue collection and ^ H~dexamethasone binding assay
Sacrifice of rats took place between 08.00-11.00 hours in a separate room at various
times 24 hrs after the last dose or following 7 days of discontinuing drug treatment.
Dissection of brain regions, thymus and adrenals was carried out as described in section
2.3.2. Trunk blood was collected and the preparation of serum was carried out as
described in section 3.2.4. All tissues were stored at -70°C until required for further
analysis.
i )  D i s p l a c e m e n t  e x p e r i m e n t s  - The antidepressant drugs being used in these studies 
were tested for displacement of ^H-dexamethasone binding to cytosolic sites prior to 
commencement of binding studies. Competition assays were carried out as described in 
section 2.5 with each of the antidepressant compounds diluted in distilled water and 
added to the assay in concentrations ranging from 5x10'^^ to 5xlO'^M.
i i )  S a tu r a t i o n  e x p e r i m e n t s  - Saturation binding assays were carried out as described in 
section 2.3. Incubations were carried out in duplicate for total binding and singly for 
binding in the presence of 5|iM hydrocortisone and 0.5pM RU28362. Saturation 
experiments in cortex, hippocampus and thymus were carried out in cytosolic 
preparations using tissue from one animal. Saturation assays in striatal and 
hypothalamic regions were carried out in cytosolic preparations using tissue pooled 
from two animals. ^H-dexamethasone binding to CR was measured at 6 ligand 
concentrations (0.625-20nM) in the DMI and venlafaxine studies and at 8 ligand 
concentrations (0.325-20nM) in the paroxetine study. Tissues from both vehicle and 
antidepressant drug treated animals were compared within the same assays in order to 
minimise the effects of daily variations in assay procedures. Protein concentrations
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were determined by the method of Lowry e t  a l  (1951) with BSA as the standard (see 
section 2.11).
3.2.4. High performance liquid chromatography (HPLC) determination o f plasma 
corticosterone concentrations
3 .2 .4 .  a  I n t r o d u c t i o n
Measurements of plasma corticosteroids are commonly performed using the 
radioimmunoassay method. However it has been shown that the quantitative analysis of 
endogenous glucocorticoids using HPLC techniques can yield accurate and 
reproducible data (Shimizu e t  a l ,  1983, Hariharan e t  a l ,  1992). We decided to use this 
method for analysis of plasma corticosterone concentrations in rats treated for up to 28 
days with DMI, paroxetine or venlafaxine.
3 .2 .4 .b  M e t h o d s
i)  S e r u m  e x t r a c t i o n  f r o m  b l o o d  s a m p l e s
Trunk blood samples were collected at the time of sacrifice, following decapitation of 
the animals. Approximately lOmL of blood was collected in a 50mL centrifuge tube 
and stored at room temperature for 30 min following which samples were placed at 4°C 
for Ihour. Samples were then removed and left at room temperature for 15 mins and 
the resulting blood clot was dislodged by gently introducing a glass rod around the clot 
and the wall of the tube. The supernatant (serum) was transferred by pipette to another 
tube and spun at 2500g for 10 min at room temperature, transferred to a cryovial and 
stored at -70° until corticosterone extraction.
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i i )  S o l i d  p h a s e  e x t r a c t i o n  o f  c o r t i c o s t e r o n e
Following the thawing of serum samples, they were heated for 10 minutes at 52°C. 
400pL of trichloroacetic acid was added to the serum sample resulting in a cloudy 
precipitate. Contents were transferred to an eppendorf tube and spun in a microfuge for 
4 minutes at 5000g. 2 5 \x L  of nortestosterone standard was added to the supernatant to 
give a final nortestosterone concentration of 2.5)Lig/mL as an internal standard. The 
sample was loaded onto a preconditioned solid phase extraction (SPE) column.
i i i )  P r e c o n d i t i o n i n g  o f  S P E  c o lu m n
Columns were prepared by rinsing with ImL methanol (Hypersolv Grade) and allowing 
elution under gravity. Flushing the column with ImL distilled water displaced the 
methanol following which, 500pL of corticosterone extract was loaded onto the 
column. The column was then washed with ImL distilled water to wash away the 
soluble particles. The analyte (consisting of hydrophobic components such as 
corticosterone) was then eluted under gravity with methanol and the eluate collected 
and stored at -70°C until ready for HPLC analysis.
iv )  H P L C  o f  s t a n d a r d s  a n d  c o r t i c o s t e r o n e  e x t r a c t
Mobile phase (65% methanol + 35% distilled water) was filtered and degassed with 
helium for 20 mins prior to use. The pump was primed with mobile phase for a 
minimum of 20 mins before the injection of samples into the HPLC apparatus. 
Standards of corticosterone and nortestosterone were prepared in Hypersolv methanol 
to give 2.5:2.5|ig/mL concentrations and loaded into the HPLC apparatus.
126
3.3 Calculations and analysis of results
3 .3 .1 .  C o m p e t i t i o n  a s s a y s
Analysis of all competition experiments was carried out as described in section 2.5. 
Competition profiles are displayed in Appendix 3.4.1.
3 .3 .2 .  S a tu r a t i o n  a s s a y s
The binding assay described in section 2.4 was used to measure total CR population 
and also GR concentrations (using RU28362) in various rat brain regions. Only data 
pertaining to total receptor population (CR) is included however, as values were found 
to be very similar for the two receptor populations. Also, it appears that CR being 
measured are comprised mostly of type II GR (as discussed in sections 2.10 and 2.12). 
Values for specific ^H-dexamethasone binding parameters to type I and II CR in 
various tissues from these studies are given in Appendices 3.4.2, 3.4.3 and 3.4.4.
3 .3 .3 .  H P L C  d e t e r m i n a t i o n  o f  p l a s m a  c o r t i c o s t e r o n e  c o n c e n t r a t i o n s
The corticosterone: nortestosterone standards injected into the HPLC were equivalent 
to concentrations of 0.05pg and 0.05|ig respectively, these being used to calculate the 
response factors (Rf) and retention time (Rt) for each peak. Following the injection of 
the sample, the nortestosterone internal standard was determined from the Rf and Rt of 
the standards. Corticosterone peaks were also identified in the sample and matched 
against the Rf and Rt for standard corticosterone. The area of this peak was used to 
calculate the concentration of corticosterone in the sample. Corrections were made for 
the data if the recovery of the internal standard was not found to be 100%.
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3.3.4. Statistical analysis
The mean (± s.e.m.) of individual determinations were calculated for each treatment 
group for body weights, adrenal weights, ^H-dexamethasone binding parameters (Bmax 
and Kd ), tissue protein content and plasma corticosterone concentrations.
Normal frequency distributions and some simple correlations were determined for data 
before it was subjected to any other statistical procedures. Data that did not conform to 
a normal distribution, such as and plasma corticosterone values were log- 
transformed prior to statistical analysis.
Data obtained in the time course experiments for all parameters were tested for 
statistically significant differences by two-way analysis of variance (ANOVA) 
followed by Student’s t-test where the F-ratio was significant (p<0.05) using GB-STAT 
v6.0.
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3.4. Results
3 .4 .1 .  D i s p l a c e m e n t  a s s a y s  u s i n g  a n t i d e p r e s s a n t  c o m p o u n d s
DMI, paroxetine and venlafaxine did not compete for ^H-dexamethasone binding to CR 
in rat cortex in a concentration dependent manner (Appendix 3.4.1).
3 .4 .2 .  D M I  s t u d y
a )  B o d y  / a d r e n a l  w e i g h t s
Data obtained for body and adrenal weight values conformed to a normal distribution.
Body weights in DMI treated animals generally remained lower than in vehicle treated 
control animals throughout the study (Table 3.4.2.A). However this effect was not 
statistically significant until day 21 of dmg administration when a reduction of 10% in 
body weight of DMI treated rats was observed (as compared to vehicle treated 
controls). Animals receiving DMI however appeared to gain weight at the same rate as 
those receiving distilled water vehicle.
Adrenal weights (per 2 adrenals) in rats receiving DMI were significantly lower than in 
controls following 14 days (-19%) and 21 days of dmg administration (-21% -  Table
3.4.2.B). No difference was observed between DMI and vehicle treated groups after 
this time. Values obtained for adrenal weights 7 days after withdrawal of DMI were no 
different from values in vehicle treated animals or those obtained after 28 days of dmg 
administration.
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b )  ^ H - d e x a m e th a s o n e  b in d i n g  to  C R
Bmax values conformed to a normal distribution however, Kj) data did not and therefore 
was log transformed before being subjected to analysis of variance.
Cortical CR concentrations were 36% higher after 14 days of DMI administration 
(Figure 3.4.2.i.A, Appendix 3.4.2). There were no differences in CR numbers between 
vehicle and DMI treated animals at any other time. The Kb of specific ^H- 
dexamethasone binding to CR in rat cortex was not consistently affected by DMI 
administration but was significantly lower (-41%) than values in vehicle treated 
animals at day 1 (Figure 3.4.2.i.B). There were no differences between values for CR 
binding parameters obtained following 7 days of DMI withdrawal as compared to 
control vehicle treated values or those measured at 28 days of treatment.
No significant effects on the Bmax and Kb of specific ^H-dexamethasone binding to CR 
in rat hippocampus were observed following the administration or withdrawal of DMI 
(Figure 3.4.2.Ü).
c )  L o w r y  p r o t e i n  a s s a y
There were no significant differences in protein content of vehicle and DMI treated 
animals in either cortex or hippocampus (Appendix 3.4.2).
Simple correlation analysis showed no statistically significant relationships between 
Bmax / Kb and protein values in both cortex and hippocampus.
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d )  P l a s m a  c o r t i c o s t e r o n e  c o n c e n t r a t i o n s
Plasma corticosterone values were log transformed prior to being analysed using 
ANOVA. Repeated DMI administration had no consistent effect on basal corticosterone 
concentration in rats (Figure 3.4.2.iii). Concentrations of corticosterone in DMI treated 
animals were significantly lower than in vehicle treated controls at day 1 of drug 
administration (-38%). Plasma corticosterone concentrations in rats receiving DMI for 
more than 7 days were generally lower than in vehicle treated animals, however no 
statistically significant effects were observed at any other time points following DMI 
administration. Corticosterone concentrations in animals withdrawn from DMI for 7 
days were significantly lower than in vehicle treated control animals (-73%).
Two-way ANOVA showed no significant interactions between drug treatment (DMI or 
distilled water) and time (1, 3, 7, 14, 21, and 28 days) for data on body weight, adrenal 
weight, CR binding parameters, tissue protein content or plasma corticosterone 
concentration in cortex or hippocampus.
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Table 3.4.2.
Time course of the effect of DMI administration on
body weight (A) and adrenal weight (B).
(A)
Tim e after adm inistration  
o f D M I or vehicle (days)
CO NTRO L  
body w eight (g)
D M I 
body w eight (g)
1 310 ±  5 (n=56) 294 ± 4  (n=56)
3 280 ± 7  (n=48) 297 ± 5  (n=48)
7 332 ±  5 (n=40) 316 ± 6  (n=40)
14 359 +  7 (n=32) 329 ± 7  (n=32)
21 384 ± 9  (n=24) 347 +  9 » (n=24)
28 401 ± 1 7  (n=16) 385 ± 1 6  (n=16)
(B)
Tim e after adm inistration  
o f  D M I or vehicle (days)
C O NTRO L  
adrenal w eight (mg)
D M I
adrenal w eight (m g)
1 5 5 ± 4 60 ±  4
3 62 ± 4 53 ± 2
7 61 ± 5 5 1 ± 3
14 54 ± 3 44 ±  2 *
21 66 ±  4 5 2 ± 3  *
28 57 ± 5 56 ± 5
7 days after w ithdrawal 56 ± 2 5 0 ± 3
Data for adrenal weights (B) are expressed as the weight per two adrenals in mg (mean ± sem). 
Rats (7-8 per group) received DMI (lOmg/kg p.o.) or distilled water once daily and were 
sacrificed after 1, 3,7,14,21 and 28 days of administration and 7 days following withdrawal of 
the drug (see section 3.2). Statistically significant differences were determined by two-way 
ANOVA followed by Student’s t-test where appropriate. A N O V A :  B o d y  w e ig h t  -  e f f e c t  o f  
tr e a tm e n t F  (1 , 9 4 )  = 2 .8 2 , p = 0 .9 7 ;  - e ffe c t o f  t im e  F  (5 ,9 4 )  = 1 8 .3 1 , p < 0 .0 0 0 1 ;  - in te r a c t io n  F  
(5 ,9 1 )  = 1 .5 , p - 2 . 0 .  A d r e n a l  w e ig h t  -  e f fe c t o f  tr e a tm e n t  F  (1 , 9 1 )  = 8 .7 8 , p = 0 .0 0 4 ;  - e f f e c t  o f  
tim e  F  (5 , 9 1 )  -  1 .7 7 , p = 0 .1 3 ;  - in te r a c t io n  F  (5 , 9 1 )  =  1 .7 9 , p = 0 .1 2 .  S tu d e n t^ s  t - te s t ;  * p < 0 . 0 5
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Figure 3.4.2.i
Time course of the effect of DMI administration on
Bmax (A) and (B) of specific ^H-dexamethasone binding to CR in rat cortex.
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Rats (6-8 per group) received DMI (10 mg/kg, p.o.) or distilled water once daily and were sacrificed after 
1, 3, 7, 14, 21 and 28 days o f administration and 7 days following withdrawal o f the drug (as described in 
section 3.2). Data are expressed as mean ± sem. Mean B^ax values ranged from 83-121 fmol/mg protein 
(vehicle groups) and 85 -136  fmol/mg protein (DMI groups). Mean values in this region ranged from 
1.6-4 nM (vehicle groups) and 1.6-2.8 nM (DMI groups). Mean protein values ranged from 161-201 
pg/assay (vehicle groups) and 257-207 pg/assay (DMI groups). Statistically significant differences were 
determined using two-way ANOVA followed by Student's t-test where appropriate. See Appendix 
3.1(A). ANOVA: CR (B„ax) - e j f e c t  o f  t r e a tm e n t  F (1 , 8 8 ) = 0 .5 ,  p = 0 .4 8 ;  - e f f e c t  o f  t im e  F (5 , 8 8 ) = 3 .4 4 ,  
p = 0 .0 0 7 4 ;  - in te r a c t io n  F (5 , 8 8 )  = 1 .7 8 ,  p = 1 .2 7 .  CR (log Ko) - e f f e c t  o f  t r e a tm e n t  F(l, 8 8 )  = 1 .7 4 ,  
p = 0 . 1 9 ;  - e f fe c t  o f  t im e  F (5 , 8 8 ) = 3 .5 ,  p = 0 .0 0 6 7 ;  - in te r a c t io n  F (5 , 8 8 ) = 0 .9 6 ,  p = 0 .4 4 .  Student’s t-test; 
* ( p < 0 .0 5 ) .
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Figure 3.4.2.11
Time course of the effect of DMI administration on
®max (A) and (B) of specific ^H-dexamethasone binding to CR in rat hippocampus.
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Rats (7-8 per group) received DMI (10 mg/kg, p.o.) or distilled water once daily and were sacrificed after 
1, 3, 7, 14, 21 and 28 days of administration and 7 days following withdrawal of the drug (as described in 
section 3.2). Data are expressed as mean ± sem Mean values ranged from 79-118 fmol/mg protein 
(vehicle groups) and 64-119 fmol/mg protein (DMI groups). Mean values in this region ranged from 
1.1-4.3 nM (vehicle groups) and 1.6-4.1 nM (DMI groups). Mean protein values ranged from 124-171 
pg/assay (vehicle groups) and 130-157 pg/assay (DMI groups). No statistically significant differences 
were determined using two-way analysis of variance or Student's t-tests. See Appendix 3.1.(B). 
ANOVA: CR (B„ax) - e f fe c t  o f  t r e a tm e n t  F  (1 , 8 9 )  =  0 .0 0 1 4 ,  p = 0 . 9 7 ;  - e f fe c t  o f  t im e  F  (5 , 8 9 )  = 4 .6 5 ,  
p = 0 .0 0 0 9 ;  - in te r a c t io n  F  (5 , 8 9 )  = 4 .6 5 ,  p = 0 .8 2 .  CR (log Kd) - e f fe c t  o f  t r e a tm e n t  F  (1 , 8 9 )  =  O.IO, 
p = 0 . 7 5 ;  - e f fe c t  o f  t im e  F  (5 , 8 9 )  =  3 .1 ,  p = 0 .0 1 3 ;  - in te r a c t io n  F  (5 , 8 9 )  =  0 .8 4 ,  p = 0 . 5 2
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Figure 3.4.2.111
Time course of the effect of DMI administration on rat
plasma corticosterone concentrations.
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Rats (7-8 per group) received DMI (10 mg/kg, p.o.) or distilled water once daily and were sacrificed after 
1, 3, 7, 14, 21 and 28 days of administration and 7 days following withdrawal of the drug (as described in 
section 3.2). Mean plasma corticosterone concentrations ranged from 5 8 -  129 pg/L (vehicle groups) and 
54 - 96 (DMI groups). Data is expressed as mean ± sem. Statistically significant differences were 
determined using two-way ANOVA followed by Student's t-test where appropriate. AAOVA: l o g  p l a s m a  
[ c o r t i c o s t e r o n e ]  - e f f e c t  o f  tr e a tm e n t  F  (1 , 9 4 )  -  2 .9 8 ,  p = 0 .0 8 8 ;  - e f f e c t  o f  t im e  F  (5 , 9 4 )  =  2 .8 6 ,  p =  
0 .0 2 ;  - in te r a c t io n  F  (5 , 9 4 )  =  0 .8 0 , p = 0 . 5 5 .  S t u d e n t ’s  t - te s t ;  * ( p < 0 .0 5 )  o r  ** ( p <  0 .0 0 0 1 ) .
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3.4.3. Paroxetine study
a) Body /  adrenal weights
Data obtained for body and adrenal weight values conformed to a normal distribution 
curve. There were no significant effects of paroxetine administration or withdrawal on 
body weight (Table 3.4.3.A). No difference was observed in adrenal weights between 
animals receiving paroxetine and distilled water vehicle at 1 and 28 days of drug 
administration (Table 3.4.3.B).
b) ^H-dexamethasone binding to CR
Bmax data conformed to a normal distribution, however values did not and therefore 
were log transformed before being subjected to analysis of variance. CR concentrations 
in rat cortex were significantly lower (-33%) than control values following 14 days of 
paroxetine administration but were not different from vehicle treated controls at any 
other time points (Figure 3.4.3.i.A, Appendix 3.4.3). There was no effect of paroxetine 
on the Kd of specific ^H-dexamethasone binding to CR in rat cortex (Figure 3.4.3.i.B).
No consistent, statistically significant differences in hippocampal Bmax values were 
observed at any time following the administration of paroxetine (Figure 3.4.3.Ü.A.).. 
The Æn of ^H-dexamethasone binding to CR at day 28 of paroxetine administration was 
significantly lower than in the control group (-41% - Figure 3.4.3.Ü.B.). Paroxetine 
withdrawal did not appear to affect Bmax or Æo values in hippocampus.
CR concentrations in rat striatum were significantly higher (+32%) than vehicle treated 
control values following 7 days of paroxetine administration but were not different 
from control values at any other time points (Figure 3.4.3.iii.A). Paroxetine withdrawal 
had no significant effects on Bmax values in the striatum. There were no significant
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effects of paroxetine administration or withdrawal on the Âb of specific ^H- 
dexamethasone binding to CR in rat striatum (Figure 3.4.3.iii.B).
The Bmax of specific ^H-dexamethasone binding to CR in the thymus was significantly 
reduced (-24%) following 28 days of paroxetine administration (Figure 3.4.3.iv.A). Æc 
values were not altered in rat thymus following drug administration or withdrawal 
(Figure 3.4.3.iv.B).
d) Lowry protein assay
There were no significant differences in protein content between vehicle and paroxetine 
treated animals, in any of the tissues investigated (Appendix 3.4.3).
Simple correlation analysis showed no statistically significant relationships between 
Bmax / and protein content (p>0.05) in either cortex or hippocampus in this study.
e) Plasma corticosterone concentrations
Plasma corticosterone values were log transformed and fitted to a normal distribution 
curve before being subjected to analysis of variance. Corticosterone concentrations 
were significantly elevated in animals receiving paroxetine for 14 days (+31% - Figure
3.4.3.V). There was a significant reduction in plasma corticosterone concentrations 
following paroxetine withdrawal (-44%) as compared to values in vehicle treated 
animals.
No significant interactions were observed between drug treatment (paroxetine or 
distilled water) and time (1,7, 14 and 28 days) for data on body weight, adrenal weight.
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CR binding parameters / protein content in cortex, hippocampus, striatum and thymus 
or plasma corticosterone concentrations using two-way ANOVA.
Table 3.4.3.
Time course of the effect of paroxetine administration on 
body weight (A) and adrenal weight (B).
(A)
Tim e after adm inistration o f  
PA R O X E T IN E  o r  vehicle (days)
CO NTR O L  
body w eight (g)
PA R O X E TIN E  
body w eight (g)
1 254 +  2  (n=40) 246 ± 3  (n=40)
7 293 +  3 (n=32) 290 ± 4  (n=32)
14 321 ± 5  (n=24) 319 ± 6  (n=24)
28 356 ± 4  (n=16) 365 +  9 (n=16)
7 days after w ithdrawal 359 ± 6  (n=8) 368 ± 1 5  (n=8)
(B)
Tim e after adm inistration o f  
P A R O X E TIN E o r  vehicle (days)
CO NTRO L  
A drenal w eight (g)
PA R O X E T IN E  
A drenal w eight (g)
1 45 ± 2 45 ± 3
7 - -
14 - -
28 59 ± 3 57 ± 3
7 days after w ithdrawal - -
Data for adrenal weights (B) are expressed as the weight per two adrenals in mg (mean ± sem). 
Rats (8 per group) received paroxetine (5mg/kg p.o.) or distilled water once daily and were 
sacrificed after 1, 7, 14 and 28 days of administration and 7 days following withdrawal of the 
dmg (as described in section 3.2). No statistically significant differences were determined using 
two-way ANOVA or Student’s t-tests. A N O V A :  B o d y  w e ig h t  -  e ffe c t o f  t r e a tm e n t  F  (1 , 6 3 )  = 
1 .3 5 , p = 0 .2 5 ;  - e f f e c t  o f  tim e  F  (3 ,6 3 )  = 2 8 .2 5 , p < 0 .0 0 0 1 ;  - in te r a c t io n  F  (3 , 5 6 )  = 0 .8 1 ,  
p = 0 .4 9 .  A d r e n a l  w e i g h t - e f f e c t  o f  tr e a tm e n t F  (1 , 3 1 )  =  0 .0 2 , p = 0 .8 9 ;  - e f f e c t  o f  t im e  F  (1 , 3 1 )  
= 2 4 .4 3 ,  p < 0 .0 0 0 1 ;  - in te ra c t io n  F  (1 , 3 1 )  — 0 .2 3 , p = 0 .6 3 .
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Figure 3.4.3.i
Time course of the effect of paroxetine administration on
Bmax (A) and^D (B) of specific ^H-dexamethasone binding to CR in rat cortex.
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Rats (7-8 per group) received paroxetine (5 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1,7,  14 and 28 days of administration and 7 days following withdrawal of the drug (see section
3.2). Data are expressed as mean ± sem. Mean B^ ax values ranged from 93-114 fmol/mg protein (vehicle 
groups) and 76-115 fmol/mg protein (paroxetine groups). Mean values in this region ranged from 
2.3-2.7 nM (vehicle groups) and 1.9-2.8 nM (paroxetine groups). Mean protein values ranged from 145- 
160 pg/assay (vehicle groups) and 150-173 pg/assay (paroxetine groups). Statistically significant 
differences were determined using two-way ANOVA followed by Student's t-test where appropriate. See 
Appendix 3.2(A). ANOVA:(CR o f  t r e a tm e n t  F ( l ,  5 8 ) = 0 .6 ,  p = 0 . 4 4 ;  - e f f e c t  o f  t im e  F (3 ,
5 8 ) = 0 .5 7 ,  p = 0 .6 4 ;  in te r a c t io n  F (3 , 5 8 ) = 2 .3 2 ,  p = 0 .0 8 7 .  CR (log Ko) - e f f e c t  o f  t r e a tm e n t  F ( l ,  5 7 ) = 1 .2 1 ,  
p = 0 .2 8 ;  - e f f e c t  o f  t im e  F (3 , 5 7 ) = 0 .4 9 ,  p = 0 .6 9 ;  - in te r a c t io n  F (3 , 5 8 ) = 0 .3 7 ,  p = 0 . 7 8 .  Student’s t-test;
* * ( p < 0 .0 1 ) .
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Figure 3.4.3.11
Time course of the effect of paroxetine administration on
Bmax (A) and Kp (B) of specific ^H-dexamethasone binding to CR in rat hippocampus.
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Rats (6-8 per group) received paroxetine (5 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1,7,  14 and 28 days of administration and 7 days following withdrawal of the drug (see section
3.2). Data are expressed as mean ± sem. Mean values ranged from 59-99 fmol/mg protein (vehicle 
groups) and 71-94 fmol/mg protein (paroxetine groups). Mean ATd values in this region ranged from 2.4- 
3.4 nM (vehicle groups) and 3-3.8 nM (paroxetine groups). Mean protein values ranged from 147-160 
pg/assay (vehicle groups) and 142-156 pg/assay (paroxetine groups). Statistically significant differences 
were determined using two-way analysis of variance and Student's t-test where appropriate. See 
Appendix 3.2(B). A N O V A :  C R  ( B ^ ) - e j f e c t  o f  t r e a m e n t  F  (1 , 5 8 ) = 0 .0 3 1 ,  p - 0 . 8 6 ;  - e f fe c t  o f  t im e  F  (3 ,
5 8 ) = 1 .0 ,  p = 0 . 4 ;  - in te r a c t io n  F  (3 , 5 8 ) = 1 .4 4 ,  p = 0 . 2 4 .  C R  (log Ko) - e f f e c t  o f  t r e a tm e n t  f  (1 , 5 8 ) = 0 .0 0 3  
p = 0 .9 6 ;  - e f f e c t  o f  t im e  F  (3 , 5 8 ) = 2 .1 2 ,  p = 0 . 1 1 ;  - in te r a c t io n  F  (3 , 5 8 ) = 1 .6 6 ,  p = 1 .9 .  Student’s t-test; 
* ( p < 0 .0 5 ) .
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Figure 3.4.3.111.
B
Time course o f  the e f fe c t  o f  paroxetine administration on
(A) and Kp (B) o f  sp ec if ic  ^H-dexamethasone binding to CR in rat striatum
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Rats (3-4 per group) received paroxetine (5 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1, 7, 14 and 28 days of administration and 7 days following withdrawal of the drug (as described in 
section 3.2). Striatal tissue was pooled from two animals in order to reliably conduct the CR binding 
assay therefore n=3-4 in each group. Data are expressed as mean ± sem. Mean B^ ax values ranged from 
66-107 fmol/mg protein (vehicle groups) and 61-98 fmol/mg protein (paroxetine groups). Mean 
values in this region ranged from 3.1-4.5 nM (vehicle groups) and 3-5.5 nM (paroxetine groups). Mean 
protein values ranged from 135-148 p.g/assay (vehicle groups) and 132-153 p.g/assay (paroxetine 
groups). Statistically significant differences were determined using two-way analysis of variance 
followed by Student’s t-test where appropriate. See Appendix 3.2(C). ANOVA: CR (Bmax) - e f f e c t  o f  
t r e a tm e n t  F  ( 1 ,2 8 ) = 0 .0 0 2 ,  p = 0 . 9 7 ;  - e f f e c t  o f  t im e  F  (3 , 2 8 ) = 0 .4 4 ,  p = 0 . 7 3 ;  - in te r a c t io n  (3 , 2 8 ) = 1 .5 6 ,  
p = 0 .2 3 .  CR (log Kd) - e f f e c t  o f  t r e a tm e n t  F  (1 , 2 8 ) = 0 .5 1 ,  p = 0 . 4 8 ;  - e f f e c t  o f  t im e  F  (3 , 2 8 )= ^ 0 .2 1 , p = 0 . 8 9 ;  
- in te r a c t io n  F  (3 , 2 8 )  =  1 .8 7 , p = 0 .1 7 .  Student’s t-test; ( p < 0 .0 5 ) .
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Figure 3.4.3.iv.
The effect of paroxetine administration on 
®max (A) and Kq (B) of specific ^H-dexamethasone binding to CR in rat thymus.
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Rats (7-8 per group) received paroxetine (5 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1 and 28 days of drug (as described in section 3.2). Data are expressed as mean ± sem. Mean B^ ax 
values ranged from 336-417 fmol/mg protein (vehicle groups) and 257-433 fmol/mg protein (paroxetine 
groups). Mean values in this region ranged from 2.8-3.3 nM (vehicle groups) and 2 .5 - 2 .1  nM 
(paroxetine groups). Mean protein values ranged from 156-160 pg/assay (vehicle groups) and 152-163 
pg/assay (paroxetine groups). Statistically significant differences were determined using two-way 
analysis of variance followed by Student's t-test where appropriate. See Appendix 3.2(D). ANOVA: CR 
(Bmax) o f  tr e a tm e n t  F  (1 , 3 0 ) = 1 .3 9 ,  p = 0 . 2 5 ;  - e f f e c t  o f  t im e  F  (1 , 3 0 ) = 2 2 .9 6 ,  p < 0 .0 0 0 1 ;  -
in te r a c t io n  F  (3 , 3 0 ) = 3 .1 7 ,  p = 0 .0 9 .  C R  ( lo g  K d )  - e f f e c t  o f  t r e a tm e n t  F  ( I ,  3 0 ) = 0 .8 3 ,  p - 0 . 3 7 ;  - e f f e c t  o f  
t im e  F  (1 , 3 0 ) = 2 .2 2 ,  p = 0 .1 5 ;  - in te r a c t io n  F  (3 , 3 0 ) = 0 .0 7 ,  p = 0 . 7 9 .  S t u d e n t ’s  t - te s t ;  * ( p < 0 .0 5 ) .
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Figure 3.4.3.V.
Time course of the effect of paroxetine administration on rat plasma
corticosterone concentrations.
à
az
g
HcmOU
OU
300-1
200-
100-
0-1
 -p
r r
01 7 14 28 0
o vehicle
• PAROXETINE
Days after PARO XEllNE 
administration
Days after 
PAROXEIINE 
withdrawal
Rats (6-8 per group) received paroxetine (5 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1,7, 14 and 28 days of administration and 7 days following withdrawal of the drug (as described in 
section 3.2). Data are expressed as mean ± sem. Mean corticosterone concentrations ranged from 125 - 
233 pg/L (vehicle groups) and 118 - 279 pg/L (paroxetine groups). Statistically significant differences 
were determined using two-way analysis of variance followed using Student's t-test where appropriate. 
A N O V A :  lo g  p l a s m a  [ c o r t i c o s t e r o n e ]  - e f fe c t  o f  t r e a tm e n t  F  (1 , 5 9 )  =  0 .6 8 ,  p = 0 . 4 1 ;  - e f fe c t  o f  t im e  F  (3 ,
5 9 )  =  4 .1 9 , p = 0 .0 1 ;  - in te r a c t io n  F  (3 , 5 9 )  =  1 .7 3 ,  p = 0 .1 7 .  S t u d e n t ’s  t - t e s t ;  * ( p < 0 .0 5 ) .
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3.4,4. Venlafaxine study 
a) Body /  adrenal weights
Data obtained for body and adrenal weight values conformed to a normal distribution.
No differences in body weight were observed following the administration of 
venlafaxine (15 mg/kg) for 28 days or 7 days of withdrawal from the drug (Table
3.4.4.A.).
There were no significant effects of venlafaxine administration for 1,14 and 28 days, on 
adrenal weights (Table 3.4.4.B.).
b)^H-dexamethasone binding to CR
Bmax values conformed to normal distributions however Kj) data did not and were log 
transformed before being subjected to analysis of variance. No statistically significant 
differences were observed in Bmax values of venlafaxine treated animals as compared to 
vehicle treated groups (Figure 3.4.4.i.A, Appendix 3.4.4).. The Kr> of specific 
dexamethasone binding to CR in rat cortex was not consistently altered by venlafaxine 
(Figure 3.4.4.i.B) but was significantly increased following 14 days of venlafaxine 
administration (+ 53%). Withdrawal of venlafaxine had no effect on Bmax or Kd values 
as compared to vehicle treated controls.
Hippocampal CR concentrations were not significantly affected by venlafaxine 
administration (Figure 3.4.4.Ü.A) and no differences were observed between values 
from vehicle or venlafaxine treated animals at any time points. The Kd of specific ^H- 
dexamethasone binding to CR was not consistently altered in rat hippocampus 
following venlafaxine (Figure 3.4.4.Ü.B) but an increase was observed following 14 
days of venlafaxine administration (+45%). Withdrawal from venlafaxine did not
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appear to have any effects on binding parameters of ^H-dexamethasone in 
hippocampus.
There were no significant effects of venlafaxine administration or withdrawal on 
striatal CR concentrations (Figure 3.4.4.iii.A). The Kd of specific ^H-dexamethasone 
binding to CR in rat striatum was not consistently affected by venlafaxine 
administration (Figure 3.4.4.iii.B) but significantly reduced after 7 days of withdrawal 
from the dmg.
No changes in the Bmax or Kd of specific ^H-dexamethasone binding to CR were 
observed in rat thymus following venlafaxine administration for 1, 14 and 28 days 
(Figure 3.4.4.iv).
Bmax values in hypothalamus were not significantly altered by the administration of 
venlafaxine over 28 days. Following the withdrawal of venlafaxine, Bmax values in 
treated animals were significantly higher (+41%) than in controls. There were no 
significant effects of venlafaxine administration or withdrawal on the Kd of specific ^H- 
dexamethasone binding to CR in rat hypothalamus (Figure 3.4.4.v).
c) Lowry protein assay
There were no significant differences in the protein content (p>0.05) of vehicle and 
venlafaxine treated animals in the various regions investigated (Appendix 3.4.4).
Simple correlation analysis showed no statistically significant relationships between 
Bmax / Kd and protein content in the cortex and hippocampus in this study.
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d) Plasma corticosterone concentrations
Values for corticosterone concentrations were log transformed prior to being subjected 
to analysis of variance. There were no statistically significant differences between 
plasma corticosterone concentrations observed in vehicle and dmg treated animals 
following administration or withdrawal of venlafaxine (Figure 3.4.4.vi).
Two-way ANOVA showed no significant interactions between dmg treatment 
(venlafaxine or distilled water) and time (1,7, 14 and 28 days) for data on body weight, 
adrenal weight, CR binding parameters / tissue protein content in cortex, hippocampus, 
striatum and thymus or plasma corticosterone concentrations.
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Table 3.4.4.
Time course of the effect of venlafaxine administration on 
body weight (A) and adrenal weight (B).
(A)
Time after administration of 
VENLAFAXINE or vehicle (days)
CONTROL VENLAFAXINE
1 274 ± 3  (n=40) 280 ± 4  (n= 40)
7 323 ± 5  (n=32) 329 + 5 (n= 32)
14 361 + 7 (n= 24) 369 ± 7  (n=24)
28 428 ± 11 (n= 16) 444 ± 13 (n= 16)
7 days after withdrawal 438 + 10 (n= 8) 471 ±21 (n= 8)
(B)
Time after administration of 
VENLAFAXINE or vehicle days)
CONTROL 
Adrenal weight (g)
VENLAFAXINE 
Adrenal weight (g)
1 54 ± 2 47 + 5
7 - -
14 47 ± 4 53 + 3
28 49 + 3 48 + 3
7 days after withdrawal - -
Data for adrenal weights (B) are expressed as the weight per two adrenals in mg (mean ± sem). Rats (8 
per group) received venlafaxine (15mg/kg p.o.) or distilled water once daily and were sacrificed after 
1, 7, 14 and 28 days of administration and 7 days following withdrawal of the drug (as 
described I section 3.2). No statistically significant differences were determined using two-way 
ANOVA, A N O V A :  B o d y  w e ig h t  -  e f f e c t  o f  tr e a tm e n t F  (1 , 6 3 )  = 0 .1 5 , p = 0 .7 0 ;  - e f f e c t  o f  tim e  
F  (3 ,6 3 )  = 5 0 .9 , p < 0 .0 0 0 1 ;  - in te r a c t io n  F  (3 , 6 3 )  = 1 .5 8 , p - 0 . 9 2 .  A d r e n a l  w e ig h t  -  e ffe c t o f  
tr e a tm e n t F  (1 , 4 7 )  = 0 .0 1 , p - 0 . 9 1 ;  - e f f e c t  o f  tim e  F  (2 , 4 7 )  = 0 .2 4 , p = 0 .7 9 ;  - in te r a c t io n  F  (2 , 
4 7 )  = 1 .9 4 , p = 0 .1 6 .
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Figure 3.4.4.1
Time course of the effect of venlafaxine administration on
®max (A) and (B) of specific ^H-dexamethasone binding to CR in rat cortex.
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Rats (7-8 per group) received venlafaxine (15 mg/kg, p.o.) or distilled water once daily and were 
sacrificed after 1,7,  14 and 28 days of administration and 7 days following withdrawal of the drug (as 
described in section 3.2). Data were expressed as mean ± sem. Mean B^ ax values ranged from 116-123 
fmol/mg protein (vehicle groups) and 120-149 fmol/mg protein (venlafaxine groups). Mean A'd values in 
this region ranged from 2.2-3.2 nM (vehicle groups) and 2.3-4.7 nM (venlafaxine groups). Mean protein 
values ranged from 140-157 pg/assay (vehicle groups) and 142-158 pg/assay (venlafaxine groups). 
Statistically significant differences were determined using two-way ANOVA followed by Student's t-test 
where appropriate. See Appendix 3.3(A). ANOVA: CR (B„ax) - e j f e c t  o f  t r e a tm e n t  F  (1 , 6 2 ) = 1 .1 8 ,  
p = 0 . 2 8 ;  - e f fe c t  o f  t im e  F  (3, 6 2 ) = 0 .4 7 ,  p = 0 . 7 1 ;  - in t e r a c t io n  F  (3, 5 5 ) = 0 .4 7 ,  p = 0 .7 1 .  CR (log Kd) - e f f e c t  
o f  t r e a tm e n t  F  (1 , 6 2 ) = 2 .9 6 ,  p = 0 . 0 9 1 ;  - e f f e c t  o f  t im e  F  (3, 6 2 ) = 0 .5 2 ,  p = 0 .6 7 ;  - in te r a c t io n  F  (3, 
6 2 ) = 1 .5 9 ,  p = 0 .2 0 .  Student’s t-test; * ( p < 0 .0 5 ) .
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Figure 3.4.4.Ü.
Time course of the effect of venlafaxine administration on
^ m a x  (A) and K g  (B) of specific ^H-dexamethasone binding to CR in rat hippocampus.
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Rats (7-8 per group) received venlafaxine (15 mg/kg, p.o.) or distilled water once daily and were 
sacrificed after 1,7, 14 and 28 days of administration and 7 days following withdrawal of the drug (as 
described in section 3.2). Data were expressed as mean ± sem. Mean B^ ax values ranged from 106-112 
fmol/mg protein (vehicle groups) and 102-139 fmol/mg protein (venlafaxine groups). Mean values in 
this region ranged from 2.1-2.6 nM (vehicle groups) and 1.5-4.2 nM (venlafaxine groups). Mean protein 
values ranged from 108-123 pg/assay (vehicle groups) and 108-119 pg/assay (venlafaxine groups). 
Statistically significant differences were determined using two-way ANOVA followed by Student's t-test 
where appropriate. See Appendix 3.3(B). A N O V A :  C R  (B ^ax) - e f fe c t  o f  t r e a tm e n t  F  (1 , 6 1 ) = 3 .7 9 ,  
p = 0 .5 7 ;  - e f f e c t  o f  t im e  F  (3 , 6 1 ) = 0 .4 4 ,  p - 0 . 7 2 ;  - in te r a c t io n  F  (3 , 6 1 ) = 0 .1 5 ,  p = 0 .9 3 .  C R  ( l o g  K o )  - e f f e c t  
o f  t r e a tm e n t  F  (1 , 6 I ) = 7 .3 7 ,  p = 0 .0 0 9 ;  - e f f e c t  o f  t im e  F  (3 , 6 1 ) = 0 .2 7 ,  p = 0 . 8 5 ;  - in t e r a c t io n  F  (3 , 
61  ) = 0 .3 6 ,p = 0 .7 8 .S t u d e n t ’s t - t e s t ;  * ( p < 0 .0 5 ) .
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Figure 3.4.4.111.
Time course of the effect of venlafaxine administration on
® m a x  (A) and (B) of specific ^H-dexamethasone binding to CR in rat striatum.
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Rats (4 per group) received venlafaxine (15 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1,7, 14 and 28 days of administration and 7 days following withdrawal of the drug (as described in 
section 3.2). Striatal tissues were pooled from two animals in order to reliably conduct the CR binding 
assay therefore n=3-4 in each group. Data were expressed as mean ± sem. Mean B^ax values ranged from 
112-170 fmol/mg protein (vehicle groups) and 105-191 fmol/mg protein (venlafaxine groups). Mean 
values in this region ranged from 1.8-3.3 nM (vehicle groups) and 1.7-2.8 nM (venlafaxine groups). 
Mean protein values ranged from 122-146 pg/assay (vehicle groups) and 130-145 pg/assay (venlafaxine 
groups). No statistically significant differences were determined using two-way analysis of variance or 
Student’s t-test. See Appendix 3.3(C). ANOVA: CR (B^ax) - e j f e c t  o f  t r e a tm e n t  F  (1 , 2 8 ) = 0 .3 3 ,  p = 0 . 5 7 ;  
- e f f e c t  o f  t im e  F  (3 , 2 8 ) = 1 .1 7 ,  p = 0 . 3 5 ;  - in te r a c t io n  F  (3 , 2 8 ) = 0 .7 6 ,  p = 0 .5 3 .  CR (log Kd) - e f f e c t  o f  
t r e a tm e n t  F  (1 , 2 8 ) = 0 .0 5 8 ,  p = 0 . 8 1 ;  - e f f e c t  o f  t im e  F  (3 , 2 8 ) = 0 .4 4 ,  p = 0 . 7 3 ;  - in t e r a c t io n  F  (3 , 2 8 ) = 0 .1 4 ,  
p = 0 .9 4 .  StudenCs t-test; * ( p < 0 .0 5 ) .
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Figure 3.4.4.iv.
Time course of the effect of venlafaxine administration on
Bmax (A) and Kd (B) of specific ^H-dexamethasone binding to CR in rat thymus.
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Rats (7-8 per group) received venlafaxine (15 mg/kg, p.o.) or distilled water once daily and were 
sacrificed after 1 , 7 ,  14 and 28 days o f administration and 7 days following withdrawal o f the drug (as 
described in section 3.2). Data were expressed as mean ± sem. Mean B^ax values ranged from 220-278  
fmol/mg protein (vehicle groups) and 219-302 fmol/mg protein (venlafaxine groups). Mean Kd values in 
this region ranged from 4.2-4.3 nM (vehicle groups) and 2 .6 -4 .7  nM (venlafaxine groups). Mean protein 
values ranged from 111-116 pg/assay (vehicle groups) and 102-111 pg/assay (venlafaxine groups). N o  
statistically significant differences were determined using two-way analysis o f variance or Student's t- 
test. See Appendix 3.3(D ). A N O V A :  C R  (B „ax) - e f f e c t  o f  t r e a tm e n t  F  (1 , 4 6 ) = 0 .0 0 4 ,  p = 0 . 9 5 ;  e f f e c t  o f  
t im e  F  (2 , 4 6 ) = 1 .0 4 ,  p = 0 . 3 7 ;  - in te r a c t io n  F  (2 , 4 6 ) = 0 .3 4 ,  p = 0 . 7 I .  C R  ( lo g  K d )  - e f f e c t  o f  t r e a tm e n t  F  ( I ,  
4 6 ) = 0 .1 8 ,  p = 0 . 6 8 ;  - e f f e c t  o f  t im e  F  (2 , 4 6 ) = 0 .5 9 ,  p = 0 . 5 6 ;  in te r a c t io n  F  (2 , 4 6 ) = 0 .6 3 ,  p = 0 . 5 4 .
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Figure 3.4.4.V.
Time course of the effect of venlafaxine administration on
®max (A) and Kp (B) of specific ^H-dexamethasone binding to CR in rat hypothalamus.
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Rats (4 per group) received venlafaxine (15 mg/kg, p.o.) or distilled water once daily and were sacrificed 
after 1,7,  14 and 28 days of administration and 7 days following withdrawal of the drug (as described in 
section 3.2). Hypothalamus tissues were pooled from two animals to increase the reliability of the CR 
binding assay in such small tissues. Data were expressed as mean ± sem. Mean B^ ax values ranged from 
88-142 fmol/mg protein (vehicle groups) and 104-174 fmol/mg protein (venlafaxine groups). Mean ATd 
values in this region ranged from 1.59-3.44 nM (vehicle groups) and 2.51-3.85 nM (venlafaxine groups). 
Mean protein values ranged from 102-143 pg/assay (vehicle groups) and 115-144 pg/assay (venlafaxine 
groups). No statistically significant differences were determined using two-way analysis of variance or 
Student's t-test where appropriate. See Appendix 3.3(E). ANOVA: CR (B ^ax) - e f f e c t  o f  t r e a tm e n t  F  (1 , 
3 1 ) = 0 .0 4 ,  p = 0 . 8 4 ;  - e f f e c t  o f  t im e  F  (3 , 3 1 ) = 1 .5 9 ,  p = 0 .2 2 ;  - in te r a c t io n  F (3 , 3 1 ) = 0 .9 9 ,  p = 0 . 4 2 .  CR (log 
K d )  - e f f e c t  o f  tr e a tm e n t  F  (  J , 3 1 ) = 0 .1 6 ,  p = 0 . 6 9 ;  - e f f e c t  o f  t im e  F  (3, 3 1 ) = 0 .1 6 ,  p = 0 . 9 2 ;  - in te r a c t io n  F  (3 , 
3 1 ) = l . l l , p = 0 . 3 7 .
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Figure 3.4.4.vi.
Time course of the effect of venlafaxine administration on
plasma corticosterone concentrations.
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Rats (7-8 per group) received venlafaxine (15 mg/kg, p.o.) or distilled water once daily and were 
sacrificed after 1, 7, 14 and 28 days of administration and 7 days following withdrawal of the drug (as 
described in section 3.2). Mean plasma corticosterone concentrations ranged from 49 - 58pg/L (vehicle 
groups) and 46 - 53 pg/L (paroxetine groups). No statistically significant differences were determined 
using two-way analysis of variance or Student’s t-test. ANOVA: log plasma [corticosterone] - e f fe c t  o f  
tr e a tm e n t  F  ( ] ,  6 2 )  -  2 .5 , p = 0 . I 2 ;  - e f fe c t  o f  t im e  F  (3 , 6 2 )  = 0 .4 0 ,  p = 0 .7 5 ;  - in te r a c t io n  F  (3 , 6 2 )  = 
1 .6 6 , p = 0 . I 9 .
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3.5. Discussion
The results of the present studies, summarised in Table 3.5, show that the 
administration of antidepressant drugs in rats produces a complex pattern of alterations 
in the parameters measured.
Table 3.5. Summary of results
PARAMETER DMI PAROXETINE VENLAFAXINE
BODY WEIGHT at day 21 ---
ADRENAL WEIGHT i  at days 14 & 21 --- ---
CR
CORTEX
T at day 14 ■I at day 14 ---
CR
HIPPOCAMPUS
CR
STRIATUM
--- T at day 7 ---
CR
HYPOTHALAMUS
CR
THYMUS
--- 4 at day 28 ---
PLASMA
CORTICOSTERONE
•I 1 days after 
withdrawal
T at day 14 
4  7 days after 
withdrawal
T/f- indicate significant increases/decreases in — denotes no change in B^ ax values. All differences 
displayed were statistically significant at a p<0.05 level as compared to vehicle controls.
DMI and corticosteroid receptors
DMI appeared to induce a reduction in body weights when administered for a period of 
more than 7 days that may be caused by the reported side effect of DMI as an appetite 
suppressant. The lower adrenal gland weights observed in DMI treated rats after 14 and 
21 days of administration are more likely to be due to the reduced body weights and 
overall smaller size of animals in these groups than DMI-induced alterations.
154
Although the administration of DMI to adrenally intact rats in the present study did not 
produce any striking effects on cortical corticosteroid receptor binding parameters, CR 
numbers were significantly increased at 14 days of DMI administration (Theodorou et 
al, 1997). However, there were no changes at 28 days of administration thus indicating 
that DMI does not consistently alter ^H-dexamethasone binding to cortical CR.
The observation that CR concentrations in the hippocampus were not affected by DMI 
administration or withdrawal appear to be in contrast with previous reports that long­
term treatment with DMI increases CR binding (+27-42%) and CR mRNA (+42%) 
concentrations in the hippocampus (Seckl & Fink, 1992; Budziszweska et al, 1994a; 
Okugawaetfl/, 1999).
Acute and long-term administration of tricyclic drugs are found to exert differing 
effects on monoamine levels in brain tissues with monoaminergic neurotransmission 
attenuated following chronic exposure (>2 weeks). It is possible that the increase in 
cortical CR may correspond with a DMI induced reduction in monoamine levels at this 
time.
As CR levels and biosynthesis are regulated to some degree by NA, it may be that the 
increase in CR induced by DMI administration is connected with the selective action of 
DMI on the NA uptake transporter and on monoaminergic transmission in brain tissues. 
Data pertaining to NA involvement in the modulation of CR is inconsistent. 6-OHDA 
lesions are demonstrated to reduce CR binding in the hippocampus and PVN but not in 
the hypothalamus (Weidenfeld et al, 1983; 1991) with some studies showing decreased 
hippocampal MR, but not GR numbers (Yau et al, 1992). Lowy (1990) demonstrated 
the reduction of type II CR in hippocampus, frontal cortex, hypothalamus, lymphocytes
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and spleen following reserpine administration and depletion of biogenic amines, 
possibly via an adrenal independent mechanism as these changes are also observed in 
adrenalectomised animals.
In contrast, Maccari et al (1992) have demonstrated increased hippocampal MRs and 
hypothalamic GRs following 6-OHDA lesions. Significantly increased hippocampal 
GR mRNA was observed following chronic DMI administration in DSP4 {N-{2- 
chloroethyl]-A-ethyl-2-bromobenzylamine) lesioned rats also supporting noradrenaline- 
independent regulation of GR mRNA by DMI (Rossby et al, 1995). The selective NA 
uptake inhibitors (desipramine and maprotiline) have also been shown to increase the 
GR mRNA level in primary cell cultures derived from rat hypothalamus in addition to 
those derived from the amygdala and/or cerebral cortex which do not contain 
monoaminergic neurones (Pepin et al, 1989). Desipramine has also been found to 
increase the GR mRNA concentration in mouse fibroblast and neuroblastoma cell 
cultures. As desipramine is found to increase GR gene promoter activity, it has been 
suggested that its action may be exerted at the genomic level (Pepin et al, 1992a).
Brady et al (1991) also demonstrated increased hippocampal MR and decreased levels 
of GR in the anterior pituitary, along with decreased CRF mRNA in the PVN and 
tyrosine hydroxylase in the LG following imipramine treatment. It has been suggested 
that, given the association of major depression with activated CRF and LC-NA 
systems, the therapeutic efficacy of imipramine may involve time-dependent effects of 
long-term administration on decreasing hypothalamic CRF mRNA and tyrosine 
hydroxylase in the LC.
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No consistent or significant alterations were observed in plasma corticosterone 
concentrations following long term DMI administration. Plasma corticosterone were 
much lower in treated groups 7 days after DMI withdrawal indicating a possible lag 
effect of DMI suppression of corticosterone output, to some degree, following repeated 
administration.
Paroxetine and corticosteroid receptors
Cortical CR were significantly decreased following 14 days of paroxetine 
administration as compared to controls (Maurya et al, 1998a). No other studies have 
reported reductions in CR binding in any brain regions following the administration of 
paroxetine though some investigations have reported a lack of effect of SSRFs on CR 
and CR mRNA measures in rat brain (Seckl & Fink, 1992; Budziszweska et al, 1994a; 
1994b).
Bmax values of ^H-dexamethasone binding to hippocampal CR were not significantly 
different from control values following chronic paroxetine administration. These results 
are in line with those of Budziszweska et a\ (1994a) who demonstrated that treatment 
with citalopram (an SSRI) had no effects on CR binding parameters in rat 
hippocampus. Repeated administration of citalopram did not induce alterations in CR 
mRNA expression in the rat hippocampus (Seckl & Fink, 1992).
^H-dexamethasone binding to CR in the striatum was elevated after 7 days of 
paroxetine treatment. Withdrawal of paroxetine appeared to have no effect on CR after 
7 days in the cortex, hippocampus or striatum.
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In the thymus, CR numbers were significantly reduced after 28 days of paroxetine 
administration (Maurya et al, 1998a). These results suggest that chronic paroxetine 
administration may induce a reduction of CR numbers in the cortex and also in a 
peripheral tissue, the thymus. If this is the case, the effects of paroxetine administration 
in the present study appear to be very region/tissue/time-specific and may be related to 
differing regulatory mechanisms for CR via different projections and innervations in 
these areas.
Plasma corticosterone concentrations in paroxetine treated animals were not 
consistently altered as compared with control groups. However a statistically 
significant increase in plasma corticosterone was observed at day 14 of paroxetine 
administration. This corresponds with the time course of the observed reduction in 
cortical CR and it may be that receptor occupancy by elevated circulating 
corticosterone concentrations is affecting CR measurements at this time.
Lesions of the 5-HT system using 5, 7-DHT (5, 7-dihydroxytryptamine) have been 
reported to decrease CR binding in rat hippocampus (Siegel et al, 1983). Serotonin and 
5 -HT2 agonists have been demonstrated to increase the Bmax of GR but not MR in 
hippocampal cell cultures (Mitchell et al, 1990; Vedder et al, 1993). In contrast to these 
results, investigations using chloripramine (5-HT reuptake inhibitor) and quipazine (a 
non-selective 5-HT agonist) have demonstrated reduced CR density in rat hippocampus 
(Angelucci etal, 1982).
The reported effects of 5-HT reuptake blockade depend on the dose and the region 
studied however, most SSRIs are found to enhance serotonergic neurotransmission 
(Pineyro & Blier, 1999). The results of the current investigation using paroxetine do not
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correspond with previous studies which have reported that elevated 5-HT levels lead to 
an induction of GR but not MR binding sites in cultured hippocampal cells (Mitchell et 
al, 1990). No up-regulation of CR was observed in any of our experiments however the 
systems being studied were very different in these investigations therefore the results 
are difficult to compare.
Venlafaxine and corticosteroid receptors
Specific ^H-dexamethasone binding to CR was not affected by venlafaxine 
administration in any of the brain regions investigated. Interestingly, the affinity of ^H- 
dexamethasone binding in the cortex and hippocampus following 14 days of 
venlafaxine administration was significantly decreased. This appears more likely to be 
a drug effect rather than a corticosterone effect, as plasma corticosterone was not 
altered at any point. Withdrawal of venlafaxine for 7 days had no significant effects on 
CR binding parameters. No changes in CR binding were observed following repeated 
venlafaxine administration in the thymus. Plasma corticosterone concentrations were 
unchanged by venlafaxine administration at all investigated time points.
Venlafaxine is reported to display both NA and 5-HT re-uptake inhibition when 
assessed using an in vivo electrophysiological paradigm. However venlafaxine 
demonstrates a greater potency to inhibit the 5-HT re-uptake process over that of NA in 
these conditions (Beique et al, 1998). Paroxetine and venlafaxine are equipotent to 
inhibit 5-HT reuptake while DMI is more potent than venlafaxine to block NA reuptake 
(Beique et al, 1998). This property of venlafaxine suggests, in light of our, and other 
studies with DMI and paroxetine, that its dual NA/5-HT reuptake properties may be 
exerting opposing actions on CR binding, resulting in no CR alterations following 
chronic administration.
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Most antidepressants affect the same neurotransmitter/receptor systems that are 
involved in HPA regulation. Modulation of various neurotransmitter systems following 
antidepressant treatment has also been reported to induce corresponding alterations in 
some elements of the HPA axis such as 5-HT receptor-mediated ACTH and 
corticosterone secretion (Li et al, 1993). However, though it is clear that the 
relationship between monoamines (especially 5-HT) and the HPA axis is extremely 
complex with multiple levels at which the two systems interact with each other, 
investigations using lesions of the 5-HT and NA systems have yielded conflicting data 
on changes in corticosteroid nuclear binding in rat hippocampus (Mitchell et al, 1990; 
Budziszweska, 1994b).
The hypothesis that antidepressants may help to maintain GR function in NA and 5-HT 
neuron-containing cell groups has been proposed by Kitayama et al (1988) who found 
that 2 weeks of imipramine administration increased GR immunoreactivity in the LC 
and raphe nucleus. This is an interesting proposal as the hippocampus, implicated in 
CR regulation and antidepressant effects, receives abundant NA and 5-HT innervation 
again, suggesting an intricate interplay of neurotransmitters and HPA axis components.
Pariante et al (1997) showed that desipramine induced GR translocation from the 
cytoplasm to the nucleus in the absence of steroids and with no effects alone on GR- 
mediated gene transcription in the mouse fibroblast cell line L929 (displaying NA 
reuptake-independent effects). Desipramine was also found to potentiate 
dexamethasone-induced GR translocation and GR-mediated gene transcription in these 
studies. These authors suggested that an important effect of antidepressants in vivo may 
involve the facilitation of GR translocation and activation of GR by circulating 
hormones, possibly via direct effects on one or more heat-shock-proteins (HSPs), thus
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facilitating dissociation from the HSP complex. This would have the overall result of 
increasing GR-mediated feedback inhibition on the HPA axis and reversing 
corticosteroid hypersecretion in depression. These findings propose a molecular 
mechanism by which antidepressants normalise HPA abnormalities and imply that GR 
up-regulation may be a consequence of these rather than their cause.
Several studies have demonstrated the up-regulation of CR binding and CR mRNA 
following the long-term treatment with tricyclic antidepressants and also reported the 
lack of effects of SSRFs on CR binding and mRNA expression mostly in the 
hippocampus (Peiffer et al, 1992; Reul et al, 1993; Budziszewska, 1994a; 1994b). The 
present studies have shown no significant changes following treatment with various 
antidepressants in the hippocampus but have demonstrated some tentative alterations in 
CR binding parameters in other brain regions and tissues. DMI administration produced 
an increase in Bmax values at specific time points -  which generally agrees with 
previous data. Bmax values at specific times following repeated paroxetine 
administration were reduced. Venlafaxine had no effects on Bmax values in any of the 
brain regions investigated. Since all the antidepressant drugs used in the present study 
have different mechanisms of action, it could be that their differing effects on CR 
binding are connected with their actions on different neurotransmitter systems. The 
increase in CR binding sites following DMI administration implies that NA projections 
from the locus coeruleus may act as in vivo GR up-regulators. It is also possible that 5- 
HT potentiation via paroxetine and/or venlafaxine causes very localised or discordant 
changes in GR expression that are undetectable in whole hippocampus, or other brain 
regions.
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The differing effects of the antidepressants used in these studies on corticosterone 
output and their correspondence with directions of alterations in CR binding are also of 
interest. It is possible that during the period of drug administration, changes in both 
monoaminergic transmission and corticosterone output could be involved in the 
modulation of brain corticosteroid receptors.
Adrenalectomy and corticosteroid receptors
Though it can be argued that accurate measures of CR can only be obtained in the 
absence of endogenous corticosteroids (Chou et al, 1988; Spencer et al, 1990), animals 
in the present study were not adrenalectomised prior to sacrifice as in all previous 
studies investigating antidepressant action on brain CR (Reul et al, 1993; 1994; 
Budziszweska et al, 1994b). Adrenally intact rats were used in these studies in order to 
determine the effects of antidepressant action on CR in the presence of endogenous 
ligand thereby allowing for a closer comparison to clinical observations of CR 
alterations following stress and antidepressant treatment. '
The presence of endogenous ligand in the system at the time of sacrifice would almost 
certainly affect measures of ^H-dexamethasone binding to CR in the present studies 
resulting in translocation of more CR (therefore a lower cytosolic availability of CR) 
than in previous investigations (Spencer et al, 1990). In the present studies circulating 
corticosterone concentrations were kept to minimal levels by sacrificing the animals 
between 08.00-1 l.OOhrs, at a time when plasma corticosterone levels are lowest (10- 
15pg/100mL - Shimuzu et al, 1983). As mentioned in section 2.12.7, this concentration 
of circulating plasma corticosterone would result in 70% and 30% type I and II receptor 
occupancy respectively, thus enabling the majority of CR in tissue preparations from 
adrenally intact rats to be investigated (Reul & De Kloet, 1985).
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The inconsistency of Bmax and Kd data obtained in the CR binding studies may reflect 
to some degree, the limitations of the CR radioligand binding assay which has involved 
the prior adrenalectomy (ADX) of animals to clear endogenous corticosteroids from 
CR binding sites. However, this procedure would in itself result in the state of the HPA 
axis being altered before any drugs were administered or measures attempted.
Several components of the HPA axis are changed by ADX. Spinedi et al (1991) have 
demonstrated enhanced ACTH synthesis and secretion following ADX with plasma 
and anterior pituitary ACTH concentrations increasing with time after ADX. Reul et al 
(1989) have demonstrated a transient increase in both type I and type II CR mRNA 
following ADX with significantly higher CR levels (2-3 fold higher than control 
values) at days 1 and 2 after ADX and a return to control values between 8-16 days 
after ADX. A significant up-regulation of CR (mostly type II receptors) has also been 
demonstrated in the frontal cortex, hippocampus, hypothalamus lymphocytes and 
spleen 3 days following ADX of rats (Lowy et al, 1990). An up-regulation of GR in the 
hippocampus and spleen has also been demonstrated several days after ADX (Chao et 
al, 1989; Spencer et al, 1991).
Investigations into CR mRNA levels following adrenalectomy have yielded 
inconsistent data. Reul et al (1989) showed a transient increase in hippocampal type I 
and type II receptor mRNA at 1-3 days post-ADX. No differences in hippocampal CR 
mRNA regulation were observed in studies by Chao et al (1989).
ADX-induced increases in CR binding capacity cannot be attributed to receptor 
occupation alone as CR levels continue to rise when all measurable plasma 
corticosterone has cleared and therefore indicates increased numbers of receptor
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molecules, a possible consequence of de novo synthesis of receptor protein (Chao et al, 
1989). The hippocampus, being the primary site of feedback control of corticosteroid 
hormones would appear to be most susceptible to alterations in CR expression 
following the removal of endogenous ligand. It appears quite possible therefore that the 
consistent up-regulation of CR binding and CR mRNA expression demonstrated in 
various tissues, especially the hippocampus, following repeated administration of 
antidepressants in ADX animals may be confounded by ADX-induced up-regulation of 
CR binding sites and CR mRNA expression.
It is apparent that quite different pharmacological effects can act clinically to alleviate 
depression. Though the notion that up-regulation of brain CR may reveal a common 
mechanism of action for many antidepressant drugs is gaining credence, in our studies 
the corresponding alterations of HPA function appear to be related to the properties of 
the neurotransmitter systems affected by the antidepressant drug. The present study 
also suggests that various brain regions may respond differently to antidepressant 
administration and/or corticosterone elevation. Many studies of CR regulation have 
focused solely on receptor levels in the hippocampus and have suggested that the 
hippocampus is uniquely sensitive to corticosteroid and stress effects on CR 
concentrations. The susceptibility of other brain regions or peripheral tissues to 
corticosteroid receptor down-regulation following chronic antidepressant 
administration has not been evaluated. Clearly, much more research is required to 
clarify the complexities of the interactions between antidepressants and components of 
the HPA axis.
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CHAPTER 4
EFFECTS OF ANTIDEPRESSANT ADMINISTRATION ON LOCOMOTOR 
ACTIVITY AND CORTICOSTEROID RECEPTOR BINDING IN 
THE OLFACTORY BULBECTOMISED RAT
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4.1 Introduction
4.1.1. The olfactory bulbectomised rat model of depression
Bilateral lesioning of the olfactory bulbs produces a variety of changes in the 
physiology, behaviour, neurochemical, immunological and endocrinological 
functioning of the rat which are largely reversed by chronic administration of 
antidepressant drugs (reviewed in Jesberger & Richardson, 1985; Kelly e t  a l ,  1995). 
The olfactory system has a highly complex sensory input, which affects a vast number 
of structures within the brain (see Figure 1). Some degree of denervation would occur 
in all of these regions following olfactory bulbectomy due to axotomy of cells and 
trans-neuronal and anterograde degeneration (Brunjes, 1992).
Figure 4.1.1. Schematic representation of the afferent and efferent connections of the 
olfactory bulbs in the rat.
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Widespread changes in various parameters induced by olfactory bulbectomy are 
generally manifested some time after bulb ablation and appear to be irreversible. The 
effects produced by removal of the olfactory bulbs are due to dismptions in non- 
sensory central processing rather than anosmia alone as illustrated by studies involving 
lavage of the nasal cavity with zinc sulphate to produce peripheral anosmia. Rats 
treated with zinc sulphate in this way were found to be similar to controls in terms of 
their gross behaviour while bulbectomised rats differed considerably (Alberts & 
Friedman, 1972; Sieck & Baumbach, 1974).
Rats subjected to olfactory bulbectomy have been reported to display changes in 
appetite/preference, fluid intake, reduced heart rates and blood pressure and disturbed 
sleep patterns and thermoregulation (Jancsar & Leonard, 1981; Redmond et al, 1995).
The hyperactivity of rats following bulbectomy is a well-documented phenomenon. 
Many studies have reported that bulbectomised rats displayed increased locomotor and 
exploratory activity in the open-field arena from two weeks after surgery. Open field 
hyperactivity was attenuated only by chronic administration of antidepressant drugs 
(reviewed in Kelly et al, 1995; Mundunkotuwa & Horton, 1996). Investigations of 
home cage activity by O’Halloran et al (1993) also revealed hyperactivity of the OB rat 
during the dark phase of the cycle, which is evident 10 days after surgery. Chronic 
treatment with imipramine was shown to reverse this hyperactivity in OB rats 
(Giardinia & Radek, 1991). Several investigations have also shown bulbectomised rats 
to display deficits in many tasks involving the use of learning and memory including 
deficits in step-down and step-through passive avoidance tests (Joly & Sanger, 1986, 
Tiong & Richardson, 1990) and altered performance in one-way active avoidance tasks
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(Broekkamp et al, 1980) and taste-aversion tests (Jancsar & Leonard, 1981, Redmond 
etal, 1995).
Performance in spatial learning tasks such as the radial maze and Morris water maze is 
also reportedly impaired in the OB rat providing strong evidence that olfactory bulb 
ablation affects non-olfactory brain regions (Hall & Macrides, 1983; Kelly et al, 1993a; 
Redmond et al, 1994). Recent experiments utilising cocaine-induced place preference 
also suggested the presence of an anhedonic condition in bulbectomised rats 
(Calcagnetti et al, 1996). Many other behaviours in the rat are impaired by olfactory 
bulbectomy and reversed by the chronic administration of antidepressants. These 
include reduced sexual behaviour (Lumia et al, 1987), impaired food-motivated 
behaviours (Kelly & Leonard, 1996) and increased muricidal and cannibalistic 
behaviour (Iwasaki et al, 1985). Many of these behavioural changes are reversed by 
chronic antidepressant administration however the specificity of some of these 
behaviours to detect antidepressant activity of drugs is questionable.
4.1.2. Neurochemical alterations in the OB rat
Reports of neurochemical alterations following olfactory bulbectomy have been 
inconsistent. However, generally NA concentrations and turnover in various brain 
regions were reduced, (Song & Leonard, 1995), p-adrenoceptor binding was increased 
(Tiong & Richardson, 1990), central ai-receptor density was increased (Hong et al, 
1987) and the growth hormone response to clonidine was blunted (Redmond, 1995).
In addition, 5-HT concentrations were found to be reduced and 5-HIAA concentrations 
increased in various brain regions of the OB rat (Jancsar & Leonard, 1984; Song & 
Leonard, 1995). Bulbectomy has also been associated with an increase in the density of
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5-HT2A receptors in the frontal cortex (Gurevich et al, 1993) and reduced platelet 5-HT 
uptake and [^H]-imipramine binding sites in the hippocampus (Butler et al, 1988). 
Increased plasma concentrations of ai-acid glycoprotein (AGP), an allosteric 
modulator of the 5-HT transporter, have also been reported in both the OB rat and 
depressed patients (Arnold & Meyerson, 1990; Nemeroff et al, 1990). Many altered 
responses to 5-HT releasing agents and 5-HT receptor agonists have also been reported 
in the OB rat suggesting changes in mechanisms of 5-HT release and receptor function 
(McGrath et al, 1996 -  PhD thesis, NUI). Behavioural normalisation following 
antidepressant administration has also frequently been correlated with restoration of 
normal 5-HT function (Mundunkotuwa & Horton, 1996; Grecksch et a\, 1997).
In the OB rat, acetycholine concentrations are reduced in the cerebral cortex and 
increases in choline acetyltransferase activity have been reported, with an increased 
response to physostigmine demonstrated in some studies suggesting that altered central 
cholinergic transmission may be involved in the bulbectomy syndrome (Broekkamp et 
al, 1986). Reduced muscarinic receptor binding in several brain regions of the OB rat, 
including the amygdaloid cortex, hippocampus and hypothalamus (Earley et al, 1994) 
has contrasted with the increased muscarinic receptor binding seen in post-mortem 
brain tissue from suicide victims (Meyerson et al, 1982).
G ABA turnover is reportedly increased in the amygdala following olfactory 
bulbectomy (Jancsar & Leonard, 1984). Dennis et al (1993) reported increased GABAa 
receptors and decreased GABAb receptors in the frontal cortex of OB rats. However, 
some of these deficits are found to normalise with time. The argument for increased 
GABAergic function in the bulbectomised rat is further supported by reported increases 
in central benzodiazepine sites (Dennis et al, 1995).
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Increases in glycine concentrations and decreases in glutamate and aspartate (Schofield 
et al, 1983) have been demonstrated following olfactory bulbectomy implying that an 
imbalance in these amino acids may form part of the OB syndrome. In recent years, 
there has been much interest in the involvement of the NMDA (N-methyl-D-aspartate) 
receptor in the pathology of depression and studies in OB rats also suggest that 
NMDA-induced responses are increased following bulbectomy (Paul et al, 1994; 
Redmond effl/, 1995).
Recent studies have claimed that the olfactory bulbectomised rat model of depression 
shares many immune alterations commonly observed in depressed patients including 
reduced neutrophil phagocytosis and mitogen-stimulated lymphocyte proliferation 
(O’Neill & Leonard, 1986; Song et al, 1994). Significant reductions in neutrophil 
catalase activity and increases in superoxide dismutase activity have been demonstrated 
in bulbectomised rats (Song et al, 1994). This study also reported altered differential 
white blood cell profiles following bulbectomy, consisting of a reduction in the 
percentage of lymphocytes and an increase in the percentage of neutrophils in the 
blood.
OB rats are also reported to show increased positive acute phase proteins, reduced 
negative phase proteins, increased leukocyte aggregation and increased ai-acid 
glycoprotein levels, as observed in depressed patients, in addition to reduced weights of 
the immune-related organs such as the thymus and spleen (Arnold & Meyerson, 1990; 
Song et aZ 1995).
Considering that olfactory bulbectomy results in a degeneration of neuronal pathways 
to the amygdala and altered innervation from the amygdala to the hypothalamus.
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coupled with alterations in the concentration and turnover of various neurotransmitters 
involved in the regulation of pituitary hormone release, it is possible that this lesion is 
associated with changes in HPA-axis function. Lesioning of the olfactory bulbs is 
reported to produce numerous effects on neuroendocrine parameters however, many 
studies have yielded inconclusive data with regards to functioning of the HPA-axis in 
the OB rat.
The HPA-axis of the hypercortisolaemic depressed patient has many features including 
impaired negative feedback and hypertrophy of the adrenal glands. The most studied 
endocrine change measured in depression is the hypersecretion of corticosteroids, 
which is achieved as a result of adaptive changes at several levels of the HPA-axis and 
the non-suppression of this drive by the administration of dexamethasone (Carroll, 
1982; Checkley, 1996). An investigation of endocrine alterations in the OB rat may 
determine whether the HPA-axis disturbances observed in clinical depression are 
features that are modelled by the OB rat.
4.1.3. Endocrinological alterations in the olfactory bulbectomised rat
Investigations have shown that bilateral olfactory bulbectomy results in elevation of 
both basal and stress-induced plasma corticosterone levels that can be reversed by 
chronic antidepressant administration (Caimcross et al, 1977; 1979; Catterelli & 
Damael, 1986). However, similar studies by Broekkamp (1986) and O’Connor & 
Leonard (1985) failed to confirm these findings. Other investigations have 
demonstrated a hypersecretion of corticosterone during the dark phase of the light:dark 
cycle with normal corticosterone secretion during the light phase (Figure 4.1.1; Song et 
al, 1994) suggesting that there may be an altered periodicity of corticosterone secretion 
in the OB rat (Marcilhac et al, 1997).
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Figure 4.1.2. Circadian pattern of corticosterone secretion following olfactory 
bulbectomy. 6 weeks after surgery, plasma corticosterone was measured at intervals during the 
24-hour cycle. Results are expressed as mean ± sem corticosterone concentration. Shaded area 
is the dark photoperiod. *p<0.05 vs. sham control, n = 5-7. Taken from Kelly e t  a l \  1995.
There is considerable evidence that, in humans, altered circadian rhythmicity occurs in 
association with several categories of depressive disorders. Patterns of rhythm 
disturbance have also been reported on behavioural, physiological and endocrinological 
parameters in the OB rat model indicating that bulb lesions may have complex effects 
on the pituitary-gonadal axis. Bulbectomy was found to affect the circadian rhythm of 
motor activity in rats (Giardina & Radek, 1991; Marcilhac et al, 1999) and mice 
(Possidente et al, 1996) and delayed the onset of entrained activity by over an hour and 
half (Possidente et al, 1990). Circadian rhythms of body temperature were also altered 
in the OB rat (Marcilhac et al, 1997) corresponding to studies in monkeys with 
maternal separation-induced depression (Reite et al, 1982) and the higher body 
temperatures seen in depressed patients (Pflug et al, 1983). Changes in circadian 
periodicity in OB rats also correspond with reports of increased basal cyclic AMP 
levels in the suprachiasmatic nucleus (SCN) of the hypothalamus (Vagell et al, 1991). 
This suggests that the observed changes could be due to a direct effect of bulbectomy
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on circadian oscillators in the SCN and not as a result of effects on the pituitary- 
gonadal axis.
Investigations of dexamethasone suppression in the bulbectomised rat found that there 
were no differences between OB and sham-operated rats (O’Connor, 1985). A modified 
DST has also been applied to the OB rat (Kelly & Leonard, 1993b) demonstrating 
suppression of corticosterone output 12 hours after dexamethasone administration 
under basal and stress-induced conditions. However, 36 hours after dexamethasone 
administration, the corticosterone surge had returned under basal conditions whereas 
there appeared to be a prolonged blunting of this effect under stress-induced conditions 
(see Figure 4.1.2). These results suggest that the OB rat may also differ to controls in 
its endocrinological response to stress.
Hypertrophy of the adrenal glands has also been demonstrated in bulbectomised rats 
(Eichelman et al, 1972) corresponding to results found in depressed patients (Nemeroff 
et al, 1992).
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Figure 4.1.3. DST in the OB rat. Two weeks after surgery, rats received dexamethasone (lOOfig/kg, 
i.p.). Blood samples were obtained 12 hours later, either under basal or stress-induced conditions. Results 
are expressed as mean ± sem corticosterone concentration. ***p<0.001 vs. relevant vehicle-treated 
group, n = 7-12. Taken from Kelly et al, 1995.
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There is substantial evidence that the olfactory bulbectomised rat fulfils most of the 
criteria of an animal model of depression. Many of the behavioural, physiological and 
neurochemical changes observed in the rat following bilateral olfactory bulbectomy 
appear to reflect symptoms and alterations seen in clinical depression. The bilaterally 
olfactory bulbectomised rat has been suggested as an appropriate model for depressive 
illness in that the consequences of disruptions in behavioural and neuronal functioning 
induced by the lesion may be largely reversed by chronic antidepressant treatment 
(Jesberger & Richardson, 1985). It appears that the OB rat may also reasonably model 
some of the neuro-endociine dysfunction observed in chronically depressed patients 
with a reversal of some symptoms following chronic antidepressant administration. It 
would be expected therefore that the OB rat would also exhibit the impaired negative 
feedback of corticosterone on corticosteroid receptors (via a reduction of MR and GR) 
commonly observed in depression. However, no studies have been performed in 
bulbectomised rats as yet to investigate this aspect of HPA-axis function.
The aims of this chapter are to study OB and antidepressant induced effects on both 
locomotor activity and ^H-dexamethasone binding to hippocampal GR. This will be 
achieved by;
• the investigation of patterns of locomotor activity (using the open-field arena) 
following olfactory bulbectomy.
• investigation of the effects of acute and chronic administration of venlafaxine, 
citalopram, DM1 or milnacipran on locomotor activity in the OB rat.
• the investigation of ^ H-dexamethasone binding to GR in the hippocampus following 
olfactory bulbectomy.
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investigation of the effects of acute and chronic administration of venlafaxine,
citalopram, DMI or milnacipran. on ^H-dexamethasone binding to hippocampal
CR in the OB rat.
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4.2 Methods
4.2.1 Animals
Male Sprague-Dawley rats (230-250g; Harlan-Olac, U.K.) were housed 4 per cage 
(45cm X 25cm x 20cm) under conditions of standard lighting (light period 08.00- 
20.00hrs) and temperature (20-22°C). A standard laboratory diet was available ad 
libitum except for the periods during which behavioural measurements were taken.
4.2.2 Olfactory bulbectomy
Following a one-week acclimatisation period, bilateral olfactory bulbectomy was 
performed essentially as described by Caimcross gr al (1978). Rats were anaesthetised 
with 2.5% w/v 2-2-2 tribromoethanol (lOml/kg i.p.). The head was shaved and a mid­
line sagittal incision was made extending at least 1cm rostral to the bregma, to expose 
the skull overlying the bulbs. Sufficient pressure was applied to ensure that the 
periostium on the underlying bone had been penetrated. Two burr holes (2mm in 
diameter) were drilled through the skull, 5mm rostral to the bregma and 2 mm lateral to 
the midline, at a point corresponding to the posterior margin of the orbit of the eye 
(Figure 4.2.2). For sham animals, the dura was carefully pierced and the wound closed. 
For OB animals the olfactory bulbs, located directly below the burr holes, were 
removed by aspiration (e.g. by means of a blunt hypodermic needle attached to a water 
pump). Care was taken to avoid damage to the frontal cortex. Post-operative bleeding 
was controlled by filling the wound with haemostatic sponge. Oxytetracyline powder 
was applied to the wound prior to closure with 7.5mm surgical clips. The animals were 
allowed to recover for 14 days following surgery and were handled daily throughout 
the recovery period to eliminate any aggressive behaviour that may otherwise arise 
(Leonard & Tuite, 1981). Following the completion of behavioural studies on the 
animals, the brains were checked for damage to the frontal cortex and/or incomplete
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removal of the olfactory bulbs. Results obtained from  any rats displaying the above 
were excluded from further analysis.
Figure 4.2.2.
A schematic diagram of the location of the burr holes relative to the main anatomical landmarks 
of the rat skull and the position of the olfactory bulbs in the cranial cavity. Modified from Van 
Riezen & Leonard, 1991).
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4.2.3. Experimental design and drug administration
Two weeks after surgery, the animals were randomly allocated to 6 sets (corresponding 
to the 6 different time points under investigation) of 10 groups (see Figure 4.2.3):
Group 1 : sham + vehicle
Group 2: sham + citalopram (5mg/kg x 2)
Group 3: sham + venlafaxine (15mg/kg x 2)
Group 4: sham + DMI (5mg/kg x 2)
Group 5: sham + milnacipran (15mg/kg x 2)
Group 6: OB + vehicle
Group 7: OB + citalopram (5mg/kg x 2)
Group 8: OB+venlafaxine (lOmg/kg x 2)
Group 9: OB + DMI (5mg/kg x 2)
Group 10:OB+milnacipran (15mg/kg x 2)
Body weights were recorded regularly throughout the study. Citalopram, venlafaxine, 
DMI and milnacipran were dissolved in distilled water to give concentrations of 5, 15, 
5 and 15 mg/kg respectively. These were administered p.o. in a dosage volume of 
ImL/kg, twice a day (08.00-09.00 and 17.00-18.00 hours). Controls received injections 
of vehicle alone.
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Figure 4.2.3.
Experimental design for OB studies
Day 3 Day 7 Day 10 Day 14 Day 21 Day 28
Day-22 to -15 Acclim. Acclim. Acclim. Acclim. Acclim. Acclim.
Day-15 OB OB OB OB OB OB
Day -14 to 0 recovery recovery recovery recovery recovery recovery
Day 1 to 3 drug drug drug drug drug drug
Day 4 OFT drug drug drug drug drug
Day 5-7 drug drug drug drug drug
Day 8 OFT drug drug drug drug
Day 9 to 10 drug drug drug drug
Day 11 OFT drug drug drug
Day 12 to 14 drug drug drug
Day 15 OFT drug drug
Day 16 to 20 drug drug
Day 21 OFT drug
Day 22 to 27 drug
Day 28 OFT
• Acclim. = acclimatisation period
• OB = OB surgery
• Dmg = drug administration
• OFT = open field testing
All rats were sacrificed immediately following open field testing.
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4,3.3. Study l . b ) -  ^H-dexamethasone binding to hippocampal CR in OB and SO rats 
following acute and chronic administration o f antidepressant drugs
Due to problems encountered with the Lowry protein assay, Bmax values are expressed 
in fmoles/mg tissue as these are more accurate than data expressed as fmoles/mg 
protein for this particular study.
i )  O l f a c t o r y  b u lb e c t o m y
There were no significant differences in the Bmax or Æo of specific ^H-dexamethasone 
binding to hippocampal CR from vehicle treated SO and bulbectomised rats (see Tables
4.3.3.B.i-iv).
it) Citalopram
No significant differences in CR numbers were observed between any of the groups at 
day 3 of citalopram administration (Table 4.3.3.B.1). At day 28, the citalopram treated 
group displayed higher Bmax values than their respective vehicle-treated controls. This 
difference in specific ^H-dexamethasone binding was significant between OB vehicle 
and citalopram treated groups and narrowly escaped statistical significance between 
SO-vehicle and SO-citalopram treated groups. ANOVA revealed a significant 
interaction between treatment x time for Bmax values.
No significant differences in values were observed between any of the groups at any 
time point neither were there any ANOVA interactions between the factors involved 
for this parameter (Table 4.3.3.B.1).
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in )  V e n la fa x in e
Bmax values were not significantly altered in any of the groups following 3 days of 
venlafaxine administration (Table 4.3.3.B.Ü). Following 28 days of venlafaxine 
administration, there was a significant increase in Bmax values in the SO animals as 
compared to their vehicle-treated controls. No differences were observed between OB 
vehicle and venlafaxine treated groups at day 28 of drug administration. ANOVA 
revealed a no significant interactions of factors for Bmax values in this study.
There were no differences in TTo values between any of the groups following 3 days of 
venlafaxine administration however Æo values were significantly increased in the SO- 
venlafaxine treated group (as compared to SO-vehicle treated group) following 28 days 
of drug administration. No significant ANOVA interactions were observed between 
any factors for Æn values.
i v )  D M I
There were no significant differences in the Bmax or Æo of specific dexamethasone 
binding to CR in any of the groups at either day 3 or day 28 of DMI administration 
(Table 4.3.3.B.iii). No significant ANOVA interactions between any of the factors were 
observed in this study.
v )  M i ln a c i p r a n
Bmax or values were not significantly altered in any of the groups following either 3 
or 28 days of milnacipran administration. A significant ANOVA interaction between 
drug treatment x lesion was observed for Bmax values however, no significant ANOVA 
effects or interactions were observed for Kr> values (Table 4.3.2.iv).
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Table 4.3.3.B.1
Bmax (A) and i^ D (B) of specific ^H-dexamethasone binding to hippocampal CR of sham-
operated (SO) and olfactory bulbectomised (OB) rats following acute and chronic
administration of citalopram.
(A) Bmax (fmol/mg tissue)
SO + vehicle SO + citalopram OB + vehicle OB 4- citalopram
3 days 2.78 ± 0.3 3.1 ±0.12 4.1 ±0.86 2.94 ±0.26
28 days 2.53 ± 0.28 3.2 ±0.19 2.88 ±0.14 3.38 ±0.14*
(B)Ko (nM)
SO + vehicle SO + citalopram OB + vehicle OB + citalopram
3 days 0.95 + 0.12 1.0 ±0.12 1.57 ±0.55 2.3 ± 0.97
28 days 1.32 ±0.3 1.5 ±0.21 1.83 ±0.26 1.8 ±0.18
Rats (7-10 per group) received citalopram (5mg/kg p.o.) or distilled water twice daily and were sacrificed 
after 3 and 28 days of administration. CR binding assays were carried out as described in section 2.3. 
Data are expressed as mean ± sem. Statistically significant differences were determined using ANOVA 
followed by Students t-tests (GB-STAT v6.0). Statistically significant differences; OB-vehicle vs. OB- 
citalopram *p<0.05, ANOVA : CR (Bmax) -  e j f e c t  o f  t r e a tm e n t  F (1, 53) = 0.11, p=0.74: e f f e c t  o f  t im e  F 
(1, 53) = 0.91, p=0.34; e f f e c t  o f  l e s io n  F (1, 53) = 3.08, p=0.085; in te r a c t io n  t r e a tm e n t  x  t im e  F (1, 53) 
= 4.3, p=0.04; in te r a c t io n  t r e a tm e n t  x  le s io n  F (1, 53) = 2.89, p=0.095; in te r a c t io n  l e s io n  x  t im e  F (1, 
53) = 0.41, p=0.52; in te r a c t io n  t r e a tm e n t  x  t im e  x  le s io n  F (1, 53) = 1.85, p=0.18. CR (log Ko) -  e f f e c t  
o f  t r e a tm e n t  F (1, 53) = 0.94, p=0.34: e f f e c t  o f  t im e  F (1, 53) = 4.26, p=0.04; e f fe c t  o f  le s io n  F (1, 53) = 
5.34, p=0.025; in te r a c t io n  t r e a tm e n t  x  t im e  F (1, 53) = 0.1, p=0.75; in te r a c t io n  t r e a tm e n t  x  le s io n  F (1, 
53) = 0.01 p=0.92; in te r a c t io n  l e s io n  x  t im e  F (1, 53) = 0.008, p-0.93; in te r a c t io n  t r e a tm e n t  x  t im e  x  
le s io n  F (1, 53) = 0.38, p=0.54.
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Table 4.3.3.B.Ü
Bmax (A) and Æo (B) of specific ^H-dexamethasone binding to hippocampal CR of sham-
operated (SO) and olfactory bulbectomised (OB) rats following acute and chronic
administration of venlafaxine.
(A) Bmax (fmol/mg tissue)
SO + vehicle SO + venlafaxine OB + vehicle OB + venlafaxine
3 days 2.78 ±0.3 2.93 ±0.28 4.1 ±0.86 3.35 ±0.39
28 days 2.53 ±0.28 3.59 ±0.2** 2.88 ±0.14 2.97 ± 0.22
(B)Ko(nM)
SO + vehicle SO + venlafaxine OB + vehicle OB + venlafaxine
3 days 0.95 ±0.12 1.3 ±0.3 1.57 ±0.55 1.8 ±0.41
28 days 1.32 ±0.3 2.1 ± 0 .23* 1.83 ±0.26 1.5 ±0.24
Rats (7-10 per group) received venlafaxine (15mg/kg p.o.) or distilled water twice daily and were 
sacrificed after 3 and 28 days of administration. CR binding assays were carried out as described in 
section 2.3. Data are expressed as mean ±  sem. Statistically significant differences were determined 
using ANOVA followed by Students t-tests (GB-STAT v6.0). Statistically significant differences; SO- 
vehicle vs. SO-citalopram *p<0.05 and 0 1 .  ANOVA :  CR (Bmax) -  e f f e c t  o f  t r e a tm e n t  F  (1 , 5 4 )  = 
0 .2 8 ,  p = 0 . 6 :  e f f e c t  o f  t im e  F (1 , 5 4 )  =  1 .2 6 , p =  0 .2 7 ;  e f f e c t  o f  le s io n  F (1 , 5 4 )  =  1 .9 5 ,  p = 0 .1 7 ;  
in te r a c t io n  t r e a tm e n t  x  t im e  F (1 , 5 4 )  =  2 .7 1 ,  p = 0 . 1 1 ;  in te r a c t io n  t r e a tm e n t  x  l e s io n  F (1 , 5 4 )  =  3 .1 2 ,  
p = 0 . 0 8 ;  in te r a c t io n  l e s io n  x  t im e  F (1 , 5 4 )  =  3 .6 2 ,  p = 0 . 0 6 ;  in te r a c t io n  t r e a tm e n t  x  t im e  x  l e s io n  F (1 , 5 4 )  
=  0 .0 0 5 ,  p = 0 . 9 5 .  CR (log Ko) -  e f fe c t  o f  t r e a tm e n t  F (1 , 5 4 )  =  1 .8 2 ,  p - 0 . 1 8 :  e f fe c t  o f  t im e  F (1 , 5 4 )  = 
4 .5 8 ,  p - 0 . 0 3 7 ;  e f f e c t  o f  le s io n  F (1 , 5 4 )  = 0 .9 5 , p = 0 . 3 3 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F (1 , 5 4 )  =  0 .0 2 ,  
p = 0 . 8 9 ;  in te r a c t io n  t r e a tm e n t  x  l e s io n  F (1 , 5 4 )  =  1 .2 9  p = 0 . 2 6 ;  in te r a c t io n  l e s io n  x  t im e  F (1 , 5 4 )  =  
1 .0 2 ,  p = 0 . 3 2 ;  in te r a c t io n  t r e a tm e n t  x  t im e  x  le s io n  F (1 , 5 4 )  =  2 .2 9 ,  p = 0 .1 4 .
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Table
Bmax (A) and Ko (B) of specific ^H-dexamethasone binding to hippocampal CR of sham-
operated (SO) and olfactory bulbectomised (OB) rats following acute and chronic
administration of DMI.
(A) Bmax (fmol/mg tissue)
SO + vehicle SO + DMI OB + vehicle OB + DMI
3 days 2.78 ±0.3 3.65 ±0.4 4.1 ±0.86 3.72 ±0.31
28 days 2.53 ± 0.28 3.13 ±0.29 2.88 ±0.14 2.95 ±0.2
i)Kjy(nM)
SO + vehicle SO + DMI OB + vehicle OB + DMI
3 days 0.95 ±0.12 0.9 ± 0.06 1.57 ±0.55 1.5 ±0.27
28 days 1.32 ±0.3 1.7 ±0.38 1.83±a.26 2.2 ±0.64
Rats 7-10 per group received DMI (5mg/kg p.o.) or distilled water twice daily and were sacrificed after 3 
and 28 days of administration. CR binding assays were carried out as described in section 2.3. Data are 
expressed as mean ± sem. Statistically significant differences were determined using ANOVA followed 
by Students t-tests where appropriate (GB-STAT v6.0) however, no statistically significant differences 
were observed in this study. ANOVA : CR (Bmax) -  e f fe c t  o f  t r e a tm e n t  F (1, 54) = 1.12, p=0.29: e f f e c t  o f  
t im e  F (1, 54) = 6.34, p= 0.015; e f fe c t  o f  le s io n  F (1, 54) = 2.04, p=0.16; i n te r a c t io n  tr e a tm e n t  x  t im e  F 
(1, 54) =  0.03, p=0.87; in te r a c t io n  t r e a tm e n t  x  l e s io n  F (1, 54) = 2.68, p=0.11; in te r a c t io n  le s io n  x  t im e  
F (1, 54) = 1.26, p=0.27; in te r a c t io n  t r e a tm e n t  x  t im e  x  l e s io n  F (1, 54) = 0.43, p=0.51. CR (log K o )  -  
e f fe c t  o f  t r e a tm e n t  F (1, 54) = 0.49, p=0.49: e f fe c t  o f  t im e  F (1, 54) =  5.85, p=0.019; e f fe c t  o f  l e s io n  F 
(1, 54) = 4.16, p=0.046; in te r a c t io n  t r e a tm e n t  x  t im e  F (1, 54) = 0.005, p=0.94; in te r a c t io n  t r e a tm e n t  x  
l e s io n  F (1, 54) = 0.018 p=0.89; in te r a c t io n  le s io n  x  t im e  F (1, 54) = 0.079, p-0 .78; in te r a c t io n  
t r e a tm e n t  X t im e  x  l e s io n  F (1, 54) -  0.64, p=0.43.
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Table 4.3.3.B.iv.
Bmax (A) and Æo (B) of specific ^H-dexamethasone binding to hippocampal CR of sham-
operated (SO) and olfactory bulbectomised (OB) rats following acute and chronic
administration of milnacipran.
(A) Bmax (fmol/mg tissue)
SO + vehicle SO + milnacipran OB + vehicle OB + milnacipran
3 days 2.78 ±0.3 2.94 ±0.25 4.1 ±0.86 2.88 ±0.15
28 days 2.53 ±0.28 3.1 ±0.31 2.88 ±0.14 2.54 ±0.31
l)^D(nM)
SO + vehicle SO + milnacipran OB + vehicle OB + milnacipran
3 days 0.95 ±0.12 1.1 ±0.12 1.57 ±0.55 1.1 ±0.15
28 days 1.32 ±0.3 2.1 ±0.36 1.83 ±0.26 1.6 ±0.28
Rats 7-10 per group received milnacipran (15mg/kg p.o.) or distilled water twice daily and were 
sacrificed after 3 and 28 days of administration. CR binding assays were carried out as described in 
section 2.3. Data are expressed as mean ± sem. Statistically significant differences were determined 
using ANOVA followed by Students t-tests where appropriate (GB-STAT v6.0) however, no statistically 
significant differences were observed in this study. ANOVA : C R  (Bmax) ~ e f f e c t  o f  t r e a tm e n t  F (1 , 5 3 )  = 
0 .6 2 , p = 0 . 4 4 :  e f f e c t  o f  t im e  F (1 , 5 3 )  =  2 .4 2 ,  p =  0 .1 3 ;  e f f e c t  o f  l e s io n  F (1 , 5 3 )  =  1 .0 , p = 0 . 3 2 ;  
in te r a c t io n  t r e a tm e n t  x  t im e  F (1 , 5 3 )  =  1 .4 9 ,  p =  0 .2 3 ;  in te r a c t io n  t r e a tm e n t  x  l e s io n  F (1 , 5 3 )  =  4 .7 ,  
p = 0 .0 3 5 ;  in te r a c t io n  l e s io n  x  t im e  F (1 , 5 3 )  =  1 .9 7 ,  p = 0 . 1 7 ;  in te r a c t io n  t r e a tm e n t  x  t im e  x  l e s io n  F (1 ,  
5 3 )  =  0 .1 9 ,  p = 0 .6 6 .  C R  ( lo g  K u )  -  e f fe c t  o f  t r e a tm e n t  F (1 , 5 3 )  =  0 .7 4 ,  p = 0 . 3 9 :  e f fe c t  o f  t im e  F (1 , 5 3 )  =  
1 0 .8 , p = 0 .0 0 1 8 ;  e f f e c t  o f  le s io n  F (1 , 5 3 )  =  0 .6 5 ,  p = 0 . 4 2 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F (1 , 5 3 )  =  0 .3 6 .  
p =  0 .5 5 ;  in te r a c t io n  t r e a tm e n t  x  le s io n  F (1 , 5 3 )  = 2 .8 6  p —0 .0 9 7 ;  in te r a c t io n  le s io n  x  t im e  F (1 , 5 3 )  =  
0 .1 5 , p = 0 . 7 ;  in te r a c t io n  t r e a tm e n t x  t im e  x  l e s io n  F (1 , 5 3 )  =  0 .9 6 ,  p - 0 . 3 3 .
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4.3.4. Study 2. a) - Determination o f open field activity in SO rats following 3, 7,10, 
14, 21 and 28 days o f antidepressant administration.
i )  C i t a l o p r a m
In sham-operated rats, citalopram administration over a period of 3 -  28 days did not 
significantly alter locomotor activity as compared to respective vehicle treated controls 
(Table 4.3.4.i.A). Ambulation scores were significantly reduced over time in both 
vehicle and citalopram administered groups, as were rearing scores. A significant 
elevation of rearing scores was observed in SO-citalopram treated animals as compared 
to the SO-vehicle treated group following 14 days of drug administration (Table
4.3.4.1.B). Grooming and defecation scores were not consistent and are not displayed 
(see Appendix 4.3.4.i). No significant interactions of time x drug treatment were 
observed in ambulation or rearing scores following ANOVA in this study however, 
each factor contributed a significant effect separately.
i i )  V e n la fa x in e
There were no differences in ambulation scores between vehicle and venlafaxine 
treated groups at any of the time points although ambulation scores were reduced over 
time in both groups (Table 4.3.4.Ü.A). No significant changes in rearing scores were 
observed in any of the groups following venlafaxine administration (Table 4.3.4.Ü.B). 
No significant ANOVA interactions between time x drug treatment were observed in 
this study for ambulation or rearing however, a significant effect of time was observed 
on both of these parameters.
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in )  D M I
Locomotor activity as measured by ambulation scores was not significantly altered by 
DMI administration over 28 days as compared to vehicle treated controls (Table 
4.3.4.iii.A). There were also no significant differences observed in rearing scores 
following DMI treatment or over time (Table 4.3.4.iii.B). No significant ANOVA 
interactions were observed in this study for either ambulation or rearing scores.
i v )  M i ln a c i p r a n
There were no differences in locomotor activity between vehicle and milnacipran 
treated groups at any of the time points. Changes observed in both ambulation and 
rearing scores were very inconsistent in the milnacipran treated group over time (Table 
4.3.4.iv.A). Rearing scores were also significantly reduced over time in the milnacipran 
treated group (Table 4.3.4.iv.B). Elevated rearing scores were observed in the 
milnacipran treated group at day 14 of drug administration as compared to vehicle- 
treated controls. No significant ANOVA interactions between factors were observed in 
this analysis for either ambulation or rearing scores.
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Table 4.3.4.:.
Time course of the effects of vehicle or citalopram administration on locomotor activity (A)
and rearing (B) in sham-operated (SO) rats.
(A) Ambulation
SO + vehicle SO + citalopram
Day 3 7 8 ± 5 82 ±12
Day 7 7 8 ± 7 89 ±10
Day 10 82 ± 7 96 ± 5
Day 14 74 ± 1 0 86 ± 6
Day 21 50 ± 1 0 67 ± 4
Day 28 48 ± 6 53 ±12
(B) Rearing
SO + vehicle SO + citalopram
Day 3 1 8± 3 14±3
Day 7 19 ± 3 2 4 ± 4
Day 10 1 9 ± 2 2 5 ± 2
Day 14 16 ± 3 2 4 ± 2 *
Day 21 9 ± 3 16±3
Day 28 9 ± 3 13 ± 3
Rats (7-10 per group) received citalopram (5mg/kg p.o.) or distilled water twice daily and were tested for 
open-field activity approximately 16 hours following the last dose as described in section 4.2.4. Data are 
expressed as mean ±  sem. Statistically significant differences were determined using ANOVA followed 
by Students t-test where appropriate and are denoted by * p<0.05. One-way ANOVA - Ambulation in  
S O - v e h ic le  F (5 , 4 9 )  =  3 .9 ,  p = 0 . 0 0 5 ;  S O - c i ta lo p r a m  F (5 , 5 0 )  =  3 .2 2 ,  p - 0 . 0 1 5 .  Rearing in  S O - v e h ic l e  F 
(5 , 4 9 )  =  2 .7 2 ,  p - 0 . 0 3 ;  S O - c i ta lo p r a m  F (5 , 5 0 )  =  3 .8 1 ,  p - 0 . 0 0 6 .  ANOVA : Ambulation -  e f f e c t  o f  
t r e a tm e n t  F (1 , 1 0 0 )  -  5 .0 4 ,  p = 0 . 0 2 7 :  e f f e c t  o f  t im e  F (5 , 1 0 0 )  =  6 .9 6 ,  p < 0 . 0 0 0 1 ;  in te r a c t io n  t r e a tm e n t  x  
t im e  F (5 , 1 0 0 )  =  0 .2 1 ,  p =  0 .9 6 .  Rearing -  e f f e c t  o f  tr e a tm e n t  F (1 , 9 8 )  =  5 .8 4 ,  p = 0 . 1 8 :  e f f e c t  o f  t im e  F 
(5 , 9 8 )  = 5 .0 8 ,  p = 0 .0 0 0 4 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F (5 , 1 0 0 )  =  1 .0 8 .  p =  0 .3 8 .
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Table 4.3.4.::.
Time course of the effects of vehicle or venlafaxine administration on locomotor activity (A)
and rearing (B) in sham-operated (SO) rats.
(A) Ambulation
SO + vehicle SO + venlafaxine
Day 3 78±5 86 ±14
Day 7 78±7 87 ±14
Day 10 82±7 97 ±11
Day 14 74 ±10 76 ±10
Day 21 50 ±10 50 ±12
Day 28 48 ± 6 48 ±12
(B) Rearing
SO + vehicle SO + venlafaxine
Day 3 18±3 19±4
Day 7 19 ±3 21 ±3
Day 10 19±2 25 ±2
Day 14 16±3 22±4
Day 21 9±3 12 ±3
Day 28 9±3 13 ±3
Rats (7-10 per group) received venlafaxine (15mg/kg p.o.) or distilled water twice daily and were tested 
for open-field activity approximately 16 hours following the last dose as described in section 4.2.4. Data 
are expressed as mean ± sem. Statistically significant were determined using ANOVA followed by 
Students t-tests where appropriate. One-way ANOVA - Ambulation in SO-vehicle F (5, 49) =3.9, 
p=0.005; SO-venlafaxine F (5, 47) =2.79, p=0.029. Rearing in SO-vehicle F (5, 49) =2.72, p=0.03; SO- 
venlafaxine F (5, 47) = 2.54, p=0.043. ANOVA : Ambulation -  effect of treatment F (1, 97) = 1.0, 
p=0.32: effect of time F (5, 97) = 6.23, p<0.0001; interaction treatment x time F (5, 97) = 0.18, p= 0.97. 
Rearing -  effect of treatment F (1, 94) = 4.56, p=0.036: effect of time F (5, 94) = 5.2, p=0.0003; 
interaction treatment x time F (5, 94) = 0.34. p=  0.89.
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Table 4.3.4.iii.
Time course of the effects of vehicle or DMI administration on locomotor activity (A) and
rearing (B) in sham-operated (SO) rats.
(A) Ambulation ______  ____  _______
SO + vehicle SO + DMI
Day 3 78±5 81 ±10
Day 7 78 + 7 69 ± 6
Day 10 82 ±7 73±5
Day 14 74 ±10 71±6
Day 21 50 ±10 47 ±10
Day 28 48 ± 6 58 ±12
[B) Rearing
SO + vehicle SO + DMI
Day 3 18±3 17 ±3
Day 7 19 ±3 21 ±2
Day 10 19±2 20±3
Day 14 16±3 20 ±3
Day 21 9±3 12±3
Day 28 9±3 10±4
Rats (7-10 per group) received DMI (5mg/kg p.o.) or distilled water twice daily and were tested for 
open-field activity approximately 16 hours following the last dose as described in section 4.2.4. Data are 
expressed as mean ±  sem. Statistically significant differences were determined using ANOVA followed 
by Students t-tests where appropriate. One-way ANOVA - Ambulation in SO-vehicle F (5, 49) =3.9, 
p=0.005; SO-DMIF (5, 51) =2.02, p=0.093. Rearing in SO-vehicle F (5, 49) =2.72, p=0.03; SO-DMl F 
(5, 51) = 2.27, p=0.063. ANOVA : Ambulation -  effect of treatment F (1, 101) = 0.13, p=0.72: effect of 
time F (5, 101) = 5.7, p=0.0001; interaction treatment x time F (5, 101) = 0.44, p= 0.82. Rearing -  
effect of treatment F (1, 98) = 0.73, p=0.4: effect of time F (5, 98) = 4.32, p=0.0015; interaction 
treatment X time F (5, 98) = 0.23, p=  0.95.
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Table 4.3.4.iv.
Time course of the effects of vehicle or milnacipran administration on locomotor activity (A)
(A) Ambulation
and rearing (B) in sham-operated (SO) rats.
SO + vehicle SO + milnacipran
Day 3 78±5 75 ±11
Day? 78 ±7 75 ±9
Day 10 82±7 96±11
Day 14 74 ±10 97±9
Day 21 50 ±10 56 ±10
Day 28 48 ±6 63 ±11
(B) Rearing
SO + vehicle SO + milnacipran
Day 3 18±3 14±3
Day 7 19 ±3 19±3
Day 10 19±2 23 ± 2.3
Day 14 16 ±3 27±4*
Day 21 9 ±3 9±2
Day 28 9±3 15 ±2
Rats (7-10 per group) received milnacipran (15mg/kg p.o.) or distilled water twice daily and were tested 
for open-field activity approximately 16 hours following the last dose as described in section 4.2.4. Data 
are expressed as mean + sem. Statistically significant differences were determined using ANOVA 
followed by Student’s t-tests where appropriate and are denoted by * p<0.05. One-way ANOVA - 
Ambulation in SO-vehicle F (5, 49) =3.9, p=0.005; SO-milnacipran F (5, 47) =2.7, p=0.033. Rearing in 
SO-vehicle F (5, 49) =2.72, p=0.03; SO-milnacipran F (5, 47) =5.55, p=0.0005. ANOVA : Ambulation 
-  effect of treatment F (1, 97) = 2.8, p=0.098: effect o f time F (5, 97) = 5.79, p=0.0001; interaction 
treatment X time F (5, 97) = 0.67, p=  0.65. Rearing -  effect of treatment F (1, 94) = 2.34, p=0.13: effect 
of time F (5, 94) = 5.47, p=0.0002; interaction treatment x time F (5, 94) = 1.79, p= 0.12.
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4.3,4. Study 2. b) - ^H-dexamethasone binding to hippocampal CR in SO rats 
following antidepressant administration for 3, 7,10,14, 21 and 28 days.
i) Citalopram
Specific ^H-dexamethasone binding to hippocampal CR was not significantly altered 
following citalopram administration over 28 days in SO animals (Figure 4.3.4.i.A). 
ANOVA revealed significant separate effects of treatment and time however there was 
no interaction between factors. The Æo of specific ^H-dexamethasone binding to CR 
was also unchanged by citalopram administration over 28 days in SO animals (Figure
4.3.4.i.B). There were no significant ANOVA interactions between factors for 
values. All CR binding values are displayed in Appendix 4.3.4.Ü.
ii) Venlafaxine
No differences were observed in the Bmax of ^H-dexamethasone binding to CR over 21 
days of venlafaxine administration. A significant increase (+30%) in Bmax was observed 
following 28 days of venlafaxine administration as compared to vehicle treated controls 
(Figure 4.3.4.Ü.A). ANOVA revealed significant effects of time and treatment 
separately but no interaction between factors. Ky> values were not significantly altered 
by venlafaxine administration for up to 21 days but were significantly increased in the 
venlafaxine treated group at day 28 of drug administration (Figure 4.3.4.Ü.B.). There 
were no significant ANOVA effects or interactions of factors on K\  ^ values in this 
study.
203
ni) DMI
DMI administration for up to 28 days did not significantly alter specific ^H- 
dexamethasone binding to CR in hippocampal tissue from SO rats (Figure 4.3.4.iii.A). 
ANOVA revealed significant effects of time and treatment separately but no interaction 
between factors. Overall, values were not significantly altered in DMI treated rats 
(Figure 4.3.4.iii.B). There were no significant ANOVA effects or interactions of factors 
on Æn values in this study.
iv) Milnacipran
Administration of milnacipran had no significant effects on specific ^H-dexamethasone 
binding to hippocampal CR (Figure 4.3.4.iv.A). Æo values were not affected by 
milnacipran treatment (see Figure 4.3.4.iv.B). No interaction of factors was observed 
on either parameter in this study.
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Figure 4.3.4.1,
Time course of the effect of citalopram administration on the B^ax (A) and (B) of
specific ^H-dexamethasone binding to hippocampal CR in sham-operated (SO) rats.
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SO rats (6-8 per group) received citalopram (5mg/kg p.o.) or distilled water twice daily and were 
sacrificed after 3, 7, 10, 14, 21 and 28 days of administration. Data are expressed as mean ±sem. Mean 
Bmax values ranged from 2.3-3.01 fmol/mg tissue (vehicle groups) and 2.16-3.92 fmol/mg tissue 
(citalopram groups). Mean Ko values ranged from 2.1-2.9 nM (vehicle groups) and 2.1-3.8 (citalopram 
groups). Statistically significant differences were determined using ANOVA followed by Students t-tests 
where appropriate and are denoted by *p<0.05. See Appendix 4.3.4.Ü. A N O V A :  C R  (Bmax) - e f f e c t  o f  
t r e a tm e n t  F  (1 , 9 4 )  =  6 .4 8 , p = 0 . 0 1 3 ;  e f fe c t  o f  t im e  F  (5 , 9 4 )  =  5 .7 ,  p = 0 .0 0 0 1 ;  in te r a c t io n  t r e a tm e n t  x  
t im e  F  (5 , 9 4 )  =  1 .3 , p =  0 .2 7 . C R  ( lo g K o )  - e f fe c t  o f  t r e a tm e n t  F  (1 , 9 4 )  =  0 .3 8 , p = 0 . 5 4 ;  e f f e c t  o f  t im e  F  
(5 , 9 4 )  =  5 .2 2 , p = 0 . 0 0 0 3 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F  (5 , 9 4 )  =  0 .8 7 ,  p = 0 .5 1 .
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Figure 4.3.4.11.
Time cou rse o f  the e f fe c t  o f  venlafaxine adm inistration on the B^ax (A) and Kp (B) o f
sp ec ific  ^H -dexam ethasone binding to hippocam pal CR in sham -operated (SO ) rats.
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SO rats (6-8 per group) received venlafaxine (15mg/kg p.o.) or distilled water twice daily and were 
sacrificed after 3, 7, 10, 14, 21 and 28 days of administration. Data are expressed as mean ±sem. Mean 
Bmax values ranged from 2.3-3.01 fmol/mg tissue (vehicle groups) and 2.28-4.0 fmol/mg tissue 
(venlafaxine groups). Mean Ko values ranged from 2.1-2.9 nM (vehicle groups) and 2.24-3.68 
(venlafaxine groups). Statistically significant differences were determined using ANOVA followed by 
Students t-tests where appropriate and are denoted by *p<0.05. See Appendix 4.3.4.Ü. A N O V A :  C R  
(Bmax) - e f f e c t  o f  t r e a tm e n t  F  (1 , 9 4 )  =  4 .2 9 ,  p = 0 . 0 4 2 ;  e f f e c t  o f  t im e  F  (5 , 9 4 )  =  3 .6 6 ,  p = 0 .0 0 4 8 ;  
in te r a c t io n  t r e a tm e n t  x  t im e  F  (5 , 9 4 )  =  1 .5 , p =  0 .2 . C R  ( lo g K o )  - e f fe c t  o f  tr e a tm e n t  F  (1 , 9 4 )  =  0 .3 ,  
p = 0 .5 8 ;  e f f e c t  o f  t im e  F  (5 , 9 4 )  =  2 .2 8 ,  p = 0 .0 5 4 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F  (5 , 9 4 )  =  2 .0 ,  p = 0 .0 8 7 .
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Figure 4.3.4.111.
Time course of the effect of DMI administration on the (A) and (B) of
specific ^H-dexamethasone binding to hippocampal CR in sham-operated (SO) rats.
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SO rats (6-8 per group) received DMI (5mg/kg p.o.) or distilled water twice daily and were sacrificed 
after 3, 7, 10, 14, 21 and 28 days of administration. Data are expressed as mean ±sem. Mean B^ ax values 
ranged from 2.3-3.01 fmol/mg tissue (vehicle groups) and 2.62-5.17 fmol/mg tissue (DMI groups). Mean 
Kd values ranged from 2.1-2.9 nM (vehicle groups) and 2.52-4.94 (DMI groups). Statistically significant 
differences were determined using ANOVA followed by Students t-tests where appropriate and are 
denoted by *p<0.05. See Appendix 4.3.4.Ü. A N O V A :  C R  (B ^ ax) - e f fe c t  o f  t r e a tm e n t  F  ( I ,  9 2 )  =  1 2 .8 8 ,  
p = 0 .0 0 0 6 ;  e f fe c t  o f  t im e  F  (5 , 9 2 )  =  4 .5 9 ,  p = 0 . 0 0 1 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F  (5 , 9 2 )  =  1 .9 2 ,  p =  
0 .1 0 .  C R  ( lo g K o )  - e f fe c t  o f  t r e a tm e n t  F  (1 , 9 2 )  =  1 .4 1 , p = 0 . 2 4 ;  e f fe c t  o f  t im e  F  (5 , 9 2 )  =  3 .4 3 ,  
p = 0 .0 0 7 4 ;  in te r a c t io n  tr e a tm e n t  x  t im e  F  (5 , 9 2 )  =  1 .0 6 , p = 0 .3 9 .
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Figure 4.3.4.iv.
Time course of the effect of milnacipran administration on the (A) and (B)
of specific ^H-dexamethasone binding to hippocampal CR in sham-operated (SO) rats.
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SO rats (6-8 per group) received milnacipran (15mg/kg p.o.) or distilled water twice daily and were 
sacrificed after 3, 7, 10, 14, 21 and 28 days of administration. Data are expressed as mean ±sem. Mean 
Bmax values ranged from 2.53-2.78 fmol/mg tissue (vehicle groups) and 2.94-3.1 fmol/mg tissue (DMI 
groups. Mean values ranged from 2.36-2.84 nM (vehicle groups) and 2.82-3.01 (DMI groups). 
Statistically significant differences were determined using ANOVA followed by Students t-tests where 
appropriate and are denoted by *p<0.05. See Appendix 4.3.4.Ü. A N O V A :  C R  (B ^ax) - e f f e c t  o f  t r e a tm e n t  
F  (1 , 3 0 )  =  1 .6 , p = 0 . 2 2 ;  e f fe c t  o f  t im e  F  (1 , 3 0 )  =  0 .0 2 ,  p = 0 . 8 9 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F  (1 , 3 0 )  = 
0 .5 2 , p =  0 .4 8 . C R  ( lo g K o )  - e f fe c t  o f  t r e a tm e n t  F  (1 , 3 0 )  =  4 .5 9 ,  p = 0 . 0 4 ;  e f f e c t  o f  t im e  F  (1 , 3 0 )  = 9 .5 1 ,  
p = 0 .0 0 4 7 ;  in te r a c t io n  t r e a tm e n t  x  t im e  F  ( I ,  3 0 )  =  1 .7 5 ,  p = 0 . 2
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4.4. Discussion
4.4.1 Effects of olfactory bulbectomy and antidepressant administration on body 
weights.
Olfactory bulbectomy did not significantly affect the body weights of rats during this 
investigation. A previous study (McGarvey, 1996) has also shown that there are no 
differences in body weights between un-operated (naïve), SO and OB rats.
Administration of citalopram, venlafaxine and milnacipran over 28 days also had no 
significant effects on body weights. However, long-term DMI administration induced a 
decrease in weight gain in the SO group. This observation is in agreement with other 
findings (see section 3.4.) and may reflect the side effect of DMI as an appetite 
suppressant (Frank et al, 1990; Redmond et al, 1995).
4.4.2. Effects o f olfactory bulbectomy and antidepressant administration on 
locomotor activity.
Study 1 confirmed the earlier findings that removal of the olfactory bulbs in rats leads 
to increased activity in the open field arena (Sieck et al, 1974; Van Riezen & Leonard, 
1990). Although it was originally believed that these behavioural differences were due 
to loss of olfaction, it is now apparent that these changes are a consequence of altered 
function of brain areas innervated by the olfactory bulbs, particularly the limbic system, 
since animals rendered peripherally anosmic with zinc sulfate do not display these 
behavioural changes (Alberts & Friedman, 1972; Sieck & Baumbach, 1974).
Defecation scores in the open field were found to be an unreliable parameter for OB 
deficits therefore were not commented upon. Rearing scores, taken as supplementary 
measures, were not generally significantly altered by bulbectomy or antidepressant
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administration. Rearing appeared to follow a similar pattern to ambulation with some 
elevated scores observed in OB-vehicle treated groups, these sometimes being 
significantly attenuated in antidepressant administered OB groups. However, these 
effects were generally found to be statistically insignificant.
Many investigators have reported on the increase in locomotor activity of OB rats in 
novel environments and increased exploration in the open-field arena. It has been 
suggested that activity and emotionality are highly correlated in the open field 
(Richman et al, 1972) and the following factors may be involved in this aspect of 
dysfunctional behaviour in the OB rat.
Many rodents respond quite specifically to odours emitted or deposited by previous 
animals. Olfactory bulbectomy reduces information received thereby decreasing the 
rats knowledge of the environment and making it more unpredictable. In the OB rat, 
this information is absent and consequently, less time is spent investing odour sources 
and more time is spent in active movement. It has been ^suggested that due to its 
distorted perception, the OB rat is more apprehensive of the novel environment and 
reacts to each new stimulus as if it is threatening (e.g.; rat escapes from A to B and 
upon finding B no more secure than A, moves to C, etc...) thus resulting in increased 
activity (Leonard & Tuite, 1981).
Removal of important sources of information by bilateral olfactory bulbectomy 
drastically reduces information-processing efficiency. The OB rat therefore, lacking a 
complete sensory input, displays impaired habituation to a novel environment and an 
inability to adequately assess the rate of environmental change. Control rats placed in 
the open-field display a progressive reduction in activity over successive tests (this was
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observed even in the SO groups in the preceding studies) however, OB rats display and 
maintain high activity levels even after twenty exposures (Kenshalo & Isaac, 1977).
The deficits demonstrated in passive avoidance tasks in OB rats also support this 
hypothesis as, when placed in the novel environment of the passive avoidance 
paradigm, the immediate response of the OB rat is to escape, resulting in deficient 
acquisition of this task as compared to SO controls (Leonard & Tuite, 1981). The 
superiority of OB rats over controls in acquisition of active avoidance tasks also lends 
support to this hypothesis (Sieck et al, 1972; 1974) though this observation is not a 
consistent one (King & Caimcross, 1974).
Since the open field test only provides a very short-term observation of locomotor 
activity, some investigators have focussed on home cage activity as an index of activity 
level. Using continuous monitoring in the home cage activity box, several studies have 
demonstrated increased activity of OB animals but only in the dark phase of the activity 
cycle (Giardina & Radek, 1991; O’Halloran et al, 1993; Marcilhac et al, 1997).
In addition to altered ‘emotional’ behaviour, deficits in cognitive functioning of the OB 
rat such as those tested using the radial arm maze and Morris water maze (Hall & 
Macrides, 1983; Redmond et al, 1994) have also been reported. These tests are 
specifically designed to investigate the function of the septohippocampal system and 
the observed deficits are attenuated by chronic antidepressant administration (Redmond 
et al, 1994) providing strong evidence that olfactory bulbectomy disrupts non-olfactory 
brain regions.
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The relationship between activity and emotionality in the open field in these studies 
supports the hypothesis of a greater stress response in animals following olfactory 
bulbectomy than in naïve or SO animals.
In our investigations, OB-induced hyperactivity was significantly attenuated only 
following chronic treatment with citalopram, venlafaxine, DMI and milnacipran. Acute 
administration of these antidepressants had no effect on this parameter (Maurya et al, 
1998b). These findings are consistent with the results of previous studies of the effects 
of repeated administration of antidepressant drugs in bulbectomised rats and suggest 
that these drugs reverse many or all of the behavioural changes produced by the lesion 
(Caimcross et al, 1978; Van Reizen et al, 1977). It appears that the mechanism of 
action of the antidepressant drug is not an issue for attenuation of the hyperactive 
response of the OB rat as the dmgs used in this study act via different mechanisms to 
alleviate clinical symptoms. The newer antidepressants venlafaxine and milnacipran 
were also found to reverse the OB-induced hyperactivity thus confirming the model’s 
status as a ‘screening test’ for compounds that display antidepressant activity in 
patients. All of the antidepressant dmgs in this investigation were also observed to 
attenuate rearing scores in the open field however, only venlafaxine significantly 
attenuated measures of this parameter.
Previous studies (McGarvey, 1996) have shown no significant differences between 
sham-operated and un-operated (naïve) controls in behavioural tests including the open 
field test. In these investigations, SO and un-operated animals displayed a similar 
response to open field testing, amongst others suggesting that sham operation does not 
result in a significantly altered “control” animal and that an un-operated control group
212
in such studies is unnecessary. These results formed the basis of Study 2, which 
investigated exploratory activity in the open field over 4 weeks in SO animals only.
Study 2 demonstrated reduced ambulation scores in the open field over 28 days in 
vehicle and antidepressant treated SO animals. These effects are most likely to be due 
to a habituation response, as observed in control animals, being developed in the SO 
groups following repeated exposure to the open field arena. Similar effects were 
observed on rearing, measures for which were generally higher in antidepressant 
groups suggesting that antidepressant administration may be facilitating rearing activity 
in some way.
4.4.3. Effects o f olfactory bulbectomy and antidepressant administration on specific 
^H-dexamethasone binding to hippocampal CR.
The antidepressant compounds used in these studies did not significantly affect specific 
^H-dexamethasone binding to CR in brain tissue (as observed in the competition 
experiments, section 4.3.1). Therefore any changes observed in CR binding parameters 
cannot be attributed to residual drug effects.
Despite the numerous correlates in disturbed endocrinological activity observed 
between human depressed patients and the OB rat, it appears that the dysfunctional 
corticosteroid feedback, characterised by a down-regulation of corticosteroid receptors 
in patients is not reflected in this animal model. The preceding experiments in Study 1 
showed no reduction in specific ^H-dexamethasone binding to CR in hippocampus 
from bulbectomised rats and Bmax values were found to be very similar to those in SO 
animals.
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The lack of a CR deficit in the OB rat was unexpected as previous studies have 
reported increased corticosterone output in this model, reversible by chronic 
antidepressant treatment (Catterelli & Damael, 1986). The ability of the OB rat to 
mount an additional corticosterone response to superimposed stress has also been 
reported (Caimcross et al, 1977; 1979) suggesting that the bulbectomised rat is 
chronically stressed, like the hypercortisolaemic depressed patient. However, there was 
quite clearly no CR deficit in the OB rat in our studies.
Although rats were sacrificed at approximately the same time of morning as in the 
naïve studies, they were subjected to a stressor (the open-field) prior to being killed. 
Some studies have reported increased and prolonged corticosterone secretion in 
bulbectomised rats, as compared to sham controls, subjected to the open-field (Kelly et 
al, 1995) and the additional response to stressors has already been mentioned.
Though a prolonged corticosteroid response to stress as implied in the OB rat, results in 
desensitised CR, frequent handling of animals produces the opposite effect resulting in 
suppression of fearful behaviour, up-regulation of GR and rapid termination of the 
stress response. Meaney et al (1989) showed that frequent handling of rats could 
increase GR binding capacity in the hippocampus of adult animals by 50%. Frequent 
handling was an integral part of the OB protocol and needed to be conducted to abolish 
the fearful and aggressive behaviour that would otherwise arise in bulbectomised rats 
(Leonard & Tuite, 1981). This may have confounded the investigation, as it is possible 
that the OB procedure and the handling procedure may act in opposite directions on CR 
and HPA-axis function.
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Olfactory bulbectomy affects circadian rhythms by an unknown mechanism (Vagell et 
al, 1991) therefore disruptions in rhythmicity of corticosterone secretion may 
contribute to inconsistent HPA function.
The extensive degeneration of innervations to various brain regions that follows 
olfactory bulbectomy is well-documented (see section 4.1). Also well documented is 
the control of HPA-axis function by various neurotransmitters and neuropeptides 
(Dinan, 1994; 1996b). It is very clear that the widespread disruptions in neuronal 
functioning following bulb ablation would affect regulation of the HPA-axis in a 
number of ways (Caimcross et al, 1977; Dinan, 1994; Marcilhac et al, 1999). For 
example, 5-HT plays an important role in the bulbectomy syndrome exerting effects on 
aggressive, explorative and motivated behaviour. 5-HT is also intimately involved with 
the release of ACTH and corticosterone as 5-HT precursors, reuptake inhibitors and 
receptor agonists are all found to stimulate ACTH and corticosterone secretion (section 
1.4.3). The 5-HT/HPA-axis loop appears to be anatomically and physiologically 
complex with multiple sites of interaction, one of these being the amygdala which has 
close connections with the limbic system (the corticomedial area of the amygdala 
inhibits ACTH secretion (Gloor et al, 1976) and is also a major site of 5-HT activity. It 
is also reported that the amygdala is heavily affected by bilateral olfactory bulbectomy 
(see section 1.6.1) thus affecting modulation of both 5-HT and HPA systems, which in 
tum appear to regulate each other. The co-localisation of GR and 5-HTia receptors in 
hippocampus may also support this (Dinan, 1996; Lopez et al, 1998). Interactions 
between all the factors involved are extremely complex and appear also to be 
multidimensional therefore the lack of impaired negative feedback of corticosteroids on 
hippocampal CR (via CR down-regulation) in the OB rat may be due to a number of 
factors. At this point, potential region specific effects must also be considered as it is
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possible that an impairment of negative feedback may exist in other regions such as the 
hypothalamus or pituitary however CR binding in these regions was not measured 
therefore cannot be commented upon.
The effects of citalopram, venlafaxine, DMI and milnacipran administration were not 
strikingly different between OB and sham groups. Chronic administration of DMI and 
milnacipran did not produce any significant effects on the specific ^H-dexamethasone 
binding to hippocampal CR in sham/OB rats. Following 28 days of administration, 
increases in Bmax of specific ^H-dexamethasone binding to CR of 26% and 30% were 
observed for citalopram and venlafaxine respectively. The observed increase in Bmax 
following chronic citalopram administration is inconsistent with our own studies in 
hippocampus (from naïve animals) using a similar antidepressant, paroxetine (see 
sections 3.4 and 3.5). The results of previous studies using other SSRI’s have also 
showed no effects of these drugs on hippocampal CR/CR mRNA following long term 
administration (Seckl & Fink, 1992; Budziszweska et al, 1994a; 1994b). Venlafaxine 
administration also had no effects on CR binding in our previous studies (see sections 
3.4 and 3.5) therefore the increase in Bmax observed in this investigation does not 
correspond with earlier observations. However, all of these investigations were 
conducted in naïve animals therefore comparisons with the OB investigations are 
difficult to make.
Due to the lack of a CR deficit in the OB rat model, it was decided to investigate the 
time course of antidepressant action on hippocampal CR in SO rats only. As mentioned 
previously, it appears that SO and un-operated animals are very similar in their 
behavioural responses. An extrapolation of this finding would suggest that sham- 
operation results in a neurochemically and endocrinologically unaltered “control”
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animal therefore making an un-operated, naïve group redundant in such studies. In that 
the sham-operated control is similar to the naïve animal, it can therefore be compared 
to the investigations in chapter 3.
The antidepressant compounds used in these studies had no significant effects on the 
Bmax of specific ^H-dexamethasone binding to hippocampal CR following chronic 
administration with the exception of venlafaxine which increased Bmax values by 30% 
at day 28.
To compare citalopram administration in this study broadly with paroxetine 
administration in the naïve study (as both drugs belong to the same group of 
antidepressants, SSRI's), it was found that chronic citalopram administration had no 
significant effects on hippocampal CR in this study. Budziszweska et al (1994a) found 
no effect of citalopram on hippocampal CR. Seckl & Fink (1992) also reported no 
effect of citalopram on GR mRNA in rat hippocampus. In the naïve study, no 
significant effects of paroxetine treatment were observed in the hippocampus, which 
generally agrees with the present study. However, a down-regulation of CR (in cortex 
and thymus) following paroxetine treatment is observed implying the presence of 
different mechanisms in different regions.
Venlafaxine administration had no effects in the naïve animals used in studies 
conducted in Chapter 3. In the SO animals, venlafaxine administration for 28 days 
induced a significant increase in Bmax values, with a corresponding increase in Kd 
values at this time point indicating potentially different mechanisms of this compound 
in naïve and SO animals.
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Due to the differences following antidepressant administration in SO and naïve 
animals, it may be that SO rats are not as similar biochemically to naïve animals used 
in chapter 3. Many factors may have complicated this study and the animals were 
treated quite differently in both studies including differences in doses of antidepressants 
given and routes of administration.
The olfactory bulbectomised rat appears to be an attractive model in which to 
investigate the neurobiological basis of depression and the mechanism of action of 
antidepressant drugs. Many neurochemical and neuroendocrine mechanisms have been 
associated with the behavioural and physiological aspects of the OB syndrome, a large 
proportion of which display impressive similarities to the clinical symptomatology. 
However, it appears that the OB rat does not model the impairment of negative 
feedback (thought to result from the down-regulation of corticosteroid receptors) 
observed in depressed patients and the restoration of HPA feedback activity (resulting 
from CR up-regulation) following chronic antidepressant treatment.
218
CHAPTERS
PREDATOR STRESS STUDIES; 
DEVELOPMENT & OPTIMISATION OF 
BEHAVIOURAL TESTING PROTOCOLS
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5.1. Introduction
Several animal models of depression attempt to parallel the putative role of stress in 
producing depressive states (Sherman & Petty, 1984; Katz et al, 1981). Alterations in 
behaviours such as locomotor activity and anhedonia represent core symptoms of 
depression and are also relatively easy to measure in laboratory animals however, 
behavioural testing can be highly subjective and variable between investigations and 
research laboratories. This chapter describes the basic developmental and optimisation 
procedures for behavioural tests conducted in our laboratory that were applied in later 
predator stress studies (see Chapter 6). Modifications were also made to the CR binding 
assay in order to adapt it for the smaller mouse tissues.
The mouse open field arena used in this, and subsequent chapters, was based on the rat 
open field arena used in chapter 4. Modifications were made to dimensions and 
markings of the arena on consultation with previous literature (Logue et al, 1997) and 
through personal communications (Karen Mellowdew - Institute of Psychiatry- see 
section 5.3). It was decided to use this test in future predator stress investigations in 
order to allow for some degree of continuity and comparison between the OB rat 
investigations and the predator stress studies.
Some studies have suggested that locomotor activity may be best measured during the 
dark phase of the light: dark cycle as rodents are nocturnal animals and measurements 
taken at this time would more accurately reflect normal activity levels (Batchelor, 
1994; Calamandrei et al, 1997). Circadian fluctuation may also affect locomotor 
activity in the open-field arena. The effects of both of these factors were investigated in 
this chapter. The period of open field testing also shows great variation across many 
different laboratories with testing times between 3 and 20 minutes per animal (de
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Angelis, 1996; Calamandrei et al, 1997). Open field measures were also taken over 
various testing times to establish an efficient and accurate test period.
The development of sucrose testing as a measure of anhedonia and decreased reward 
sensitivity was initially used by Willner et al in 1987(a). Since then, the protocol for 
sucrose testing has undergone numerous modifications and is found to display 
enormous variation between research groups.
The concentration of the sucrose solution (the reward substance) is very important in 
measuring anhedonic behaviour using sucrose tests. This is dictated by the fact that the 
sucrose concentration-intake function is bell-shaped (Muscat & Willner, 1989; Phillips 
et al, 1991b; Monleon et al, 1995). A sucrose concentration gradient was established 
prior to testing in order that an appropriate sucrose concentration could be chosen for 
future studies.
Sucrose tests can be conducted using 1 bottle (consumption) or 2-bottle (preference) 
tests and differences have been found in the relationship between sucrose concentration 
and reward sensitivity using both of these types of tests (Phillips et al, 1991a; Muscat 
& Willner, 1992). Sucrose test periods are also found to differ between laboratories 
therefore an accurate and efficient test period was established by investigating intake 
over various test times.
As suggested for tests measuring locomotor activity, the implication for sucrose testing 
is also that it may be more appropriate to conduct these tests in the dark phase of the 
animals activity cycle. The effect of testing in light or dark phases of the activity cycle 
was also investigated in this chapter using reversed light: dark cycles.
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The issue of food and water restriction/deprivation prior to sucrose testing has been a 
controversial one (Muscat & Willner, 1992a; Willner et al, 1996; Harris et al, 1998; 
Forbes et al, 1996). Sucrose intake was established with and without prior food and 
water deprivation to ascertain the effects, if any, on intake volumes.
As in initial experiments that aimed to optimise the CR binding assay for rat cytosolic 
preparations (see section 2.6), it was also necessary to establish appropriate mouse 
tissue concentrations in CR binding assays for future investigations in this chapter.
As the following investigations (Chapter 6) involved the development of a potential 
“predator stress” paradigm in mice, many preliminary investigations were undertaken 
prior to beginning of the stress studies. The main purpose of this chapter was to 
establish optimum behavioural test and assay conditions in our laboratory. Methods 
used in the preliminary investigations are initially presented with the data generated, 
followed by the standard procedures adopted as a consequence of these preliminary 
experiments.
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5.2. Animals
Male adult BALB/c mice from the NES COT breeding stock were used in these 
investigations. Animals were 12-14 weeks old and weighed 20-25 g at the start of the 
studies. Mice were individually housed beginning one week before the start of the 
experiments. All animals were maintained on 12:12 hour light:dark cycle (lights on
06.00-1 S.OOhrs) and were allowed free access to standard laboratory mouse food and 
water except as described in sections 5.3.1.iii, 5.5.1.Ü and 5.5.1.iii (open field / sucrose 
testing under reversed light: dark cycles and following food and water deprivation).
5.3. Optimisation of open field testing protocol
The aim of these preliminary experiments was to establish optimum conditions in our 
laboratory, under which to observe the open-field behaviour of BALB/c mice in order 
to obtain an efficient and realistic measure of locomotor activity.
5.3.1. Methods
Locomotor activity was determined using a circular open-field arena (diameter of 
60cm) made of vinyl with a white base subdivided by yellow lines into centre, mid and 
outer circles which were each further divided into smaller segments (Figure 5.3.1). The 
inside surface of the arena was coated with reflective aluminium paint and the arena 
was illuminated directly from above using a 100-watt bulb. Individual mice were 
transferred from the home cage to the open field arena. The test was started by placing 
the animal in the centre of the open-field arena. The behaviour of the mice was then 
observed and video recorded for various periods of time. Locomotor activity of each 
animal was observed by means of a television monitor in a separate room in order to 
minimise the amount of external stress experienced by the animals. All measurements 
were taken in a darkened room.
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Figure 5.3.1. Mouse open-field arena
LIGHT SOURCE
Open field markings
A
75cm
100cm
60cm
OUTER
MID
CENTRE
 60cm .................... ►
 40cm ......
20cm ►
The following behaviours were recorded in the open-field arena:
a) ambulation : the number of crossings of lines with both forepaws.
b) grooming : the number of times the mouse stopped and groomed itself.
c) rearing : the number of times the mouse simultaneously raised both forepaws off 
the floor of the apparatus.
d) defecation : the number of faecal boli deposited.
e) mobility latency : time taken from 0 mins for the mouse to start moving within the 
apparatus.
f )  orientation : the portion of the apparatus in which the mouse spent the most amount 
of time.
The open-field arena was cleaned with 3% alcohol and dried after each test.
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The following open-field investigations were conducted in order to ascertain a protocol 
for future studies;
i )  D e t e r m i n a t i o n  o f  o p e n - f i e l d  a c t i v i t y  o f  B A L B /c  m i c e  d u r i n g  l i g h t : d a r k  p h a s e  o f  th e  
d i u r n a l  a c t i v i t y  c y c l e .  Open-field activity was measured in animals that were housed 
under normal (lights on 06.00-18.00 hrs) and reversed (lights on 18.00-06.00 hrs) light 
cycles in order to ascertain diurnal variations of activity levels. Animals were placed in 
the open field arena for a 5-minute period (between 09.00-11.00 hrs) and the activity 
recorded as described above. Differences in activity during the light or dark phase were 
determined by subjecting the data to t-tests/Mann-Whitney tests (GraphPad Prism 3.0).
i t )  D e te r m in a t io n  o f  o p e n - f i e l d  a c t i v i t y  o f  B A L B /c  m i c e  a t  d i f f e r e n t  t i m e s  d u r i n g  th e  
d a y .  Activity in the open-field arena was observed at different times of day to 
determine the effects of circadian fluctuations on the locomotor activity of BALB/c 
mice housed under normal light:dark cycles. Open-field behaviour was recorded over a 
5-minute period in the morning (between 09.00-11.00 hrs) o^r the afternoon (between
13.00-15.00 hrs). Experiments were conducted twice and data pooled, with differences 
being determined by t-tests or Mann-Whitney tests (using GraphPad Prism 3.0).
H i) O p e n - f i e ld  a c t i v i t y  o f  B A L B /c  m i c e  o v e r  d i f f e r e n t  t e s t  p e r i o d s .  Locomotor activity 
of BALB/c mice was measured over different periods of time (3, 5 and 10 minutes) to 
allow for comparison of the observations made over these periods and determination of 
a suitable time “window” during which to measure open-field activity. This experiment 
was conducted four times using animals housed under normal light:dark cycles, the 
data pooled and analysed using one-way ANOVA or Kruskal-Wallis test (using 
GraphPad Prism 3.0).
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5.3.2. Results
i )  D e t e r m i n a t i o n  o f  o p e n - f i e l d  a c t i v i t y  o f  B A L B /c  m i c e  d u r i n g  l i g h t : d a r k  p h a s e  o f  th e  
d i u r n a l  a c t i v i t y  c y c l e .  Ambulation and defecation scores conformed to a normal 
distribution therefore were analysed using t-tests. Grooming and rearing scores did not 
conform to a normal distribution and were consequently analysed using the non- 
parametric Mann-Whitney test.
Ambulation scores of BALB/C mice in the open-field were not significantly different 
when measured in the light or dark phase (see Table 5.3.2.I.). Grooming scores were 
significantly lower in animals tested during the dark phase however, there were no 
significant differences in rearing and defecation counts from animals tested in the light 
or dark phase. There were no significant differences in the orientation within the open 
field arena of mice tested in the light or dark phases.
Table 5.3.2.:. Open-field activity of BALB/c mice in light/dark phase of the diurnal cycle.
PARAMETER LIGHT PHASE DARK PHASE
Ambulation 32 ±7 45 ± 8
Grooming 0.88 ±0.18 0.33 ±0.13*
Rearing 0.38 ±0.38 0.07 ±0.07
Defecation 4.6 ± 0.4 6.1 ±0.8
Orientation outer mid / outer
Open-field activity of BALB/c mice was measured as described in section 5.3.l.i. Data are expressed as 
mean ± sem (n=15-16) and were subjected to t-tests (ambulation and defecation counts) and Mann- 
Whitney tests (grooming and rearing counts) using GraphPad Prism 3.0. Statistically significant 
differences are denoted by * p<0.05.
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i i )  D e te r m in a t io n  o f  o p e n - f i e l d  a c t i v i t y  o f  B A L B /c  m i c e  a t  d i f f e r e n t  t i m e s  d u r i n g  th e  
d a y .  There were no significant differences in ambulation scores of animals tested in the 
morning or afternoon (see Table 5.3.2.Ü). Grooming counts were significantly higher in 
mice tested in the afternoon as compared to those tested in the morning. No differences 
were observed between rearing scores measured in the morning or afternoon. 
Defecation counts were significantly higher when measured in the morning as 
compared to afternoon values. There were no significant differences in the proportion 
of time spent by the animals in the various regions of the open-field arena at different 
times of testing.
Table 5.3.2.Ü. Open-field activity of BALB/c mice tested at different times of day (AM/PM).
PARAMETER MORNING AFTERNOON
Ambulation 52 ± 9 49 ± 9
Grooming 0.56 ±0.18 1.78 ±0.35 *
Rearing 0.38 ±0.38 0.7 ±0.27
Defecation 4.2 ± 0.5 * 2.9 ±0.5
Orientation mid / outer outer
Open field activity of BALB/c mice (housed under a normal light:dark cycle) was measured as described 
in section 5.3.Lii. Data are expressed as mean ± sem (n=16-18) and were subjected to t-tests (ambulation 
and defecation counts) and Mann-Whitney tests (grooming and rearing counts) using GraphPad Prism 
3.0. Significant differences are denoted by * p<0.05.
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Hi) Open-field activity of BALB/c mice over different test periods. All activity measures 
were significantly increased with length of test period therefore statistical differences 
are not displayed (see Table 5.3.2.iii). Variability of these measures was highest with 
the shortest test period. Standard errors were approximately 15% of the mean for 3 
minute test periods and approximately 10% of the mean for 5 and 10 minute test 
periods. Animals spent the majority of the test in the mid/outer region of the open-field 
arena whether the testing time was 3, 5 or 10 minutes.
Table 5.3.2.iii.Open-field activity of BALB/c mice recorded over different test periods
PARAMETER 3 min test 5 min test 10 min test
Ambulation 30± 4 50± 6 76 ±8
Grooming 0.59 ±0.15 1.21 ±0.23 2.0 ±0.38
Rearing 0.06 ±0.04 0.5 ± 0.22 0.88 ±0.39
Defecation 2.2 ± 0.2 3.6 ± 0.4 7.4 ±0.6
Orientation mid / outer mid / outer mid / outer
The activity of BALB/c mice, housed under a normal lightidark cycle, was measured over periods of 3, 5 
(n=34, over several different experiments) and 10 minutes (n=8, over two different experiments) as 
described in section 5.3.1.iii. Data are expressed as mean ± sem and were subjected to one-way ANOVA 
(ambulation and defecation counts) and Kruskal-Wallis tests (grooming and rearing counts) using 
GraphPad Prism v3.0. All groups were significantly different from each other therefore no symbols 
denoting statistical significance are shown. Statistically significant differences of measured parameters 
between each test period (p<0.001 - ambulation, p<0.01 - grooming, p<0.01 - rearing, p<0.0001 - 
defecation).
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5.3.5. Discussion
These investigations aimed to establish an optimal open-field test (OFT) protocol for 
BALB/c mice in our laboratory. Following the testing of BALB/c mice in both the light 
and dark phases of their cycles, it was found that most of the measures obtained in the 
OFT were not affected by the light phase of the animal. The noctumality of mice is 
well documented and it has been suggested that, in order to gain a true measure of 
activity in nocturnal animals, testing should be carried out in the dark phase of the 
lightidark cycle (de Angelis et al, 1996) however, we found no differences in measures 
taken in the light or dark phase. Open-field testing in future studies was conducted 
during the light phase of the mice, as this was more convenient and avoided disruption 
of the animal holding facilities.
Following a decision to perform open-field testing in the light phase of the BALB/c 
mice, we tested the effects of circadian rhythms on OFT measures by comparing data 
from tests conducted in the morning and afternoon. Again, many of the measures taken 
were not significantly affected by the time of day. On the basis of these data, it was 
decided to conduct subsequent OFTs at a consistent time in the morning (08.00- 
1 l.OOhrs) in order to avoid the possible influences of circadian rhythmicity.
In order to establish our OFT protocol, we conducted experiments in which BALB/c 
mice were subjected to OFT for periods of 3, 5 and 10 minutes. Three minute test 
periods were too short as the counts obtained were not high enough to allow accurate 
measurement of possible alterations following other experimental procedures. This 
group also displayed larger standard errors. Open-field activity measured over 5 and 10 
minutes gave measurable counts and similar values for standard errors. As the 10
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minute test was rather time-consuming and laborious, open-field testing was conducted 
over a 5 minute period in future investigations.
Locomotor activity is found to have a strong genetic influence and studies correlating 
strain of mice with activity have demonstrated enormous quantitative differences in 
measures of locomotor activity across genotypes (Logue et al, 1997). In an assessment 
of locomotor activity in various mouse strains using the open field arena, mean 
ambulation scores in BALB/c mice were quite low (-80 over a 5 minute test period) 
with locomotor activity being divided almost equally over the first and second 2.5 
minutes of the test. Defecation scores in the BALB/c strain was the highest (-8 over the 
5 minute test period) of all strains tested. As BALB/c mice are an albino/visually 
impaired strain, these researchers have suggested that the gene for albinism may have 
an impact on locomotor activity (but is not an absolute predictor of low activity). This 
may explain the generally low activity levels observed in our mice.
Open field measures are also found to be influenced by the type of arena used to record 
activity. This can have a very large effect on the type of behaviour displayed by the 
animal (Lister et al, 1990). Individual housing has also been proposed as a factor that 
may influence activity -  this is further discussed in chapter 6.
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5.4. Determination of optimal concentration for sucrose tests
This phase of the investigations consisted of i) ascertaining any preference of BALB/c 
mice for sucrose solutions over water and ii) choosing an appropriate sucrose 
concentration to be used in later sucrose intake experiments.
5 . 4 . L  M e t h o d s
It was not clear at this stage whether sucrose consumption (1-bottle) or preference (2- 
bottle) tests would be utilised in later studies therefore a sucrose gradient was 
determined using both types of sucrose intake tests.
i )  D e t e r m i n a t i o n  o f  a  s u c r o s e  g r a d i e n t  u s in g  s u c r o s e  p r e f e r e n c e  ( 2 - b o t t l e )  te s t .  Forty- 
eight mice were divided into 8 groups (n=6) and their intake of both water and sucrose 
solutions at various concentrations (0%, 0.5%, 1%, 2%, 4%, 8%, 16% and 32%) was 
measured. Two bottles, one containing water and the other containing one of the above 
sucrose concentrations were presented per cage (in a random manner) over 24 hours 
and intake was measured by weighing the bottles before and after the test period.
i i )  D e t e r m i n a t i o n  o f  s u c r o s e  g r a d i e n t  u s i n g  s u c r o s e  c o n s u m p t i o n  ( 1 - b o t t l e )  t e s t s  
Forty-eight mice were divided into 8 groups (n=6) and tested for their intake of sucrose 
solutions at various concentrations (0%, 0.5%, 1%, 2%, 4%, 8%, 16% and 32%) over 
24 hours when a bottle containing one of the above sucrose concentrations was given 
(in a randomised position), in place of water. The intake of sucrose was measured by 
weighing the bottle containing the solution before and after the test period.
Sucrose and water intake values were corrected for leakage from the test bottles, which 
had been previously determined from a number of experiments. Corrected values were 
used in the analysis of experiments.
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5.4.2. Results
i) Determination o f a sucrose gradient using sucrose preference (2-bottle) tests. The 
mean sucrose and water intakes over the 24 hour testing period using the 2-bottle test 
are shown in Figure 5.4.2.i. Sucrose intake generally increased as a function of sucrose 
concentration up to a concentration of 16% but decreased at higher concentrations. 
Water intake was much lower than sucrose intake with the greatest difference at a 
sucrose concentration of 16%.
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Figure 5.4.2.L Intake of water and different concentrations of sucrose (0%, 0.5%, 1%, 2%, 4%, 8%, 16% 
and 32%) over 24 hours using the 2-bottle intake test in BALB/c mice. Results are expressed as mean ± 
sem (n=6 per concentration).
ii) Determination o f sucrose gradient using sucrose consumption (1-bottle) tests. Mean 
sucrose intake over the 24 hour testing period is shown in Figure 5.4.2.ii. Intake 
generally increased up to sucrose concentrations of 16% but decreased at higher 
concentrations.
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Figure 5.4.2.11. Consumption of different concentrations of sucrose (0%, 0.5%, 1%, 2%, 4%, 8%, 16% 
and 32%) over 24 hours using the 1-bottle intake test in BALB/c mice. Results are expressed as mean ± 
sem (n=6 per concentration).
5.4.3. Discussion
These experiments aimed to establish an appropriate sucrose concentration for use in 
future experiments. Sucrose intake in our experiments followed an inverted U-shaped 
function in both preference and consumption studies however this observation was 
more pronounced in the preference experiments. Data obtained in our sucrose gradient 
experiments were consistent with those of Towell et al (1987), Muscat & Willner 
(1989) and Phillips et al (1991a; 1991b).
The sucrose concentration-intake function has previously been demonstrated as being 
bell-shaped in sucrose gradient experiments conducted in rats (Muscat & Willner, 
1989; Phillips et al, 1991a; 1991b) and in mice (Monleon et al, 1995). At low 
concentrations, on the ascending limb of the concentration-intake function, sucrose
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intake rises monotonically with concentration and is related to reward value (as 
assessed by preference measures in choice tests). However, at high concentrations, on 
the descending limb of the concentration-intake function, sucrose intake is no longer 
related in a simple way to reward value yet cannot be associated with aversive or 
satiety effects (Towell et al, 1987; Muscat & Willner, 1989; Phillips et al, 1991a; 
1991b).
On the basis of these experiments, a sucrose concentration of 3% was chosen for 
subsequent experiments as it was thought that this would allow for accurate 
measurement of alterations in sucrose intake in later studies therefore would reflect 
changes in the reward value of the sucrose solution. Previous sucrose intake 
experiments in mice have used 2% sucrose solutions (Monleon et al, 1995; D’Aquila et 
al, 1997a; 1997b). Sucrose concentrations of 6-12% displayed the highest intake 
therefore would not be likely to reveal any increases in intake. At the higher 
concentrations of sucrose solutions, intake was observed to decrease as in the 
aforementioned studies.
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5.5.Determination of sucrose intake testing protocol
5.5.1. Methods
The aim of these preliminary experiments was to determine the sucrose intake of 
BALB/c mice using either 2-bottle preference or 1-bottle consumption tests. Sucrose 
intake was measured by weighing the bottles before and after the test period following 
which, values were corrected for leakage. The following experiments were conducted 
in order to establish a standard protocol for sucrose testing in BALB/c mice.
i) Sucrose tests over 1 and 3 hour periods. Sucrose intake testing was initially 
conducted over periods of 1 and 3 hours in order to ascertain intake volumes that would 
reflect changes in future studies. BALB/c mice, housed under a normal lightidark cycle, 
were tested for intake of water or 3% sucrose solutions over these periods using both 1 
and 2 bottle tests.
it) Sucrose tests following food and water deprivation. Sucrose intake tests (1 bottle) 
were conducted in animals subjected to 3 hours of food and water deprivation and also 
in mice that had not been deprived in order to ascertain any differences between the 
groups. All mice were housed under a normal lightidark cycle.
Hi) Sucrose tests at different times of the light:dark activity cycle. Sucrose intake tests 
(1 bottle) were carried out in BALB/c mice which had been housed under normal 
(06.00-1 S.OOhrs) and reversed (18.00-06.00hrs) lightidark cycles to ascertain any 
differences in intake at various times during the activity cycle.
Experiments were repeated in several groups of mice, the data pooled and subjected to 
t-tests (using GraphPad Prism v3.0) in order to determine any significant differences 
between the groups.
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5.5.2. Results
i) Sucrose tests over 1 and 3 hour periods. BALB/c mice demonstrated a clear 
preference for the 3% sucrose solution over water in both the 1 and 3 hour 2-bottle 
preference tests (see Table 5.5.2.I.). The intake of a 3% sucrose solution in BALB/c 
mice over 1 hour and 3 hours in 1-bottle consumption tests was not significantly 
different although 3 hour tests did provide higher volumes of sucrose intake. However, 
longer testing times yielded increased intake in 2-bottle preference tests as these values 
differed for both water and 3% sucrose over 1 and 3 hour tests. Sucrose intake over a 1 
hour test period was significantly higher in the 1-bottle test as compared to that in the 
2-bottle test. Over a 3 hour test period however, sucrose intake values obtained using 1- 
bottle tests were not different from those obtained using 2-bottle tests.
Table 5.5.2.:. Sucrose and water intake in BALB/c mice using 1 and 2 bottle tests
over 1 and 3 hour test periods.
test time 1-BOTTLE TEST 2-BOTTLE TEST
sucrose intake (g) water intake 
(g)
sucrose intake 
(g)
1 hour 1.06 ±0.24 0.41 ±0.06 0.63 ± 0.06 *A
3 hours 1.21 ±0.1 0.8 ±0.13# 1.16±0.11 *#
Sucrose and water intake of BALB/c mice (n=12 for 1-bottle test over 1 hour; n=20-21 for all other 
groups, across several different experiments) was tested over 1 and 3 hour periods as described in section 
5.5.l.i. Data are expressed as mean ± sem. Statistically significant differences were determined using t- 
tests (GraphPad Prism v3.0) and are denoted by; * p<0.05 - as compared to water intakes in 2-bottle tests 
over 1 and 3 hours, # p<0.05 - as compared to 1 hour test intake values in 2-bottle tests and A p<0.05 - as 
compared to the 1-bottle sucrose intake values over the same test period.
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ii) Sucrose tests following food and water deprivation.
Animals that had been deprived of food and water for 3 hours prior to testing displayed 
a significantly higher sucrose intake than non-deprived mice (see Table 5.5.2.Ü). 
Variability was similar in both groups of animals.
Table 5.5.2.11. Sucrose intake in food and water deprived and non-deprived BALB/c mice
food + water deprived non-deprived
sucrose Intake 1.08 ±0.05 0.80 ± 0.06 *
(g)
Sucrose intake tests in i) non-deprived mice and ii) mice deprived of food and water for 3 hours (n=60 
for each group, across several experiments). Tests were conducted as described in section 5.5.I.Ü. Data 
are expressed as mean ±  sem. Statistically significant differences were determined using t-tests 
(GraphPad Prism v3.0) and are denoted by; * p<0.05.
Hi) Sucrose tests at different times o f the light:dark activity cycle. Though mice tested 
in the dark phase appeared to consume more of the 3% sucrose solution than those 
tested in the light phase, there were no statistically significant differences in sucrose 
intake of mice during the light or dark phases of their activity cycles (Table 5.5.2.iii)
Table 5.5.2.111. Sucrose intake in BALB/c mice in the light and dark phase of the activity cycle.
light phase dark phase
sucrose Intake 1.06 ±0.24 1.32 ±0.2
(g)
Sucrose intake in BALB/c mice (n=12 across several experiments) using 1-bottle tests i) in the light 
phase ii) in the dark phase of the activity cycle. Tests were conducted as described in section 5.5.1.iii. 
Data are expressed as mean ± sem. No statistically significant differences were determined using t-tests 
(GraphPad Prism v3.0).
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5.5.3. Discussion
BALB/c mice displayed a clear preference for the 3% sucrose solution over water in 2- 
bottle preference tests suggesting that the intake of this solution may constitute a 
reward stimulus. The test period did affect the intake volume and, as we were 
attempting to maximise these, it was decided to use 3-hour test periods in all future 
experiments. As there were no significant differences between sucrose intakes over 3 
hour periods using 1 or 2 bottle tests, it was decided to usé 1 bottle consumption tests in 
future studies as these were more conveniently conducted. The relationship between 
sucrose concentration and intake using 1-bottle tests is also thought to be more robust 
than that using 2-bottle sucrose tests (Muscat & Willner, 1992b).
In our experiments, intake volumes were significantly higher in the group that had been 
deprived of food and water prior to sucrose testing. No differences were observed in 
variability between the deprived and non-deprived groups. Therefore it was decided to 
subject animals to a 3-hour deprivation period prior to sucrose testing in future studies. 
This is a controversial issue as several studies have suggested that decreased intake of 
sucrose following chronic, unpredictable, mild stress (CMS) in food and water deprived 
laboratory animals may be related to loss of body weight and calorie intake (Forbes et 
al, 1996), or dependant on their dehydration state (Harris et al, 1998). However, other 
studies have also demonstrated that sucrose consumption in not secondary to loss of 
body weight (Willner et al, 1996) and unrelated to calorie content (Muscat et al, 1991; 
see section 6.3.4).
Mice tested in our experiments showed no difference in sucrose consumption whether 
tested in the light or dark phase. Consequently, it was decided to conduct all sucrose
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testing in the light phase of the mouse activity cycle, as this was more convenient and 
also would avoid disruption of the animal holding facilities.
Previous studies in which 2% sucrose solutions were used in order to measure 
anhedonia following CMS in mice have demonstrated considerable deficits in sucrose 
consumption following stress. Our tests using 3% sucrose were consistent with these 
and ensured that the sucrose concentration being utilised was on the ascending limb of 
the concentration-intake function.
Recent investigations have identified a genetic basis of preference for sweet substances 
among inbred strains of mice (Capeless & Whitney, 1995). The BALB/c strain used in 
our studies is thought to have preference for sodium saccharin at high concentrations 
(2-bottle, 48 hour preference test) due to the involvement of the genetic loci. Sac and 
dpa, suggested as important factors in the observed variation among inbred mouse 
strains for response to sweet substances (see section 6.3.4).
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5.6. Determination of a linear relationship between specific binding and 
concentration of mouse cortical cytosol
These experiments were conducted to demonstrate the presence of artefacts if any, in 
the binding assay and also to ensure that an appropriate tissue concentration was 
utilised in the assay to yield measurable specific binding values (see section 2.6). The 
smaller size of mouse brain regions also made it necessary to repeat these experiments 
as the concentration of mouse tissue required may have differed considerably from that 
used in binding assays using rat tissue.
5.6.1. Methods
Mouse cortical cytosol fractions were prepared as described in section 2.3 except that 
cortical tissue was homogenised in 1:10 w/v of incubation buffer and following 
centrifugation, the tissue supernatant was diluted to the required concentration. lOOpL 
aliquots of the tissue supernatant were incubated with either 10% ethanol or 5pM 
hydrocortisone and 3nM ^H-dexamethasone and subsequent procedures were carried 
out as described in section 2.3.
The specific binding of ^H-dexamethasone to CR in the cytosol preparation was 
calculated by subtracting NSB from TB and plotted against tissue concentration. Linear 
regression analysis was performed on the data, using GraphPad Prism v.3.0, to 
determine the effects of tissue concentration on the specific binding of ^H- 
dexamethasone.
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5.6.2, Results
Specific binding of ^H-dexamethasone increased linearly with increasing tissue 
concentration (see Figure 5.6.2.i). The values of specific binding observed at tissue 
concentrations of 5, 3.3 and 2.5 mg wet weight original tissue were 2115, 1334 and 937 
dpm (corresponding to 12.7, 12.0 and 11.9 fmol/mg protein) respectively, thus giving 
measurable values for the specific binding of ^ H-dexamethasone at these concentrations 
of tissue. The mean values for added ^H-dexamethasone in these assays was 171065 ± 
4029 dpm and the amount of radioactivity bound as a percentage of added radioactivity 
was 1.4%.
5.6.3. Discussion
These investigations demonstrated that the use of the CR binding assay described in 
chapter 2 to measure the binding parameters of CR in mouse cytosolic preparation 
yields consistent results, which appear to be free of artefacts. A tissue concentration of 
3.3mg wet weight original tissue was chosen from the linear portion of the graph 
(Figure 5.6.2.i.) and employed routinely in all subsequent binding experiments. This 
concentration of tissue did not bind more than 10% of the added radioligand in the 
assay and also gave measurable specific ^H-dexamethasone binding to CR in mouse 
cytosolic fractions.
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Figure 5.6.2.1.
Determination of the linear relationship between specific ^H-dexamethasone 
binding and mouse cortical cytosol concentration
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Mouse cytosolic fractions homogenised in 1:10 w/v of incubation buffer were 
prepared as described in section 5.6.1. The resulting supernatant was diluted to 
give cortical cytosolic concentrations of 2-lOmg wet weight of tissue / 
incubation. Assay procedures were carried out as described in section 2.3. The 
data shown represents the mean (± sem) from five experiments.
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5.7. Overall discussion
Our experimental results for each of the present studies do not vary greatly from those 
obtained in previous studies. It is not surprising that, with all the differences resulting 
from genetic, physiological and laboratory influences, that there should be so much 
variation in behavioural experiments and data. There are many factors that may affect 
behaviour patterns and we attempted as far as possible to control for these within our 
laboratory. Standard protocols were established following these investigations for each 
of the behavioural tests and also appropriate modifications made to the CR binding 
assay for mouse tissue.
Open field behaviour was assessed in future studies between 08.00-11.00 hours (during 
the light phase of the activity cycle) over a period of 5 minutes per animal. Sucrose 
intake testing in future studies was conducted as follows; animals were deprived of 
food and water for a period of 3 hours (09.00-12.00 hours) following which a single 
bottle containing a 3% sucrose solution was presented to them for a period of 3 hours 
(12.00-15.00 hours). Sucrose intake was calculated by weighing the bottles containing 
the solution before and after the test.
The use of the CR binding assay described in chapter 2 to measure specific binding of 
^H-dexamethasone to CR in mouse cytosolic preparations appears to yield consistent 
and accurate data. A tissue concentration of 3.3mg wet weight original tissue was 
employed routinely in all subsequent mouse CR binding experiments.
All behavioural testing and assay procedures were conducted as described above for 
subsequent predator stress studies presented in the following chapter.
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CHAPTER 6
PREDATOR STRESS/ANTIDEPRESSANT STUDIES
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6.1. Introduction
6.1.1. Predator stress as a model for stress/depression
Exposure of rats to the presence or odour of a cat constitutes a non-invasive, species­
relevant, life threatening, inescapable stress that results in changes in affective 
functioning of the rat. Investigation of various behaviours measured during cat 
exposure suggest that these may reflect a phobic anxiety state (File, 1996a; 1996b). 
Several physiological, behavioural, immunological and neurochemical alterations have 
been reported in rats following exposure to cat odour suggesting that this predator 
stimulus may be a potent stressor.
There is some evidence to suggest that predator exposure may reduce growth in rats 
(Adamec et al, 1998). Predator exposure was also found to induce increases in blood 
glucose in male rats (Bialik et al, 1989); this effect was absent in animals that had their 
adrenal medullae surgically removed. Depletion of brain NA potentiated the increase in 
blood glucose observed following predator odour rather than impairing the blood 
glucose response.
The most commonly observed result of predator exposure is increased avoidance 
behaviour of responsive rats with little evidence of habituation following repeated 
exposure (File et al, 1993a; Zangrossi & File, 1994). Clear increases in avoidance 
behaviour have also been displayed in 7-day old chicks following exposure to predator 
odour (Ruck et al, 1996). Behavioural measures in the elevated plus maze have been 
investigated following predator exposures. Adamec & Shallow (1993a) demonstrated 
that a 5 minute exposure to a cat decreased activity/explorative behaviour for up to 3 
weeks after exposure. Risk assessment behaviours as measured in the plus maze were 
also reduced by cat exposure indicating an enhanced state of anxiety in the stressed rats
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(Adamec et al, 1993a). Zangrossi et al (1992a; 1992b) bave also examined the after­
effects of exposing rats to cat odour and found that anxiety-like behaviours were 
observed for some time after exposure. These investigations suggest that predator 
exposure may possess a long-lasting stress component.
The development of the anxiety/defence test battery to investigate defensive reactions 
of rats to a natural predator, the cat, have been very useful (Blanchard et al, 1990). 
Three paradigms have been used to study the effects of predator exposure; 
i) proxemics/activity, ii) eat/drink test and iii) risk assessment. In cat exposed rats, there 
was an increase in proxemic avoidance and decreased rearing and transits between 
sections. In the eat/drink test, there was a constant inhibition of non-defensive 
behaviour including reduced eating frequency and duration. Predator odour also 
induced increases in risk assessment and fear/anxiety behaviours including stretch- 
attend, flat back postures. The chronic administration of imipramine prior to testing 
reduced defensive stress-induced behaviours (Blanchard et al, 1993).
Numerous investigations have indicated that the various behaviours displayed by rats in 
the presence of a predator may relate to fear and those evoked by the odour of a 
predator suggest anxiety as the administration of anxiolytics is found to reverse some 
predator-induced effects (Adamec et al, 1993a; 1993b).
6.1.2. Neurochemical changes following predator exposure
Significant decreases in G ABA enhancement of benzodiazepine binding have been 
observed in chicks following exposure to predator odour -  changes associated with 
increased fear (Fluck et al, 1996). Hogg & File (1994) also demonstrated significantly 
lower benzodiazepine receptor binding in hippocampus and frontal cortex in responder
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groups following predator stress. Increases in [^"^C]-GABA release in both cortex and 
hippocampus, accompanied by decreases in uptake were observed in rat brain slices 
following cat odour exposure (File et al, 1993). Investigations conducted by Kavaliers 
& Colwell (1995) have also implicated the GAB A system in predator-induced stress 
responses. Mice infected with a natural parasite were found to display reduced anxiety 
and spent more time in the vicinity of the cat odour as compared to non-infected mice. 
These altered predator responses were reduced by peripheral administration of the 
GABAa antagonists, bicuculline and picrotoxin indicating that parasite infection in 
mice reduces avoidance of predators at least partly though GABAa receptor 
mechanisms.
Changes in the release and uptake of 5-HT in rat brain slices following cat odour 
exposure were found to be markedly time dependent, with decreased hippocampal 
[^H]-5-HT uptake and higher basal release in rats sacrificed immediately after stress. In 
rats killed 30 minutes after stress, there was increased ^[H]-5-HT uptake and lower 
basal release in both cortical and hippocampal slices (File et al, 1993). Reduced 5-HT 
availability (as shown by lower basal and evoked ^[H]-5-HT release) has also been 
demonstrated in chicks following exposure to predator odour (Fluck et al, 1996).
6.1.3. Endocrinological changes following predator exposure
Laboratory animals demonstrate a variety of endocrinological changes in response to 
predator exposure. Groups of rats exposed to cat odour for the first time displayed 
significant increases in plasma corticosterone concentrations. However, this effect was 
found to habituate following five exposures (File et al, 1993) thus demonstrating a 
dissociation of behavioural and corticosterone responses to predator odour exposure.
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Rat pups exposed to predator odour display significantly elevated corticosterone 
concentrations (Tanapat et al, 1998). Lu et al (1998) have also demonstrated elevated 
ACTH and plasma corticosterone levels in mice following exposure to rats. These 
findings may be influenced by the species of mouse used in the experiments as higher 
responses were observed in BALB/c than in C57 mice.
Increased ACTH and plasma corticosterone concentrations were reported in rats five 
minutes after cat exposure as compared to non-stressed controls (Adamec et al, 1998). 
This study also measured CRF, A VP and bombesin concentrations in specific regions 
of HPA circuitry. CRF levels were increased in the anterior hypothalamus and 
decreased in the dorsomedial hypothalamus. A VP concentrations were found to be 
reduced in the lateral hypothalamus. Bombesin is a neuropeptide which potently 
stimulates NA release from the adrenal medullae, ACTH from the pituitary and elicits 
behaviours typically associated with increased emotionality and arousal (Kent et al, 
1998). Concentrations of this neuropeptide were altered in a number of hypothalamic 
areas following exposure of rats to cat odour (decreased in PVN and anterior 
hypothalamus / increased in ventromedial hypothalamic nuclei).
These changes indicate that the status of the HPA axis is significantly altered following 
predator (odour) exposure. These data also verify the predator exposure procedure as 
being a stressful stimulus to many animals as elevations of ACTH and the concomitant 
release of corticosterone are hallmarks of the stress response. Involvement of the HPA 
axis following predator exposure implies a helpless state (as described by Henry, 1993; 
see section 1.4.4) which may be associated with stress beyond control that could result 
in the manifestation of depressive symptoms.
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Given the acute response of rats to predator exposure, it follows that applying this 
potential stressor in a chronic fashion may induce a long-term stress response in 
laboratory animals - this is what we have attempted to achieve in this chapter. Predator 
stress has not been applied in a chronic fashion in any previous studies, and the 
parameters being measured in the following studies have not yet been investigated. We 
decided to use BALB/c mice in our studies, as these are known to display high 
reactivity to stress (Lu et al, 1998; Karen Mellowdew, Institute of Psychiatry, personal 
communication) - with Brown Norwegian rats as the predator species (as these are not 
commonly kept in our animal facility and would possess a novel odour). Assessments 
of normal and stressed behaviours were made by measuring locomotor activity and 
anhedonic responses in the mice before and after acute and chronic exposure to the 
predator stressor. It was decided to use these measures for examining stress-related 
effects as these represent core symptoms of depressive syndromes and changes in these 
behaviours have been demonstrated numerous times following chronic stress in 
laboratory animals (Willner et al, 1987a; Monleon et al, 1995).
In addition to any behavioural changes, plasma corticosterone concentrations were 
assessed following acute and chronic exposure to the predator. Specific binding of ^H- 
dexamethasone to cortical and hippocampal CR was also investigated following 
predator exposure and we were particularly interested to see if any reductions in brain 
CR would occur following chronic predator stress which would be consistent with a CR 
down-regulation hypothesis in depression.
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6.2. ACUTE STRESS STUDY
These studies aimed to investigate the effects of acute exposure of BALB/c mice to a 
non-contact predator stressor in order to determine whether predator exposure was 
producing any stress in the mice. Parameters being measured in this study were open 
field activity, sucrose intake, plasma corticosterone and specific ^H-dexamethasone 
binding to CR in the cortex and hippocampus.
6.2.1 Study design
Experiment 1 - The aim of the first investigation was to determine the immediate 
effects of the predator stress on open field activity, sucrose intake, plasma 
corticosterone concentrations and CR binding. In this experiment, mice were killed or 
tested for behavioural changes (in a separate room) immediately following exposure to 
the predator stress.
Experiment 2 aimed to determine residual effects of the initial predator exposure on the 
various parameters measured in experiment 1 and also any effects of predator odour 
over 24 hours. In this experiment, mice remained in the stress room for a 24 hour 
period following the initial exposure to predator stress (as described above) before 
measurements were recorded for the various parameters.
6.2.2. Methods
6,2.2.i. Animals
Male adult BALB/c mice used in these investigations were obtained and maintained as 
described in section 5.2. Mice were individually housed under a normal lightidark cycle 
(lights on 06.00-1 S.OOhrs) with free access to standard laboratory food and water 
except when undergoing deprivation periods prior to sucrose testing. Brown Norwegian
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rats obtained from the Institute of Psychiatry animal facilities were used as the predator 
stress stimulus. Rats were housed in pairs, in a separate room from the mice and were 
maintained on 12:12 hour lightidark (lights on 06.00-18.00 hours) cycles with free 
access to standard laboratory rat food and water.
6.2.2.lï. Predator stress procedure
All mice allocated to the stress groups were housed in the same room as the Brown 
Norwegian rats in order to be subjected continuously to a predator odour stress 
stimulus. This formed the constant long-term exposure to predator odour. All visual 
predator exposures, constituting acute visual contact with the predator, took place in the 
same room. All nesting material and food and water were removed from the mouse 
cage for the duration of the acute predator exposure thereby removing all objects under 
which the mice could possibly find shelter. Mouse cages were wedged into a large 
“playpen” filled with polystyrene foam pieces to stabilise the mouse cages. Three 
Brown Norwegian rats were released into the playpen for a 5 minute period and 
allowed to freely roam over the tops of the mouse cages, through which both mice and 
rats could clearly see each other but could not make physical contact.
6.2.2. Hi. Open field tests
Open field tests were conducted in a separate room over a 5 minute duration in the 
morning during the light phase of the mice (as discussed in section 5.7.). Control 
animals were tested before the stress group to prevent any residual predator odour from 
stressed mice affecting the test. Data was analysed using Student t-tests or Mann- 
Whitney tests between the control and stress group (using GB-STAT v6.5).
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6,2,2.iv. Sucrose intake tests
Sucrose intake tests were conducted using one bottle containing a 3% sucrose solution 
(determined from the sucrose gradient -  see sections 5.4. and 5.7.). This was presented 
to the mice following a 3-hour food and water deprivation period for a three-hour test 
period (see sections 5.5 and 5.7). Prior to the introduction of the stressor, mice were 
trained to drink 3% sucrose over a period of 24 hours followed by four 3-hour sucrose 
consumption tests over two weeks. These tests allowed for the measurement of baseline 
values and also for the division of animals into sub-groups depending on their intake of 
sucrose. For experiment 1 of the acute stress studies, mice were exposed to the 
predator stress towards the end of the 3-hour deprivation period in order for sucrose 
intake to be measured immediately after exposure. Data were analysed using Students 
t-test to compare sucrose intakes in control and stress groups (GB-STAT v6.5).
6.2.2.V. Radioimmunoassay o f plasma corticosterone concentrations
a) Preparation of plasma serum from mouse blood - Serum samples were prepared 
from trunk blood that was obtained from the sacrificed animals by decapitation and 
exsanguination using a funnel and collection tube. Approximately 2mL of blood were 
collected from each mouse. Following the removal of the blood from the animal, the 
samples were allowed to stand for approximately half an hour, then shaken to dislodge 
the clot. After 1-hour storage at 4°C, the samples were left at room temperature for 20 
minutes prior to removal of the clot from the tube. The supernatant was transferred to a 
clean tube and spun at 3800 rpm for 10 minutes using a bench top centrifuge.
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b) D e t e r m i n a t i o n  o f  p l a s m a  c o r t i c o s t e r o n e  - Plasma corticosterone concentrations were 
quantified using a Gamma-B ^^^I-corticosterone double antibody radioimmunoassay 
(RIA) kit (Immunodiagnostic Systems Ltd, Tyne & Wear, U.K.). Tubes were prepared 
in duplicate for total counts (TC), non-specific binding (NSB), maximum binding (Bo), 
corticosterone standards and samples as described in the RIA kit protocol. The amount 
of radioactivity in all tubes was counted for at least 1 minute in a gamma counter.
c )  C a lc u l a t i o n  o f  r e s u l t s  - Average counts (cpm) were determined for each set of 
duplicate assay tubes. Average NSB counts were subtracted from average Bo, standards 
and unknown samples and this number multiplied by 100 to give the % B / Bo for each 
sample.
% B /  Bo = cpm (standard or unknown) -  cpm (NSBl x 100
cpm (Bo) -  cpm (NSB)
% B / Bo was plotted for each standard vs. standard concentration enabling the 
concentration of corticosterone in unknown samples to be read directly from this 
standard curve. Statistically significant differences between groups were determined 
using Students t-test to compare control and stress groups (GB-STAT v6.5).
6.2.2,vi. Specific binding of^H-dexamethasone to mouse cytosolic CR 
All sacrifice and dissection procedures were conducted as described in section 2.3. 
Preparation of mouse cytosolic fractions was carried out essentially as described in 
section 2.3 (with the modifications made in section 5.6. in order to yield 3.3mg wet 
weight original tissue). Tissues were homogenised in 1:30 w/v assay buffer and, 
following centrifugation, lOOjiL aliquots were incubated with either 10% ethanol or 
5pM hydrocortisone. ^H-dexamethasone was added to the assay at concentrations 
ranging from 0.625 -  20nM for cortex samples and at a single concentration of lOnM
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for hippocampus samples. Subsequent procedures and analysis was carried out as 
described in section 2.3. Statistical comparisons between the control and stress groups 
were made using Students t-test (GB-STAT v6.5).
6.2.3. Results
6.2.3,i. Open field  tests
In both experiments 1 and 2, the exposure of BALB/c mice to predator stress increased 
ambulation scores in the open-field arena (Figures 6.2.3.i.A and B) however, these 
results did not reach statistical significance. There were no differences in grooming 
scores in both experiments 1 or 2. Rearing scores also did not differ between non­
stressed and stressed groups in either experiment 1 or 2. Defecation was not 
significantly different in the stressed group immediately or 24 hours following predator 
stress as compared to non-stressed values. Animals subjected to the open field test 
immediately following predator stress displayed a significant reduction in mobility 
latency as compared to non-stressed controls (see Figures 6.2.3.i.C. and 6.2.3.i.D.). The 
latency to movement of stressed mice (37 seconds) in the open field 24 hours after 
predator stress was also lower than in control animals (94 seconds), however this effect 
was not significantly different from non-stressed values. See Appendix 6.2.3.A for OFT 
values for ambulation, grooming, rearing, defecation and mobility latency.
6.2.3M. Sucrose intake tests
Predator stress significantly reduced the sucrose intake of BALB/c mice as compared to 
non-stressed controls when tested immediately after exposure (Figure 6.2.3.Ü.A.). 
Sucrose intake of stressed mice was not different from that of unstressed animals when 
tested 24 hours after exposure to predator stress (Figure 6.2.3.Ü.B). See Appendix
6.2.3.B for sucrose intake values.
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Figure 6.2.3.1.
Open field activity of BALB/c mice following acute exposure to predator stress
(A)
50-
40-
I
I 20 -  
10 -  
0
(B)
75-1
5 0 -
2 5 -
non-stressed stressed non-stressed stressed
(C)
200-1
-2 100-
**
non-stressed stressed
(D)
150n
100 -
50-
non-stressed stressed
BALB/c mice (n=8 per group) were subjected to open field tests immediately, or 24 hours after 
exposure to predator stress. Data are expressed as mean ± sem, see Appendix 6.1.A. (A) 
ambulation scores immediately following exposure to predator stress, (B) ambulation scores 24 
hours after exposure to predator stress, (C) mobility latency immediately following exposure to 
predator stress, (D) mobility latency 24 hours after exposure to predator stress. Statistically 
significant differences were determined using t-tests (GB-STAT v6.5) and are denoted by **
(p<0.01).
255
Figure 6.2.3.Ü.
Sucrose intake of BALB/c mice following acute exposure to predator stress
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BALB/c mice (n=10 per group) were subjected to one-bottle sucrose consumption tests immediately or 
24 hours after exposure to predator stress. Sucrose intake tests were conducted over a 3-hour period 
following 3-hours o f food and water deprivation. Data are expressed as mean (± sem) intake in g, see 
Appendix 6.1. B. (A) sucrose intake immediately following exposure to predator stress, (B) sucrose 
intake 24 hours after exposure to predator stress. Statistically significant differences were determined 
using t-tests (GB-STAT v6.5) and are denoted by ** (p<0.01).
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6.2.3Mt Radioimmunoassay o f plasma corticosterone
There were no statistically significant differences in plasma corticosterone 
concentrations between non-stressed and stressed animals immediately (Figure
6.2.3.iii.A) or 24 hours (Figure 6.2.3.iii.B) after predator exposure. See Appendix
6.2.3.C for plasma corticosterone values.
6,23.iv. ^H-dexamethasone binding to cortical/hippocampal CR
There were no significant differences in the Bmax or of ^ H-dexamethasone binding to 
CR in cortex taken from animals killed immediately after predator stress compared to 
non-stressed values (Figures 6.2.3.iv.A. and B.). Values for Bmax and Zd in cortex taken 
from mice that had been killed 24 hours after stress were also not significantly different 
from non-stressed values (see Figures 6.2.3.iv.C. and D.).
No significant differences were found between Bmax values in hippocampus taken from 
animals sacrificed immediately or 24 hours after stress compared to non-stressed 
animals (Figures 6.2.3.iv.B. and F.). See Appendix 6.2.3.D for ^H-dexamethasone 
binding values.
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Figure 6.2.3.111.
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Plasma corticosterone levels in BALB/c mice (n=6-7 per group) were assessed in samples taken 
immediately or 24 hours following exposure to predator stress. Concentrations of plasma corticosterone 
were quantified using the radioimmunoassay methods described in section 6.2.3.iii. Data are expressed as 
mean (±sem), see Appendix 6.I.C. (A) plasma corticosterone concentrations immediately following 
exposure to predator stress, (B) plasma corticosterone concentrations 24 hours after exposure to predator 
stress. No statistically significant differences were determined between control and stress groups.
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Figure 6.2.3.iv.
Specific binding of ^ H-dexamethasone to cortical and hippocampal
cytosolic fractions following acute exposure to predator stress
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Specific H-dexamethasone binding to CR in cortex/hippocampus (taken from BALB/c mice (n=7-8 per 
group)) was measured following acute exposure to predator stress. Samples were taken immediately or 
24 hours after exposure to predator stress and cortical cytosolic fractions were prepared as described in 
sections 2.3 and 6.2.3.v. Data are expressed as mean ± sem, see Appendix 6. I D. (A) B^ax of cortical CR 
binding immediately following exposure to predator stress, (B) B^ax of cortical CR binding 24 hours 
after exposure to predator stress, (C) of cortical CR binding immediately following exposure to 
predator stress, (D) K d  of cortical CR binding 24 hours after exposure to predator stress, (E) B^ax of 
hippocampal CR binding 24 hours after exposure to predator stress, (F) B^ax of hippocampal CR binding 
24 hours after exposure to predator stress . No statistically significant differences were found between 
control and stress groups.
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6.3. CHRONIC STRESS AND ANTIDEPRESSANT STUDIES
This study was designed to firstly, investigate the effects of chronic exposure to
predator stress on various behavioural and neuroendocrine parameters measured in 
BALB/c mice and secondly, to ascertain the effects, if any, of long-term administration 
of DMI and paroxetine on these parameters.
6.3.1. Chronic stress and drug study design
60 BALB/c mice were initially exposed to bottles containing a 3% sucrose solution for 
a period of 48 hours, followed by a number of sucrose intake tests in order to train the 
animals to drink the sucrose solution and to establish baseline sucrose consumption 
values (Monleon et al, 1995). On the basis of these values, mice were divided into 8 
groups (n=6-8) that were to undergo various control/stress and drug administration 
procedures (Figure 6.3.1).
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Figure 6.3.1. Chronic predator stress and antidepressant drug study schedule
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6.3.2. Methods
6.3.2.L Animals
As described in section 6.2.2.i. Mice were weighed once weekly for the duration of the 
investigation.
6.3,2.ii. Predator stress procedure
All mice allocated to the stress group following initial sucrose intake tests were housed 
in a separate room, which was occupied by Brown Norwegian rats. This provided a 
constant, chronic exposure to predator odour, which was not considered to be stressful 
enough to produce behavioural changes in the mice (personal communication; Karen 
Mellowdew, Institute of Psychiatry, London.). Therefore, in addition to the continuous 
predator odour, an acute, visual predator stress was administered for different durations 
on different days at varying times and sometimes more than once daily. The duration 
and time of predator stress were varied in order to make the stressor more unpredictable 
for the mice and to minimise the possibility of habituation. Also, different Brown 
Norwegian rats were used as the stress stimulus in the presence/absence of 
food/water/nesting material (so the mice had nothing under which to shelter). The 
procedure described in section 6.2.2.Ü. was repeated with all cages, until all the mice in 
the stress group had received acute exposure to the predator stress. A detailed stress 
schedule was kept throughout the study. Mice were subjected to predator stress for the 
first 5 weeks of the investigation (group SI) and also throughout the period of drug 
administration (groups S2, S3 and S4).
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6.3.2ML Antidepressant drug administration 
The antidepressant drugs used in this study were;
1) The tricyclic antidepressant, desmethylimipramine (DMI)
2) The selective serotonin reuptake inhibitor, paroxetine
Animals were randomly assigned to 6 groups comprised of 3 control groups and 3 
stress groups. Each of the non-stress and stress groups were treated once daily p.o. 
(between 08.00 -  09.00 hours) with either distilled water vehicle, DMI (15mg/kg) or 
paroxetine (7.5 mg/kg). Animals were dosed in this manner for 28 days during which, 
the stress groups were also undergoing exposure to predator stress. Drug/vehicle 
administration began following a 4 week exposure to predator stress.
6.3.2.iv. Body weights
Body weights of all BALB/c mice in the study were recorded once weekly. Data were 
analysed using analysis of variance followed by Student’s t-tests (GB-STAT).
6.3.2.v.Open field tests
Open field-testing was conducted as described in sections 5.3. and 5.7, and was 
conducted over two days for ease of operation and in order to keep test times between 
08.00 -  11.00 hours on each day. Equal numbers of mice from each group were tested 
on each day to minimise bias between groups. Tests were carried out with the BALB/c 
mice every two weeks over the 14-week investigation in an attempt to establish normal 
activity and activity following predator stress and antidepressant administration. 
Results were analysed using analysis of variance or non-parametric tests followed by 
Student’s t-test or Mann Whitney U-tests (GB-STAT v6.5).
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6 .3.2. VI. Sucrose intake tests
The intake of a 3% sucrose solution by the mice was used as a measure of hedonic 
responsiveness in these studies. One-bottle consumption tests were conducted 
following a 3-hour food and water deprivation period (see sections 5.4, 5.5 and 5.7). 
Sucrose intake tests were conducted twice a week over the 14-week investigation. 
Results were analysed using analysis of variance followed by Student’s t-test (GB- 
STAT v6.5). Water intake was also monitored over three 3-hour test periods in the 
baseline, stress and drug administration periods of the investigation.
6.3.2.vii. Radioimmunoassay o f plasma corticosterone
The radioimmunoassay of plasma corticosterone samples was conducted as described 
in section 6.2.2.V. Samples were randomised in order to minimise bias on each assay 
day. Results were analysed using analysis of variance followed by Student’s t-tests 
(GB-STAT v6.5).
6.3.2.viii. Specific ^H-dexamethasone binding to mouse cytosolic CR
CR binding assays were conducted in cortical and hippocampal tissues as described in 
section 6.2.2.vi.. Samples from each group were randomised to minimise bias on each 
experimental day. Results were analysed using analysis of variance followed by 
Student’s t-tests using GB-STAT v6.5.
6.3.2.viiiL Calculations and analysis
Data were tested for statistical significance using ANOVA or non-parametric Kruskal- 
Wallis tests (GB-STAT v6.0) followed by Student’s t-tests or Mann-Whitney tests 
where the F-ratio was significant (p<0.05).
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6.3.3. Results
6.3.3.L Body weights
Body weights of mice were consistently lower in the stressed animals than in non­
stressed groups following introduction of the stress stimulus. This effect was not 
statistically significant; the maximum difference in weights between non-stressed and 
stressed groups was 5% at week 5 (Figure 6.3.3.i.(l). The stress factor separately had a 
significant effect on body weights. No effect of time and no significant ANOVA 
interactions of stress x time were observed.
In the vehicle treated groups, body weights of stressed animals were significantly lower 
than the non-stressed group at weeks 9, 10, 11 and 12 (Figure 6.3.3.i.(2)). In the DMI 
treated groups, there were no statistically significant differences between body weights 
of non-stressed and stressed animals but stressed animals had consistently lower body 
weights than non-stressed controls. Administration of paroxetine had no statistically 
significant effects on the body weights of non-stressed and stressed mice. A significant 
ANOVA interaction between drug treatment and time was  ^observed on body weights 
following analysis of variance. See Appendix 6.3.3.A for body weight values.
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Figure 6.3.3.i.(l)
Effect of predator stress on body weights of BALB/c mice.
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Body weights of individually housed BALB/c mice (n=7-8) were measured before and after the 
introduction of a predator stress stimulus (see section 6.3.2.iv). Data are expressed as mean ± sem, see 
Appendix 6.3.A. No statistically significant differences were observed using ANOVA followed by 
Students t-test (GB-STAT v6.5). Open circles = non-stressed group, closed circles = stressed group. 
ANOVA; e f fe c t  o f  s t r e s s  -  F  (1 , 2 3 9 ) =  7 .8 4 ,  p = 0 .0 0 6 ;  e f fe c t  o f  t im e -  F  (3 , 2 3 9 } =  2 .1 4 ,  p = 0 .0 9 5 ;  
in te r a c t io n  s t r e s s  x  t im e -  F  (3 , 2 3 9 ) =  0 .1 3 ,  p =  0 .9 4 .
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Figure 6.3.3.i.(2)
Effects of chronic exposure to predator stress and administration of vehicle (A),
DMI (B) and paroxetine (C) on the body weights of BALB/c mice
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Body weights of BALB/c mice (n=7-8) were recorded over 8 weeks before and after the introduction of a 
predator stress stimulus (see section 6.3.2.iv). Administration of distilled water vehicle, DMI (15 mg/kg) 
and paroxetine (7.5mg/kg) commenced at week 8 for 28 days. Data are expressed as mean ± sem, see 
Appendix 6.3.A. Statistically significant differences were determined using ANOVA followed by 
Student's t-tests (GB-STAT v6.5) and are denoted by *p<0.05. Open circles = non-stressed group, 
closed circles = stressed group. ANOVA; effect of stress -  F (J, 206)= 22.7, p<0.0001; effect of 
treatment- F (2, 206)= 8.91, p= 0.022; effect of time- F (4, 206)= 6.97, p<0.0001; interaction stress x 
treatment F (2, 206)= 2.71, p= 0.069; interaction stress x time- F (4, 206)= 0.31, p= 0.87; interaction 
treatment x time- F (8, 206)= 2.15, p= 0.033; interaction stress x treatment x time- F (8, 206)= 0.13, p=  
1. 0.
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6.3,3.ii. Open field tests
Ambulation scores were significantly reduced in the stress group immediately 
following the introduction of the predator stress stimulus (Figure 6.3.3.ii.(l))- Two 
weeks after the introduction of predator stress, there were no significant differences in 
ambulation scores between stressed and non-stressed groups. Ambulation scores were 
also significantly lower in stressed animals following 4 weeks of vehicle administration 
(Figure 6.3.3.ii.(2).A). No statistically significant differences were observed in either 
stressed or non-stressed groups following the administration of DMI or paroxetine 
(Figures 6.3.3.ii.(2).B and C).
The time taken for the animal to start moving following its placement in the open-field 
arena (mobility latency) was significantly increased in mice subjected to predator stress 
for two and four weeks (Figure 6.3.3.ii.(3)). This effect was not observed after the 
beginning of vehicle administration or the administration of DMI or paroxetine. There 
were no significant differences between non-stressed and stressed groups following 
drug administration (Figure 6.3.3.ii.(4)). A significant effect of stress on mobility 
latency was revealed following ANOVA. No significant interactions between stress, 
drug treatment and time were observed for this parameter.
Defecation counts in the open-field were significantly reduced immediately after the 
introduction of predator stress but were no different to non-stressed values after 4 
weeks of predator exposure (Figure 6.3.3.ii.(5)). Defecation counts were also 
significantly different in stressed animals following vehicle administration over 4 
weeks as compared to the non-stressed controls (Figure 6.3.3.ii.(6)). There were no 
significant differences between stressed and non-stressed groups following the
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administration of DMI and paroxetine. Significant effects of stress and dmg 
administration were revealed on defecation counts, with significant interactions 
between stress x dmg administration also observed following ANOVA.
Grooming scores were found to be very erratic and no significant differences or 
interactions between any of the groups or factors investigated could be determined. 
Data is shown in Appendix 6.3.3.B.
The data obtained for rearing of mice in the open-field arena was also found to be 
irregular and no trends or significant differences or interactions between any of the 
groups or factors could be ascertained. Data is shown in Appendix 6.3.3.B.
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Figure 6.3.3.ii.(l)
Effects of predator stress on ambulation scores of BALB/c mice
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Ambulation counts of individually housed BALB/c mice were measured (in the open-field arena, see 
section 6.3.2v) before and after the introduction of a predator stress stimulus. Data were expressed as 
mean ± sem, see Appendix 6.3.B. Statistically significant differences were determined by ANOVA 
followed by Student’s t-test (GB-STAT) and are denoted by *p<0.05. Open bars = non-stressed group, 
closed bars = stressed group. ANOVA; e f fe c t  o f  s t r e s s  -  F  (1 , 1 1 9 ) =  9 .1 4 ,  p = 0 . 0 0 3 ;  e f fe c t  o f  t im e -  F  (1 , 
1 1 9 ) =  0 .7 5 , p = 0 . 3 9 ;  in te r a c tio n  s t r e s s  x  t im e -  F  (1 , 1 1 9 ) =  0 .3 4 ,  p =  0 .5 6 .
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Figure 6.3.3.ii.(2)
Effects of chronic exposure to predator stress and administration of vehicle (A), DMI
(B) and paroxetine (C) on ambulation scores of BALB/c mice
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Ambulation scores of BALB/c mice were measured, (using the open-field arena - see section.6.3.2.v) over 8 
weeks (4 weeks before, and after the introduction of a predator stress stimulus). Administration of distilled water 
vehicle, DMI (15 mg/kg) and paroxetine (7.5mg/kg) began at the start of week 8 for 28 days. Data are expressed 
as mean ± sem, see Appendix 6.3.B. Statistically significant differences were determined using ANOVA followed 
by Student's t-tests (GB-STAT v6.5) and are denoted by *p<0.05. Open bars = non-stressed group, closed bars= 
stressed group. ANOVA; effect of stress -  F (1, 82)= 2.1, p=0.15; effect of treatment- F (2, 82)= 1.25, p= 0.29; 
effect of time- F (1, 82)= 0.21, p=0.65; interaction stress x treatment F (2, 82)= 0.13, p= 0.88; interaction stress 
X time- F (1, 82)= 15.89, p= 0.0001; interaction treatment x time- F (2, 82)= 0.08, p= 0.92; interaction stress x 
treatment X time- F (2, 82)= 0.34, p= 0.72.
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Figure 6.3.3.ii.(3)
Effects of predator stress on the mobility latency of BALB/c mice.
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The mobility latency (time after beginning of test at which movement started) of individually housed 
BALB/c mice was measured (in the open-field arena - see section 6.3.2.v) before and after the 
introduction of a predator stress stimulus. Data are expressed as mean ± sem, see Appendix 6.3.B. 
Statistically significant differences were determined by ANOVA followed by Student's t-test (GB-STAT 
v6.5) and are denoted by **p<0.05. Open bars = non-stressed group, closed bars = stressed group. 
ANOVA; effect of stress -  F (1, 119)= 11.97, p=0.0008; effect of time- F (1, 119)= 1.83, p=0.18; 
interaction stress x time- F (1, 119)= 0.49, p= 0.49.
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Figure 6.3.3.ii.(4)
EfiFects of chronic exposure to predator stress and administration of vehicle (A), DMI (B)
and paroxetine (Q on the mobility latency of BALB/c nice
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Mobility latency (time after beginning of test that movement was started) of BALB/c mice was measured 
(in the open-field arena - see section 6.3.2.v) over 8 weeks (4 weeks before, and after the introduction of 
a predator stress stimulus). Administration of distilled water vehicle, DMI (15 mg/kg) and paroxetine 
(7.5mg/kg) began at the start of week 8 for 28 days. Data are expressed as mean ± sem, see Appendix 
6.3.B. Statistically significant differences were determined using ANOVA followed by Student's t-tests 
and are denoted by *p<0.05. Open bars -  non-stressed group, closed bars= stressed group. ANOVA; 
effect of stress -  F (1, 82)= 4.77, p=0.032; effect of treatment- F (2, 82)= 0.65, p= 0.52; effect of time- F 
(1, 82)= 0.48, p=0.49; interaction stress x treatment F (2, 82)= 0.47, p= 0.62; interaction stress x time- 
F (1, 82)= 0.21, p= 0.64; interaction treatment x time- F (2, 82)= 0.27, p=  0.76; interaction stress x 
treatment X time- F (2, 82)= 0.09, p= 0.91
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Figure 6.3.3.ii.(5)
Effects of predator stress on defecation counts of BALB/c mice.
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Defecation counts of individually housed BALB/c mice were measured (in the open-field arena - see 
section 6.3.2.v) before and after the introduction of a predator stress stimulus. Data were expressed as 
mean ± sem, see Appendix 6.3.B. Statistically significant differences were determined by ANOVA 
followed by Student's t-test and are denoted by *p<0.05. Open bars = non-stressed group, closed bars = 
stressed group. ANOVA; effect of stress -  F (1, 119)= 5.18, p=0.025; effect of time- F (1, 119)= 0.25, 
p=0.62; interaction stress x time- F (1, 119)= 0.16, p= 0.69.
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Figure 6.3.3.ii.(6)
Effects of chronic exposure to predator stress and administration of vehicle (A), DMI (B)
and paroxetine (Q on defecation counts of BALB/c nice
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Defecation counts of BALB/c mice were measured, (in the open-field arena - see section 6.3.2.v) over 8 
weeks (4 weeks before, and after the introduction of a predator stress stimulus). Administration of 
distilled water vehicle, DMI (15 mg/kg) and paroxetine (7.5mg/kg) commenced at the start of week 8 for 
28 days. Data are expressed as mean ± sem, see Appendix 6.3.B. Statistically significant differences 
were determined using ANOVA followed by Student's t-test (GB-STAT v6.5) and are denoted by 
*p<0.05. Open bars = non-stressed group, closed bars= stressed group. ANOVA; effect of stress -  F (1, 
82)= 5.17, p= 0.026; effect of treatment- F (2, 82)= 4.95, p= 0.009; effect of time- F (1, 82)= 0.04, 
p=0.85; interaction stress x treatment F (2, 82)= 4.99, p= 0.009; interaction stress x time- F (1, 82)= 
3.93, p=  0.05; interaction treatment x time- F (2, 82)= 1.36, p= 0.26; interaction stress x treatment x 
time- F (2, 82)= 0.03, p= 0.97.
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6.3.3.Hi. Sucrose intake tests
Sucrose intake values in predator exposed groups were significantly reduced at weeks 
3, 4, 5, 6 and 7 following the introduction of the predator stress stimulus. These 
changes were somewhat erratic with no differences in sucrose intake between non- 
stressed and stressed animals in three of the nine consumption tests conducted over the 
stress baseline period (Figure 6.3.3.iii.(l)). Reductions in sucrose intake ranged from 
2% - 49 % of non-stressed values over all of the tests. Significant effects of stress and 
time were observed following analysis of variance alongside a significant stress x time 
interaction.
During the subsequent period of vehicle administration, sucrose intakes in stressed 
animals were also significantly lower than those in the non-stressed animals in most of 
the consumption tests conducted over this period. (Table 6.3.3.iii. and Figure
6.3.3.iii.(2)); these effects were also somewhat erratic. The chronic administration of 
DMI brought sucrose intake values in non-stressed and stressed groups closer to each 
other with fewer statistically significant differences being observed between the groups 
(Figure 6.3.3.iii.(2).B). Chronic paroxetine administration stabilised sucrose intake 
values in both stressed and non-stressed groups and also bought these values closer 
together (Table 6.3.3.iii and Figure 6.3.3.iii.(2).C). At week 12 of drug administration, 
there were no significant differences in sucrose intakes between DMI / paroxetine 
administered stressed and non-stressed animals. Significant separate effects of stress 
and time on sucrose intake were revealed following ANOVA however no significant 
interactions between stress, dmg treatment and time were observed. See Appendix
6.3.3.C for intake values.
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Sucrose intake data, when expressed as mg sucrose intake/g body weight, also 
displayed a general decrease in sucrose intake in relation to reductions in body weights 
in predator exposed groups (Figures 6.3.3.iii.(3) and 6.3.3.iii(4)) and followed a similar 
pattern to that of sucrose intake in drug administered groups (Appendix 6.3.3.D). There 
were no differences in water intake in any the groups. Water intake remained constant 
throughout the investigation (Table 6.3.3.iii).
Significant effects of stress and time were revealed on sucrose intake following 
ANOVA however no significant interactions of stress, drug treatment or time were 
observed.
Table 6.3.3.iii Average water/sucrose intake values in BALB/c mice following baseline 
measures, introduction to predator stress and administration of vehicle/antidepressants.
WATER
non-stress
WATER
stress
SUCROSE
non-stress
SUCROSE
stress
Baseline 0.5 ± 0.03 1.11 ±0.07
(week 1) (n=60) (n=60)
Stress baseline 0.48 ± 0.04 0.52 ±0.03 0.96 ± 0.06 0.63 ±0.04*
(week 6) (n=30) (n=30) (n=30) (n=30)
Vehicle 0.47 ±0.07 0.47 ±0.1 0.86 ±0.15 0.56 ±0.05 *
(week 10) (n=8) (n=8) (n=8) (n=8)
DMI 0.49 ± 0.08 0.5 ±0.09 0.84 ±0.12 0.92 ± 0.36
(week 10) (n=8) (n=8) (n=8) (n=8)
Paroxetine 0.46 ± 0.07 0.44 ± 0.09 0.75 ±0.08 0.36 ±0.05*
(week 10) (n=8) (n=8) (n=8) (n=8)
Data are expressed as mean ± sem for week 1, 6 and 10 of the study. Statistically significant differences 
were determined using Student’s t-tests or ANOVA and are denoted by *p<0.05 as compared to non- 
stressed controls. ANOVA; effect o f  stress -  F (1, 47)= 0.004, p=0.96; effect o f time- F (2, 47)= 0.14, 
p=0.87; interaction stress x time- F (2, 47)= 0.026, p=  0.97.
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Figure 6.3.3.111. (1)
Effects of predator stress on the sucrose Intake of Individually
housed BALB/c mice.
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Intake of a 3% sucrose solution by BALB/c mice was measured using one-bottle consumption tests over 
a 3 hour period following a 3-hour food and water deprivation period (see section. 6.3.3.iii). Tests were 
conducted over 8 weeks (4 weeks before, and after the introduction of a predator stress stimulus). Data 
are expressed as mean ± sem, see Appendix 6.3.C. Statistically significant differences were determined 
using ANOVA followed by Student's t-test (GB-STAT v6.5) and are denoted by **p<0.01 and *** 
p<0.001. Open circles = non-stressed group, closed circles = stressed group. ANOVA; effect of stress -  
F (1, 597)= 111.9, p<0.0001; effect o f time- F (9, 597)= 30.08, p<0.0001; interaction stress x time- F 
(9, 597)= &77,
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Figure 6.3.3.111.(2)
Effects of chronic exposure to predator stress and administration of vehicle (A),
DMI (B) and paroxetine (C) on sucrose Intake of BALB/c mice
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Intake of a 3% sucrose solution by BALB/c mice was measured using one-bottle consumption tests over 
a 3 hour period following a 3-hour food and water deprivation period (see section 6.3.3.iii). Tests were 
conducted over 8 weeks (4 weeks before, and after the introduction of a predator stress stimulus). 
Administration of distilled water vehicle, DMI (15 mg/kg) and paroxetine (7.5mg/kg) began at week 8 
for 28 days. Data are expressed as mean ± sem, see Appendix 6.3.C. Statistically significant differences 
were determined using ANOVA followed by Student’s t-tests (GB-STAT v6.5) and are denoted by 
*p<0.05, ** p<0.01 or ***p<0.0001. Open circles = non-stressed group, closed circles = stressed 
group. ANOVA; effect of stress -  F (1, 329)= 20.35, p<0.0001; effect of treatment- F (2, 329)= 1.15, p=  
0.32; effect of time- F (7, 329)= 2.72, p=0.009; interaction stress x treatment F (2, 329)= 1.94, p= 0.15; 
interaction stress x time- F (7, 329)= 1.47, p=  0.18; interaction treatment x time- F (14, 329)= 1.2, p=  
0.27; interaction stress x treatment x time- F (14, 329)= 0.95, p= 0.5.
279
Figure 6.3.3.iii. (3)
Effects of predator stress on sucrose intake/ body weight (mg/g) of individually
housed BALB/c mice.
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Sucrose intake / body weight (mg/g) of BALB/c mice (see section. 6.3.3.iii). Tests were conducted over 
8 weeks before and after the introduction of the predator stress stimulus. Data are expressed as mean ± 
sem, see Appendix 6.3.D. Statistically significant differences were determined using ANOVA followed 
by Student's t-test (GB-STAT v6.5) and are denoted by ** p<0.01 and *** p<0.0001. Open circles = 
non-stressed group, closed circles = stressed group. ANOVA; effect of stress -  F (1, 238)= 27.65, 
p<0.0001; effect of time- F (3, 238)= 15.16, p<0.0001; interaction stress x time- F (3, 238)= 4.19, p=  
0.0063.
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Figure 6.3.3.111.(4)
Effects of chronic exposure to predator stress and administration of vehicle (A), DMI
(B) and paroxetine (C) on sucrose Intake /  body weight (mg/g) of BALB/c mice
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Sucrose intake / body weight (mg/g) o f BALB/c mice (see section 6.3.3.iii). Tests were conducted over 8 
weeks (4 weeks before, and after the introduction o f  the predator stress stimulus). Administration o f  
distilled water vehicle, DMI (15 mg/kg) and paroxetine (7.5mg/kg) began at week 8 for 28 days. Data are 
expressed as mean ± sem, see Appendix 6.3.D. Statistically significant differences were determined 
using ANOVA followed by Student's t-tests (GB-STAT v6.5) and are denoted by *p<0.05, ** p<0.01 or 
***p<0.0001. Open circles = non-stressed group, closed circles = stressed group. ANOVA; effect of 
stress -  F (], 203)= 22.7, p<0.0001; effect of treatment- F (2, 206)= 1.26, p= 0.29; effect of time- F (4, 
203)= 3.1, p=0.017; interaction stress x treatment F (2, 203)= 0.71, p=  0.49; interaction stress x time- F 
(4, 203)= 0.31, p= 0.87; interaction treatment x time- F (8, 203)= 0.73, p= 0.66; interaction stress x 
treatment X time- F (8, 203)= 1.01, p= 0.43.
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6.3.3.iv. Radioimmunoassay o f plasma corticosterone concentrations
Non-stress and stress groups used to establish baseline values showed no differences in
plasma corticosterone concentrations. Following commencement of drug/vehicle 
administration, plasma corticosterone levels were significantly higher in both stressed 
and non-stressed groups, as compared to respective baseline values. There were no 
significant differences in plasma corticosterone concentrations between stressed and 
non-stressed groups following 28 days of vehicle or drug administration (Table 
6.3.3.iv). There were no significant effects or interactions of stress or drug treatment on 
plasma corticosterone concentrations following ANOVA.
Table 6.3.3.iv Plasma corticosterone concentrations (ng/mL) of BALB/c mice following 
chronic exposure to predator stress and 28 days of antidepressant administration.
NON-STRESS STRESS
Baseline 23.1 ±1.8 21.4 ±5.0
Drug treatment NON-STRESS STRESS
Vehicle 42.5 ± 5.0 * 32.3 ±3.3 *
DMI 35.0 ±5.6 45.8 ±8.2
Paroxetine 42.3 ± 8.94 32.4 ± 2.8
BALB/c m ice (n=6-8) were exposed to predator stress for 5 weeks follow ing which they received the 
antidepressant drugs, DMI (15 mg/kg, p.o.) and paroxetine (7.5 mg.kg, p.o), once daily for 28 days. 
Animals were sacrificed after the 28 days o f  dmg administration and blood samples collected for the 
radioimmunoassay o f plasma corticosterone (see section 6.3.2.vii.), Values ranged from 19-79ng/mL  
non-stressed group; 12-70ng/mL stressed group. Data are expressed as mean ±  sem. N o statistically 
significant differences were determined using two-way AN O V A. Students t-tests revealed statistically 
significant differences which are denoted by * p<0.05 (as compared to respective baseline values). 
ANOVA; effect of stress -  F (J, 43)= 0.45, p=0.51; effect o f time- F (2, 43)= 0.19, p=0.83; interaction 
stress X time- F (2, 43)= 2.22, p= 0.12.
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6,3.3.v. Specific ^H-dexamethasone binding to mouse cytosolic CR
There were no significant differences in ^H-dexamethasone binding to CR in mouse
cortex taken from the non-stressed and stressed baseline groups (Table 6.3.3.V.A).
Cortical Bmax values were not different from baseline non-stressed and stressed groups 
in vehicle treated non-stressed and vehicle treated stressed groups, Bmax values in 
mouse cortex did not differ from vehicle treated groups following 28 days of DMI or 
paroxetine administration in both non-stressed and stressed groups. No significant 
effects or interactions of stress or drug administration were observed following analysis 
of variance.
No significant differences were found between transformed log Kd values in the cortex 
between any of the groups using ANOVA or Student’s t-tests. ANOVA results showed 
no significant effects or interactions of stress or drug administration on ^H- 
dexamethasone binding parameters to CR in mouse cortex (Table 6.3.3.v.A).
In the hippocampus, ^H-dexamethasone binding to CR in the non-stress baseline group 
was not different to that in the stress group. No differences in Bmax values were found 
using two-way ANOVA or Student’s t-tests in any of the other groups or following 
chronic administration of vehicle, DMI or paroxetine (Table 6.3.3.V.B). No significant 
effects or interactions of stress or drug administration on ^H-dexamethasone binding to 
hippocampal CR were observed following ANOVA.
There were no significant differences in protein values obtained in cortex or 
hippocampus using the Lowry method between any of the groups investigated (see 
Tables 6.3.3.v).
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Table 6.3.3.V. ^H-dexamethasone binding to CR in cortex (A) and hippocampus (B) taken
from BALB/c mice following chronic exposure to predator stress and 28 days of antidepressant
administration.
(A) CORTEX
Drug
treatment
NON-STRESS STRESS
Bmax(fmol/mg
protein)
Kd (nM) Protein
(pg/assay)
Bmax(fmoI/mg
protein)
Kd (nM) Protein
(pg/assay)
Baseline 161±20 1.62+0.35 94 ± 7 193 + 34 2.38+0.55 78 + 6
Vehicle 184 ± 7 2.96 ±0.58 81 + 85 195+10 2.67 + 0.45 85 + 7
DMI 185 + 13 2.27 + 0.79 91 ± 4 167 + 13 2.05 + 0.51 89 + 9
Paroxetine 163 ± 6 * 2.42 ± 0.63 72 + 6 188+11 2.52 + 0.49 72 + 4
(B) HIPPOCAMPUS
Drug treatment NON-STRESS STRESS
Bmax
(fmol/mg protein)
Protein
(pg/assay)
Bmax
(fmol/mg protein)
Protein
(pg/assay)
Baseline 142 + 6 68 + 8 172+15 63 + 7
Vehicle 139+16 59 + 8 146 +16 63 + 5
DMI 143 + 23 64 + 7 144+17 57 + 6
Paroxetine 146+13 62 + 5 160+13 66 + 4
BALB/c mice (n=6-8) were exposed to predator stress for 5 weeks following which they received the 
antidepressant drugs, DMI (15 mg/kg, p.o.) and paroxetine (7.5 mg.kg, p.o), once daily for 28 days. 
Animals were sacrificed after the 28 days of drug administration and cortical and hippocampal tissue 
samples collected for the CR binding assay (see section 6.3.2.viii.). Values ranged from; CORTEX B^ ax - 
91-239 and 108-273 fmol,mg protein (non-stressed, stressed groups respectively) / ATp - 0.27-5.81 and 
0.62-6.1 nM (non-stressed, stressed groups respectively) / HIPPOCAMPUS - B^ax- 72-223 and 86-221 
fmol,mg protein (non-stressed, stressed groups respectively). Data are expressed as mean ± sem. Results 
were analysed using two-way ANOVA followed by Students t-test (for all vehicle/drug administered 
groups) and statistically significant differences are denoted by **p<0.05 -as compared to non-stressed 
vehicle-treated group. ANOVA ( CORTEX CR Bmax)>’ effect of stress-F (1, 43)= 0.48, p=0.49; effect of 
time- F (2, 43)= 1.3, p=0.2S; interaction stress x time- F (2, 43)= 2.52, p= 0.09. (CORTEX CR Kd); 
effect of stress-F (I, 43)= 0.055, p=082; effect of time- F (2, 43)= 1.3, p=0.3; interaction stress x time- 
F (2, 43)= 0.06, p= 0.94. ANOVA (HIPPOCAMPUS CR R„«); effect of stress -  F (1, 45)= 0.3, 
p=0.59; effect of time- F (2, 45)= 0.26, p=0.77; interaction stress x time- F (2, 45)= 0.07, p= 0.93.
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6.4. Discussion
6,4.i. Body weights
Acute stress studies - Animals were not weighed over the acute stress studies, as these 
were too short for any changes to be observed.
Chronic stress and antidepressant studies - Body weights were generally lower in 
stressed animals as compared to non-stressed controls following introduction of the 
predator stress. Differences in body weights between stressed and non-stressed animals 
became significant in the vehicle treated stress group after 9-10 weeks of predator 
stress and when the dosing regime began.
Though body weights of mice exposed to the predator were lower than those of non­
exposed mice, it seems that predator exposure could be classified as a mild stressor as it 
does not appear to have significant effects on body weight. Adamec & Shallow (1993) 
have also suggested that the lasting effects of rodent anxiety following cat exposure are 
mild, as they also found no changes in body weight in stressed animals. Reductions in 
body weight would be expected at all times if this stressor were a severe one.
Significant reductions in mouse body weights were observed only after the 
commencement of the dosing regime. It is possible that the dosing procedure itself may 
have been an additional stress inducing factor and, added to the effects of predator 
exposure, lead to reduced body weights in the stress group. This effect was prominently 
observed in the vehicle treated stressed group.
Body weights were also lower in predator exposed animals which had been given DMI 
or paroxetine over four weeks though these effects were not statistically significant 
suggesting that the antidepressant administration may be preventing weight loss due to
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predator exposure or dosing, or both. DMI treated animals appeared to gain weight 
slower than those treated with paroxetine- this may be an effect of the appetite 
suppression properties of DMI.
It appears from these data that predator stress stimulus is mild, having insignificant 
effects on body weights. Predator exposure, in combination with the stress experienced 
during dosing, has a greater effect on body weights and the combination of these 
factors appears to be very stressful with regards to this parameter.
6.4.ii. Open field test
Acute stress studies - Locomotor activity in the open field arena of mice immediately, 
and 24 hours after exposure to the predator was not significantly different from non­
exposed controls. Significantly reduced freezing behaviour was observed in the stressed 
groups as compared to controls (as demonstrated by decreased mobility latency). This 
observation may indicate the onset of a hyperactivity-like syndrome in animals acutely 
exposed to predator exposure.
No significant effects were observed in any of the other parameters measured in the 
open field test. Changes in rearing and grooming have been demonstrated in other 
studies (Blanchard et al, 1993) however these measurements were conducted in 
different arenas (hole board tests and plus maze) and it is difficult to compare them 
with our investigations and results.
Chronic stress and antidepressant studies -  Ambulation scores were significantly 
lower in the stressed groups following several days of exposure to predator stress and 
four weeks of predator stress + vehicle administration. This may reflect reduced
286
activity suggesting anxiety-like behaviour in response to the stress of chronic predator 
exposure (Lister, 1990). This observation does not correspond with the higher 
ambulation scores observed in predator exposed animals in the acute stress studies. 
Freezing behaviour was also significantly increased in animals chronically exposed to 
predator stress (reflected by increased mobility latency as compared to non-stressed 
groups). These observations suggest a dissociation of locomotor activity responses 
following acute and chronic predator exposure. Acute predator stress appears to induce 
hyperactivity like syndrome in stressed animals whereas chronic exposure to the same 
stressor induces more immobility and freezing behaviour.
Alterations in either direction in the open field can be considered to reflect different 
types of stress. Hyperactivity in the open field is also a feature of the olfactory 
bulbectomised rat model of depression in which it is thought to result from a deficit in 
risk assessment and adaptation due to the malfunctioning of various neurotransmitter 
systems (see chapter 4). It may be that similar mechanisms have been triggered 
following acute exposure to predator stress. If this is the case, then our acute study data 
support the notion that exposure to the predator is having a stressful effect on the mice. 
Reduced activity in an open field environment has been suggested as being a useful 
index of anxiety (Lister, 1990) therefore it appears that chronic predator stress may be 
producing anxiety-like behaviour in the BALB/c mice.
Ambulation scores in stressed groups were not significantly altered in stressed or non- 
stressed groups following vehicle, DMI and paroxetine administration. Antidepressant 
administration did not exert any significant effects on the reduced activity of BALB/c 
mice following chronic predator exposure. Freezing time in chronically stressed 
animals was significantly reduced following 28 days of DMI and paroxetine
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administration. However, this reduction was also observed following vehicle 
administration therefore cannot be attributed to antidepressant effects. These results are 
not consistent with those of Blanchard et al (1993) who demonstrated that pre­
treatment for 15 days with imipramine reduced anti-defensive behaviours (eg. reduced 
freezing, proxemic avoidance) of rats when exposed to a cat however, this investigation 
was conducted in a very different manner from our own and comparisons are made 
difficult.
Defecation of BALB/c mice exposed to predator stress for several days was lower than 
that of unstressed controls. This effect was more pronounced in the vehicle treated 
group following the introduction of the dosing regime; though there were several 
changes in the non-stressed group. Stress experienced by the mice whilst dosing may 
have some effect on defecation measures; maybe more so in the non-stressed control 
group than those exposed to predator stress. Administration of DMI and paroxetine 
brought the defecation counts in stressed animals more in line with non-stressed values.
It could be argued that some of the effects observed in these studies may be attributed 
to some degree of habituation effect of the mice to the open field arena. A decline in 
exploratory behaviour and activity is generally observed as tests are repeated and the 
novelty of the test conditions disappears. Some studies have demonstrated day-to-day 
reductions in the activity of rats tested repeatedly on an enclosed plus maze but no such 
decline is observed in the open arm maze (Montgomery, 1954; Lister, 1990). 
Experiments by Montgomery (1954) demonstrated that novel stimulation evokes both 
the exploratory drive and the fear drive thus generating approach-avoidance conflict 
behaviour in rats. The strength of the fear drive decreased with time of direct exposure
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to the stimulus. Representation of the novel stimulation following a period of non­
exposure resulted in a spontaneous recovery of fear.
There are few valid arguments as to why these findings should not also apply to mice. 
In line with these suggestions, the open space component of the OFT, in addition to the 
frequency of testing (each OFT was 2 weeks apart) and relatively short testing time (5 
minutes), may confer some degree of resistance to habituation to this test.
The open field arena constitutes a stressful, novel environment for the subjects 
however, the purpose of using this method in our investigations has not heen solely to 
mount an additional stress challenge on the subjects but to obtain a ‘snapshot’ measure 
of activity over normal, stress and drug administration periods. In both acute and 
chronic studies, mice were exposed to the open field test on more than one occasion so 
none of the values recorded, even in the acute study were measured during a first test in 
the open field arena. Also, in the event of any behavioural habituation occurring to the 
open field arena, effects would be observed in both unstressed and stressed groups 
alike; this has not been found to be the case in our experiments.
Blanchard et al (1993) demonstrated behavioural changes consistent with a high level 
of risk assessment (scored mainly by stretch-attend posture towards the stimulus) and 
fear/anxiety in rats on presentation of cat odour. The acute effects of predator exposure 
in our studies using the open field are consistent with increased risk assessment 
behaviour, which are associated with reduced anxiety.
Some studies have however reported reduced exploration behaviour (open-arm entry in 
the plus maze) and risk assessment behaviour of rats (activity and rearing in hole board
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tests) as lasting effects following cat exposure (Adamec et al, 1993a; 1998). These 
investigations involved a single exposure to the predator and measured various 
behaviours up to 21 days after the exposure. Reduced risk assessment behaviour is 
associated with increased anxiety therefore it appears that the BALB/c mice in our 
study may be experiencing high levels of anxiety following chronic exposure to 
predator stress.
6.4.ÜL Sucrose tests
Many alterations in various parameters have been found following exposure to 
predators and/or their odour in rats (see section 6.1). Numerous studies have also 
successfully employed sucrose intake tests to measure reward behaviour and anhedonic 
responses in rats and mice following CMS procedures (Muscat & Willner, 1992; 
Willner et al, 1996). The aim of these experiments was to investigate any possible 
changes in sucrose intakes of BALB/c mice following acute or chronic exposure to a 
predator.
Acute stress studies - Consumption of a 3% sucrose solution was significantly reduced 
immediately following acute exposure to predator stress. These data support the idea 
that exposure to a predator may be inducing some kind of stress response in BALB/c 
mice. The reduction of sucrose intake over sub-chronic and chronic periods of time has 
been compared to anhedonic effects in previous models of stress and depression (see 
section 5.1.) and the results of experiment 1 may support the hypothesis of an 
anhedonic response following predator stress. However, the acute time course of this 
effect also raises the possibility that the reduction of sucrose intake may be due directly 
to a short-term fear/anxiety response. The results of experiment 2 appear to support this 
possibility as, 24 hours after the predator exposure, there were no differences in sucrose
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intake between control and stressed animals, thus suggesting that single exposure to 
predator stress may not cause long-lasting effects in sucrose consumption tests.
Blanchard et al (1993) have also demonstrated a reliable reduction in eating 
frequencies, levels and duration in groups of rats following a single exposure to a cat 
suggesting that predator exposure may act to suppress feeding behaviour.
Chronic stress and antidepressant studies -  Sucrose intake was significantly reduced 
(albeit erratically) in BALB/c mice following repeated exposure to a predator. 
Decreases in sucrose intake were seen after the first exposure (in keeping with the 
findings of the acute stress study -  experiment 1) and are generally maintained after 
predator exposure for approximately 4 weeks. It appears also that sucrose intake is 
reduced, again erratically, both in stressed and unstressed mice following the 
commencement of the dosing regime suggesting that this may be an additional stressful 
component of the study with regards to this particular measure. Sucrose intake remains 
lower in the vehicle treated stress groups than in non-stressed controls indicating that 
the predator stress stimulus is still exerting some effect.
The long-term administration of DMI and paroxetine appeared to bring sucrose intake 
values in stressed and non-stressed mice closer together. However, this effect was, on 
closer inspection due to reductions in intake in the non-stressed control groups rather 
than a restorative effect of antidepressant administration on decreased sucrose intakes 
following predator stress. These data are partly inconsistent with the reported 
restoration of chronic stress-induced reduced sucrose intake following antidepressant 
administration in mice (Monleon et al] 1995) and rats (Muscat & Willner, 1992a; 
1992b; Papp et al, 1994a; 1994b) following the administration of imipramine in several
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CMS studies. Our results are also inconsistent with those of D’Aquila et al (1997a) and 
Muscat et al (1992), who found that chronic administration of fluoxetine gradually 
restored sucrose intakes in mice and rats stressed using the CMS procedure. The 
reversal of CMS induced anhedonia has also been demonstrated following 
administration of the antidepressant compounds, maprotiline and flibanserin in 
laboratory animals (Muscat et al, 1992; D’Aquila et al, 1997a). The variability of the 
sucrose test data however made it very difficult to evaluate the time course of DMI or 
paroxetine effects on sucrose intake.
Though numerous investigations using CMS have reported reductions in sucrose 
intake as a measure of decreased reward, the reliability of sucrose intake as a measure 
of anhedonic status has always been a controversial issue (Forbes et al, 1996; Harris et 
al, 1998). There appears to be some conflict regarding the reliability of this measure 
(D’Aquila et al, 1997a; 1997b; Willner, 1997) and sucrose intake has been found to be 
rather erratic in various studies. It is possible that this parameter could be influenced by 
a variety of factors unrelated to hedonic tone (Willner; 1992).
It has been argued that the reduction in sucrose intake observed in many CMS studies 
may be due to an accompanying loss of body weight, dehydration state and/or calorie 
restriction following long food and water deprivation periods (Forbes et al, 1996; 
Harris et al, 1998). In applying these criticisms to our studies, it is agreed that body 
weights are lower in stressed groups however, this is not a significant effect and the 
size of this effect (maximum -5%) is minimal when compared to the size of the effects 
on sucrose consumption (25%-week 3, 49%-week 4, 44%-week 5, 48%-week 6, 34%- 
week 7 and 40%-week 8). Sucrose intake data, when expressed as mg intake/g hody 
weight (Figures 6.3.3.iii.(3) and (4)) also generally demonstrated reduced intake
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following stress. The general lack of significant differences in sucrose intakes 
following DMI and paroxetine administration may have resulted from reduced sucrose 
intakes in the non-stressed control groups rather than “restored” intakes in the stressed 
groups. This is inconsistent with the findings in CMS studies (Willner et al, 1992; 
1996; D’Aquila e/flZ, 1997).
Reductions in sucrose intake may be also attributed to a general decrease in non­
specific consummatory behaviour. Water intake in stressed and non-stressed animals 
did not differ throughout this particular study. Food intake (as measured in a parallel 
study, Theodorou & Bate - personal communication) was found to be gradually 
reduced in both groups throughout the study.
It could also be argued that reduced sucrose intake may not model an anhedonic 
response as, though the animal’s consumption of a sweet sucrose solution may have 
altered, this may not necessarily be indicative of a loss of preference. In our studies, 2- 
bottle tests were abandoned (section 5.5) as they gave similar results to, and did not 
provide any more additional information than the more convenient 1-bottle test 
therefore preference for sucrose was not recorded in this study. Water intake was 
measured at various points and remained constant (and lower than sucrose intake in no­
stressed animals) throughout the investigation. These data also concur with results of 
experiments following CMS in rats (Muscat et al, 1992a; 1992b).
The data obtained in these experiments shows that exposure of mice to the odour and 
visual contact with a predator is effective in reducing the intake of a 3% sucrose 
solution (which has been shown to be preferred by the mice over water -  section 5.2.4). 
This suggests the presence of decreased reward sensitivity and induction of an
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anhedonic state in mice chronically exposed to a predator. No reversal of this effect 
following chronic antidepressant treatment was observed in this study.
6.4.iv. Plasma corticosterone concentrations
Acute stress study -  No statistically significant differences were observed in plasma 
corticosterone concentrations following acute exposure to predator stress though 
corticosterone concentrations were elevated by 39% immediately after exposure. 
Previous studies have reported increased rat plasma corticosterone concentrations in 
response to predator odour (File et al, 1993a; Lu et al, 1998; Tanapat et al, 1998) and 
have suggested that this effect may reflect an acute fear/anxiety response that appears 
to fade with time after exposure (File et al, 1993a). Lasting effects of a single exposure 
to a predator on plasma corticosterone are found to vary with studies reporting 
increased corticosterone for up to one week after exposure in Hooded rats but not in 
Wistar rats (Adamec et al, 1997a; 1997b). Acute exposure to a predator in our studies 
however did not produce these effects.
Chronic stress and antidepressant study - Plasma corticosterone concentrations were 
not significantly affected by chronic exposure to predator stress. No effects of chronic 
predator stress were observed in the plasma corticosterone concentrations of the 
baseline non-stress and stress groups. However, these observations are in line with 
studies conducted by File et al (1993a) which found that the corticosterone response to 
predator odour stress in rats diminishes with increased number of exposures to the 
predator. The corticosterone response represents the ‘disturbance’ component of the 
phobic reaction of rats to predator odour and is found to habituate more readily in rats 
than the behavioural ‘avoidance’ response (File et al, 1993a). Bearing this in mind (and 
also unpublished observations by Karen Mellowdew, Institute of Psychiatry that odour
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alone does not appear to induce significant stress in mice), the mice in these 
experiments were also exposed to visual predator stress in an attempt to make the 
predator stimulus more stressful. The results of our studies indicate that the protocol 
used for predator stress may not be sufficient to elicit a corticosterone response in 
BALB/c mice. Any possible intermediate responses may have been overlooked as 
plasma corticosterone was only measured at the end of the investigation and may be 
subject to rapid habituation, not only to the odour but also to visual contact with the 
predator.
The largest differences in corticosterone levels were observed between the baseline 
non-stress/stress groups and the vehicle treated non-stress/stress groups suggesting that 
the dosing procedure itself may be inducing some degree of stress in all of the animals. 
The similarity of plasma corticosterone concentrations in the non-stressed vehicle 
treated group and stressed vehicle treated group indicates that exposure to predator 
stress in combination with the stress of dosing is not a factor leading to elevated 
corticosterone levels in this group. The degree of handling experienced by the animals 
may also be a factor affecting the corticosterone response as animals were regularly 
handled throughout the study.
There were no overall significant effects of chronic antidepressant treatment on plasma 
corticosterone in this study.
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6.4.V. Specific ^H-dexamethasone binding to cortical and hippocampal CR
Acute stress studies - No changes were observed in any of the parameters of specific 
^H-dexamethasone binding to CR in cortex or hippocampus following acute exposure 
to predator stress. It is likely that the stressor may be too acute to cause receptor 
changes. Also, the lack of any significant increase in plasma corticosterone 
concentrations may not be sufficient to induce changes in receptor occupancy in the 
stressed animals.
Chronic stress and antidepressant studies -  There were no significant changes in 
specific ^H-dexamethasone binding to CR in either cortex or hippocampus following 
long term exposure to predator stress. This indicates that there is no mechanism acting 
to down-regulate CR in these brain regions following chronic predator exposure or that 
this stimulus may not be stressful enough to produce a clear reduction in CR numbers. 
It may also be possible that the presence of endogenous corticosterone in the system at 
the time of sacrifice is confounding data and reducing the CR signal being measured by 
the assay. However, the lack of effects observed in plasma corticosterone indicates that 
this is not likely.
The dosing procedure appeared to have no effect on the Bmax of ^H-dexamethasone 
binding in the cortex or hippocampus. No effects of chronic dosing with DMI were 
observed in non-stressed or stressed animals. Treatment with paroxetine in the non­
stress control group significantly reduced ^H-dexamethasone binding to cortical CR as 
compared to the non-stressed vehicle treated group. This observation agrees with the 
results of the naïve study using paroxetine (Chapter 3) in which chronic administration 
of paroxetine down-regulated CR in rat cortex.
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These data may reflect habituation to the stressor as Zangrossi & File (1993) have 
demonstrated a dissociation of behavioural and corticosterone responses to cat odour in 
rats. Though behavioural responses are maintained following repeated exposure to a 
predator (File et al, 1993a), corticosterone responses rapidly habituate. It follows that 
no changes will be seen in CR binding as no dysfunction of the HP A axis is observed in 
this paradigm.
6.4.vL General
Though several previous studies have demonstrated a lasting effect of predator 
exposure (Blanchard et al, 1993; Adamec et a/, 1993; 1998), few have investigated the 
effects of repeated predator exposure on any particular measures. One such study, 
conducted by Pico-Alfonso et al (1998) demonstrated no changes in sucrose intake or 
plus maze behaviour following 15 days of exposure to predator stress. The results of 
this are consistent with our data and suggests that 15 days of exposure may not be 
enough to produce stress effects.
More methodological considerations of this investigation involve possible criticisms of 
housing conditions, the effects of circadian fluctuation in measures and more 
prominently, the effects of food and water deprivation. Some investigations have 
indicated that social isolation is associated with increased food consumption and 
anxiety in rats (Scalera et al, 1992). Mice however, have a different social organisation 
and are found to be behaviourally isolated in natural situations in that they do not 
tolerate male conspecifics in their territory. This situation may be different in the case 
of laboratory mice however. Moles et al (1995) found no differences in sucrose intake 
measures in individually housed mice.
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It can be argued that more accurate measures of activity and intake could be obtained in 
the dark phase of the activity cycle as mice are nocturnal animals. However, our 
preliminary experiments (Chapter 5) demonstrated there were no significant differences 
in measures taken in the light or dark phase.
The issue of food and water deprivation is an important one; however it appears that the 
changes observed in our studies are not directly attributed to body weights, dehydration 
status or calorie restriction. Food deprivation however, is also found to affect a number 
of other factors. Insulin has been demonstrated to target the striatum and regulate the 
activity of the dopamine transporter (the major mechanism of DA clearance). As a 
result of food deprivation, Patterson et al (1998) reported decreased DA transporter 
mRNA levels in the striatum. Though these studies involved long periods of fasting for 
rats, a regular restriction of food intake may have some impact on DA systems, which 
are involved in the reward behaviour being measured by sucrose testing. Restriction of 
food intake has also been reported to increase corticosterone concentrations in rats and 
also produce a dysregulation of 5-HT2c receptor mRNA and abolish the normal diurnal 
variation in hippocampal GR and MR (Holmes et al, 1997).
Neural mechanisms of anhedonia have been investigated using CMS, place preference 
conditioning and intra-cranial self-stimulation (ICSS). The mesolimbic DA projection 
from the ventral tegmental area (VTA) to the nucleus accumbens is thought to play a 
crucial role in mediating the behavioural effects of rewards. Behavioural effects 
induced by CMS have much in common with the effects of DA receptor antagonists 
such as SCH-23390, pimozide, sulpiride and raclopride. Primary features of these 
include the selective suppression of dilute sucrose intake/preference, attenuation of 
place preference conditioning and an increase in the electrical threshold for ICSS
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through VTA implanted electrodes (Willner et al, 1992). Changes in sensitivity to 
rewards are likely to be mediated post-synaptically following subsensitivity of D2  
receptors in the nucleus accumbens (Towell et al, 1987; Muscat & Willner, 1989; 
Muscat et al, 1992b, Papp et al, 1994b), this effect being secondary to a prolonged and 
persistent overexposure to increased DA release. There is also strong evidence to 
suggest that chronic antidepressant administration may reverse anhedonia by 
potentiating DA transmission. Therapeutic responses to antidepressants are found to be 
reversed by DA receptor antagonists, all of these reducing sucrose intake only in 
antidepressant treated, stressed animals. Muscat et al (1992b) also reported that the 
therapeutic effects of fluoxetine and maprotiline, which act mainly as 5-HT and NA 
reuptake inhibitors, were reversed by acute administration of raclopride suggesting that 
sensitised D2 receptors in the nucleus accumbens may provide a common mechanism 
of action of antidepressant dmg actions on anhedonic behaviour.
Changes in 5-HT are associated with many, but not all, anxiogenic and stressful 
situations. Increased G ABA release, with accompanying decreases in uptake, have been 
reported in cortical and hippocampal rat brain slices following cat exposure. Changes in 
release and uptake of G ABA after novel environment exposure were in the opposite 
direction. (File et al, 1993b). Hippocampal 5-HT concentrations did not appear to be 
significantly affected by cat exposure and were found to be time-dependent and region 
specific, as were measurements of 5-HT concentrations following novel environment 
exposure. This investigation suggests that anxiogenic responses may not always be 
associated with altered 5-HT levels as traditionally thought.
It appears, from our data and also previous studies, that the nature of the effects of 
predator stress may be dependent on the behavioural measure. The acute nature of the
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stressor may indicate a fear response to this stressor on measures of open field activity, 
sucrose intake and also plasma corticosterone concentrations. As alterations in all/many 
of these parameters are expected in an anxiety model, it is not clear whether this 
stressor is producing anxiety or stress/depression effects. The changes seen in sucrose 
intake are indicative of anhedonic effects following chronic predator exposure, which 
reflects a core symptom of melancholia; however the lack of antidepressant effects 
implies that this paradigm may not be responsive to antidepressant compounds. 
Depressed activity following chronic predator exposure may reflect a core symptom of 
melancholia (in which motor activity can be either increased or decreased) or a typical 
anxiety pattern. The lack of significant effects on biochemical parameters indicates 
that, though this paradigm may model some of the behavioural aspects of stress and 
anxiety, it does not model the endocrinological or biochemical symptoms to any great 
degree. The nature of the stressor plays an important role in the activation of stress 
responses resulting in various symptoms being displayed (Herman et al, 1997). Many 
of the alterations observed in this paradigm suggest that it may be a useful model of 
post-traumatic-stress disorder (PTSD) and related anxiety.
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CHAPTER 7
DISCUSSION
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Discussion
Major biological manifestations of major depression include alterations in 
limbic/hypothalamic centres that govern food intake, libido, circadian rhythms and 
hormone secretion. The preceding experiments used these observations as their starting 
points in attempting to elucidate the mechanisms that underlie antidepressant activity. 
Consistent defects have been observed in corticosteroid regulation of the HP A axis in 
both hypercortisolaemic, depressed patients and stressed animals, which appear to be 
normalised following antidepressant treatment. The main objectives of the present 
investigation were to determine whether stress syndromes and antidepressant 
administration in animals were associated with alterations in corticosteroid 
receptors/secretion and if CR alterations may form a common pathway for the 
mechanism of action of various antidepressant drugs.
7.1. Methodological considerations
^H-dexamethasone binding assay] CR radioligand binding studies have used various 
ligands (^H-corticosterone, ^H-dexamethasone, ^H-RU28362, ^H-aldosterone) for 
measuring CR -  and dextran coated charcoal, gel filtration or centrifugation as 
separation methods (Luttge et al, 1984; Reul & de Kloet, 1985; Reul et al, 1993; 
Budziszweska et al, 1994b). Previous investigations have utilised various radioligands 
to measure CR including ^H-corticosterone (Jacobsen et al, 1993), ^H-aldosterone 
(Vedder et al, 1993) and ^H-RU28362 (Reul et al, 1987a; 1987b). In our studies, ^H- 
dexamethasone was used as a radioligand allowing us to measure CR in various brain 
tissues and also the thymus. The interaction between this ligand and the binding site in 
our experiments was found to be a saturable, simple bimolecular reaction that follows 
the law of mass action, thereby fulfilling the fundamental criteria of receptor binding 
analysis. The use of the rapid vacuum filtration method of separation of bound and free
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ligand was also supported by the observation that the values obtained in our studies 
agreed closely with those obtained in other laboratories (Szuran et al, 1997); and also 
with studies obtained in our own laboratory using column chromatography (Rosser et 
al, 1995). The CR binding assay may be subject to the criticism that it is a rather 
sensitive assay that has the potential to be affected by numerous external factors. In our 
laboratory however, this assay has proven to be consistent over the years and the results 
of the studies conducted over the duration of this thesis have not been subject to large 
fluctuations over time.
Attempts to clarify the status of CR involvement with stress/depression and/or 
antidepressant action have mainly relied on the use of adrenalectomised animals for in 
vitro studies (Sapolsky et al, 1984a; 1984b; Reul et al, 1993; 1994; Budziszweska et al, 
1994a). Our data was generated using adrenally-intact animals which contained 
endogenous circulating corticosterone at the time of death. Therefore many precautions 
were taken in order to ensure that basal corticosterone concentrations remained within 
the normal range with minimal fluctuations.
In order to obtain valid data pertaining to plasma corticosterone concentrations, it was 
important to use controlled conditions throughout. Any deviations from normal 
light/dark cycles, noise, light intensity and temperature may have generated the 
possibility of altering basal hormone levels, as well as inducing shifts in normal 
circadian rhythms. The circadian pattern of corticosteroid secretion also required 
samples to be collected at the same time each day. Animals were also minimally 
disturbed at all times to reduce the risk of stress-induced corticosteroid secretion. The 
levels of circulating corticosterone at the time of sacrifice corresponded with a 70-90% 
occupation of type I MR indicating that most of the CR being measured in our
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investigations were type H GR. This conclusion was supported by the demonstration of 
a GR-like competition profile and similar binding parameters were obtained in 
saturation experiments using the selective GR agonist RU28362 to define specific 
binding.
Behavioural investigations'. The subjective nature of these and the lack of standardised 
behavioural testing procedures across laboratories makes it difficult to compare data 
from various studies. Optimisation of testing procedures (as described in Chapter 5) for 
our own studies ensured that protocols were consistently observed. The species of 
animals used also appears to greatly impact any behavioural measurements (Capeless & 
Whitney, 1995; Logue et al, 1997). As the use of behavioural models and transgenic 
animals in the development of psychiatric disorders increases so does the importance of 
choosing animals with the appropriate genetic background, again, an issue raised by the 
lack of standardisation of protocols. Discrepancies between studies may be attributed to 
numerous possible variations in animal species used, the testing protocols and the 
receptor binding assays.
Depressed patients exhibit an altered timing of rest/activity. It may be useful, in future 
studies, to constantly monitor activity in animal model investigations instead of 
obtaining ‘snapshot measures’, as animals with HPA disorders are more likely to 
display altered circadian rhythmicity (maybe also incorporating hyperphagia- and 
hypersomnia-type syndromes).
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7.2. Corticosteroid receptors and antidepressants
There is clear evidence to suggest that antidepressant compounds may act via the 
regulation of corticosteroid receptors to correct the defective feedback observed in 
stress/depression. Several investigations have suggested that CR and/or CR mRNA are 
down-regulated following stress (Sapolsky et al, 1984a; Young et al, 1990; Brooke et 
al, 1994a; Gomez et al, 1996; Gomez et al ,1998; Kitraki et al, 1999) yet few have 
investigated any potential normalisation of this deficit following chronic administration 
of various antidepressant drugs. Suggestions that up-regulation of CR may comprise a 
common mechanism of action for the different classes of antidepressant treatments 
through which therapeutic efficacy of these compounds is achieved, have been derived 
primarily from work in adrenalectomised, unstressed animals (Reul et al, 1993; 1994; 
Budziszweska et fl/, 1994a).
Our studies using naïve animals, indicated that the antidepressants DMI, paroxetine and 
venlafaxine may have different effects on CR in various brain regions following long­
term administration in adrenally-intact rats. Inconsistent results were observed, with 
chronic administration (14 days) of DMI inducing increases in cortical CR; paroxetine 
inducing decreases in CR in the cortex and thymus following 14 and 28 days of 
administration, respectively, however an increase in striatal CR was observed after 7 
days; venlafaxine had no consistent effects on CR in any of the regions investigated.
Previous studies have reported increases in hippocampal CR/CR mRNA following 
long-term administration of tricyclic antidepressants or moclobemide -  these studies 
were conducted in adrenalectomised animals thus possibly rendering CR in this region 
more sensitive to fluctuations induced by antidepressant administration. The observed 
neuroanatomical specificities of the antidepressant effects in our studies could possibly
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also relate to differing monoaminergic innervations of theses areas which may 
indirectly be affecting CR in these regions. In our studies, any changes have been 
observed primarily in the cortex and not in the hippocampus, suggesting a different 
mechanism may be active in the presence of endogenous ligand. The data obtained may 
have been confounded by the presence of endogenous corticosterone in the system at 
the time of assay as previous investigations used adrenalectomised animals only. 
However, the procedure of adrenalectomy itself can also interfere with the status of the 
HPA axis (see section 3.5) and though, in our studies, we may have been measuring 
only -70-90% of the total CR population, this was sufficient to enable reflections of 
any changes in numbers of receptors following various procedures.
Previous investigations have not always used the same radioligand to measure CR; 
Budziszweska et al (1994b) used ^H-corticosterone whereas Reul et al, 1993; 1994 
have used ^H-dexamethasone and ^H-aldosterone in their experiments -  these 
variations in CR measurement methods may also contribute to observed differences in 
results.
The lack of a consistent up- or down regulation of CR in our studies may also he 
attributed to the doses of antidepressants used as these differed between previous 
studies and our own, as did the route/method of administration. Future experiments 
may benefit from establishing dose-response effects of antidepressants and also the 
measurement of type I MR in these samples.
Our investigations also displayed no significant effects of stress or antidepressants on 
plasma corticosterone concentrations which may have been more accurately detected 
(in conscious animals) if we had used in-dwelling catheters to collect serial samples
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rather than the trunk blood method. Serial sampling greatly increases the information 
obtained and also the investigative power of neuroendocrine challenge testing which 
could be used in future experiments of this nature.
The involvement of various neurotransmitter systems with HPA axis regulation is well 
documented (Dinan, 1996a; 1996b; Tritos et al\ 1999). It is not clear however whether 
the HPA abnormalities observed in depression occur as a secondary result of primary 
neurotransmitter alterations or vice versa and arguments have been put forward for both 
mechanisms (Budziszweska; 1994a, Dinan; 1996b). Many investigations have 
demonstrated the responsivity of HPA axis elements to modulation of neurotransmitter 
levels and it has become clear that the relationship between monoamines (especially 
catecholamines and 5-HT) and the HPA axis is extremely complex with multiple levels 
at which the systems interact with each other. Other neuroactive peptides synthesised 
by the brain are also affected by the administration of antidepressants (CRF, BDNF, 
etc...) and these may also be involved in the cascade of events leading to HPA 
normalisation in depression.
Direct effects of antidepressant action on the HPA axis are also firmly established. It 
has been suggested that antidepressants may help to maintain CR function in NA and 5- 
HT containing neuron-containing cell groups, eg. the hippocampus (Holsboer & 
Barden, 1996) via their acute affects on neurotransmitter concentrations. None of the 
CR alterations in our studies were observed in the hippocampus therefore did not 
consolidate these suggestions.
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7.3. Animal models of stress/depression
The role of animal models of depression may be considered as a critical interface 
between basic behavioural neuroscience and the clinic. In this respect, the preceding 
experiments used epidemiological, behavioural and endocrine correlates found in 
patients suffering from stress/depression as their starting points with attempts to 
reproduce similar syndromes in laboratory animals.
The OB rat, appearing to share many of the characteristics observed in 
stressed/depressed patients (Table 1.6.1.1) that are normalised by chronic antidepressant 
administration, was first investigated. All antidepressant compounds used in our studies 
normalised OB induced hyperactivity in the open field demonstrating that this 
parameter is replicable from study to study and reliable for use in the screening of 
compounds for antidepressant activity in the OB rat. These results were very consistent 
with the results of numerous previous investigations (section 4.1) Receptor binding 
studies failed to show any CR deficits in the bulbectomised rat suggesting that the OB 
rat does not model the dysfunctional corticosteroid feedback characterised by CR 
down-regulation observed in many depressed patients.
Time course studies, similar to those conducted in naïve animals were conducted in 
sham operated animals following the analysis of results from experiments that 
demonstrated that sham-operated controls are very similar to un-operated controls. The 
results of these investigations showed no consistent alterations in hippocampal CR 
following chronic administration of DMI, citalopram and milnacipran. These 
observations must also be tempered by the fact that CR binding was only tested at one 
dose of each of the antidepressants; a dose-response experiment may be useful here. 
Venlafaxine however did increase CR binding following 28 days of administration
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displaying some differences between these data and those obtained in the naïve study 
and indicating that sham-operated rats may not be suitable for use as a control animal. 
The actual doses of antidepressants given in each of the investigations also differed 
however, providing more potential variation in experimental design.
Several of the classical alterations associated with the depressive syndrome in animal 
models however have not yet been observed in the predator stress paradigm. 
Investigations being conducted in this area are still in early stages however and the 
hypothesis that this behavioural paradigm may constitute to some degree, an animal 
model of depression/anxiety is recent. Overall responses of rats and mice to predator 
exposure indicate that this stimulus is a stressful one (see section 6.1). Responses to 
this stressor also indicate a high level of anxiety-like behaviour in animals exposed to 
predator stress. Some of the changes observed in this paradigm can be compared to 
those observed in human stress situations and also in a number of various other putative 
models of depression and anxiety.
Our predator stress studies showed some conflicting data with open field hyperactivity 
being observed following acute stress; this was reversed following chronic stress. No 
antidepressant effects were observed on open field activity. The open field arena is an 
established method by which activity levels are measured in laboratory animals. In 
attempting to simulate the psychomotor agitation or retardation observed in depressed 
patients, measurements in animals were made difficult by the demonstration of both 
increased and reduced activity following stress. However it is generally thought that 
reduced activity levels reflect more of an anxiety-like state (Lister, 1990; Adamec et al, 
1993a) indicating that the predator stress paradigm may be more useful in the study of 
anxiety.
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Sucrose intake was reduced following acute and chronic predator stress however the 
variability of the data made it difficult to evaluate accurately the effects of 
antidepressant administration on this parameter. Given the difficulties encountered in 
attempting to establish a sucrose intake baseline and recent controversy surrounding the 
issues of reliability of sucrose intake measures in stress models (Willner, 1997a; 1997b; 
Weiss, 1997; Moreau, 1997), the inconsistency of these results may be warranted.
The validity of using anhedonia as a measure of the ‘loss of pleasure’ experienced is 
also questionable. Anhedonia is found to occur to some degree in over 50% of 
psychiatric patients regardless of diagnosis (Silverstone, 1991- cited in Argyropoulos & 
Nutt, 1997). However, it has been suggested that anhedonia in chronic stress studies 
may result from motor retardation (Nelson & Chamey, 1981, Argyropoulos & Nutt, 
1997). The dopaminergic reward system (ascending from the mesencephalon to the 
ventral striatum/nucleus accumbens) is functionally and anatomically closely connected 
to the nigrostriatal extrapyramidal pathways therefore a dysfunction of both in 
psychiatric disorders may lead to both anhedonia and motor retardation. This must be 
kept in mind when looking at the predator stress studies as both behavioural syndromes 
were observed.
As with the OB rat, mice subjected to predator stress also did not display any 
alterations in corticosterone output and/or CR binding parameters, again indicating that 
defective CR regulation was not being modelled in this stress-based animal paradigm.
The lack of CR effects in the animal models investigated suggest that more work may 
need to be conducted along these lines. The predator stress clearly needs further 
behavioural, neurochemical and endocrinological characterisation and investigation.
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HP A axis changes in both of the models used may be more pronounced following a 
stress challenge prior to sacrifice superimposed on the chronic stress administered. The 
predator stress, though ethologically sound, does not appear to be severe enough to 
cause changes in the parameters being measured. It is possible that the use of different 
predators (eg. cats or ferrets) may be more effective. However in using external 
stressors to induce stress syndromes in laboratory animals, one issue that has always 
caused concern is that of severity of the stressors utilised. Many behavioural and 
physiological alterations have been reported when stressors are severe (eg. 
immobilisation stress -  Katz et al, 1981; 1982a; 1982b; Bonaz et al, 1998; Howell et 
al, 1998, Karandrea et al, 2000; Chowdhury et al, 2000) or caused by lesioning 
(Chapter 4). However in attempting to reproduce stress syndromes resulting in an 
animal model for depression, many investigations have preferred the use of milder, 
(Willner et al, 1991a; 1991b; 1997) or ethologically relevant stressors (Zangrossi et al, 
1992a; Adamec et al, 1993; Chapter 6) which appear to provide a more realistic method 
of stress induction. This has certainly been the objective of the experiments presented 
in Chapter 6.
7.4. General
Although the original biochemical hypotheses of depression envisaged a single 
transmitter disorder, subsequent neuroscientific developments have highlighted the 
complex inter-relations between various systems (Rossby et al, 1994). This alone 
suggests that the physiological processes associated with depression may occur in 
various stages which may involve different systems at different times. This could 
provide some information regarding the large variety of depressive symptoms and why 
they are not uniformly experienced by all patients. It could be that seemingly
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contrasting experimental findings may simply reflect different types or stages of 
depressive episodes.
There is much evidence for the existence of interactive communication between the 
CNS, endocrine and immune systems (Connor, 1998; Elenkov et al, 2000). Regulation 
of the immune response is partly controlled by the experience of stress, which appears 
to play a prominent role in depression aetiology. Glucocorticoids also mediate 
immunosuppression -  a mechanism thought to have evolved in response to the 
fight/flight reaction. As with corticosteroid secretion, this is advantageous acutely but 
when chronically activated may have debilitating effects. It is quite possible that the 
immunological alterations observed in depression also occur as a result of excessive 
activation of the HPA axis and defective regulatory mechanisms of the stress response.
Though it was anticipated that decreased CR numbers would be observed in our animal 
model studies, the possibility cannot be excluded also that mechanisms operative in 
provoking alterations in various models are different. Therefore generalisations 
concerning the impact of stressors on different parameters should be approached with 
caution. Different environmental stressors are likely to trigger different 
neurotransmitter pathways and neuroendocrine systems therefore resulting in a 
different underlying neurobiological state of the organism. That depression may be 
associated with other clinical diagnoses such as anxiety has been long recognised. 
Thus, anxiety, stress and depression are inter-related and it is possible that the 
depressive syndrome may be the cumulative effect of chronic exposure to stress and 
anxiety-inducing stimuli. A multivariate approach is needed to adequately assess the 
specificity of effects of any given manipulations.
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Contemporary therapy of major depression is dominated by drug therapy, this 
dependence being unlikely to change. Even if direct effects of antidepressants on CR 
are established and lead to modulation of CR as treatment for depression, anti­
glucocorticoid agents, though useful, are not likely to become first line option in the 
treatment of depression. In many clinical trials of anti-glucocorticoid drugs, 
glucocorticoid supplimentations have to be given with plasma glucocorticoid levels 
monitored closely and doses being adjusted accordingly (Brown et al, 1999; Patten et 
al, 2000). The potential side effects of these drugs may also prove to be inconvenient. 
Given the enormous interactive capabilities of various stress systems and the unspecific 
effects of antidepressants after chronic administration, it is possible that drugs 
developed to target several systems simultaneously (eg. specifically up-regulate GRs 
and 5-HTi A receptors) may prove to be superior.
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APPENDIX 2.3.1.
Drugs and chemicals
ITEM DESCRIPTION SUPPLIER
Bovine serum albumin Fraction V Sigma-Aldrich Co. 
Ltd, U.K.
Cupric sulphate CUSO4 .5 H2O AnalaR, U.K.
Dithiothreitol C4H10O2S2 Sigma-Aldrich Co. 
Ltd, U.K.
1,2,4, 6,7 [^H-dexamethasone] Concentration = Amersham Int. Pic,
ImCi/mmol U.K.
Ethylenediamine-tetraacetic acid (EDTA) CioHi4N20gNa2. Sigma-Aldrich Co.
2 H2O Ltd, U.K.
Folin Ciocalteu’s Reagant Sigma-Aldrich Co. 
Ltd, U.K.
Glycerol (approx. 99%) C3H8O3 Sigma-Aldrich Co. 
Ltd, U.K.
Hydrocortisone (Up, 17a, 21- C21H30O5 Sigma-Aldrich Co.
trihydroxypregn-4-ene, 3.20-dione) Ltd, U.K.
Optiphase Safe scintillation cocktail Wallac, U.K.
Polyethylenimine (PEI) 50 wt % solution in Sigma-Aldrich Co.
water Ltd, U.K.
RU28362 (lip , 17a,dihydroxy-6-methy 1- 17a 
(prop-l-ynyl)androsta 1,4, 6 trien-3-one)
Roussel-Uclaf, France.
Scintillation vials Canberra-Packard Int., 
U.K.
Sodium carbonate Anhydrous BDH, U.K.
Sodium hydroxide Pellets ProLabo, U.K.
Sodium molybdate NaN04.2H20 Sigma-Aldrich Co. 
Ltd, U.K.
Sucrose C12H22O11 Sigma-Aldrich Co.
min 99.5% Ltd, U.K.
Trisodium citrate C6H5Na30? Sigma-Aldrich Co. 
Ltd, U.K.
Whatman GF/F Alters Glass fibre filter Whatman Int. Ltd.,
sheets (45x67cm) UK
Tris (hydroxymethyl)-aminomethane (TRIS) C4H11NO3 ProLabo, U.K.
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APPENDIX 2.3.1 (continued)
Drugs and Chemicals
DRUG SUPPLIER
Citalopram hydrobromide Lundbeck & Co., Copenhagen, Denmark.
Desipramine hydrochloride Sigma-Aldrich Co. Ltd, Dorset, U.K.
Paroxetine hydrochloride SmithKline Beecham, U.K.
Milnacipran hydrochloride Centre de development, Pierre Fabre, Castres,
France.
Venlafaxine hydrochloride Wyeth-Ayerst Laboratories, Taplow, U.K.
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APPENDIX 3.4.1.
Displacement of ^H-dexamethasone binding from CR in rat cytosolic preparations by 
DMI (A), paroxetine (B) and venlafaxine (C). Rat cytosolic fractions were prepared as 
described in section 2.5.2. Data shown represents individual replicates from four 
experiments.
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APPENDIX 3.4.2.
^H-dexamethasone binding parameters (B^ ax and Xd) to type I + II / II CR/GR and tissue 
protein content in cortex from animals receiving vehicle or DMI.
(A) see Figure 3.4.2.1
DAYS VEHICLE DMI
BmaxCR 
tvpe I+ll
BmaxÇR 
tvpe II
Kd£E  
tvpe l+II
KdCR 
Tvpe 11
nrotein
content
ImaxCR 
tvpe I+II
BmaxCR
tvpe II
KpCR 
tvpe I+II
Kd CR 
tvne II
protein
content
1 114±12
(8)
97 ±14 
(8)
3.6 ±0.4 
(8)
2.6 ±0.49 
(8)
161 ±9  
(8)
103 ±10 
(8)
102 ±8  
(8)
2.1 ±0.4* 
(8)
2.3 ±0.4 
(8)
187 ±8  
(8)
3 109 ±7 
(8)
94±4
(8)
2.8 ±0.5
(8)
2.4 ±0.32 
(8)
201±9
(8)
100 ±4  
(7)
85 ±6  
(7)
2.1 ±0.2 
(7)
1.7 ±0.3 
(7)
196 ± 6 
(7)
7 83 ±14 
(6)
84 ±12
(7)
4±1
(6)
4.2 ±0.7 
(7)
171 ±7  
(7)
85 ±12 
(7)
103 ±7  
(7)
3.3 ± 0.5 
(7)
3.8 ±0.5 
(7)
183 ±5 
(7)
14 92±6
(7)
85 ± 7
(7)
1.6 ±0.2 
(7)
1.6 ±0.21 
(7)
196 ±7  
(7)
125±11* 
(8)
103 ±7  
(8)
1.6 ±0.2 
(8)
1.3 ±0.2 
(8)
207 ±4  
(8)
21 112±5
(8)
105 ±5 
(8)
2.7 ±0.5 
(8)
2.6 ± 0.6 
(8)
181±8
(8)
136±11
(8)
129 ± 14 
(8)
2.8 ±0.6 
(8)
2.7 ±0.9 
(8)
188 ±9 
(8)
28 121 ±10
(8)
117±10
(8)
3.3 ±0.4 
(8)
2.7 ±0.21 
(8)
179 ±6  
(8)
108 ±17 
(6)
102 ±16 
(6)
2.6 ± 0.4 
(6)
2.5 ±0.4 
(6)
173±10
(6)
7 w.d 117±13
(8)
120 ±15 
(8)
1.8 ±0.6 
(8)
2.0 ±0.74 
(8)
177 ±3  
(8)
135 ±16 
(8)
136±15
(8)
2.3 ±0.6 
(8)
2.2 ±0.5 
(8)
157±11
(8)
Rats received DMI (10 mg/kg, p.o) or water vehicle once daily for up to 28 days and were sacrificed 
after 1, 3, 7, 14, 21 and 28 days of administration or 7 days after withdrawal of the dmg (7 wd). All 
procedures and CR assays were conducted as described in section 3.2. Data are expressed as mean ±  
sem. Numbers in parentheses =n per group. Individual B^ ax values ranged from 55 - 172 fmol/mg protein 
in vehicle treated animals and 3 6 -2 1 4  fmol/mg protein in DMI treated animals. Individual ^  values 
ranged from 0.34 - 7.94 nM in vehicle treated animals and 0.42 -  6.59 nM in DMI treated animals. 
Individual protein content values ranged from 132 - 243 pg/assay in vehicle treated animals and 126 - 
222 pg/assay in DMI treated animals. Statistically significant differences were determined using 
ANOVA followed by Student’s t-tests and are denoted by * p<0.05, as compared to respective vehicle 
treated control group.
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APPENDIX 3.4.2. (continued)
^H-dexamethasone binding parameters (Bmax and Xd) to type I + II /  II CR/GR and tissue 
protein content in hippocampus from animals receiving vehicle or DMI.
(B) see Figure 3.4.2.Ü
DAYS VEHICLE DMI
BmaxCR
tvoe I+II
BmaxCR 
tvpe II
KdCR 
tvne I+II
KdCR 
Tvne II
protein
content
BmaxCR
tvpe I+II
Bmax_CR 
tvpe II
Kd CR 
tvne I+II
KnCR 
tvpe II
protein
content
1 118 + 10 
(8)
114±9
(8)
2.1 ±0.5 
(8)
2 ±0.51 
(8)
131±11
(8)
119±8
(7)
110±8
(7)
3.3 ±1.0 
(7)
3.1 ±0.9 
(7)
145±12
(7)
3 79+11
(8)
75 ±22 
(8)
4.3 ±1 
(8)
3.4 ±1.1 
(8)
146 ±9  
(8)
64 ±8  
(7)
62±9
(7)
2.7 ±0.6 
(7)
2.7 ±0.6 
(7)
138±8
(7)
7 99 + 9 
(7)
95 ±9
(7)
4.3 ±1 
(7)
4.7 ±1.5 
(7)
146±13
(7)
112±10
(7)
105 ± 12 
(7)
4.1 ±0.8 
(7)
3.9 ±0.8 
(7)
130±9
(7)
14 95 ±13 
(8)
82±11
(8)
2.5 ± 0.6 
(8)
1.9 ±0.2 
(8)
143 ±8  
(8)
102 ±6 
(8)
84±9
(8)
1.9 ±0.4 
(8)
1.1 ±0.1 
(8)
146 ±8  
(8)
21 99 ±12 
(8)
100 ±8  
(8)
2.3 ±0.5 
(8)
2.4 ±0.5 
(8)
171 ±7  
(8)
97 ±10 
(8)
94±9
(8)
1.6 ±0.3 
(8)
1.6 ±0.2 
(8)
157±14
(8)
28 96±11
(7)
102±11
(7)
2.7 ±0.5 
(7)
3.1 ±0.8 
(7)
124 ±9  
(7)
94±11
(7)
86 ±8  
(7)
3.0 ±0.2 
(7)
3 ±0.8 
(7)
136±8
(7)
7 w.d 108 ±9  
(7)
106 ±7 
(7)
1.1 ±0.2 
(7)
1.2 ±0.3 
(7)
147 ±9  
(7)
110±6
(8)
108 ±7  
(8)
1.4 ±0.5 
(8)
1.3 ±0.3 
(8)
137 ±8  
(8)
Rats received DMI (10 mg/kg, p.o) or water vehicle once daily for up to 28 days and were sacrificed 
after 1, 3, 7, 14, 21 and 28 days of administration or 7 days after withdrawal of the drug (7 wd). All 
procedures and CR assays were conducted as described in section 3.2. Data are expressed as mean ±  
sem. Numbers in parentheses =n per group. Individual B^ ax values ranged from 50 - 180 fmol/mg protein 
in vehicle treated animals and 33 - 155 fmol/mg protein in DMI treated animals. Individual Kq values 
ranged from 0.38 - 7.86 nM in vehicle treated animals and 0.42- 7.57 nM in DMI treated animals. 
Individual protein content values ranged from 7 9 -2 1 0  pg/assay in vehicle treated animals and 91 - 221 
pg/assay in DMI treated animals. No statistically significant differences were determined using ANOVA 
followed by Student’s t-tests.
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APPENDIX 3.4.3.
^H-dexamethasone binding parameters (B^ ax and Æn) to type I+II CR and tissue protein 
content in cortex (A) taken from animals receiving vehicle or paroxetine.
(A) See Figure 3.4.3.1
DAYS VEHICLE PAROXETINE
Bmax CR 
tvne I+II
Kd CR 
tvpe I+II
protein
content tvoe I+II
KnCR 
tvne I+II
protein
content
1 101 ±18  
(8)
2.7 ± 0.5 
(8)
145 ± 7  
(8)
115±13
(8)
1.9 ±0.4  
(8)
173 ± 7  
(8)
7 93 ±11  
(7)
2.5 ± 0.7
(7)
160 ± 5  
(7)
104 ± 9  
(7)
2.3 ±0.5  
(7)
150 ± 8  
(7)
14 114± 13 
(7)
2.7 ± 0.7
(7)
157 ± 8  
(7)
76 ±3**  
(8)
2.3 ± 0.6 
(7)
159 ± 6  
(8)
28 102 ± 9  
(8)
2.5 ± 0.6 
(8)
153 ± 7  
(8)
92 ± 8  
(7)
2.8 ±0.7  
(7)
167 ± 6  
(7)
7 w.d 103 ± 12 
(8)
2.3 ±0.8
(8)
157 ± 4  
(8)
101 ±12  
(7)
2.1 ±0.5  
(7)
165 ± 7  
(7)
Rats received paroxetine (5 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and were 
sacrificed after 1,7, 14 and 28 days of administration or 7 days after withdrawal of the drug (7 w.d). All 
procedures and CR binding assays were conducted as described in section 3.2. Data are expressed as 
mean ±  sem. Numbers in parentheses = n per group. Individual B^ ax values ranged from 44 - 193 
fmol/mg protein in vehicle treated animals and 39 - 154 fmol/mg protein in paroxetine treated animals. 
Individual ^  values ranged from 0.73 -  7.32 nM in vehicle treated animals and 0.81 -  5.34 nM in 
paroxetine treated animals. Individual protein content values ranged from 119 - 178 pg/assay in vehicle 
treated animals and 9 9 -2 1 4  pg/assay in paroxetine treated animals. Statistically significant differences 
were determined using ANOVA followed by Student’s t-tests and are denoted by ** p<0.01, as 
compared to respective vehicle treated control groups.
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APPENDIX 3.4.3. (continued)
^H-dexamethasone binding parameters (B^ ax and Kd) to type I + II CR and tissue protein
content in hippocampus (B) taken from animals receiving vehicle or paroxetine.
(B) see Figure 3.4.3.Ü
DAYS VEHICLE PAROXETINE
Bmax CR 
tvne I+II
Ed CR 
tvne I+II
protein
content
B ^  CR 
tvpe I+II
KnCR 
tvne I+II
protein
content
1 69 ±13  
(7)
3.4 ± 0 .6  
(7)
164 ±  6 
(7)
75 ± 1 0  
(7)
3.8 ±0 .6  
(7)
156 ± 6  
(7)
7 5 9 ± 9
(7)
2.4 ±  0.6
(7)
147 ± 4  
(7)
7 9 ±  13 
(8)
3.2 ± 0.9 
(8)
146 ± 6 
(8)
14 67 ±11  
(8)
2.6 ±  0.9 
(8)
156 ± 5  
(8)
71 ± 1 2  
(8)
3.1 ±0 .7  
(8)
142 ± 7  
(8)
28 9 9 ±  15 
(6)
5.2 ±0 .7  
(6)
150 ± 7  
(8)
73 ± 7  
(8)
3 ± 0.6* 
(8)
147 ± 5  
(8)
7 w.d 73 ±14  
(8)
3.3 ±  0.9 
(8)
160 ± 5  
(8)
9 4 ±  18 
(7)
3.5 ±0 .8  
(7)
156 ±  6 
(7)
Rats received paroxetine (5 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and were 
sacrificed after 1,7, 14 and 28 days of administration or 7 days after withdrawal of the drug (7 w.d). All 
procedures and CR binding assays were conducted as described in section 3.2. Data are expressed as 
mean + sem. Numbers in parentheses = n per group. Individual B^ ax values ranged from 21 - 154 
fmol/mg protein in vehicle treated animals and 39 - 185 fmol/mg protein in paroxetine treated animals. 
Individual Kn values ranged from 0.59 - 8 nM in vehicle treated animals and 0.89 -  7.39 nM in 
paroxetine treated animals. Individual protein content values ranged from 127 - 192 pg/assay in vehicle 
treated animals and 108 - 177 pg/assay in paroxetine treated animals. Statistically significant differences 
were determined using ANOVA followed by Student’s t-tests and are denoted by * p<0.05 as compared 
to respective vehicle treated control groups.
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APPENDIX 3.4.3. (continued)
^H-dexamethasone binding parameters (B^ ax and K^ ) to type I + II CR and tissue protein
content in striatum (C) taken from animals receiving vehicle or paroxetine.
(C) see Figure 3.4.3.iii
DAYS VEHICLE PAROXETINE
Bmax ÇR 
tvne I+II
Kd CR 
tvpe I+II
protein
content
B ^  CR 
tvpe I+II
^ C R  
tvne I+II
protein
content
1 95 + 17 
(3)
4.5 ±0.8  
(3)
137 ± 7  
(3)
83 ± 3  
(3)
3.7 ±1  
(3)
141 ± 5  
(3)
7 66 + 6 
(4)
3.1 ±1.3  
(4)
143 ± 3  
(4)
88 ±4*
(4)
5.5 ±1.2  
(4)
143 ± 10 
(4)
14 79+ 11
(4)
3 ±0.48  
(4)
148 ± 5  
(4)
98 ±15  
(3)
4.1 ± 1
(3)
132 ± 6  
(4)
28 107 + 27 
(4)
4.1 ± 1
(4)
135 ± 2  
(4)
76±11
(4)
3 ±0.7  
(4)
153 ±7*  
(4)
7 w.d 88 + 9 
(4)
3.2 ±0 .9  
(4)
145 ± 5  
(4)
61 ± 9  
(4)
1.8 ±0.4  
(4)
133 ±16  
(4)
Rats received paroxetine (5 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and were 
sacrificed after 1,7, 14 and 28 days of administration or 7 days after withdrawal of the drug (7 w.d). All 
procedures and CR binding assays were conducted as described in section 3.2. Data are expressed as 
mean ± sem. Numbers in parentheses = n per group (tissues were pooled from two animals in these 
experiments). Individual B^ ax values ranged from 52 - 185 fmol/mg protein in vehicle treated animals 
and 36 -114 fmol/mg protein in paroxetine treated animals. Individual values ranged from 1.12 - 6.89 
nM in vehicle treated animals and 1.02 -  6.99 nM in paroxetine treated animals. Individual protein 
content values ranged from 123 - 157 pg/assay in vehicle treated animals and 121 - 170 pg/assay in 
paroxetine treated animals. Statistically significant differences were determined using ANOVA followed 
by Student’s t-tests and are denoted by * p<0.05, as compared to respective vehicle treated control 
groups.
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APPENDIX 3.4.3. (continued)
^H-dexamethasone binding parameters (B^ ax and Xd) to type I + II CR and tissue protein
content in thymus (D) taken from animals receiving vehicle or paroxetine.
(D) see Figure 3.4.3.iv
DAYS VEHICLE PAROXETINE
Bmnx CR 
tvpe I+II
^ C R  
tvne I+II
protein
content
BmaxCR
tvne I+II
Kd CR 
tvpe I+II
protein
content
1 417 + 30 
(8)
2.8 ± 0.7 
(8)
156 ± 7  
(8)
433 ± 34 
(7)
2.5 ± 0.6
(7)
152±10
(7)
28 336 + 22 
(8)
3.3 ±0.3  
(8)
160 ± 5  
(8)
257 ± 22* 
(8)
2.7 ±0.3  
(8)
163±10
(8)
Rats received paroxetine (5 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and were 
sacrificed after 1 and 28 days of administration. All procedures and CR binding assays were conducted 
as described in section 3.2. Data are expressed as mean ±  sem. Numbers in parentheses = n per group. 
Individual B^ ax values ranged from 227 - 601 fmol/mg protein in vehicle treated animals and 155 - 615 
fmol/mg protein in paroxetine treated animals. Individual ATd values ranged from 1.28 -  6.93 nM in 
vehicle treated animals and 1.34 -  5.6 nM in paroxetine treated animals. Individual protein content 
values ranged from 127 - 168 pg/assay in vehicle treated animals and 135 - 176 pg/assay in paroxetine 
treated animals. Statistically significant differences were determined using ANOVA followed by 
Student’s t-tests and are denoted by * p<0.05, as compared to respective vehicle treated control groups.
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APPENDIX 3.4.4.
^H-dexamethasone binding parameters (Bmax and to type I + II CR and tissue protein
content in cortex (A) taken from animals receiving vehicle or venlafaxine.
(A) see Figure 3.4.4.1
DAYS VEHICLE VENLAFAXINE
Bmax£R 
tvpe I+II
Kd CR 
tvpe I+II
protein
content
BmaxCR
tvne I+II
KnCR 
tvoe I+II
protein
content
1 121 + 17 
(8)
3.1 ±0.7  
(8)
157 ± 5  
(8)
120 ± 1 4  
(8)
2.4 ± 0 .6  
(8)
146 ± 5  
(8)
7 123 + 16 
(8)
3.2 ± 1  
(8)
147 ± 5  
(8)
127 ± 15  
(8)
2.3 ±0 .3  
(8)
142 ± 4  
(8)
14 116+10
(8)
2.2 ±0.5  
(8)
140 ± 8  
(8)
126 ±11  
(8)
4.7 ± 1*  
(8)
158 ± 8  
(8)
28 121 + 13 
(7)
2.2 ± 0.6 
(7)
148 ± 3  
(7)
149 ± 7  
(8)
3.8 ± 0 .7  
(8)
151 ± 3  
(8)
7 w.d 119+11
(8)
3.1 ±0.8  
(8)
144 ± 7  
(8)
129 ±11  
(8)
2.7 ±  0.5 
(8)
152 ± 6  
(8)
Rats received venlafaxine (15 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and 
were sacrificed after 1 ,7 , 14 and 28 days of administration or 7 days after withdrawal of the drug (7 
w.d). All procedures and CR binding assays were conducted as described in section 3.2. Data are 
expressed as mean ± sem. Numbers in parentheses = n per group. Individual Bmax values ranged from 58 - 
223 fmol/mg protein in vehicle treated animals and 38 - 198 fmol/mg protein in venlafaxine treated 
animals. Individual values ranged from 0.23 -  7.59 nM in vehicle treated animals and 0.52 -  6.8 nM 
in venlafaxine treated animals. Individual protein content values ranged from 107 - 185 pg/assay in 
vehicle treated animals and 119 - 204 pg/assay in venlafaxine treated animals. Statistically significant 
differences were determined using ANOVA followed by Student’s t-tests and are denoted by * p<0.05, 
as compared to respective vehicle treated control groups.
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APPENDIX 3.4.4. (continued)
^H-dexamethasone binding parameters (Bmax and Xd) to type I + II CR and tissue protein
content in hippocampus (B) taken from animals receiving vehicle or venlafaxine.
(B) see Figure 3.4.4.Ü
DAYS VEHICLE VENLAFAXINE
Bmnx CR 
tvne I+II
KdQR 
tvne I+II
protein
content
B ^  CR 
tvne I+II
KnCR 
tvne I+II
protein
content
1 109 ± 14 
(8)
2.1 ±0.3  
(8)
108 ± 9  
(8)
127 ± 20 
(7)
3.5 ±0.8  
(7)
108 ± 8  
(7)
7 116+12
(8)
2.6 ± 0.6 
(8)
116±4
(8)
129 ± 1 6  
(7)
2.8 ± 0.4 
(7)
1 18±4
(7)
14 106 + 11 
(8)
2.3 ± 0.4 
(8)
108 ± 7  
(8)
118±8
(8)
4.2±0.7*
(8)
1 15±7
(8)
28 112 + 7 
(8)
2.4 ± 0.5 
(8)
119±3
(8)
139 ± 1 2  
(8)
3.2 ±0.5  
(8)
11 4 ± 6
(8)
7 w.d 104 + 5 
(8)
2 ±0.31 
(8)
123 ± 7  
(8)
102 ± 10 
(8)
1.5 ±0.3  
(8)
119± 4
(8)
Rats received venlafaxine (15 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and 
were sacrificed after 1, 7, 14 and 28 days of administration or 7 days after withdrawal of the drug (7 
w.d). All procedures and CR binding assays were conducted as described in section 3.2. Data are 
expressed as mean + sem. Numbers in parentheses = n per group. Individual B^ ax values ranged from 39 - 
174 fmol/mg protein in vehicle treated animals and 38 - 208 fmol/mg protein in venlafaxine treated 
animals. Individual Kd values ranged from 0.7 -  5.94 nM in vehicle treated animals and 0.4 -  7.17 nM in 
venlafaxine treated animals. Individual protein content values ranged from 62 - 160 pg/assay in vehicle 
treated animals and 84 - 150 pg/assay in venlafaxine treated animals. Statistically significant differences 
were determined using ANOVA followed by Student’s t-tests and are denoted by * p<0.05, as compared 
to respective vehicle treated control groups.
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APPENDIX 3.4.4. (continued)
^H-dexamethasone binding parameters (Bmax and Kq) to type I + II CR and tissue protein
content in striatum (C) taken from animals receiving vehicle or venlafaxine.
(C) see Figure 3.4.4.iii
DAYS VEHICLE VENLAFAXINE
tvne I+II
Kd CR 
tvpe I+II
protein
content
BmaxCR
tvpe I+II
KnCR 
tvne I+II
protein
content
1 112±5
(4)
2.5 ±0 .8  
(4)
129 ± 4  
(4)
134 ± 9  
(4)
2 ±0.5  
(4)
132±7
(4)
7 167 ± 2 2  
(4)
2.7 ± 1  
(4)
136 ± 6 
(4)
152 ± 7  
(3)
1.8 ±0.5  
(3)
138 ± 1  
(4)
14 122 ±31  
(4)
1.8 ±0 .8  
(4)
127 ± 7  
(4)
105 ± 26 
(4)
1.7 ±0.8  
(4)
130±11
(4)
28 123 ± 17 
(4)
1.8 ±0 .7  
(4)
146 ± 7  
(4)
191 ±56  
(4)
2.8 ± 1.9 
(4)
145±11
(4)
7 w.d 170 ±28  
(4)
3.3 ± 0.4 
(4)
122 ± 8  
(4)
121 ±23  
(4)
1.5 ±0.3 * 
(4)
141 ± 4  
(4)
Rats received venlafaxine (15 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and 
were sacrificed after 1 ,7 , 14 and 28 days of administration or 7 days after withdrawal of the drug (7 
w.d). All procedures and CR binding assays were conducted as described in section 3.2. Data are 
expressed as mean ± sem. Numbers in parentheses = n per group (tissues were pooled from two animals 
in these experiments). Individual Bmax values ranged from 66 - 227 fmol/mg protein in vehicle treated 
animals and 44 -  336 fmol/mg protein in venlafaxine treated animals. Individual values ranged from 
0.51 -  5.17 nM in vehicle treated animals and 0.56 -  6.58 nM in venlafaxine treated animals. Individual 
protein content values ranged from 99 - 164 pg/assay in vehicle treated animals and 101 - 156 pg/assay 
in venlafaxine treated animals. Statistically significant differences were determined using ANOVA 
followed by Student’s t-tests and are denoted by * p<0.05, as compared to respective vehicle treated 
control groups.
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APPENDIX 3.4.4. (continued)
^H-dexamethasone binding parameters (B^ ax and Kd) to type I + II CR and tissue protein
content in thymus (D) taken from animals receiving vehicle or venlafaxine,
(D) see Figure 3.4.4.iv
DAYS VEHICLE VENLAFAXINE
Bmax CR 
tvoe I+II
Kd CR 
tvne I+II
protein
content
BmaxCR 
tvpe I+II
Kd CR 
tvne I+II
protein
content
1 278 ± 47 
(8)
4.3 + 1 
(8)
111 ± 4  
(8)
245 ± 54 
(8)
3.3 ±0.6  
(8)
109 ± 3  
(8)
14 220 ± 28 
(8)
4.2 ± 0.9 
(8)
115 + 3 
(8)
219 + 27 
(8)
2.6 ± 0.6 
(8)
111 ± 4  
(8)
28 262 + 48 
(8)
4.2 ± 0.7 
(8)
116 + 5 
(8)
302 + 54 
(7)
4.7 ± 0.7 
(7)
102 ± 9  
(7)
Rats received venlafaxine (15 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and 
were sacrificed after 1, 14 and 28 days of administration. All procedures and CR binding assays were 
conducted as described in section 3.2. Data are expressed as mean ± sem. Numbers in parentheses = n 
per group. Individual B^ ax values ranged from 7 4 -5 1 9  fmol/mg protein in vehicle treated animals and 
106 - 532 fmol/mg protein in venlafaxine treated animals. Individual values ranged from 1.4 -  8.65 
nM in vehicle treated animals and 1.06 -  7.2 nM in venlafaxine treated animals. Individual protein 
content values ranged from 93 - 133 pg/assay in vehicle treated animals and 64 - 126 pg/assay in 
venlafaxine treated animals. No statistically significant differences were determined using ANOVA 
followed by Student’s t-tests.
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APPENDIX 3.4.4. (continued)
^H-dexamethasone binding parameters (Bnmx and Xd) to type I + II CR and tissue protein
content in hypothalamus (E) taken from animals receiving vehicle or venlafaxine.
(E) see Figure 3.4.4.V
Time VEHICLE VENLAFAXINE
B m ax C R
tvpe I+II
K^CR 
tvpe I+II
protein
content
B ^  CR 
tvpe I+II
KnCR 
tvoe I+II
protein
content
1 121 + 6 
(4)
2.23 ±0.51  
(4)
102±11
(4)
133 ±13  
(4)
3.17 ±1.35  
(4)
125 ±21  
(4)
7 142+16
(4)
2.61 ± 0.75 
(4)
140 ± 4  
(4)
130 ± 17  
(4)
2.63 ± 0.6 
(4)
115±13
(4)
14 129 ± 29 
(4)
3.44 ± 0.65 
(4)
103 ± 13 
(4)
104 ±21  
(4)
2.37 ± 0.66 
(4)
125 ±  10 
(4)
28 139 + 22 
(4)
2.16 ±0.33  
(4)
143 ± 11 
(4)
174 ± 23 
(4)
3.85 ± 0.84 
(4)
120 ±15  
(4)
7 w.d 88 + 8 (4) 1.59 ±0.71  
(4)
115± 14 
(4)
150±31
(4)
2.51 ±0.69  
(4)
144 ±  9 * 
(4)
Rats received venlafaxine (15 mg/kg, p.o.) or distilled water vehicle once daily for up to 28 days and 
were sacrificed after 1, 7, 14 and 28 days of administration or 7 days after withdrawal of the drug (7 
w.d). All procedures and CR binding assays were conducted as described in section 3.2. Data are 
expressed as mean ± sem. Numbers in parentheses = n per group (tissues were pooled from two animals 
in these experiments). Individual Bmax values ranged from 62 - 200 fmol/mg protein in vehicle treated 
animals and 61 -243 fmol/mg protein in venlafaxine treated animals. Individual values ranged from 
0.48 -  4.69 nM in vehicle treated animals and 0.87 -  5.21 nM in venlafaxine treated animals. Individual 
protein content values ranged from 77 - 172 pg/assay in vehicle treated animals and 67 - 166 pg/assay in 
venlafaxine treated animals. Statistically significant differences were determined using ANOVA 
followed by Student’s t-tests and are denoted by * p<0.05, as compared to respective vehicle treated 
control groups.
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APPENDIX 4.3.1.
Displacement of ^H-dexamethasone binding from CR in rat cytosolic preparations by 
citalopram (A) & milnacipran (B). Rat cytosolic fractions were prepared as described 
in section 2.5.2. Data shown is taken from a single experiment.
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APPENDIX 4.3.3.
The effects of acute and chronic administration of citalopram (A), venlafaxine (B), 
DMI (C) and milnacipran (D) on grooming scores in the open field of sham-operated 
(SO) and olfactory bulbectomised (OB) rats (Data not displayed in Chapter 4).
(A)
SO + vehicle SO + citalopram OB + vehicle OB + citalopram
DAY 3
grooming
DAY 28
0.6 ± 0.3 0.2 ± 0.2 0.1 ±0.1 0.6 ± 0.4
grooming 0.0 ± 0.0 0.1 ±0.1 0.0 ±0.0 0.0 ± 0.0
(B)
SO + vehicle SO + venlafaxine OB + vehicle OB + venlafaxine
DAY 3
grooming
DAY 28
0.6 ±0.3 0.3 ± 0.3 0.1 ±0.1 0.3 ± 0.3
grooming 0.0 ±0.0 0.3 ± 0.3 0.0 ±0.0 0.0 ± 0.0
(C)
SO + vehicle SO + DMI OB + vehicle OB + DMI
DAY 3
grooming
DAY 28
0.6 ± 0.3 0.9 ± 0.6 0.1 ±0.1 0.0 ±0.0
grooming 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0
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(D)
APPENDIX 4.3.3. (continued)
SO + vehicle 8 0  + 
milnacipran
OB + vehicle OB + 
milnacipran
DAY 3
grooming
DAY 28
0.6 ±0.3 0.1 ±0.1 0.1 ±0.1 0.5 ±0.3
grooming 0.0 ±0.0 0.0 ± 0.0 0.0 ±0.0 0.0 ± 0.0
Rats (7-10 per group) received citalopram (5mg/kg p.o.) or distilled water twice daily and were 
tested for open-field activity approximately 16 hours following the last dose as described in 
section 4.2.4. Data are expressed as mean ± sem. Statistically significant differences are not 
displayed as the data were too erratic and standard errors too large for statistical determinations 
(used ANOVA followed by Students t-tests where appropriate (GB-STAT v6.0)).
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APPENDIX 4.3.4.:
Grooming (A) and defecation (B) scores in sham-operated (SO) rats following administration 
of vehicle, citalopram, venlafaxine, DMI or milnacipran for 3,7, 10,14, 21 and 28 days 
(data not displayed in Chapter 4).
(A) grooming
SO + SO + SO + SO + S0 +
vehicle citalopram venlafaxine DMI milnacipran
Day 3 0.6 ± 0.3 0.2 ± 0.2 0.2 ± 0.3 0.9 ± 0.6 0.1 ± 0.1
Day 7 0.6 ± 0.3 0.4 ± 0.2 0.6 ± 0.3 0.9 ± 0.3 0.6 ± 0.4
Day 10 0.1 ± 0.1 0.3 ± 0.2 0.0 ± 0.0 0.1 ± 0.1 0.1 ± 0.1
Day 14 0.0 ± 0.0 0.2 ± 0.2 1.1 ± 0.4 0.4 ± 0.2 0.6 ± 0.4
Day 21 0.3 ± 0.2 0.1 ± 0.1 0.4 ± 0.4 0.4 ± 0.4 0.0 ± 0.0
Day 28 0.0 ± 0.0 0.1 ±0.1 0.3 ± 0.3 0.0 ± 0.0 0.1 ± 0.1
(B) defecation
SO + SO + SO + SO + SO +
vehicle citalopram venlafaxine DMI milnacipran
Day 3 3.6 ± 0.6 3.1 ± 0.7 3.6 ± 1.3 4.8 ± 1.0 2.3 ± 0.7
Day 7 3.6 ±0.8 3.0 ± 0.9 3.6 ± 1.1 3.9 ± 0.6 3.4 ± 0.8
Day 10 2.1 ± 0.5 3.6 ± 0.9 1.3 ± 0.6 2.2 ± 0.7 1.6 ± 0.9
Day 14 1.6 ± 0.9 3.8 ± 1.0 3.5 ± 0.8 3.2 ± 1.1 3.0 ± 0.9
Day 21 4.6 ± 1.0 3.6 ± 0.7 2.4 ± 1.0 5.1 ± 0.9 4.3 ± 0.9
Day 28 4.3 ± 0.8 3.4 ± 0.7 2.5 ± 0.7 3.5 ± 0.8 2.3 ± 1.0
Rats (7-10 per group) received citalopram, venlafaxine, DMI or milnacipran twice daily over 28 days and 
wer tested for open field activity approximately 16 hours after the last dose as described in section 4.2.4. 
Data are expressed as mean ± sem. Statistically significant differences were not determined for grooming 
scores as these were too erratic with very large sem values. Statistically significant differences for 
defecation values were determined using ANOVA followed by Student’s t-tests where appropriate and 
are denoted by * p<0.05. ANOVA: Citalopram - effect of treatment F (1, 84) = 0.95, p=0.33: effect of 
time F (5, 84) =  0.43, p -0 .83; interaction treatment x  time F (5, 84) -  1.86, p=0.1L. Venlafaxine - 
effect of treatment F (1, 76) -  2.87, p=O.II: effect of time F (5, 76) -  1.56, p-0 .18; interaction 
treatment x  time F (5, 76) -  1.02, p=0.41. DMI - effect of treatment F (1, 84) = 4.53, p=0.37: effect of 
time F (5, 84) =  1.78, p=0.13; interaction treatment x  time F (5, 84) -  1.45, p=0.22.. Milnacipran - 
effect of treatment F (1, 75) = 1.87, p=0.49: effect of time F (5, 75) ~ 0.42, p-0 .83; interaction 
treatment x time F (5, 75) -1 .36 , p=0.25.
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APPENDIX 4.3.4.Ü.
^H-dexamethasone binding parameters (Bmax and K^) to type I + II CR in hippocampus taken 
from sham-operated (SO) animals receiving citalopram (A), venlafaxine (B), DMI (C) or 
milnacipran (D) over 28 days.
(A) see Figure 4.3.4.i
DAYS VEHICLE CITALOPRAM
Bmax CR KdCR B ^ C R Kd OR
(■fmol/ms tissue) (nM) (fmol/ms tissue) (nM)
3 2.78 ± 0.3 0.95 ±0.12 3.1 ±0.12 1.03 ±0.12
(7) (7) (7) (7)
7 2.97 ± 0.29 1.19 ±0.15 3.92 ±0.51 1.28 ±0.17
(8) (8) (8) (8)
10 3.01 + 0.24 2.27 ± 0.45 3.56 ±0.21 1.96 ±0.3
(8) (8) (8) (8)
21 2.67 + 0.16 1.77 ±0.35 2.62 ±0.16 1.07 ±0.1
(8) (8) (8) (8)
21 2.29 + 0.26 1.22 ±0.31 2.16±0.17 0.97 ±0.1
(8) (8) (8) (8)
28 2.53 ±0.28 1.32 ±0.3 3.2 ±0.19 1.47 ±0.21
(8) (8) (8) (8)
(B) see Figure 4.3.4.Ü
DAYS VEHICLE VENLAFAXINE
Bjnax_ÇR 
(fmol/mg tissue)
Kd CR
(nM)
B ^ C R  
(fmol/mg tissue)
I^ C R
(nM)
3 2.78 ± 0.3 
(7)
0.95 ±0.12
(7)
2.93 ±0.28 
(8)
1.32 ±0.3 
(8)
7 2.97 ± 0.29 
(8)
1.19±0.15
(8)
4.0 ±0.62 
(8)
1.84 ±0.40 
(8)
10 3.01 ±0.24 
(8)
2.27 ± 0.45 
(8)
3.12 ±0.39 
(8)
1.69 ±0.42 
(8)
21 2.67 ±0.16 
(8)
1.77 ±0.35 
(8)
2.54 ±0.09 
(8)
1.11±0.11
(8)
21 2.29 ±0.26 
(8)
1.22 ±0.31 
(8)
2.28 ±0.25 
(8)
1.21 ±0.18 
(8)
28 2.53 ± 0.28 
(8)
1.32 ±0.3 
(8)
2.59 ±0.2 * 
(8)
2.11 ±0.11 * 
(8)
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APPENDIX 4.3.4.Ü (continued)
(C) see Figure 4.3.4.iii
DAYS VEHICLE DMI
BmaxCR 
(fmol/mg tissue)
KdCR
(nM)
B m a a
(fmol/mg tissue)
I^CR
(nM)
3 2.78 ± 0.3 
(7)
0.95 ±0.12 
(7)
3.65 ± 0.40 
(8)
0.92 ±0.06 
(8)
7 2.97 ± 0.29 
(8)
1.19±0.15
(8)
5.17 ±1.25 
(6)
1.22 ±0.22 
(6)
10 3.01+0.24
(8)
2.27 ± 0.45 
(8)
3.78 ± 0.37 
(8)
1.42 ±0.27 
(8)
21 2.67 + 0.16 
(8)
1.77 ±0.35 
(8)
2.69 ±0.12 
(8)
1.26 ±0.09 
(8)
21 2.29 ± 0.26 
(8)
1.22 ±0.31 
(8)
2.62 ± 0.20 
(8)
0.93 ±0.13 
(8)
28 2.53 + 0.28 
(8)
1.32 ±0.3 
(8)
3.13 ±0.29 
(8)
1.71 ±0.38 
(8)
(D) see Figure 4.3.4.iv
DAYS VEHICLE MILNACIPRAN
B^CR KdCR Bmnx CR KnCR
(fmol/mg tissue) (nM) (fmol/mg tissue) (nM)
3 2.78 ± 0.3 0.95 ±0.12 2.94 ± 0.25 0.95 ±0.12
(7) (7) (8) (8)
28 2.53 ±0.28 1.32 ±0.3 3.1 ±0.31 1.07 ±0.36
(8) (8) (8) (8)
Rats received citalopram (5 mg/kg, p.o.), venlafaxine (15 mg/kg, p.o.), DMI (5 mg/kg, p.o.), milnacipran 
(15 mg/kg, p.o.) or distilled water vehicle twice daily for up to 28 days and were sacrificed after 3,7, 10, 
14, 21 and 28 days of administration. All procedures and CR binding assays were conducted as described 
in section 3.2. Also see section 4.3.4. Data are expressed as mean ± sem. Numbers in parentheses = n per 
group. Statistically significant differences were determined using ANOVA followed by Student’s t-tests 
and are denoted by * p<0.05 as compared to vehicle treated control groups.
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APPENDIX 6.2.3.A.
Open field activity of BALB/c mice following acute exposure to predator stress
(see Figure 6.2.3.i).
IMMEDIATELY AFTER POS 24 HOURS AFTER POS
AMBULATION
GROOMING
(not shown in chap 6) 
REARING 
(not shown in chap 6) 
DEFECATION
MOBILITY
LATENCY
NON-STRESSED STRESS 
20+ 5 3 9±  8
0.5 ± 0.27
NON-STRESSED 
52 ± 13 
0.88 ± 0.35 0.63 ± 0.18
0.25 ± 0.16 0.13+ 0.13 0.25 ± 1.63
2.88 ± 0 .7 2  1.13 ± 0.48 4 ±  4.6
160± 35 1 4 ± 4 * *  3 7 ± 11
STRESS
24 ± 6 
0.63 ± 0.26
1.38 ± 0.96
4.13 ± 0.97
94 ± 37
BALB/c mice (n=8 per group) were subjected to open field tests immediately, or 24 hours after exposure 
to predator stress. Data are expressed as mean ± sem. Table shows scores for ambulation, grooming (not 
shown in Chapter 6), rearing (data not shown in Chapter 6), defecation and mobility latency immediately 
and 24 hours after predator exposure. Statistically significant differences were determined using t-tests 
(ambulation, defecation and mobility latency) or Mann-Whitney U tests (grooming and rearing) and are 
denoted by ** p<0.01.
APPENDIX 6.2.3.B.
Sucrose intake of BALB/c mice following acute exposure to predator stress
(see Figure 6.2.3.Ü).
(A) IMMEDIATELY AFTER POS (B) 24 HOURS AFTER POS
NON-STRESSED STRESS NON-STRESSED STRESS
1.28 ± 0.12 0.74 ± 0.1 ** 0.91 ± 0.06 1.1 ± 0.15
BALB/c mice (n=10 per group) were subjected to 1-bottle sucrose consumption tests immediately or 24 
hours after exposure to predator stress (see section 6.2.3.ii). Data are expressed as mean ± sem in g. (A) 
sucrose intake immediately following exposure to predator stress, (B) sucrose intake 24 hours following 
exposure to predator stress. Statistically significant differences were determined using t-tests (using GB- 
STAT v6.5) and are denoted by ** p<0.01.
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APPENDIX 6.2.3.C.
Plasma corticosterone concentrations in BALB/c mice following acute exposure to predator
stress (see Figure 6.2.3.iii).
(A) IMMEDIATELY AFTER POS (B) 24 HOURS AFTER POS
NON-STRESSED STRESS NON-STRESSED STRESS
2 8 + 6 4 3 + 6 37+ 6 26 ± 4
Plasma corticosterone concentrations in BALB/c mice (n=6-7 per group) were assessed in blood samples 
taken following exposure to predator stress (see section 6.3.2.iii). Data are expressed as mean ± sem (in 
ng/mL). (A) plasma corticosterone concentrations immediately following exposure to predator stress, (B) 
plasma corticosterone concentrations 24 hours following exposure to predator stress. No statistically 
significant differences were determined between control and stressed groups.
APPENDIX 6.2.3.D.
Specific ^H-dexamethasone binding to cortical/hippocampal cytosolic fractions following acute 
exposure to predator stress (see Figure 6.2.3.iv).
Cortex
(A) IMMEDIATELY AFTER POS (B) 24 HOURS AFTER POS
NON-STRESSED 
Bmax (fmol/mg protein) 143 ± 14 
Kd 1.02 ± 0.29
STRESS NON-STRESSED 
147 ±  10 15 3+ 6  
1.51 ± 0.54 1.58 ± 0.68
STRESS 
180 ± 16 
1.67 ± 0.51
Hippocampus (Bmax only)
(C) IMMEDIATELY AFTER POS (D) 24 HOURS AFTER POS
NON-STRESSED STRESS 
138+12 131 ± 18
NON-STRESSED 
142 ± 3
STRESS 
153± 17
Specific ^H-dexamethasone binding to CR in cortex/hippocampus (from BALB/c mice (n=8 per group)) 
was measured following acute exposure to predator stress. See sections 2.3 and 6.2.3.iv. Data are 
expressed as mean ± sem (in fmol/mg protein -  B^ ax and nM -  K^). (A) B a^x of cortical CR binding 
immediately after predator exposure, (B) B^ ax of cortical CR binding 24 hours after predator exposure,
(C) Kj) of cortical CR binding immediately following predator exposure, (D) ATd of cortical CR binding 
24 hours after predator exposure, (E) B^ ax of hippocampal CR binding immediately after predator 
exposure, (F) Bmax of hippocampal CR binding 24 hours after predator exposure. No statistically 
significant differences were found between control and stressed groups.
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APPENDIX 6.3.3.A.
Body weights (g) of BALB/c mice following chronic exposure to predator stress and
antidepressant administration (see Figures 6.3.3.i.l/2).
WEEK No. NON-STRESSED CONTROL STRESSED
1
VEHICLE
31.1+0.3
(n= 60) 
2 31.1+0.4
(n= 60) 
3 31.4 ±0.4
(n= 60) 
4 32.4 + 0.7
(n= 30) 
5 32.6 + 0.7
(n= 30) 
6 32.8 + 0.8
(n= 30) 
7 33.7 + 0.7
(n= 30) 
8 34.1 + 1.4
(n= 8) 
9 32.1 + 1.1
(n= 8) 
10 32.5 + 1.0
(n= 8) 
11 32.8 + 0.9
(n= 8) 
12 33.1+0.9
(n= 8)
DMI PAROX VEHICLE DMI PAROX
32.4 + 0.7 32.4 ±0.7 31.4 ±0.5 31.4 ±0.5 31.4 ±0.5
32.6 + 0.7 32.6 ± 0.7 31 ±0.5 31 ±0.5 31 ±0.5
32.8 + 0.8 32.8 ±0.8 31.8 ±0.5 31.8 ±0.5 31.8 ±0.5
33.7 ± 0.7 33.7 ± 0.7 32.7 ± 0.5 32.7 ± 0.5 32.7 ±  0.5
36.2 ±1.02 31.8 ±1.2 32 ±0.9 34.9 ±1.1 32.1 ±0 .8
32.6 ±0.9 29.8 ±0.9 29.5 ±0.7  * 29.9 ±1.4 28.9 ±0 .9
33.5 ± 0.74 31.4±1.1 28.7 ± 0.7 * 31.3±1.1 31.1 ±0.8
33.7 ± 0.9 33 ±1.4 29.6 ± 0.7 * 31.4 ±1 .0 31.9 ±0 .9
32.1 ± 1.01 33.8 ±1.6 29.9 ± 0.7 * 31 ±1.1 32.7 ±0 .9
Body weights of individually housed mice were recorded before and after the introduction of a predator 
stress stimulus, see section 6.3.3 .i. Administration of distilled water vehicle, DMI (15 mg/kg) and 
paroxetine (7.5 mg/kg) began at the start of week 8 for 28 days. Data are expressed as mean ± sem (in g). 
Statistically significant differences were determined using ANOVA followed by Students t tests and are 
denoted by * p<0.05 as compared to respective non-stressed controls.
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APPENDIX 6.3.3.B.
Open field activity (ambulation, defecation and mobility latency) of BALB/c mice 
following chronic exposure to predator stress and antidepressant administration (see Figures
6.3.3.Ü.1-6).
(A) AMBULATION
WEEK No. NON-STRESSED CONTROLS STRESSED
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 5 3 ± 4
(n=60)
3 44 ± 4
(n=60)
5 45 + 5 2 9 ± 4 *
(n= 30)
7 39 + 4 28 ± 3
(n= 30)
9 47 + 10 5 2 ±  14 42 ± 6 3 0 ± 5 38 ± 13 32 ± 5
(n= 7-8)
11 52 + 8 6 0 ±  16 5 1 ± 8 2 4 ± 5  * 3 1 ± 7 3 0 ± 8
(n= 7-8)
(B) MOBIILITY LATENCY
WEEK No. NON-STRESSED CONTROLS STRESSED
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 95 ± 1 0
(n=60)
3 115±10
(n=60)
5 91 ±17 164 ± 2 0 *
(n= 30)
7 80 ±15 128 ±  18 *
(n= 30)
9 54 ±28 63 ±41 56 ±14 74 ± 2 2 84 ±41 103 ± 3 6
(n=7-8)
11 58 ± 24 47 ± 3 9 49 ±18 83 ± 2 4 104 ±  37 67 ± 3 3
(n= 7-8)
(C) DEFECATION
WEEK No. NON-STRESSED CONTROLS STRESSED
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 5.2 ± 0.2
(n=60)
3 4.3 ±0.3
(n=60)
5 4.3 ±0.3 3.4 ± 0.3 *
(n= 30)
7 4.0 ±0.4 3.4 ±  0.4
(n= 30)
9 4.9 ± 0.4 3.3 ± 0 .6 3.6 ± 0.6 3.3 ± 0.6 * 3.8 ± 0 .7 4.5 ± 0 .6
(n= 7-8)
11 6.1 ±0.9 2.9 ±  0.2 4.5 ±0.3 3.4 ± 0.6 * 2.5 ±  0.5 3.9 ± 0 .5
(n= 7-8)
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APPENDIX 6.3.3.B. (continued)
Open field activity (grooming and rearing) of BALB/c mice following chronic exposure to
predator stress and antidepressant administration.
(D) GROOMING (data not shown in chapter 6)
WEEK No. NON-STRESSED CONTROLS STRESSED
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 0.4 ± 0.08
(n=60)
3 0.65 ±0.1
(n=60)
5 1.07 ±0.63 0.6 ± 0.16
(n= 30)
7 0.67 ±0.19 0.6 ±0.14
(n= 30)
9 0.63 ± 0.3 0.86 ± 0.34 0.5 ±0.19 0.88 ± 0.4 1.25 ±0.53 1.75 ± 1.21
(n= 7-8)
11 0.89 ± 0.4 0.25 ±0.17 0.25 ± 0.25 0.5 ± 0.2 1.25 ±0.59 0.38 ±0.18
(n= 7-8)
(E) REARING (data not shown in chapter 6)
WEEK No. NON-STRESSED CONTROLS STRESSED
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 0.65 ±0.21
(n=60)
3 0.53 ±0.17
(n=60)
5 0.57 ±0.16 0.63 ±0.13
(n= 30)
7 0.33 ±0.11 1.1 ±0.54
(n= 30)
9 0.38 ± 0.26 1.71 ± 0.99 0.38 ± 0.26 0.63 ± 0.32 2.0 ± 1.61 0.88 ±0.61
(n= 7-8)
11 0.25 ±  0.25 2.75 ± 1.92 0.5 ±0.19 0.0 ± 0.0 0.25 ± 0.25 0.6 ± 0.27
(n= 7-8)
Open field activity in individually housed mice, recorded before and after the introduction of a predator 
stress stimulus, see section 6.3.3.Ü. Administration of distilled water vehicle, DMI (15 mg/kg) and 
paroxetine (7.5 mg/kg) began at the start of week 8 for 28 days. Data are expressed as mean ± sem. A- 
ambulation scores, B-defecation scores, C-mobility latency, D-grooming scores and E-rearing scores. 
Statistically significant differences between non-stressed and stressed groups are denoted by p<0.05.
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APPENDIX 6.3.3.C
Sucrose intake (g) of BALB/c mice following chronic exposure to predator stress and
_____________ antidepressant administration (see Figures 6.3.3.iii.l/2)._____________
Wee 
k no
Test
no
NON-STRESSED CONTROLS STRESSED
10
11
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 1.11 ±0.07
(n=60)
2 1.07 ±0.07
(n=60)
3 1.01 ±0.05
(n=60)
4 0.79 ± 0.04
(n=30)
5 1.03 ±0.08
(n=30)
6 1.18 ±0.07 0.89 ± 0.05*
(n= 30)
7 1.01 ±0.04 0.99 ± 0.08
(n= 30)
8 0.6 ± 0.05 0.56 ± 0.08
(n= 30)
9 1.06 ±0.13 0.54 ±0.06*
(n= 30)
10 1.09 ±0.07 0.61 ±0.07*
(n= 8)
11
(n= 8)
12 1.35 ±0.09 0.7 ± 0.09*
(n= 8)
13 0.96 ± 0.06 0.63 ±0.04*
(n= 8)
14 0.74 ± 0.04 0.72 ± 0.05
(n= 8)
15 1.17 ±0.06 0.71 ±0.06*
(n= 8)
16 0.75 ±0.11 0.65 ±0.08 0.59 ±0.05 0.52 ± 0.06 0.38 ±0.04* 0.26 ±  0.05*
(n= 8)
17 0.52 ± 0.05 0.56 ± 0.07 0.58 ±0.05 0.38 ± 0.07 0.89 ±0.41 0.48 ±  0.09
(n= 8)
18 0.91 ±0.36 0.66 ± 0.09 0.64 ± 0.04 0.36 ±0.1 0.59 ±0.16 0.41 ±0.13
(n= 8)
19 0.54 ± 0.08 0.37 ± 0.07 0.54 ±0.11 0.27 ± 0.05* 0.37 ±0.1 0.33 ± 0.08
(n= 8)
20 0.36 ± 0.07 0.51 ±0.11 0.70 ±0.05 0.66 ±0.1* 0.47 ± 0.09 0.52 ±0.11
(n= 8)
21 0.64 ± 0.04 0.81 ±0.15 0.59 ± 0.03 0.43 ±0.07* 0.44 ± 0.04* 0.39 ± 0.07*
(n= 8)
22 0.86 ±0.15 0.84±0.12 0.75±0.08 0.56 ± 0.05* 0.92 ±0.36 0.36 ± 0.05*
(n= 8)
23 0.72 ±0.14 0.53 ±0.1 0.69 ±0.12 0.49 ± 0.08 0.35 ±0.08 0.45 ±0.12
(n= 8)
Sucrose intakes of individually housed mice were recorded before and after the introduction of a predator 
stress stimulus, and administration of vehicle, DMI (15 mg/kg) and paroxetine (7.5 mg/kg), see section 
6.3.3.iii. Data are expressed as mean ± sem (in g). Statistically significant differences were determined 
using ANOVA followed by Students t tests and are denoted by * p<0.05 as compared to respective non- 
stressed controls.
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APPENDIX 6.3.3.D.
Sucrose intake/g body weight of BALB/c mice following acute exposure to predator stress
and antidepressant administration (see Figures 6.3.3.iii.3/4).
WEEK No. NON-STRESSED CONTROLS STRESSED
VEHICLE DMI PAROX VEHICLE DMI PAROX
1 30.4 ±1.4
(n=60)
2 35.8 ± 2.4
(n=60)
3 25.7 ±1.6
(n=60)
4 37.2 ± 2.5 28.5 ±1 .8  *
(n= 30)
5 18.4 ±1.5 18.4 ±3 .0
(n= 30)
6 33.6 ±2.1 19.7 ± 2 .6 *
(n= 30)
7 29.0 ±2 .0 19.3 ± 1 .2 *
(n= 30)
8 22.9 ± 4 17.9 ±2.2 18.7 ± 1.9 16.7 ±2.3 10.9 ±1.1 8.3 ±1.8
(n= 8)
9 28.7 ±11.1 17.7 ± 2.7 21.3 ±2 .2 12.4 ± 3.4 21.3 ± 6 .9 14.9 ±4.8
(n= 8)
10 16.7 ±2.5 9.6 ±1.9 17.1 ±3 .2 9.4 ± 1 .8 * 11.6 ± 3 .0 10.7 ± 2.8
(n= 8)
11 19.4 ± 1.1 21.3 ±1.5 17.9 ±0 .9 14.2 ±  2.2 * 14.1 ±  1.3 * 12.3 ±2.3  *
(n= 8)
12 22.0 ±4.4 14.9 ±3.5 20.1 ±3 .0 16.4 ± 3.0 11.4 ±2 .6 13.9 ±3.9
(n= 8)
Sucrose intake /  g body weight of individually housed mice was calculated for periods before and after 
the introduction of a predator stress stimulus, see section 6.3.3.3.iii. Administration of distilled water 
vehicle, DMI (15 mg/kg) and paroxetine (7.5 mg/kg) began at the start of week 8 for 28 days. Data are 
expressed as mean ± sem (in g). Statistically significant differences were determined using ANOVA 
followed by Students t tests and are denoted by * p<0.05 as compared to respective non-stressed 
controls.
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